
<html lang="en"     class="pb-page"  data-request-id="77db37e9-6095-4d4e-9602-19b9684ae67c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2015.58.issue-23;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.5b01545"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects" /></meta><meta name="dc.Creator" content="Julien P. N.  Papillon" /></meta><meta name="dc.Creator" content="Changgang  Lou" /></meta><meta name="dc.Creator" content="Alok K.  Singh" /></meta><meta name="dc.Creator" content="Christopher M.  Adams" /></meta><meta name="dc.Creator" content="Gary M.  Ksander" /></meta><meta name="dc.Creator" content="Michael E.  Beil" /></meta><meta name="dc.Creator" content="Wei  Chen" /></meta><meta name="dc.Creator" content="Jennifer  Leung-Chu" /></meta><meta name="dc.Creator" content="Fumin  Fu" /></meta><meta name="dc.Creator" content="Lu  Gan" /></meta><meta name="dc.Creator" content="Chii-Whei  Hu" /></meta><meta name="dc.Creator" content="Arco Y.  Jeng" /></meta><meta name="dc.Creator" content="Daniel  LaSala" /></meta><meta name="dc.Creator" content="Guiqing  Liang" /></meta><meta name="dc.Creator" content="Dean F.  Rigel" /></meta><meta name="dc.Creator" content="Kerry S.  Russell" /></meta><meta name="dc.Creator" content="John A.  Vest" /></meta><meta name="dc.Creator" content="Catherine  Watson" /></meta><meta name="dc.Description" content="Human clinical studies conducted with LCI699 established aldosterone synthase (CYP11B2) inhibition as a promising novel mechanism to lower arterial blood pressure. However, LCI699’s low CYP11B1/CYP..." /></meta><meta name="Description" content="Human clinical studies conducted with LCI699 established aldosterone synthase (CYP11B2) inhibition as a promising novel mechanism to lower arterial blood pressure. However, LCI699’s low CYP11B1/CYP..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 18, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01545" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01545" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01545" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01545" /></link>
        
    
    

<title>Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01545" /></meta><meta property="og:title" content="Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0009.jpeg" /></meta><meta property="og:description" content="Human clinical studies conducted with LCI699 established aldosterone synthase (CYP11B2) inhibition as a promising novel mechanism to lower arterial blood pressure. However, LCI699’s low CYP11B1/CYP11B2 selectivity resulted in blunting of adrenocorticotropic hormone-stimulated cortisol secretion. This property of LCI699 prompted its development in Cushing’s disease, but limited more extensive clinical studies in hypertensive populations, and provided an impetus for the search for cortisol-sparing CYP11B2 inhibitors. This paper summarizes the discovery, pharmacokinetics, and pharmacodynamic data in preclinical species and human subjects of the selective CYP11B2 inhibitor 8." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01545"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01545">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01545&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01545&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01545&amp;href=/doi/10.1021/acs.jmedchem.5b01545" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 9382-9394</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01542" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01566" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of <i>N</i>-[5-(6-Chloro-3-cyano-1-methyl-1<i>H</i>-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julien+P.+N.++Papillon">Julien P. N. Papillon</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Changgang++Lou">Changgang Lou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alok+K.++Singh">Alok K. Singh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+M.++Adams">Christopher M. Adams</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gary+M.++Ksander">Gary M. Ksander</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+E.++Beil">Michael E. Beil</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Chen">Wei Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Leung-Chu">Jennifer Leung-Chu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fumin++Fu">Fumin Fu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lu++Gan">Lu Gan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chii-Whei++Hu">Chii-Whei Hu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arco+Y.++Jeng">Arco Y. Jeng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++LaSala">Daniel LaSala</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guiqing++Liang">Guiqing Liang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dean+F.++Rigel">Dean F. Rigel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kerry+S.++Russell">Kerry S. Russell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+A.++Vest">John A. Vest</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Catherine++Watson">Catherine Watson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>‡</sup>Global Discovery Chemistry, <sup>∥</sup>Metabolism and Pharmacokinetics, <sup>§</sup>Translational Medicine, and <sup>†</sup>Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">∇</span> <span class="aff-text">Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: +1 617 871 7653. E-mail: <a href="/cdn-cgi/l/email-protection#ec869980858982c29c8d9c8580808382ac82839a8d9e98859fc28f8381"><span class="__cf_email__" data-cfemail="fe948b92979b90d08e9f8e9792929190be9091889f8c8a978dd09d9193">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01545&amp;href=/doi/10.1021%2Facs.jmedchem.5b01545" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 9382–9394</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 5, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 October 2015</li><li><span class="item_label"><b>Published</b> online</span>18 November 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01545" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01545</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9382%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJulien%2BP.%2BN.%2BPapillon%252C%2BChanggang%2BLou%252C%2BAlok%2BK.%2BSingh%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D23%26contentID%3Dacs.jmedchem.5b01545%26title%3DDiscovery%2Bof%2BN-%255B5-%25286-Chloro-3-cyano-1-methyl-1H-indol-2-yl%2529-pyridin-3-ylmethyl%255D-ethanesulfonamide%252C%2Ba%2BCortisol-Sparing%2BCYP11B2%2BInhibitor%2Bthat%2BLowers%2BAldosterone%2Bin%2BHuman%2BSubjects%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9394%26publicationDate%3DDecember%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01545"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1496</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">18</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01545" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Julien&quot;,&quot;last_name&quot;:&quot;P. N. Papillon&quot;},{&quot;first_name&quot;:&quot;Changgang&quot;,&quot;last_name&quot;:&quot;Lou&quot;},{&quot;first_name&quot;:&quot;Alok&quot;,&quot;last_name&quot;:&quot;K. Singh&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;M. Adams&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;M. Ksander&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;E. Beil&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Leung-Chu&quot;},{&quot;first_name&quot;:&quot;Fumin&quot;,&quot;last_name&quot;:&quot;Fu&quot;},{&quot;first_name&quot;:&quot;Lu&quot;,&quot;last_name&quot;:&quot;Gan&quot;},{&quot;first_name&quot;:&quot;Chii-Whei&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Arco&quot;,&quot;last_name&quot;:&quot;Y. Jeng&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;LaSala&quot;},{&quot;first_name&quot;:&quot;Guiqing&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Dean&quot;,&quot;last_name&quot;:&quot;F. Rigel&quot;},{&quot;first_name&quot;:&quot;Kerry&quot;,&quot;last_name&quot;:&quot;S. Russell&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;A. Vest&quot;},{&quot;first_name&quot;:&quot;Catherine&quot;,&quot;last_name&quot;:&quot;Watson&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;9382-9394&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01545&quot;},&quot;abstract&quot;:&quot;Human clinical studies conducted with LCI699 established aldosterone synthase (CYP11B2) inhibition as a promising novel mechanism to lower arterial blood pressure. However, LCI699’s low CYP11B1/CYP11B2 selectivity resulted in blunting of adrenocorticotropic hormone-stimulated cortisol secretion. This property of LCI699 prompted its development in Cushing’s disease, but limited more extensive clinical studies in hypertensive populations, and provided an impetus for the search for cortisol-sparing CYP11B2 inhibitors. This paper summarizes the discovery, pharmacokinetics, and pharmacodynamic data in preclinical species and human subjects of the selective CYP11B2 inhibitor 8.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01545&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01545" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01545&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01545" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01545&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01545" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01545&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01545&amp;href=/doi/10.1021/acs.jmedchem.5b01545" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01545" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01545" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01545%26sid%3Dliteratum%253Aachs%26pmid%3D26540564%26genre%3Darticle%26aulast%3DPapillon%26date%3D2015%26atitle%3DDiscovery%2Bof%2BN-%255B5-%25286-Chloro-3-cyano-1-methyl-1H-indol-2-yl%2529-pyridin-3-ylmethyl%255D-ethanesulfonamide%252C%2Ba%2BCortisol-Sparing%2BCYP11B2%2BInhibitor%2Bthat%2BLowers%2BAldosterone%2Bin%2BHuman%2BSubjects%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D23%26spage%3D9382%26epage%3D9394%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=291594" title="Silica">Silica</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/jmcmar.2015.58.issue-23/20151210/jmcmar.2015.58.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Human clinical studies conducted with LCI699 established aldosterone synthase (CYP11B2) inhibition as a promising novel mechanism to lower arterial blood pressure. However, LCI699’s low CYP11B1/CYP11B2 selectivity resulted in blunting of adrenocorticotropic hormone-stimulated cortisol secretion. This property of LCI699 prompted its development in Cushing’s disease, but limited more extensive clinical studies in hypertensive populations, and provided an impetus for the search for cortisol-sparing CYP11B2 inhibitors. This paper summarizes the discovery, pharmacokinetics, and pharmacodynamic data in preclinical species and human subjects of the selective CYP11B2 inhibitor <b>8</b>.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06007" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06007" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Aldosterone is the principal mineralocorticoid in man and is produced in the zona glomerulosa (outer zone) of the adrenal cortex by aldosterone synthase (CYP11B2). Aldosterone is a key component of the renin-angiotensin-aldosterone system (RAAS) and acts primarily at the renal distal convoluted tubules as a critical regulator of fluid and electrolyte homeostasis. Consequently, increases in aldosterone can result in elevated blood pressure and fluid retention. Elevated serum aldosterone has been linked to resistant hypertension,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> which represents a significant medical need.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Patients with an aldosterone excess are more susceptible to premature vascular disease, cardiac fibrosis, vessel wall inflammation, left ventricular hypertrophy, atrial fibrillation, stroke, myocardial infarction, and metabolic syndrome.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Aldosterone escape<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> due to inadequate suppression of aldosterone levels during long-term blockade of RAAS with either angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) is also associated with end organ damage. Suppression of aldosterone’s untoward effects, therefore, represents an attractive therapeutic approach to reduce blood pressure and cardiovascular disease burden. Mineralocorticoid receptor antagonists (MRAs) spironolactone and eplerenone have demonstrated efficacy in hypertension, primary aldosteronism, obstructive sleep apnea, or renal disease. In addition MRAs have shown morbidity and mortality benefits in patients with both mild and severe heart failure on standard therapy,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> in patients with left ventricular dysfunction after myocardial infarction,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and in heart failure patients with a preserved ejection fraction and elevated brain natriuretic peptide.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> However, there are significant limitations associated with MRAs. The use of spironolactone is associated with hormonal side effects including breast pain, gynecomastia, impotence in males, and menstrual irregularities in females. Eplerenone is more selective for MR receptors and consequently has a lower incidence of sex hormone-related adverse events. However, eplerenone is less potent than spironolactone and, due to an increased risk of hyperkalemia, is contraindicated in diabetic hypertensive patients with microalbuminuria and various degrees of renal impairment. Importantly, treatment with MRAs is associated with a reactive elevation of circulating aldosterone levels, which is postulated to potentially limit efficacy by activating central mineralocorticoid receptors and increasing sympathetic neural drive in the heart failure setting.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Moreover, substantial evidence exists suggesting a pathological role of aldosterone via non-MR-mediated pathways.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Therefore, therapeutic agents that inhibit the production of aldosterone may confer additional benefits over MRAs.</div><div class="NLM_p last">Early studies with FAD286, an aldosterone synthase inhibitor (ASI), suggested that pharmacological inhibition of CYP11B2 might indeed be clinically useful. Chronic administration of FAD286 in rat models showed positive effects on inflammatory markers, fibrosis, and progression of heart failure.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Later studies with LCI699<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> provided additional support for the development of ASIs. Treatment of double-transgenic rats prevented the development of cardiac and renal functional abnormalities and prolonged survival, independent of blood pressure.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> LCI699 dose-dependently lowered aldosterone in healthy males<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and lowered blood pressure in patients with primary hyperaldosteronism,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> essential hypertension,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and resistant-hypertension.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> LCI699 was also found to blunt cortisol secretion in response to adrenocorticotropic hormone (ACTH) stimulation,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> a finding that is most likely related to potent inhibition of CYP11B1 by LCI699 (human rCYP11B2 IC<sub>50</sub> = 0.7 nM, rCYP11B1 IC<sub>50</sub> = 2.5 nM).<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> Although this finding led to cessation of further exploration of the relationship between aldosterone lowering, electrolytes modulation and blood pressure regulation with LCI699, it created an opportunity to address an unmet medical need in Cushing’s disease. LCI699 was shown to normalize urinary free cortisol in a 10-week proof-of-concept study in 12 patients.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The results from this study may spur further exploration of CYP11B1 selective inhibitors.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> However, antihypertensive proof-of-concept with a CYP11B2-selective ASI is still needed,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and much effort has been devoted to identifying such compounds.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Herein, we describe the discovery, pharmacokinetics, and pharmacodynamics data in preclinical species and human subjects of the cortisol-sparing ASI <i>N</i>-[5-(6-chloro-3-cyano-1-methyl-1<i>H</i>-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide (<b>8</b>).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48180" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48180" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The lead compound identified from the Novartis archive was pyridinyl indole <b>1</b>, which had been previously described in 1969 as useful in the treatment of hyperaldosteronism by Geigy Chemical Corporation.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> As shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, despite its low molecular weight, <b>1</b> showed excellent inhibition of aldosterone secretion in an H295R cellular assay<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (IC<sub>50</sub> = 21 nM) and potent inhibition of recombinant CYP11B2<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (IC<sub>50</sub> = 3 nM). Most importantly, the selectivity over CYP11B1 was an order of magnitude superior to that of LCI699 (<i>S</i> = 27 vs 3), which led us to optimize <b>1</b>. One area of focus was the unacceptable level of aromatase (CYP19) inhibition, namely 94% at 10 μM and 59% at 1 μM. Capping the indole hydrogen with methyl, as in <b>2</b>, did not impact aromatase inhibition but had a positive impact on biochemical and cellular potency, as well as selectivity over CYP11B1. We quickly identified that nitrile substitution at the 3-position of the indole, such as in <b>3</b>, gave further improvement in selectivity over both CYP11B1 and aromatase, while also improving stability in rat liver microsomes (LM), but at the expense of on-target potency. Further substitution of the indole at the 6-position with chlorine, as in <b>4</b>, regained potency and dramatically improved stability in human liver microsomes. While <b>4</b> had an attractive combination of potency, CYP selectivity and in vitro metabolic stability, more extensive profiling revealed potent inhibition of monoamine oxidase A (MAO-A), with an IC<sub>50</sub> = 0.21 μM. MAO-A regulates neurotransmitter levels by oxidation of biogenic amines and, like CYP11B2, is expressed in mitochondrial membranes. Intestinal MAO-A inhibition can lead to hypertensive crisis, when foods containing tyramine are consumed (so-called “cheese reaction”)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a>, or hyperserotonemia, if foods containing tryptophan are consumed.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> We found that introduction of polar groups at the 5-position of the pyridine ring effectively eliminated MAO-A inhibition. A sulfamate group, as in <b>5</b>, not only removed inhibition of MAO-A (IC<sub>50</sub> > 10 μM) but also increased selectivity over CYP11B1 and aromatase. However, <b>5</b> showed inadequate in vitro metabolic stability. We surmised that a sulfonamide might afford improved stability. Although sulfonamide <b>6</b>, the matched pair of <b>5</b>, was a weak ASI, adding the chlorine back to the indole ring afforded <b>7</b>, which exhibited improved potency against CY11B2, excellent microsomal stability, and was also devoid of aromatase and MAO-A activity. However, <b>7</b> possessed only moderate selectivity over CYP11B1 (<i>S</i> = 43). Further gains in potency and selectivity were achieved with <b>8</b>, albeit at the expense of selectivity over aromatase. Nevertheless, aromatase inhibition by <b>8</b> (IC<sub>50</sub> = 3.4 μM) was still nearly 1000-fold weaker than CYP11B2.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> We also found that the indole core could be replaced with a 7-aza-, but not 5-azabenzimidazole core. Compound <b>10</b> showed comparable cellular potency and selectivity over CYP11B1 as <b>8</b>, albeit with improved selectivity over aromatase, despite lacking the nitrile at the 3-position of the azaindole ring.</div><div class="NLM_p">Although much of the early literature around ligand efficiency metrics was being published at the time these studies were conducted and did not impact our decisions, it is interesting to consider a retrospective analysis (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). As optimization proceeded from <b>1</b> to <b>8</b>, LEI gradually decreased as functionalities were appended to dial out off-target activities (0.53 to 0.32), but LipE remained remarkably constant (5.4 to 5.7).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Optimization of Potency, Selectivity, and Microsomal Stability of Lead Compound <b>1</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0008.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">LM <i>t</i><sub>1/2</sub> (min)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center">Aldo<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">hB2<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>S</i><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">CYP11B2 LEI<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">CYP11B2 LipE<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">CYP19%i at 10 μM</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="char" char=".">0.53</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">38</td><td class="colsep0 rowsep0" align="char" char=".">0.52</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">0.44</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">0.47</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">259</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>5</b></td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">103</td><td class="colsep0 rowsep0" align="char" char=".">0.35</td><td class="colsep0 rowsep0" align="char" char=".">6.8</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">380</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7</b></td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">176</td><td class="colsep0 rowsep0" align="char" char="."> >400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="char" char=".">82<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>9</b></td><td class="colsep0 rowsep0" align="char" char=".">169</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">0.37</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">21</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Aldosterone secretion in H295R cells.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Human recombinant CYP11B2.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Ratio of CYP11B1 IC<sub>50</sub> over CYP11B2 IC<sub>50</sub>.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">LEI = −log(IC<sub>50</sub>)/HA.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">LipE = −log(IC<sub>50</sub>) – clog<i>P</i>.</p></div><div class="footnote" id="t1fn6"><sup>f</sup><p class="last">IC<sub>50</sub> = 3.4 μM.</p></div></div></div><div class="NLM_p">Equilibrium solubility and pharmacokinetic data for <b>8</b> and <b>10</b> are summarized in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. The 7-azabenzimidazole afforded much improved solubility over the indole core, however, <b>10</b> suffered from high clearance and very short half-life. Despite its low equilibrium solubility, <b>8</b> showed good oral exposure and excellent oral bioavailability, which, combined with its cellular potency and favorable selectivity profile, prompted us to select this compound for further evaluation.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Equilibrium Solubility and Rat Pharmacokinetics of <b>8</b> and <b>10</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="4" align="center">in vivo SD rat PK<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> - dose (mg/kg): 3 (po), 1 (iv)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center" char=".">equilibrium solubility (mM) in buffer pH 6.8</th><th class="colsep0 rowsep0" align="center">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub></th><th class="colsep0 rowsep0" align="center">AUC(0–24 h) (nM·h) po</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="char" char="."> <0.005</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">5785</td><td class="colsep0 rowsep0" align="char" char=".">84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">0.45</td><td class="colsep0 rowsep0" align="char" char=".">68</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">750<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Dosing vehicle for <b>8</b>: NMP (10%), PEG400 (30%), cremophor-EL (10%), ETPGS (5%), and <b>10</b>: NMP (5%), PEG 300 (10%), Cremophor-EL (5%), WFI.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">po dose: 1 mg/kg.</p></div></div></div><div class="NLM_p">Up to this point, we had relied on a continuous angiotensin II infusion Sprague–Dawley (SD) rat model<a onclick="showRef(event, 'cit10c'); return false;" href="javascript:void(0);" class="ref cit10c">(10c)</a> to evaluate PK/PD relationships, a model successfully used to support the discovery of LCI699<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> as well as profile follow-up candidates in vivo.<a onclick="showRef(event, 'cit17a'); return false;" href="javascript:void(0);" class="ref cit17a">(17a)</a> However, profiling of <b>1</b> and subsequent analogs in rat recombinant CYP11B2 and CYP11B1<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> revealed a profound disconnect between inhibition of human and rat enzymes (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Indeed plotting rat CYP11B2 IC<sub>50</sub> against human CYP11B1/CYP11B2 IC<sub>50</sub> ratio for 786 internal compounds possessing a human CYP11B2 IC<sub>50</sub> < 20 nM shows a positive correlation between increased human selectivity and loss of potency against rat CYP11B2 (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Potency of Compounds <b>1</b>, <b>3</b>–<b>5</b>, <b>7</b>, <b>8</b>, and <b>10</b> against Human, Rat, and Monkey CYP11B2 and Comparison of Selectivity Ratio for Human versus Monkey</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="3" align="center">CYP11B2 IC<sub>50</sub> (μM)</th><th class="rowsep1 colsep0" colspan="2" align="center"><i>S</i><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center">human<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">rat<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">monkey<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">monkey</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="char" char=".">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">10.9</td><td class="colsep0 rowsep0" align="char" char=".">0.009</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">396</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>5</b></td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">103</td><td class="colsep0 rowsep0" align="char" char=".">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7</b></td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">53.1</td><td class="colsep0 rowsep0" align="char" char=".">0.013</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">636</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">27.4</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">640</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">99</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Recombinant enzyme.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Adrenal homogenate.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Ratio of CYP11B1 IC<sub>50</sub> over CYP11B2 IC<sub>50</sub>.</p></div></div></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Rat CYP11B2 IC<sub>50</sub> plotted against human CYP11B1/CYP11B2 IC<sub>50</sub> ratio for 786 compounds with human CYP11B2 IC<sub>50</sub> < 20 nM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Fortunately, a survey of aldosterone secretion from adrenal homogenates of various mammalian species revealed that the activity of human selective ASIs could be assessed in cynomolgus monkeys (<i>Macaca fascicularis</i>). As shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, inhibition of human recombinant CYP11B2 was comparable to inhibition of aldosterone secretion in monkey adrenal homogenates. Selectivity for CYP11B2 over CYP11B1 was also observed in both species. Based on these data, a model was developed using conscious, chair-trained chronically cannulated male cynomolgus monkeys.<a onclick="showRef(event, 'ref12 ref28'); return false;" href="javascript:void(0);" class="ref ref12 ref28">(12, 27)</a> Plasma aldosterone (PAC) and plasma cortisol (PCC) concentrations were measured over time in response to an ACTH challenge (3 μg/kg iv) given 3 h after dosing with the test article. Time-course data for <b>8</b> delivered as a methylcellulose suspension at 0.03, 0.1, 0.3, and 3 mg/kg po are shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>. Plasma concentrations of <b>8</b> dose-dependently increased following oral dosing with the compound (top panel). At the 3 lowest doses, the maximum concentration (<i>C</i><sub>max</sub>) was not achieved until 4–6 h after dosing. In contrast, at the highest dose, the <i>C</i><sub>max</sub> was reached rapidly. Plasma concentrations remained high at 8 h and declined by an order of magnitude at 24 h. Group mean baseline PAC ranged from 0.42 to 1.00 nM (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, middle panel). ACTH injection at 3 h rapidly stimulated an increase in PAC to a peak of 2.02 nM (peak ΔPAC = 1.52 nM) in the vehicle group. Responses were compared to those evoked by vehicle administration in the same animals. Oral dosing with <b>8</b> dose-dependently blunted the ACTH-stimulated PAC response. At the highest dose, the peak PAC was 0.14 ± 0.03 nM, which reflects an approximately 95% decrease from the corresponding monkeys’ vehicle-control response. The ED<sub>50</sub> and EC<sub>50</sub> values of <b>8</b> for blunting the 3 h postdosing ACTH-stimulated PAC response (peak ΔPAC) were 61 μg/kg and 8.5 nM, respectively. Consistent with the low plasma concentrations of <b>8</b> at 24 h, ACTH injection 24 h postdosing showed that the blunting of the PAC response had largely dissipated (data not shown).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0012.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Time courses of total compound plasma concentration, PAC and PCC following administration of methylcellulose vehicle (<i>n</i> = 6) and <b>8</b> at 0.03, 0.1, 0.3, and 3 mg/kg (<i>n</i> = 3/dose), and an ACTH challenge 3 h postdosing (error bars excluded for clarity).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Group mean baseline plasma cortisol concentrations (PCCs) were approximately 1000 times higher than the PACs and ranged from 679 to 839 nM (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, bottom panel). There were no significant decreases in the baseline or ACTH-stimulated PCC values after administration of <b>8</b>, as expected from its high (640) in vitro aldosterone/cortisol selectivity in monkey adrenal homogenate (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). However, LCI699 also had no significant effect on the ACTH-stimulated PCC in this model, despite its poor in vitro selectivity (<b>5</b>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> On the basis of the in vivo efficacy, a 30-fold improvement in human in vitro selectivity over LCI699, and a favorable toxicology profile, compound <b>8</b> was progressed to human studies.</div><div class="NLM_p">A double-blind, randomized, placebo-controlled study in healthy male and female volunteers 18–63 years old on a restricted sodium/potassium diet was conducted. Subjects were orally administered bid doses of 30, 60, 100, and 200 mg of <b>8</b> or placebo (the ratio of subjects receiving <b>8</b> to placebo was 5:2). In these cohorts, median <i>T</i><sub>max</sub> was 3–4 h, and plasma exposure, namely AUC<sub>tau</sub> and <i>C</i><sub>max</sub>, both increased under-proportionally between 30 and 200 mg (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). A dose-dependent decrease in plasma aldosterone levels relative to baseline was observed (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, left panel), with a maximum decrease of 70% at 200 mg bid. Consistent with plasma aldosterone measurements, a dose-dependent decrease in aldosterone excretion measured in urine was observed, also with a maximum of 70% at the highest dose (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, right panel). Gratifyingly, and in good accord with the 100-fold selectivity for CYP11B2 over CYP11B1 in vitro, no notable decreases in urinary cortisol (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, left panel) or increases in urinary 11-deoxycortisol (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, right panel) were observed at any dose. Plasma cortisol, 11-deoxycortisol, and ACTH levels were also not affected (data not shown). These data suggest that <b>8</b> is a potent and selective inhibitor of aldosterone synthase in humans.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Parameters in Healthy Volunteers Upon bid Dosing of <b>8</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">dose</th><th class="colsep0 rowsep0" align="center" char=".">N</th><th class="colsep0 rowsep0" align="center" char=".">median <i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>tau</sub> (ng*h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>tau</sub>/dose (ng*h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub>/dose (ng/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">768</td><td class="colsep0 rowsep0" align="char" char=".">117</td><td class="colsep0 rowsep0" align="char" char=".">25.6</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">1030</td><td class="colsep0 rowsep0" align="char" char=".">173</td><td class="colsep0 rowsep0" align="char" char=".">17.1</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">1270</td><td class="colsep0 rowsep0" align="char" char=".">173</td><td class="colsep0 rowsep0" align="char" char=".">12.7</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">200</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">2180</td><td class="colsep0 rowsep0" align="char" char=".">306</td><td class="colsep0 rowsep0" align="char" char=".">10.9</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td></tr></tbody></table></div></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0001.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Plasma aldosterone AUC(0–24 h) (left panel) and amount of aldosterone excreted in urine over 24 h (right panel), expressed as mean placebo-adjusted percent of baseline, following 30, 60, 100, and 200 mg bid dosing of <b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0002.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Amount of cortisol (left panel) and 11-deoxycortisol (right panel) excreted in urine over 24 h, expressed as mean placebo-adjusted percent of baseline, following 30, 60, 100, and 200 mg bid dosing of <b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24431" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24431" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Various methodologies were used to synthesize 3-pyridyl indoles <b>1</b>–<b>10</b>. A classic Fischer indole synthesis was employed to prepare <b>1</b>, which was converted into <b>2</b> using standard conditions (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). 3-Cyanoindoles paired with unsubstituted pyridines were accessed from a Madelung reaction as described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The product of the Madelung reaction, <b>14</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(28)</a> was methylated to give <b>3</b>, which could be chlorinated with <i>N</i>-chlorosuccinimide to give <b>4</b>. For more complex pyridines, we relied on the Suzuki reaction as shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Either <i>N</i>-methyl or <i>N</i>-Boc-indol-2-yl boronic acid was used to couple with 5-substituted 3-bromopyridines using anhydrous s-Phos/Pd<sub>2</sub>dba<sub>3</sub> conditions, with the exception of <b>22</b>, for which Pd(PPh<sub>3</sub>)<sub>4</sub> was used. One-pot electrophilic substitution of indole <b>19</b>, <b>21</b>, <b>22</b>, and <b>25</b> with chlorosulfonyl isocyanate, followed by treatment with DMF was used as a mild method to introduce the nitrile group at the 3-position of the indole ring.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(29)</a> Also of note is the use of mild heating and silica gel under vacuum to cleave Boc groups in compounds <b>23</b> and <b>27</b>. 5-Azaindole <b>34</b> was prepared using a Sonogashira/<i>t</i>BuOK-mediated electrophilic cyclization sequence and was then converted into indole <b>9</b> using standard procedures (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). As for 7-azaindole <b>10</b>, we reverted back to using Suzuki couplings, given the commercial availability of precursor <b>37</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of ASIs <b>1</b> and <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Phenylhydrazine hydrochloride (0.95 equiv), ethanol, reflux, 1 h, then catalytic HCl, reflux, 3 h, 63%; (b) NaH (60%, 2.2 equiv), DMF, 0 °C, 30 min, then MeI (1.1 equiv), 1.5 h, then NaH (60%, 1.4 equiv), 16 h, 16%.</p></p></figure><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of ASIs <b>3</b> and <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Nicotinoyl chloride (1.1 equiv), diisopropylethylamine (2.5 equiv), DCM, rt, 16 h, 31%; (b) NaH (60%, 1.0 equiv), DMF, 130 °C, 18 h, 45%; (c) NaH (60%, 3.0 equiv), DMF, 30 min, then MeI (1.5 equiv), rt, 1 h, 65%. (d) <i>N</i>-chlorosuccinimide (2.5 equiv), dichloroethane, reflux, 2 days, 10%.</p></p></figure><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of ASIs <b>5</b>–<b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) K<sub>3</sub>PO<sub>4</sub> (2.0 equiv), s-Phos (0.05 equiv), Pd<sub>2</sub>dba<sub>3</sub> (0.02 equiv), toluene, 85 °C, 45–90 min, 87% (<b>19</b>), 72% (<b>20</b>) [Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05 equiv) in DMF was used for <b>22</b>, 89%]; (b) ethanesulfonyl chloride (3–5 equiv), di-isopropylethylamine (3–4 equiv), DCM, rt, 1–16 h, 98% (<b>21</b>); (c) silica gel, 60–65 °C under high vacuum, 2–48 h, 73% (2 steps, <b>24</b>); (d) MeI (1.4 equiv), NaH (60%, 1.6 equiv), DMF, 0 °C to rt, 1 h, quant. (<b>25</b>); (e) chlorosulfonyl isocyanate (3–5 equiv), DCM, or acetonitrile, rt, 10–45 min, then DMF, 10–120 min, 19% (<b>5</b>); (f) aqueous NaOH, methanol, rt, 1 h, 51% (2 steps, <b>6</b>), 53% (4 steps, <b>7</b>); (g) ethanesulfonamide (2 equiv), Ti(O<i>i</i>Pr)<sub>4</sub> (1.5 equiv), toluene, reflux, 16 h then NaBH<sub>4</sub> (2 equiv), DCM, MeOH, 0 °C, 30 min, 37% (2 steps, <b>8</b>).</p></p></figure><figure id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of ASI <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Trimethylsilylacetylene (3.0 equiv), CuI (0.05 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (0.05 equiv), TEA, 50 °C, 1 h; (b) K<sub>2</sub>CO<sub>3</sub> (0.25 equiv), MeOH, rt, 30 min, 67% (2 steps); (c) ICl (1.05 equiv), NaOAc (6 equiv), acetic acid, 60 °C, 2 h, 45%; (d) <b>30</b> (1.0 equiv), CuI (0.05 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (0.05 equiv), TEA, 100 °C, 3 h; (e) KO<i>t</i>Bu (3.0 equiv), NMP, rt, 16 h, then MeI (3.0 equiv), 0 °C, 30 min; (f) LAH (2.0 equiv), THF, 0 °C to rt, 45 min, 11% (3 steps); (g) MnO<sub>2</sub> (10 equiv), dioxane, reflux, 16 h; (h) ethanesulfonamide (2 equiv), Ti(O<i>i</i>Pr)<sub>4</sub>, (1.5 equiv), toluene, reflux, 16 h then NaBH<sub>4</sub> (4 equiv), DCM, MeOH, 0 °C, 30 min, 17% (2 steps).</p></p></figure><figure id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of ASI <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) NaH (2.0 equiv), DMF, 0 °C, 20 min then MeI (1.2 equiv), 0 °C to rt, 2 h; (b) <i>t</i>BuLi (2.5 equiv), THF, – 78 °C, 2 h, then B(OMe)<sub>3</sub> (1.5 equiv), – 78 °C to rt, 16 h; (c) 5-bromo-3-pyridine carboxaldehyde (0.66 equiv), 2 M aqueous K<sub>2</sub>CO<sub>3</sub> (2 equiv), PS-Pd(PPh<sub>3</sub>)<sub>4</sub> (0.03 equiv), dioxane, 85 °C, 2 h, 31% (3 steps); (d) ethanesulfonamide (2 equiv), Ti(O<i>i</i>Pr)<sub>4</sub>, (1.5 equiv), toluene, reflux, 16 h then NaBH<sub>4</sub> (4 equiv), DCM, MeOH, 0 °C, 30 min, 20%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last"><i>N</i>-[5-(6-chloro-3-cyano-1-methyl-1<i>H</i>-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide (<b>8</b>) is an orally available CYP11B2 inhibitor with 100-fold selectivity over CYP11B1 that reduces plasma and urinary aldosterone in healthy volunteers. The lack of concomitant effect on cortisol, 11-deoxycortisol, or ACTH in humans effectively validates the selectivity for CYP11B2 over CYP11B1 observed in biochemical assays using recombinant proteins.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimentals</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87136" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87136" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Pharmacology Studies</h3><div class="NLM_p">Measurement of cellular aldosterone synthase inhibition,<a onclick="showRef(event, 'cit17a'); return false;" href="javascript:void(0);" class="ref cit17a">(17a)</a> aromatase inhibition,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and recombinant human CYP11B1 and human and rat CY11B2 inhibition<a onclick="showRef(event, 'ref22 ref12 cit17a'); return false;" href="javascript:void(0);" class="ref ref22 ref12 cit17a">(22, 12, 17a)</a> were conducted as previously described. The monkey in vitro assays were conducted similarly, using adrenal homogenates and 11-DOC as a substrate.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The microsomal stability assay was previously described.<a onclick="showRef(event, 'cit17a'); return false;" href="javascript:void(0);" class="ref cit17a">(17a)</a></div><div class="NLM_p last">The study protocols for the monkey model have been described.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Briefly, 30 min before the start of the experiment, a Huber needle was inserted transdermally into the vascular access port for the collection of blood samples and injection of ACTH. Blood samples (0.3 mL in 15 U/mL heparin) for baseline pharmacokinetic and pharmacodynamic assessments were collected at 0.5 h, 0.25 h, and immediately before dosing. Compound <b>8</b> or vehicle was administered followed 3 h later by ACTH(1–24) (Cortrosyn; Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, CA, U.S.A.) 3000 ng/kg iv in 0.1 mL/kg (over ∼2 min). Blood samples were collected at 0.125, 0.25, 0.5, 0.75, and 1 h after ACTH injection to assess the time course of plasma aldosterone and cortisol stimulation. Further blood samples were collected up to 8 h and at 23.5 and 24 h after <b>8</b>/vehicle administration. Plasma aldosterone and cortisol were determined by radioimmunoassay.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Plasma concentration of <b>8</b> was measured by a liquid chromatography separation coupled with tandem mass spectrometric detection (LC/MS/MS) method (LLOQ 0.26 nmol/L). Samples with compound <b>8</b> concentrations below the LLOQ were treated as zero.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Rat Pharmacokinetic Studies</h3><div class="NLM_p last">Male Sprague–Dawley rats (200–300 g) (Harlan Laboratories Inc., Indianapolis, IN, U.S.A.) were used in the experiments. All animal experiments were performed in accordance with IACUC protocol. Two rats received 0.3 mg/1 mL/kg (free base equivalents) by slow intravenous injection via the jugular vein, and three rats received 1 mg/5 mL/kg or 3 mg/5 mL/kg in solution via oral gavage. Approximately 0.2 mL of venous whole blood was collected from the jugular vein catheter of each animal at 5 min (iv dose only) and 0.25, 0.5, 1, 2, 4, 6, and 8 h postdose and transferred to a EDTA tube. The blood was centrifuged at 3000 rpm, and the plasma was transferred to a polypropylene tube, capped, and stored frozen (−20 °C) for parent compound analysis. Protein precipitation was employed for sample preparation. A 25 μL aliquot of sample was subjected to protein precipitation using 150 μL of acetonitrile containing 100 ng/mL of internal standard (Glyburide). After vortex and centrifugation for 5 min at 4000 rpm, the supernatant (125 μL) was transferred to a 1 mL 96-well plate, followed by the addition of 50 μL of water. The analysis was conducted by using HPLC separation coupled with mass spectrometric detection. All pharmacokinetic (PK) parameters were derived from concentration–time data by noncompartmental analyses. All pharmacokinetic parameters were calculated with the computer program WinNonlin (Enterprise, version 5.2) purchased from Pharsight Corporation (St. Louis, MO, U.S.A.).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Chemical Methods</h3><div class="NLM_p">Starting materials, reagents, and solvents were obtained from commercial sources and used as received. THF and diethyl ether were anhydrous grade. Progress of the reactions was monitored by thin-layer chromatography (TLC) analysis (Merck, 0.2 mm silica gel 60 F254 on glass plates) or by analytical LC-MS using an Agilent 1100 series with UV detection at 214 and 254 nm and an electrospray mode (ESI) coupled with a Waters ZQ single quad mass detector. Purification of intermediates and final products was carried out on normal phase using an ISCO CombiFlash system or an Analogix Intelliflash 280 or a Biotage SP1 system and prepacked SiO<sub>2</sub> cartridges eluted with optimized gradients of either heptane–ethyl acetate mixture or dichloromethane–methanol as described. Preparative high-pressure liquid chromatography (HPLC) was performed on Waters or Gilson instruments. Systems were run with either a 5–95% or 10–90% acetonitrile/water gradient with either a 0.1% TFA or 0.1% NH<sub>4</sub>OH modifier. All target compounds had purity of >95% as established by analytical HPLC. NMR spectra were recorded on a Bruker AV400 (Avance 400 MHz) instrument. Chemical shifts (δ) are reported in parts per million (ppm) relative to deuterated solvent as the internal standard (CDCl<sub>3</sub> 7.26 ppm, DMSO-<i>d</i><sub>6</sub> 2.50 ppm, CD<sub>3</sub>OD 3.31), and coupling constants (<i>J</i>) are in hertz (Hz). Peak multiplicities are expressed as follows: singlet (s), doublet (d), doublet of doublets (dd), triplet (t), quartet (q), multiplet (m), and broad singlet (br s).</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 3-Methyl-2-pyridin-3-yl-1H-indole (<b>1</b>)</h4><div class="NLM_p last">A flask was charged with 3-propionylpyridine (1.004 g, 7.279 mmol), phenylhydrazine hydrochloride (1.010 g, 6.915 mmol), and ethanol (15 mL). The mixture was heated to reflux for 1 h and cooled to room temperature. To a portion of the reaction mixture (2.5 mL) was added HCl (4 M in dioxane, 1 mL, 4 mmol), and the mixture was heated to reflux. After 3 h, the mixture was concentrated in vacuo. The solid was dissolved in the minimum amount of boiling methanol (17 mL) and allowed to cool slowly to room temperature. A solid precipitated, and after cooling to 0 °C for 30 min, the solid was filtered off, washed with portions of cold methanol and dried under high vacuum to give <b>1</b> as the hydrochloride salt (0.177 g, 0.723 mmol, 63%) as yellow needles. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm (HCl salt) 2.56 (s, 3 H), 7.09–7.13 (m, 1 H), 7.23–7.26 (m, 1 H), 7.43 (d, <i>J</i> = 8.1 Hz, 1 H), 7.63 (d, <i>J</i> = 8.1 Hz, 1 H), 8.14–8.18 (m, 1 H), 8.74 (d, <i>J</i> = 5.8 Hz, 1 H), 8.83–8.85 (m, 1 H), 9.08 (s, 1 H).</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 1,3-Dimethyl-2-(pyridin-3-yl)-1H-indole (<b>2</b>)</h4><div class="NLM_p last">To a suspension of <b>1</b> hydrochloride (205 mg, 0.838 mmol) in DMF (10 mL) at 0 °C was added NaH (60% in mineral oil, 73 mg, 1.84 mmol), and the mixture was stirred at 0 °C for 30 min. MeI (131 mg, 0.92 mmol) was added, and after 1.5 h, another portion of NaH (60% in mineral oil, 50 mg, 1.22 mmol) was added. The mixture was stirred overnight, whereupon it was quenched with methanol (2 mL). The mixture was purified by reverse phase HPLC to give <b>2</b> (30 mg, 0.134 mmol, 16%) as a beige solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.23 (s, 3 H), 3.62 (s, 3 H), 7.06–7.12 (m, 1 H), 7.22 (td, <i>J</i> = 7.6, 1.1 Hz, 1 H), 7.48 (d, <i>J</i> = 8.3 Hz, 1 H), 7.55–7.61 (m, 2 H), 7.93 (dt, <i>J</i> = 7.9, 2.0 Hz, 1 H), 8.66 (dd, <i>J</i> = 4.8, 1.5 Hz, 1 H), 8.69 (dd, <i>J</i> = 2.3, 0.8 Hz, 1 H). HRMS: (ESI) <i>m</i>/<i>z</i> 223.1236 [(M + H)<sup>+</sup> Calcd for C<sub>15</sub>H<sub>15</sub>N<sub>2</sub>: 223.1230].</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>N</i>-(2-Cyanomethyl-phenyl)-nicotinamide (<b>13</b>)</h4><div class="NLM_p last">In dry dichloromethane (200 mL), 2-aminophenylacetonitrile (5.0 g, 37.1 mmol) and nicotinoyl chloride (7.5 g, 40.8 mmol) were added, and diisopropylethylamine (12.1 g, 92.7 mmol) was added while cooling the mixture with a cold water bath. The mixture was stirred overnight at room temperature, whereupon it was washed twice with saturated aqueous sodium bicarbonate. The combined aqueous layer was back-extracted with ethyl acetate. The combined organic phase was dried over MgSO<sub>4</sub> and concentrated in vacuo to give a residue, which was purified by silica gel flash chromatography (dichloromethane-methanol, 1:0 to 19:1) to give <b>13</b> (2.70 g, 11.37 mmol, 31%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 4.02 (s, 2 H), 7.32–7.37 (m, 1 H), 7.39–7.44 (m, 2 H), 7.50 (d, <i>J</i> = 7.1 Hz, 1 H), 7.59 (dd, <i>J</i> = 8.1, 4.8 Hz, 1 H), 8.30–8.33 (m, 1 H), 8.78 (dd, <i>J</i> = 4.8, 1.5 Hz, 1 H), 9.14 (d, <i>J</i> = 1.8 Hz, 1 H), 10.36 (s, 1 H).</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 2-Pyridin-3-yl-1H-indole-3-carbonitrile (<b>14</b>)</h4><div class="NLM_p last">In DMF (3 mL)<b>13</b> (0.095 g, 0.384 mmol) was dissolved. NaH (60%, 0.015 g, 0.384 mmol) was added, and the mixture was heated to 130 °C. After 18 h, the mixture was cooled down, diluted with ethyl acetate, and washed with 1 M aqueous sodium hydroxide. The combined washings were back-extracted with ethyl acetate. The combined organic phase was dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel flash chromatography (dichloromethane-methanol, 99:1 to 19:1) to give <b>14</b> (0.038 mg, 0.17 mmol, 45%) as a brown solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 7.29–7.32 (m, 1 H), 7.34–7.39 (m, 1 H), 7.57 (d, <i>J</i> = 8.0 Hz, 1 H), 7.66 (dd, <i>J</i> = 8.0, 4.9 Hz, 1 H), 7.70 (d, <i>J</i> = 7.8 Hz, 1 H), 8.39–8.44 (m, 1 H), 8.68 (dd, <i>J</i> = 4.8, 1.5 Hz, 1 H), 9.15 (d, <i>J</i> = 1.5 Hz, 1 H).</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 1-Methyl-2-pyridin-3-yl-1H-indole-3-carbonitrile (<b>3</b>)</h4><div class="NLM_p last">To <b>14</b> (1.0 g, 4.56 mmol) in DMF (17 mL) was added 60% sodium hydride in mineral oil (547 mg, 13.68 mmol), and the suspension was stirred for 30 min. Iodomethane (971 mg, 6.84 mmol) was then added to the reaction mixture, which was stirred at ambient temperature for 1 h. Aqueous NaHCO<sub>3</sub> (3 mL) was added, and the mixture was concentrated in vacuo. The residue was purified by silica gel flash chromatography (dichloromethane-methanol gradient) to give <b>3</b> (0.70 g, 3.00 mmol, 65%) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 3.83 (s, 3 H), 7.35 (t, <i>J</i> = 7.5 Hz, 1 H), 7.40–7.46 (m, 1 H), 7.64 (d, <i>J</i> = 8.3 Hz, 1 H), 7.67–7.74 (m, 2 H), 8.16 (dt, <i>J</i> = 8.0, 2.0, 1.9 Hz, 1 H), 8.76 (dd, <i>J</i> = 5.1, 1.5 Hz, 1 H), 8.86 (d, <i>J</i> = 1.5 Hz, 1 H). HRMS (ESI) <i>m</i>/<i>z</i> 234.1029 [(M + H)<sup>+</sup> Calcd for C<sub>15</sub>H<sub>12</sub>N<sub>3</sub>: 234.1031].</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 6-Chloro-2-pyridin-3-yl-1-methyl-1H-indole-3-carbonitrile (<b>4</b>)</h4><div class="NLM_p last"><i>N</i>-chlorosuccinimide (0.086 g, 0.644 mmol) was added to <b>3</b> (150 mg, 0.644 mmol) in dichloroethane (10 mL), and the mixture was refluxed for 2 days. Three additional portions of <i>N</i>-chlorosuccinimide (0.043 g, 0.322 mmol) were added at 1 h intervals, whereupon the volatiles were removed in vacuo. Purification by reverse phase HPLC afforded <b>4</b> (18 mg, 0.067 mmol, 10%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 3.79 (s, 3 H), 7.37 (dd, <i>J</i> = 8.5, 1.9 Hz, 1 H), 7.69 (dd, <i>J</i> = 7.5, 4.4 Hz, 1 H), 7.73 (d, <i>J</i> = 8.6 Hz, 1 H), 7.98 (d, <i>J</i> = 1.5 Hz, 1 H), 8.17 (dt, <i>J</i> = 8.1, 2.0, 1.8 Hz, 1 H), 8.82 (dd, <i>J</i> = 4.9, 1.6 Hz, 1 H), 8.90 (d, <i>J</i> = 1.5 Hz, 1 H). HRMS (ESI) <i>m</i>/<i>z</i> 268.0653 [(M + H)<sup>+</sup> Calcd for C<sub>15</sub>H<sub>11</sub>ClN<sub>3</sub>: 268.0642].</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Dimethyl-sulfamic Acid 5-Bromo-pyridin-3-yl Ester (<b>15</b>)</h4><div class="NLM_p last">A flask was charged with 5-bromo-pyridin-3-ol (0.200 g, 1.126 mmol), potassium phosphate (0.631 g, 2.884 mmol), and acetone (5 mL) and cooled to 0 °C. Dimethylsulfamoyl chloride (0.261 g, 1.802 mmol) was then added dropwise, and the cooling bath was removed. After 2 h, the mixture was diluted with acetone and filtered, and the filtrate was concentrated in vacuo. The residue was dissolved in THF (30 mL), and polymer-supported trisamine (3.85 mmol/g, 0.7 g, 2.7 mmol) was added. After 1 h, the mixture was filtered. Concentration in vacuo gave a residue which was purified by silica gel flash chromatography (heptane-ethyl acetate, 9:1 to 4:1) to give <b>15</b> (0.228 g, 0.811 mmol, 72%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 3.05 (s, 3 H), 7.86 (m, 1 H), 8.50 (d, <i>J</i> = 2.3 Hz, 1 H), 8.62 (d, <i>J</i> = 1.9 Hz, 1 H).</div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Dimethyl-sulfamic Acid 5-(1-Methyl-1H-indol-2-yl)-pyridin-3-yl Ester (<b>19</b>)</h4><div class="NLM_p last">A flask was charged with <b>15</b> (0.225 g, 0.76 mmol), <i>N</i>-methyl-indole boronic acid (0.200 g, 1.14 mmol), s-Phos (0.016 g, 0.038 mmol), finely crushed potassium phosphate (0.323 g, 1.52 mmol), and toluene (5 mL). After sparging with nitrogen for 15 min, Pd<sub>2</sub>dba<sub>3</sub> (0.014 g, 0.015 mmol) was added, the flask was flushed with nitrogen, and the mixture was heated to 85 °C. After 45 min, the mixture was allowed to cool to rt, diluted with ethyl acetate, and filtered through a plug of silica gel (elution with ethyl acetate). The volatiles were removed in vacuo, and the residue was purified by silica gel flash chromatography (heptane-ethyl acetate, 3:7 to 0:1) to give to give <b>19</b> (220 mg, 0.664 mmol, 87%); MS (ESI) <i>m</i>/<i>z</i> 332.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Dimethyl-sulfamic Acid 5-(3-Cyano-1-methyl-1H-indol-2-yl)-pyridin-3-yl Ester (<b>5</b>)</h4><div class="NLM_p last">A flask was charged with <b>19</b> (220 mg, 0.664 mmol) and dichloromethane (10 mL). Chlorosulfonyl isocyanate (0.282 g, 1.99 mmol) was added, and the reaction was stirred for 45 min, whereupon DMF (3 mL) was added. After another 2 h, the reaction was concentrated in vacuo, and the residue was purified by reverse phase HPLC to give <b>5</b> (46 mg, 0.129 mmol, 19%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.99 (s, 6 H), 3.82 (s, 3 H), 7.35–7.40 (m, 1 H), 7.43–7.48 (m, 1 H), 7.74 (d, <i>J</i> = 7.8 Hz, 1 H), 7.79 (d, <i>J</i> = 8.3 Hz, 1 H), 8.24 (dd, <i>J</i> = 2.5, 1.8 Hz, 1 H), 8.85 (d, <i>J</i> = 2.5 Hz, 1 H), 8.91 (d, <i>J</i> = 1.8 Hz, 1 H). HRMS (ESI) <i>m</i>/<i>z</i> 357.1018 [(M + H)<sup>+</sup> Calcd for C<sub>17</sub>H<sub>17</sub>N<sub>4</sub>O<sub>3</sub>S: 357.1021].</div></div><div id="sec5_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-(5-Amino-pyridin-3-yl)-1-methyl-1H-indole (<b>20</b>)</h4><div class="NLM_p last">A flask was charged with 3-amino-5-bromopyridine (4.05 g, 22.71 mmol), <i>N</i>-methyl-indole-2-boronic acid (5.27 g, 29.52 mmol), s-Phos (0.625 g, 1.476 mmol), finely crushed potassium phosphate (9.74 g, 45.41 mmol), and toluene (75 mL). After sparging with nitrogen for 60 min, Pd<sub>2</sub>dba<sub>3</sub> (0.420 g, 0.454 mmol) was added, the flask was flushed with nitrogen, and the flask was lowered into a preheated oil bath at 85 °C. After 1.5 h, the mixture was allowed to cool to rt, diluted with ethyl acetate, and filtered through a plug of silica gel (elution with ethyl acetate). The residue was purified by silica gel flash chromatography (heptane-ethyl acetate, 3:7 to 0:1) to give <b>20</b> (3.64 g, 16.30 mmol, 72%) as an off-white powder. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 3.74 (s, 3 H), 5.49 (s, 2H), 6.56 (s, 1H), 7.05–7.09 (m, 1H), 7.09–7.10 (m, 1H), 7.17–7.21 (m, 1H), 7.49 (d, <i>J</i> = 7.6 Hz, 1 H), 7.57 (d, <i>J</i> = 7.6 Hz, 1 H), 7.94 (d, <i>J</i> = 2.0 Hz, 1 H), 7.99 (d, <i>J</i> = 2.5 Hz, 1 H). MS (ESI) <i>m</i>/<i>z</i> 224 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Ethanesulfonic Acid [5-(1-Methyl-1H-indol-2-yl)-pyridin-3-yl]-<i>N</i>-ethanesulfonyl-amide (<b>21</b>)</h4><div class="NLM_p last">To a solution of <b>20</b> (223 mg, 1.0 mmol) in dichloromethane (20 mL) were added ethanesulfonyl chloride (386 mg, 3.0 mmol) and diisopropylethylamine (517 mg, 4.0 mmol). The mixture was stirred at room temperature for 1 h. Saturated NaHCO<sub>3</sub> in water (0.5 mL) and silica gel (10 g) were added, and the mixture was concentrated in vacuo. The residue was purified by silica gel chromatography (heptane-ethyl acetate, 1:0 to 1:9) to give <b>21</b> (400 mg, 0.98 mmol, 98%) as a white solid. MS (ESI) <i>m</i>/<i>z</i> 408.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Ethanesulfonic Acid [5-(3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-yl]-amide (<b>6</b>)</h4><div class="NLM_p last">Chlorosulfonyl isocyanate (0.162 g, 1.15 mmol) was added to <b>21</b> (96 mg, 0.23 mmol) in acetonitrile (10 mL), and the mixture was stirred for 20 min before adding DMF (1 mL). After 10 min, the solvent was removed, and the crude mixture was used with no further purification; MS (ESI) <i>m</i>/<i>z</i> 432.96 (M + H)<sup>+</sup>. The crude mixture in DMF (2 mL), methanol (10 mL), and 5 M NaOH in water (1 mL) was stirred at room temperature for 1 h. The mixture was purified by reverse phase HPLC on Xbridge C18 eluting with a 1:9 to 9:1 acetonitrile–water gradient to give <b>6</b> (40 mg, 0.117 mmol, 51%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.25 (t, <i>J</i> = 7.3 Hz, 3 H), 3.24–3.32 (m, 2 H), 3.80 (s, 3 H), 7.32–7.38 (m, 1 H), 7.43 (td, <i>J</i> = 7.8, 1.1 Hz, 1 H), 7.70 (d, <i>J</i> = 7.8 Hz, 1 H), 7.75 (d, <i>J</i> = 8.3 Hz, 1 H), 7.90 (t, <i>J</i> = 2.3 Hz, 1 H), 8.58–8.62 (m, 2 H), 10.42 (s, 1 H). HRMS (ESI) <i>m</i>/<i>z</i> 341.1078 [(M + H)<sup>+</sup> Calcd for C<sub>17</sub>H<sub>17</sub>N<sub>4</sub>O<sub>2</sub>S: 341.1072].</div></div><div id="sec5_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 3-[Bis[[(1,1-Dimethylethyl)oxy]carbonyl]amino]-5-bromo-pyridine (<b>17</b>)</h4><div class="NLM_p last">To 5-amino-3-bromo-pyridine (1.73 g, 10 mmol) and Boc<sub>2</sub>O (4.8 g, 22 mmol) in acetonitrile (100 mL) at ambient temperature was added DMAP (212 mg, 1 mmol), and the reaction mixture was heated to 60 °C and stirred overnight. The reaction mixture was then cooled to room temperature. The solvent was removed in vacuo, and the residue was purified by silica gel flash chromatography (heptane-ethyl acetate, 1:0 to 7:3) to afford <b>17</b> (3.0 g, 8.04 mmol, 80%) as a white solid. MS (ESI) <i>m</i>/<i>z</i> 374.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-[Bis[[(1,1-Dimethylethyl)oxy]carbonyl]amino]-5-(6-chloro-1-methyl-1H-indol-2-yl)-pyridine (<b>22</b>)</h4><div class="NLM_p last">A flask was charged with <b>17</b> (3.0 g, 8.0 mmol), <i>N</i>-methyl-6-chloroindole-2-boronic acid (2.0 g, 9.65 mmol), finely crushed potassium phosphate (3.4 g, 16.0 mmol), and DMF (40 mL). After sparging with nitrogen for 15 min, Pd(PPh<sub>3</sub>)<sub>4</sub> (465 mg, 0.402 mmol) was added. The flask was flushed with nitrogen, and the mixture was heated to 90 °C and stirred overnight. The mixture was then cooled to room temperature and poured into water (300 mL). The mixture was extracted with EtOAc three times, and the combined organic phase was then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by silica gel flash chromatography (ethyl acetate-heptane, 0:1 to 1:9) to give <b>22</b> (3.3 g, 7.2 mmol, 89%). MS (ESI) <i>m</i>/<i>z</i> 458.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Ethanesulfonic Acid [5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-yl]-amide (<b>7</b>)</h4><div class="NLM_p last">Chlorosulfonyl isocyanate (4.08 g, 28.8 mmol) was added to a solution of <b>22</b> (3.3 g, 7.2 mmol) in acetonitrile (200 mL), and the reaction mixture was stirred for 10 min. DMF (3 mL) was added, and the reaction mixture was stirred for 2 h. To the mixture, 20 g silica gel was added, and the solvent was removed in vacuo. The resulting solid was heated to 65 °C under high vacuum for 2 h. The mixture was cooled to room temperature and then purified by silica gel flash chromatography (dichloromethane-methanol-triethylamine, 83:8:9) to afford 2-(5-amino-pyridin-3-yl)-6-chloro-1-methyl-1H-indole-3-carbonitrile mixed with triethylammonium chloride. The combined fractions were concentrated and taken up in DCM. After washing with water and drying over Na<sub>2</sub>SO<sub>4</sub>, a residue was obtained (1.8 g), which was used with no further purification; MS (ESI) <i>m</i>/<i>z</i> 283.0 (M + H)<sup>+</sup>. A portion (512 mg) was dissolved in DCM (10 mL). Di-isopropylethylamine (0.898 g, 6.88 mmol) and ethanesulfonyl chloride (0.68 g, 5.16 mmol) were added, and the reaction mixture was stirred overnight. Another portion of ethanesulfonyl chloride (0.68 g, 5.16 mmol) was added, and after 2 h, the mixture was concentrated and purified by silica gel flash chromatography (heptane-ethyl acetate 1:1) to give a residue (260 mg), which was used with no further purification. A portion (200 mg) was redissolved in methanol (5 mL). Aqueous 1 M NaOH (4 mL) was added, and the reaction mixture was stirred for 1 h. The pH was adjusted to 5 with 1 M aqueous HCl, and the mixture was extracted with DCM twice. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed in vacuo, and the residue was purified by silica gel flash chromatography (methanol-dichloromethane, 1:19) to give <b>7</b> (115 mg, 0.306 mmol, 53%, 4 steps) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.25 (t, <i>J</i> = 7.3 Hz, 3 H), 3.23–3.33 (m, 2 H), 3.79 (s, 3 H), 7.36 (dd, <i>J</i> = 8.6, 1.8 Hz, 1 H), 7.72 (d, <i>J</i> = 8.6 Hz, 1 H), 7.90 (t, <i>J</i> = 2.3 Hz, 1 H), 7.95 (d, <i>J</i> = 1.5 Hz, 1 H), 8.61 (d, <i>J</i> = 2.3 Hz, 2 H), 10.43 (s, 1 H). HRMS (ESI) <i>m</i>/<i>z</i> 375.0692 [(M + H)<sup>+</sup> Calcd for C<sub>17</sub>H<sub>16</sub>ClN<sub>4</sub>O<sub>2</sub>S: 375.0682].</div></div><div id="sec5_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 5-(6-Chloro-1H-indol-2-yl)-pyridine-3-carbaldehyde (<b>24</b>)</h4><div class="NLM_p last">A flask was charged with <i>N</i>-(<i>tert</i>-butoxycarbonyl)-6-chloro-1H-indol-2-ylboronic acid (10 g, 33.8 mmol), 5-bromonicotinaldehyde (5.25 g, 28.2 mmol), K<sub>3</sub>PO<sub>4</sub> (11.97 g, 56.4 mmol), s-Phos (0.579 g, 1.410 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub> (0.516 g, 0.564 mmol), and the flask was flushed with N<sub>2</sub>. Toluene (200 mL) was added, and the mixture was heated to 90 °C for 1 h. The mixture was cooled to room temperature. Ethyl acetate (250 mL) was added, and the mixture was filtered through a pad of silica gel, which was washed with EtOAc. Silica gel was added to the combined filtrate, which was concentrated in vacuo. The residue was placed under high vacuum at 60 °C for 2 days, and after elution with ethyl acetate, <b>24</b> (5.6 g, 20.7 mmol, 73%) was obtained. MS (ESI) <i>m</i>/<i>z</i> 257.0 and 258.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 6-Chloro-2-(5-formyl-pyridin-3-yl)-1-methyl-1H-indole (<b>25</b>)</h4><div class="NLM_p last">A flask was charged with <b>24</b> (5.6 g, 17.3 mmol), MeI (3.41 g, 24.0 mmol), and DMF (200 mL), and 60% NaH in mineral oil (1.134 g, 28.4 mmol) was added at 0 °C. The mixture was stirred for 1 h. Water (200 mL) was added. The mixture was extracted with EtOAc (2 × 300 mL), and the combined organic phase was washed with water (3 × 100 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (heptane-ethyl acetate, 3:2 to 1:1) to give <b>25</b> (5.2 g, 17.3 mmol, quant.). MS (ESI) <i>m</i>/<i>z</i> 271.0, 272.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide (<b>8</b>)</h4><div class="NLM_p last">A flask was charged with <b>25</b> (3.00 g, 11.1 mmol) and acetonitrile (300 mL), and chlorosulfonyl isocyanate (4.73 g, 33.4 mmol) was added at 0 °C. The mixture was stirred for 10 min. DMF (4.01 g, 54.9 mmol) was added at 0 °C, and the mixture was stirred for another 10 min. Saturated NaHCO<sub>3</sub> (30 mL) was added, and the volatiles were removed in vacuo. The mixture was taken up in ethyl acetate and washed with water. The aqueous phase was extracted with ethyl acetate, and the combined organic phase was washed with water and dried over sodium sulfate. After filtration and concentration, <b>28</b> (2.0 g) was obtained, which was used with no further purification; MS (ESI) <i>m</i>/<i>z</i> 296.0, 297.8 (M + H)<sup>+</sup>. To a solution of <b>28</b> (2.0 g, 6.09 mmol) and ethanesulfonamide (1.33 g, 12.17 mmol) in toluene (250 mL) was added titanium(IV) isopropoxide (2.59 g, 9.13 mmol). The mixture was refluxed overnight, then concentrated in vacuo. The residue was taken up in DCM (150 mL) and MeOH (150 mL), and NaBH<sub>4</sub> (0.461 g, 12.17 mmol) was added at 0 °C. The mixture was stirred at 0 °C for 30 min. Water (50 mL) was added, and the mixture was stirred for 5 min. The suspension was filtered through a pad of Celite. The Celite layer was washed with DCM (3 × 50 mL). The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give a residue was purified by silica gel flash chromatography (ethyl acetate). The resulting fractions containing the product were concentrated and repurified by silica gel flash chromatography (dichloromethane-methanol, 1:0 to 97:3). The concentrated product was redissolved in MeOH (500 mL) at 60 °C and concentrated in vacuo to give <b>8</b> (1.60 g, 4.11 mmol, 37%, 2 steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.20 (t, <i>J</i> = 7.3 Hz, 3 H), 3.06 (q, <i>J</i> = 7.3 Hz, 2 H), 3.78 (s, 3 H), 4.34 (d, J = 6.3 Hz, 2 H), 7.37 (dd, <i>J</i> = 8.6, 1.8 Hz, 1 H), 7.73 (d, <i>J</i> = 8.3 Hz, 1 H), 7.77 (t, <i>J</i> = 6.2 Hz, 1 H), 7.97 (d, <i>J</i> = 1.8 Hz, 1 H), 8.09 (t, <i>J</i> = 2.1 Hz, 1 H), 8.78 (d, <i>J</i> = 1.8 Hz, 1 H), 8.80 (d, <i>J</i> = 1.8 Hz, 1 H). HRMS (ESI) <i>m</i>/<i>z</i> 389.0853 [(M + H)<sup>+</sup> Calcd for C<sub>18</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>2</sub>S: 389.0839].</div></div><div id="sec5_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Methyl 5-Ethynylnicotinate (<b>30</b>)</h4><div class="NLM_p last">To a solution of methyl 5-bromonicotinate (3.0 g, 13.89 mmol) in TEA (50 mL) under N<sub>2</sub> were added ethynyltrimethylsilane (4.09 g, 41.7 mmol), copper iodide (0.132 g, 0.694 mmol), and bis(triphenylphosphine)palladium(II)chloride (0.487 g, 0.694 mmol). The reaction was stirred at 50 °C for 1 h, cooled to room temperature, and filtered to remove solids, which were washed with ethyl acetate. The filtrate was taken and washed with water thrice and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated in vacuo to afford a black solid. The crude was dissolved in MeOH (50 mL), and potassium carbonate (0.480 g, 3.47 mmol) was added. The reaction was stirred for 30 min, filtered, and purified by silica gel flash chromatography (DCM-MeOH, 9:1) to afford <b>30</b> (1.5 g, 9.31 mmol, 67%) as a light yellow solid.</div></div><div id="sec5_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-Chloro-5-iodopyridin-4-amine (<b>32</b>)</h4><div class="NLM_p last">To 2-chloropyridin-4-amine (3.0 g, 23.34 mmol) in acetic acid (60 mL) were added sodium acetate (11.49 g, 140 mmol) and iodine monochloride (3.98 g, 24.50 mmol). The reaction was stirred at 60 °C for 2 h, whereupon it was cooled to room temperature, quenched with 1 M aqueous sodium bisulfite, and extracted with dichloromethane. The organic layer was separated, dried over sodium sulfate, and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (DCM-MeOH, 19:1) to afford <b>32</b> (2.7 g, 10.61 mmol, 45%) and 2-chloro-3,5-diiodopyridin-4-amine (3.0 g, 11.79 mmol, 50%) as white solids; MS (ESI) <i>m</i>/<i>z</i> 255.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (5-(6-Chloro-1-methyl-1H-pyrrolo[3,2-<i>c</i>]pyridin-2-yl)pyridin-3-yl)methanol (<b>35</b>)</h4><div class="NLM_p last">To <b>32</b> (1.0 g, 3.93 mmol) in TEA (50 mL) under N<sub>2</sub> were added <b>30</b> (0.633 g, 3.93 mmol), copper iodide (0.037 g, 0.196 mmol), and bis(triphenylphosphine)palladium(II) chloride (0.138 g, 0.196 mmol). The reaction was stirred at 100 °C for 3 h, cooled to room temperature, and filtered to remove solids, which were washed with ethyl acetate. The filtrate was taken and washed with water thrice and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated in vacuo to afford <b>28</b> (0.95 g) as a brown solid which was dissolved in NMP (15 mL). Potassium <i>t</i>-butoxide (1.11 g, 9.91 mmol) was added. The reaction was stirred for 16 h at room temperature and cooled to 0 °C, and methyl iodide (0.619 mg, 9.91 mmol) was added. The reaction was stirred for 30 min, then quenched with water, and extracted with ethyl acetate twice. The organic layer was dried over sodium sulfate and concentrated in vacuo to afford <b>29</b> (0.78 g) as a brown oil which was dissolved in THF (10 mL). The solution was cooled to 0 °C, and LAH (1 M in THF, 5.17 mL, 5.17 mmol) was added. The reaction was stirred at room temperature for 45 min, then quenched with water (1 mL), then washed with 2 M NaOH solution (2 mL), and extracted with DCM twice. The organic layer was separated, dried over sodium sulfat,e and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (DCM-MeOH, 9:1) to afford <b>35</b> (125 mg, 0.457 mmol, 11%, 3 steps) as a light yellow solid. MS (ESI) <i>m</i>/<i>z</i> 274.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-((5-(6-Chloro-1H-pyrrolo[3,2-<i>c</i>]pyridin-2-yl)pyridin-3-yl)methyl)ethanesulfonamide (<b>9</b>)</h4><div class="NLM_p last">To <b>35</b> (128 mg, 0.468 mmol) in dioxane (5 mL) was added manganese dioxide (0.407 g, 4.68 mmol). The mixture was refluxed for 16 h. The reaction was cooled to room temperature and filtered through Celite. The Celite layer was washed with methanol. The filtrate was concentrated in vacuo to afford <b>36</b> (120 mg) as a yellow solid. A portion (58 mg, 0.213 mmol) was dissolved in toluene (5 mL), and ethanesulfonamide (46 mg, 0.427 mmol) was added. Titanium(IV) isopropoxide (91 mg, 0.320 mmol) was added dropwise, and the reaction mixture was stirred at 120 °C for 16 h. The mixture was concentrated in vacuo, and the residue was then dissolved in DCM-MeOH 1:1 (10 mL) and cooled to 0 °C, and sodium borohydride (32.2 mg, 0.854 mmol) was added. The mixture was stirred at 0 °C for 30 min and then quenched with water (1 mL). After 5 min, DMF (3.5 mL) was added, the solids were filtered off, and the filtrate was purified using Xbridge C18 eluting with a 10 to 100% ACN-water to afford <b>9</b> as a yellow solid (14 mg, 0.038 mmol, 17%, 2 steps). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 1.38 (t, <i>J</i> = 7.5 Hz, 3 H), 3.15 (q, <i>J</i> = 7.3 Hz, 2 H), 3.83 (s, 3 H), 4.44 (s, 2 H), 6.91 (s, 1 H), 7.66 (s, 1 H), 8.14 (t, <i>J</i> = 1.9 Hz, 1 H), 8.67 (s, 1 H), 8.69 (d, <i>J</i> = 2.0 Hz, 1 H), 8.75 (d, <i>J</i> = 2.0 Hz, 1 H). MS (ESI) <i>m</i>/<i>z</i> 365.1 (M + H)<sup>+</sup></div></div><div id="sec5_3_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 5-(6-Chloro-1-methyl-1H-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)nicotinaldehyde (<b>40</b>)</h4><div class="NLM_p last">To a solution of 6-chloro-1H-pyrrolo[2,3-<i>b</i>]pyridine (1.00 g, 6.55 mmol) in DMF (30 mL) at 0 °C was added sodium hydride (60%, 0.524 g, 13.11 mmol), and the mixture was stirred for 20 min at 0 °C. Methyl iodide (0.512 mL, 8.18 mmol) was added at 0 °C, and the mixture was warmed to room temperature and stirred for 2 h. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated in vacuo to afford <b>38</b> (1.01 g) as a brown oil, which was dissolved in THF (60 mL) and cooled to −78 °C. 1.7 M <i>t</i>-BuLi in pentane (9 mL, 15.31 mmol) was added. After 2 h, trimethyl borate (0.954 g, 9.18 mmol) was added. The mixture was allowed to warm to room temperature and stirred for 16 h. The reaction was quenched with water (2 mL) and concentrated in vacuo to afford <b>39</b> (2.1 g) as a brown solid which was taken in the next step with no further purification. To a portion (1.00 g) in dioxane (40 mL) under N<sub>2</sub> were added 5-bromonicotinaldehyde (0.589 g, 3.17 mmol), aqueous 2 M potassium carbonate (4.75 mL, 9.50 mmol), and PS-Pd(PPh<sub>3</sub>)<sub>4</sub> (1.760 g, 0.158 mmol). The reaction was stirred for 2 h at 85 °C, then cooled to room temperature. The solids were filtered off, and the precipitate washed thoroughly with methanol. The filtrate was concentrated in vacuo to give a residue which was purified by silica gel flash chromatography (DCM-MeOH, 9:1) to afford <b>40</b> (280 mg, 1.03 mmol, 31%, 3 steps) as a solid. MS (ESI) <i>m</i>/<i>z</i> 272.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-((5-(6-Chloro-1H-pyrrolo[3,2-<i>c</i>]pyridin-2-yl)pyridin-3-yl)methyl)ethanesulfonamide (<b>10</b>)</h4><div class="NLM_p last">To <b>40</b> (91 mg, 0.335 mmol) in toluene (5 mL) was added ethanesulfonamide (73.1 mg, 0.670 mmol). Titanium(IV) isopropoxide (143 mg, 0.502 mmol) was added, and the reaction mixture was refluxed for 16 h. The mixture was concentrated in vacuo to give a residue which was then dissolved in DCM-MeOH (1:1) (10 mL) and cooled to 0 °C, and sodium borohydride (50.7 mg, 1.34 mmol) was added. The mixture was stirred at 0 °C for 30 min and then quenched with water (1 mL). The resulting residue was diluted with DMF (3.5 mL), and the mixture was filtered. The filtrate was purified using Xbridge C18 eluting with a 10–100% ACN-water to afford <b>10</b> (25 mg, 0.068 mmol, 20%) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 1.38 (t, <i>J</i> = 7.3 Hz, 3 H), 3.15 (q, <i>J</i> = 7.3 Hz, 2 H), 3.89 (s, 3 H), 4.44 (s, 2 H), 6.77 (s, 1 H), 7.19 (d, <i>J</i> = 8.3 Hz, 1 H), 8.03 (d, <i>J</i> = 8.3 Hz, 1 H), 8.15 (d, <i>J</i> = 2.0 Hz 1 H), 8.67 (d, <i>J</i> = 1.8 Hz, 1 H), 8.76 (d, <i>J</i> = 2.0 Hz, 1 H). MS (ESI) <i>m</i>/<i>z</i> 365.2 (M + H)<sup>+</sup>.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="NOTES-d10718e3240-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01545">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58128" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58128" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01545" class="ext-link">10.1021/acs.jmedchem.5b01545</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Compound data (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01545/suppl_file/jm5b01545_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01545/suppl_file/jm5b01545_si_001.csv">jm5b01545_si_001.csv (0.88 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01545" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37628" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37628" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julien P. N. Papillon</span> - <span class="hlFld-Affiliation affiliation">‡Global Discovery Chemistry, ∥Metabolism and Pharmacokinetics, §Translational Medicine, and †Drug Metabolism
and Pharmacokinetics, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b1dbc4ddd8d4df9fc1d0c1d8dddddedff1dfdec7d0c3c5d8c29fd2dedc"><span class="__cf_email__" data-cfemail="7e140b12171b10500e1f0e17121211103e1011081f0c0a170d501d1113">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Changgang Lou</span> - <span class="hlFld-Affiliation affiliation">‡Global Discovery Chemistry, ∥Metabolism and Pharmacokinetics, §Translational Medicine, and †Drug Metabolism
and Pharmacokinetics, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alok K. Singh</span> - <span class="hlFld-Affiliation affiliation">‡Global Discovery Chemistry, ∥Metabolism and Pharmacokinetics, §Translational Medicine, and †Drug Metabolism
and Pharmacokinetics, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher M. Adams</span> - <span class="hlFld-Affiliation affiliation">‡Global Discovery Chemistry, ∥Metabolism and Pharmacokinetics, §Translational Medicine, and †Drug Metabolism
and Pharmacokinetics, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary M. Ksander</span> - <span class="hlFld-Affiliation affiliation">‡Global Discovery Chemistry, ∥Metabolism and Pharmacokinetics, §Translational Medicine, and †Drug Metabolism
and Pharmacokinetics, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael E. Beil</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Chen</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Leung-Chu</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fumin Fu</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lu Gan</span> - <span class="hlFld-Affiliation affiliation">‡Global Discovery Chemistry, ∥Metabolism and Pharmacokinetics, §Translational Medicine, and †Drug Metabolism
and Pharmacokinetics, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chii-Whei Hu</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arco Y. Jeng</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel LaSala</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guiqing Liang</span> - <span class="hlFld-Affiliation affiliation">‡Global Discovery Chemistry, ∥Metabolism and Pharmacokinetics, §Translational Medicine, and †Drug Metabolism
and Pharmacokinetics, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dean F. Rigel</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kerry S. Russell</span> - <span class="hlFld-Affiliation affiliation">‡Global Discovery Chemistry, ∥Metabolism and Pharmacokinetics, §Translational Medicine, and †Drug Metabolism
and Pharmacokinetics, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John A. Vest</span> - <span class="hlFld-Affiliation affiliation">‡Global Discovery Chemistry, ∥Metabolism and Pharmacokinetics, §Translational Medicine, and †Drug Metabolism
and Pharmacokinetics, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Catherine Watson</span> - <span class="hlFld-Affiliation affiliation">‡Global Discovery Chemistry, ∥Metabolism and Pharmacokinetics, §Translational Medicine, and †Drug Metabolism
and Pharmacokinetics, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Cardiovascular
and Metabolism, Novartis Institutes for
BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><sup>#</sup>(C.-W.H.) Retired.<br /></br><sup>○</sup>(G.M.K.) Deceased.<br /></br></div></li></ul></div><div class="ack" id="ACK-d10718e3231-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Prof. Joël Ménard for his work on the ASI program. We thank Dr. Lac Lee and Dr. Toshiyuki Honda for their contributions to the IC<sub>50</sub> shifts and reversibility studies with <b>8</b>.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i50" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i50"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i51" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i51"> Abbreviations Used</h2><tr><td class="NLM_term">ACTH</td><td class="NLM_def"><p class="first last">adrenocorticotropic hormone</p></td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">ASI</td><td class="NLM_def"><p class="first last">aldosterone synthase inhibitor</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DOC</td><td class="NLM_def"><p class="first last">deoxycorticosterone</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electronspray ionization</p></td></tr><tr><td class="NLM_term">LAH</td><td class="NLM_def"><p class="first last">lithium aluminum hydride</p></td></tr><tr><td class="NLM_term">LEI</td><td class="NLM_def"><p class="first last">ligand efficiency index</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">LM</td><td class="NLM_def"><p class="first last">liver microsomes</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">MC</td><td class="NLM_def"><p class="first last">methylcellulose</p></td></tr><tr><td class="NLM_term">MR</td><td class="NLM_def"><p class="first last">mineralocorticoid receptor</p></td></tr><tr><td class="NLM_term">PAC</td><td class="NLM_def"><p class="first last">plasma aldosterone concentration</p></td></tr><tr><td class="NLM_term">PCC</td><td class="NLM_def"><p class="first last">plasma cortisol concentration</p></td></tr><tr><td class="NLM_term">RAAS</td><td class="NLM_def"><p class="first last">renin-angiotensin-aldosterone system</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">Sprague–Dawley</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">WFI</td><td class="NLM_def"><p class="first last">water-for-injection</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27532" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27532" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Vasan, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meigs, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, D.</span><span> </span><span class="NLM_article-title">Serum aldosterone and the incidence of hypertension in non-hypertensive persons</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span><span class="refDoi"> DOI: 10.1056/NEJMoa033263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1056%2FNEJMoa033263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=15229305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltlOjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2004&pages=33-41&author=R.+S.+Vasanauthor=J.+C.+Evansauthor=M.+G.+Larsonauthor=P.+W.+Wilsonauthor=J.+B.+Meigsauthor=N.+Rifaiauthor=E.+J.+Benjaminauthor=D.+Levy&title=Serum+aldosterone+and+the+incidence+of+hypertension+in+non-hypertensive+persons&doi=10.1056%2FNEJMoa033263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Serum aldosterone and the incidence of hypertension in non-hypertensive persons</span></div><div class="casAuthors">Vasan, Ramachandran S.; Evans, Jane C.; Larson, Martin G.; Wilson, Peter W. F.; Meigs, James B.; Rifai, Nader; Benjamin, Emelia J.; Levy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-41</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Primary hyperaldosteronism is a well-recognized cause of secondary hypertension.  It is unknown whether serum aldosterone levels within the physiol. range influence the risk of hypertension.  METHODS: We investigated the relation of baseline serum aldosterone levels to increases in blood pressure and the incidence of hypertension after four years in 1688 non-hypertensive participants in the Framingham Offspring Study (mean age, 55 yr), 58 % of whom were women.  We defined an increase in blood pressure as an increment of at least one blood-pressure category (as defined by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) and defined hypertension as a systolic blood pressure of 140 mm Hg or higher, a diastolic blood pressure of 90 mm Hg or higher, or the use of antihypertensive medications.  RESULTS: At follow-up, the blood-pressure category had increased in 33.6 % of the participants, and hypertension had developed in 14.8 %.  In multivariable models, a 16 % increase in the risk of an elevation in blood pressure (P=0.002) and a 17 % increase in the risk of hypertension (P=0.03) were obsd. per quartile increment in the serum aldosterone level.  The highest serum aldosterone quartile, relative to the lowest, was assocd. with a 1.60-fold risk of an elevation in blood pressure (95 % confidence interval, 1.19 to 2.14) and a 1.61-fold risk of hypertension (95 % confidence interval, 1.05 to 2.46). The assocns. between the serum aldosterone level and blood-pressure outcomes were not significantly affected by adjustment for urinary sodium excretion or left ventricular thickness or internal dimensions.  CONCLUSIONS: In our community-based sample, increased aldosterone levels within the physiol. range predisposed persons to the development of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM3YrkjLmb_7Vg90H21EOLACvtfcHk0lijlsiDoEtn5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltlOjsLY%253D&md5=f1f72f54aac5a12fc11795492949a8be</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa033263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa033263%26sid%3Dliteratum%253Aachs%26aulast%3DVasan%26aufirst%3DR.%2BS.%26aulast%3DEvans%26aufirst%3DJ.%2BC.%26aulast%3DLarson%26aufirst%3DM.%2BG.%26aulast%3DWilson%26aufirst%3DP.%2BW.%26aulast%3DMeigs%26aufirst%3DJ.%2BB.%26aulast%3DRifai%26aufirst%3DN.%26aulast%3DBenjamin%26aufirst%3DE.%2BJ.%26aulast%3DLevy%26aufirst%3DD.%26atitle%3DSerum%2520aldosterone%2520and%2520the%2520incidence%2520of%2520hypertension%2520in%2520non-hypertensive%2520persons%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D351%26spage%3D33%26epage%3D41%26doi%3D10.1056%2FNEJMoa033263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Xanthakis, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasan, R. S.</span><span> </span><span class="NLM_article-title">Aldosterone and the risk of hypertension</span> <span class="citation_source-journal">Curr. Hypertens. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1007/s11906-013-0330-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1007%2Fs11906-013-0330-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=23378101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslSnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=102-107&author=V.+Xanthakisauthor=R.+S.+Vasan&title=Aldosterone+and+the+risk+of+hypertension&doi=10.1007%2Fs11906-013-0330-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone and the Risk of Hypertension</span></div><div class="casAuthors">Xanthakis, Vanessa; Vasan, Ramachandran S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Hypertension Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">102-107</span>CODEN:
                <span class="NLM_cas:coden">CHRUCG</span>;
        ISSN:<span class="NLM_cas:issn">1522-6417</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Aldosterone, the key hormone in the mineralocorticoid pathway, plays a fundamental role in salt and water homeostasis, blood pressure regulation, and cardiovascular remodeling.  Both genomic and nongenomic mechanisms influence aldosterone-induced renal sodium reabsorption.  Furthermore, the mineralocorticoid receptors in nonepithelial tissues, including the heart and vascular smooth muscle cells, have recently been discovered.  Thus, aldosterone likely has pleiotropic effects that contribute to the modulation of blood pressure.  Among patients with hypertension in general, and among those with more severe or resistant hypertension in particular, a higher-than-expected prevalence of primary hyperaldosteronism is noted.  Among individuals with resistant hypertension, aldosterone antagonists have also been shown to be effective in lowering blood pressure.  Most significantly, recent community-based studies among non-hypertensive individuals in the general population have demonstrated that both higher serum aldosterone concns. and a higher aldosterone to renin ratio portend a greater risk of developing hypertension.  The combination of the aforementioned observations underscores the importance of the mineralocorticoid pathway in the pathogenesis of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj7vTvphddlrVg90H21EOLACvtfcHk0lijlsiDoEtn5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslSnu70%253D&md5=ee82a738d920d666ae9465eee5dd9b38</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1007%2Fs11906-013-0330-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11906-013-0330-y%26sid%3Dliteratum%253Aachs%26aulast%3DXanthakis%26aufirst%3DV.%26aulast%3DVasan%26aufirst%3DR.%2BS.%26atitle%3DAldosterone%2520and%2520the%2520risk%2520of%2520hypertension%26jtitle%3DCurr.%2520Hypertens.%2520Rep.%26date%3D2013%26volume%3D15%26spage%3D102%26epage%3D107%26doi%3D10.1007%2Fs11906-013-0330-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Clark, D.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calhoun, D. A.</span><span> </span><span class="NLM_article-title">Resistant hypertension and aldosterone: an update</span> <span class="citation_source-journal">Can. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span><span class="refDoi"> DOI: 10.1016/j.cjca.2012.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.cjca.2012.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=22521297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCmu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2012&pages=318-325&author=D.+Clarkauthor=M.+I.+Ahmedauthor=D.+A.+Calhoun&title=Resistant+hypertension+and+aldosterone%3A+an+update&doi=10.1016%2Fj.cjca.2012.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Resistant Hypertension and Aldosterone: An Update</span></div><div class="casAuthors">Clark, Donald, III; Ahmed, Mustafa I.; Calhoun, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Cardiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-325</span>CODEN:
                <span class="NLM_cas:coden">CJCAEX</span>;
        ISSN:<span class="NLM_cas:issn">0828-282X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Resistant hypertension (RHTN) is defined as a blood pressure remaining above goal despite the concurrent use of 3 antihypertensive medications of different classes, including, ideally a diuretic.  RHTN is an important health problem with a prevalence rate expected to increase as populations become older, more obese, and at higher risk of having diabetes and chronic kidney disease, all of which are important risk factors for development of RHTN.  The role of aldosterone has gained increasing recognition as a significant contributor to antihypertensive treatment resistance.  In prospective studies, the prevalence of primary aldosteronism (PA) has ranged from 14%-21% in patients with RHTN, which is considerably higher than in the general hypertensive population.  Furthermore, marked antihypertensive effects are seen when mineralocorticoid antagonists are added to the treatment regimen of patients with RHTN, further supporting aldosterone excess as an important cause of RHTN.  A close assocn. exists between hyperaldosteronism, RHTN, and obstructive sleep apnea (OSA) based upon recent studies which indicate that OSA is worsened by aldosterone-mediated fluid retention.  This interaction is supported by preliminary data which demonstrates improvement in OSA severity after treatment with spironolactone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOYBTBPO5DibVg90H21EOLACvtfcHk0ljBLX2uMALvIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCmu7%252FM&md5=1851d4f473b75f7ac84395fa1351fe73</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1016%2Fj.cjca.2012.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cjca.2012.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DD.%26aulast%3DAhmed%26aufirst%3DM.%2BI.%26aulast%3DCalhoun%26aufirst%3DD.%2BA.%26atitle%3DResistant%2520hypertension%2520and%2520aldosterone%253A%2520an%2520update%26jtitle%3DCan.%2520J.%2520Cardiol.%26date%3D2012%26volume%3D28%26spage%3D318%26epage%3D325%26doi%3D10.1016%2Fj.cjca.2012.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Calhoun, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Textor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goff, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toto, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cushman, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sica, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferdinand, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falkner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carey, R. M.</span><span> </span><span class="NLM_article-title">Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research</span> <span class="citation_source-journal">Hypertension</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1403</span><span class="NLM_x">–</span> <span class="NLM_lpage">1419</span><span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.108.189141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1161%2FHYPERTENSIONAHA.108.189141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=18391085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvFaitLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1403-1419&author=D.+A.+Calhounauthor=D.+Jonesauthor=S.+Textorauthor=D.+C.+Goffauthor=T.+P.+Murphyauthor=R.+D.+Totoauthor=A.+Whiteauthor=W.+C.+Cushmanauthor=W.+Whiteauthor=D.+Sicaauthor=K.+Ferdinandauthor=T.+D.+Gilesauthor=B.+Falknerauthor=R.+M.+Carey&title=Resistant+hypertension%3A+Diagnosis%2C+evaluation%2C+and+treatment.+A+scientific+statement+from+the+American+Heart+Association+Professional+Education+Committee+of+the+Council+for+High+Blood+Pressure+Research&doi=10.1161%2FHYPERTENSIONAHA.108.189141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Resistant Hypertension: Diagnosis, Evaluation, and Treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research</span></div><div class="casAuthors">Calhoun, David A.; Jones, Daniel; Textor, Stephen; Goff, David C.; Murphy, Timothy P.; Toto, Robert D.; White, Anthony; Cushman, William C.; White, William; Sica, Domenic; Ferdinand, Keith; Giles, Thomas D.; Falkner, Bonita; Carey, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1403-1419</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Resistant hypertension is a common clin. problem faced by both primary care clinicians and specialists.  While the exact prevalence of resistant hypertension is unknown, clin. trials suggest that it is not rare, involving perhaps 20% to 30% of study participants.  As older age and obesity are 2 of the strongest risk factors for uncontrolled hypertension, the incidence of resistant hypertension will likely increase as the population becomes more elderly and heavier.  The prognosis of resistant hypertension is unknown, but cardiovascular risk is undoubtedly increased as patients often have a history of long-standing, severe hypertension complicated by multiple other cardiovascular risk factors such as obesity, sleep apnea, diabetes, and chronic kidney disease.  The diagnosis of resistant hypertension requires use of good blood pressure technique to confirm persistently elevated blood pressure levels.  Pseudoresistance, including lack of blood pressure control secondary to poor medication adherence or white coat hypertension, must be excluded.  Resistant hypertension is almost always multifactorial in etiol.  Successful treatment requires identification and reversal of lifestyle factors contributing to treatment resistance; diagnosis and appropriate treatment of secondary causes of hypertension; and use of effective multidrug regimens.  As a subgroup, patients with resistant hypertension have not been widely studied.  Observational assessments have allowed for identification of demog. and lifestyle characteristics assocd. with resistant hypertension, and the role of secondary causes of hypertension in promoting treatment resistance is well documented; however, identification of broader mechanisms of treatment resistance is lacking.  In particular, attempts to elucidate potential genetic causes of resistant hypertension have been limited.  Recommendations for the pharmacol. treatment of resistant hypertension remain largely empiric due to the lack of systematic assessments of 3 or 4 drug combinations.  Studies of resistant hypertension are limited by the high cardiovascular risk of patients within this subgroup, which generally precludes safe withdrawal of medications; the presence of multiple disease processes (eg, sleep apnea, diabetes, chronic kidney disease, atherosclerotic disease) and their assocd. medical therapies, which confound interpretation of study results; and the difficulty in enrolling large nos. of study participants.  Expanding our understanding of the causes of resistant hypertension and thereby potentially allowing for more effective prevention and/or treatment will be essential to improve the long-term clin. management of this disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1K_lQcMkaSLVg90H21EOLACvtfcHk0ljBLX2uMALvIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvFaitLw%253D&md5=f03659a23f19e2f89439672dfdb416e6</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.108.189141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.108.189141%26sid%3Dliteratum%253Aachs%26aulast%3DCalhoun%26aufirst%3DD.%2BA.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DTextor%26aufirst%3DS.%26aulast%3DGoff%26aufirst%3DD.%2BC.%26aulast%3DMurphy%26aufirst%3DT.%2BP.%26aulast%3DToto%26aufirst%3DR.%2BD.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DCushman%26aufirst%3DW.%2BC.%26aulast%3DWhite%26aufirst%3DW.%26aulast%3DSica%26aufirst%3DD.%26aulast%3DFerdinand%26aufirst%3DK.%26aulast%3DGiles%26aufirst%3DT.%2BD.%26aulast%3DFalkner%26aufirst%3DB.%26aulast%3DCarey%26aufirst%3DR.%2BM.%26atitle%3DResistant%2520hypertension%253A%2520Diagnosis%252C%2520evaluation%252C%2520and%2520treatment.%2520A%2520scientific%2520statement%2520from%2520the%2520American%2520Heart%2520Association%2520Professional%2520Education%2520Committee%2520of%2520the%2520Council%2520for%2520High%2520Blood%2520Pressure%2520Research%26jtitle%3DHypertension%26date%3D2008%26volume%3D51%26spage%3D1403%26epage%3D1419%26doi%3D10.1161%2FHYPERTENSIONAHA.108.189141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Daugherty, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magid, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masoudi, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolis, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P. M.</span><span> </span><span class="NLM_article-title">Incidence and prognosis of resistant hypertension in hypertensive patients</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">1635</span><span class="NLM_x">–</span> <span class="NLM_lpage">1642</span><span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.111.068064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1161%2FCIRCULATIONAHA.111.068064" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=1635-1642&author=S.+L.+Daughertyauthor=J.+D.+Powersauthor=D.+J.+Magidauthor=H.+M.+Tavelauthor=F.+A.+Masoudiauthor=K.+L.+Margolisauthor=P.+J.+O%E2%80%99Connorauthor=J.+V.+Selbyauthor=P.+M.+Ho&title=Incidence+and+prognosis+of+resistant+hypertension+in+hypertensive+patients&doi=10.1161%2FCIRCULATIONAHA.111.068064"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.068064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.068064%26sid%3Dliteratum%253Aachs%26aulast%3DDaugherty%26aufirst%3DS.%2BL.%26aulast%3DPowers%26aufirst%3DJ.%2BD.%26aulast%3DMagid%26aufirst%3DD.%2BJ.%26aulast%3DTavel%26aufirst%3DH.%2BM.%26aulast%3DMasoudi%26aufirst%3DF.%2BA.%26aulast%3DMargolis%26aufirst%3DK.%2BL.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%2BJ.%26aulast%3DSelby%26aufirst%3DJ.%2BV.%26aulast%3DHo%26aufirst%3DP.%2BM.%26atitle%3DIncidence%2520and%2520prognosis%2520of%2520resistant%2520hypertension%2520in%2520hypertensive%2520patients%26jtitle%3DCirculation%26date%3D2012%26volume%3D125%26spage%3D1635%26epage%3D1642%26doi%3D10.1161%2FCIRCULATIONAHA.111.068064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">He, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M. E.</span><span> </span><span class="NLM_article-title">Aldosterone and cardiovascular disease: the heart of the matter</span> <span class="citation_source-journal">Trends Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1016/j.tem.2012.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.tem.2012.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=23040074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKgsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=21-30&author=B.+J.+Heauthor=M.+E.+Anderson&title=Aldosterone+and+cardiovascular+disease%3A+the+heart+of+the+matter&doi=10.1016%2Fj.tem.2012.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone and cardiovascular disease: the heart of the matter</span></div><div class="casAuthors">He, B. Julie; Anderson, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Aldosterone contributes to the endocrine basis of heart failure, and studies on cardiac aldosterone signaling have reinforced its value as a therapeutic target.  Recent focus has shifted to new roles of aldosterone that appear to depend on coexisting pathol. stimuli, cell type, and disease etiol.  This review evaluates recent advances in mechanisms underlying aldosterone-induced cardiac disease and highlights the interplay between aldosterone and Ca2+/calmodulin dependent protein kinase II, whose hyperactivity during heart failure contributes to disease progression.  Increasing evidence implicates aldosterone in diastolic dysfunction, and there is a need to develop more targeted therapeutics such as aldosterone synthase inhibitors and molecularly specific antioxidants.  Despite accumulating knowledge, many questions still persist and will likely dictate areas of future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT-5BWMzRWh7Vg90H21EOLACvtfcHk0ljBLX2uMALvIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKgsLzE&md5=8d77025ca07baf45d782d00baab87355</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2012.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2012.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DM.%2BE.%26atitle%3DAldosterone%2520and%2520cardiovascular%2520disease%253A%2520the%2520heart%2520of%2520the%2520matter%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D24%26spage%3D21%26epage%3D30%26doi%3D10.1016%2Fj.tem.2012.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Briet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffrin, E. L.</span><span> </span><span class="NLM_article-title">Vascular actions of aldosterone</span> <span class="citation_source-journal">J. Vasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span><span class="refDoi"> DOI: 10.1159/000345243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1159%2F000345243" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2013&pages=88-99&author=M.+Brietauthor=E.+L.+Schiffrin&title=Vascular+actions+of+aldosterone&doi=10.1159%2F000345243"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1159%2F000345243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000345243%26sid%3Dliteratum%253Aachs%26aulast%3DBriet%26aufirst%3DM.%26aulast%3DSchiffrin%26aufirst%3DE.%2BL.%26atitle%3DVascular%2520actions%2520of%2520aldosterone%26jtitle%3DJ.%2520Vasc.%2520Res.%26date%3D2013%26volume%3D50%26spage%3D88%26epage%3D99%26doi%3D10.1159%2F000345243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Young, M. J.</span><span> </span><span class="NLM_article-title">Mechanisms of mineralocorticoid receptor mediated cardiac fibrosis and vascular inflammation</span> <span class="citation_source-journal">Curr. Opin. Nephrol. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">174</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1097/MNH.0b013e3282f56854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1097%2FMNH.0b013e3282f56854" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=174-180&author=M.+J.+Young&title=Mechanisms+of+mineralocorticoid+receptor+mediated+cardiac+fibrosis+and+vascular+inflammation&doi=10.1097%2FMNH.0b013e3282f56854"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.1097%2FMNH.0b013e3282f56854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMNH.0b013e3282f56854%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DM.%2BJ.%26atitle%3DMechanisms%2520of%2520mineralocorticoid%2520receptor%2520mediated%2520cardiac%2520fibrosis%2520and%2520vascular%2520inflammation%26jtitle%3DCurr.%2520Opin.%2520Nephrol.%2520Hypertens.%26date%3D2008%26volume%3D17%26spage%3D174%26epage%3D180%26doi%3D10.1097%2FMNH.0b013e3282f56854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Brown, N. J.</span><span> </span><span class="NLM_article-title">Aldosterone and end-organ damage</span> <span class="citation_source-journal">Curr. Opin. Nephrol. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">241</span><span class="refDoi"> DOI: 10.1097/01.mnh.0000165889.60254.98</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1097%2F01.mnh.0000165889.60254.98" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2005&pages=235-241&author=N.+J.+Brown&title=Aldosterone+and+end-organ+damage&doi=10.1097%2F01.mnh.0000165889.60254.98"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3d&amp;dbid=16384&amp;doi=10.1097%2F01.mnh.0000165889.60254.98&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.mnh.0000165889.60254.98%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%2BJ.%26atitle%3DAldosterone%2520and%2520end-organ%2520damage%26jtitle%3DCurr.%2520Opin.%2520Nephrol.%2520Hypertens.%26date%3D2005%26volume%3D14%26spage%3D235%26epage%3D241%26doi%3D10.1097%2F01.mnh.0000165889.60254.98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Stowasser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marwick, T. H.</span><span> </span><span class="NLM_article-title">Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type 1</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">5070</span><span class="NLM_x">–</span> <span class="NLM_lpage">5076</span><span class="refDoi"> DOI: 10.1210/jc.2005-0681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1210%2Fjc.2005-0681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=15941863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWkur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2005&pages=5070-5076&author=M.+Stowasserauthor=J.+Sharmanauthor=R.+Leanoauthor=R.+D.+Gordonauthor=G.+Wardauthor=D.+Cowleyauthor=T.+H.+Marwick&title=Evidence+for+abnormal+left+ventricular+structure+and+function+in+normotensive+individuals+with+familial+hyperaldosteronism+type+1&doi=10.1210%2Fjc.2005-0681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3eR"><div class="casContent"><span class="casTitleNuber">3e</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I</span></div><div class="casAuthors">Stowasser, Michael; Sharman, James; Leano, Rodel; Gordon, Richard D.; Ward, Gregory; Cowley, Diane; Marwick, Thomas H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5070-5076</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">To explore whether aldosterone excess can induce adverse cardiovascular effects independently of effects on blood pressure (BP), we sought evidence of disturbed cardiovascular structure or function in normotensive individuals with primary aldosteronism.  Eight normotensive subjects with genetically proven familial hyperaldosteronism type I (FH-I) were compared with 24 age- and sex-matched normotensive controls in terms of BP, biochem. parameters, pulse wave velocity, and echocardiog. characteristics.  Subjects with FH-I demonstrated higher serum aldosterone levels and aldosterone/renin ratios than controls, as expected.  Despite having similar 24-h ambulatory BPs, subjects with FH-I demonstrated evidence of concentric remodeling with greater septal (mean ± SD, 9.4±1.1 vs. 7.9±0.9 mm; P < 0.001), posterior wall (9.2±1.7 vs. 7.7±1.0 mm; P < 0.01), and relative wall (0.29±0.03 vs. 0.24±0.02; P < 0.001) thicknesses, and lower mitral early peak velocities (0.74±0.10 vs. 0.90±0.16 m/s; P < 0.05), ratios of early to late peak diastolic transmitral flow velocity (1.56±0.24 vs. 2.06±0.41; P < 0.01), and myocardial early peak velocities (8.3±1.8 vs. 10.3±2.6 cm/s; P < 0.05).  There were no significant differences in pulse wave velocity or left ventricular ejection fraction, long axis strain rate, peak systolic strain, cyclic variation of integrated backscatter, or posterior wall calibrated integrated backscatter.  Aldosterone excess is assocd. with increased left ventricular wall thicknesses and reduced diastolic function, even in the absence of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppRlwdEw69ULVg90H21EOLACvtfcHk0lhuFKPryzTivg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWkur%252FN&md5=9b40580fbaa4779e62ced778554fcf43</span></div><a href="/servlet/linkout?suffix=cit3e&amp;dbid=16384&amp;doi=10.1210%2Fjc.2005-0681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2005-0681%26sid%3Dliteratum%253Aachs%26aulast%3DStowasser%26aufirst%3DM.%26aulast%3DSharman%26aufirst%3DJ.%26aulast%3DLeano%26aufirst%3DR.%26aulast%3DGordon%26aufirst%3DR.%2BD.%26aulast%3DWard%26aufirst%3DG.%26aulast%3DCowley%26aufirst%3DD.%26aulast%3DMarwick%26aufirst%3DT.%2BH.%26atitle%3DEvidence%2520for%2520abnormal%2520left%2520ventricular%2520structure%2520and%2520function%2520in%2520normotensive%2520individuals%2520with%2520familial%2520hyperaldosteronism%2520type%25201%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2005%26volume%3D90%26spage%3D5070%26epage%3D5076%26doi%3D10.1210%2Fjc.2005-0681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Milliez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girerd, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plouin, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blacher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safar, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mourad, J. J.</span><span> </span><span class="NLM_article-title">Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1243</span><span class="NLM_x">–</span> <span class="NLM_lpage">1248</span><span class="refDoi"> DOI: 10.1016/j.jacc.2005.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.jacc.2005.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=15837256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlagt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=1243-1248&author=P.+Milliezauthor=X.+Girerdauthor=P.+F.+Plouinauthor=J.+Blacherauthor=M.+E.+Safarauthor=J.+J.+Mourad&title=Evidence+for+an+increased+rate+of+cardiovascular+events+in+patients+with+primary+aldosteronism&doi=10.1016%2Fj.jacc.2005.01.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3fR"><div class="casContent"><span class="casTitleNuber">3f</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism</span></div><div class="casAuthors">Milliez, Paul; Girerd, Xavier; Plouin, Pierre-Francois; Blacher, Jacques; Safar, Michel E.; Mourad, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1243-1248</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The aim of this report was to show that the rate of cardiovascular events is increased in patients with either subtype of primary aldosteronism (PA).  Primary aldosteronism involves hypertension (HTN), hypokalemia, and low plasma renin.  The two major PA subtypes are unilateral aldosterone-producing adenoma (APA) and bilateral adrenal hyperplasia.  During a three-year period, the diagnosis of PA was made in 124 of 5,500 patients referred for comprehensive evaluation and management.  Adenomas were diagnosed in 65 patients and idiopathic hyperaldosteronism in 59 patients.  During the same period, clin. characteristics and cardiovascular events of this group were compared with those of 465 patients with essential hypertension (EHT) randomly matched for age, gender, and systolic and diastolic blood pressure.  A history of stroke was found in 12.9% of patients with PA and 3.4% of patients with EHT (odds ratio [OR] = 4.2;95% confidence interval [CI]2.0 to 8.6).  Non-fatal myocardial infarction was diagnosed in 4.0% of patients with PA and in 0.6% of patients with EHT (OR = 6.5;95% CI 1.5 to 27.4).  A history of atrial fibrillation was diagnosed in 7.3% of patients with PA and 0.6% of patients with EHT (OR = 12.1; 95% CI 3.2 to 45.2).  The occurrence of cardiovascular complications was comparable in both subtypes of PA.  Patients presenting with PA experienced more cardiovascular events than did EHT patients independent of blood pressure.  The presence of PA should be detected, not only to det. the cause of HTN, but also to prevent such complications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9B0Dj7HXiQbVg90H21EOLACvtfcHk0lhuFKPryzTivg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlagt70%253D&md5=17c6f546d21e178ea28008ed26521185</span></div><a href="/servlet/linkout?suffix=cit3f&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2005.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2005.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DMilliez%26aufirst%3DP.%26aulast%3DGirerd%26aufirst%3DX.%26aulast%3DPlouin%26aufirst%3DP.%2BF.%26aulast%3DBlacher%26aufirst%3DJ.%26aulast%3DSafar%26aufirst%3DM.%2BE.%26aulast%3DMourad%26aufirst%3DJ.%2BJ.%26atitle%3DEvidence%2520for%2520an%2520increased%2520rate%2520of%2520cardiovascular%2520events%2520in%2520patients%2520with%2520primary%2520aldosteronism%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2005%26volume%3D45%26spage%3D1243%26epage%3D1248%26doi%3D10.1016%2Fj.jacc.2005.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Staessen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lijnen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verschueren, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amery, A.</span><span> </span><span class="NLM_article-title">Rise in plasma concentration of aldosterone during long-term angiotensin II suppression</span> <span class="citation_source-journal">J. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">457</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span><span class="refDoi"> DOI: 10.1677/joe.0.0910457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1677%2Fjoe.0.0910457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=7035596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADyaL38XhtFGlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1981&pages=457-465&author=J.+Staessenauthor=P.+Lijnenauthor=R.+Fagardauthor=L.+J.+Verschuerenauthor=A.+Amery&title=Rise+in+plasma+concentration+of+aldosterone+during+long-term+angiotensin+II+suppression&doi=10.1677%2Fjoe.0.0910457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Rise in plasma concentration of aldosterone during long-term angiotensin II suppression</span></div><div class="casAuthors">Staessen, J.; Lijnen, P.; Fagard, R.; Verschueren, L. J.; Amery, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endocrinology</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">457-65</span>CODEN:
                <span class="NLM_cas:coden">JOENAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-0795</span>.
    </div><div class="casAbstract">The plasma concn. of aldosterone (I)  [52-39-1] was followed in 7 hypertensive patients before and during long-term angiotensin II  [11128-99-7] suppression with the orally active angiotensin I converting enzyme inhibitor captopril  [62571-86-2].  The plasma concn. of I decreased initially from 74 to 21 pg/mL after 1 mo of administration of captopril (≤600 mg/day).  Thereafter, the plasma concn. of I began to rise and after 1 yr reached a level of 165 pg/mL.  During long-term captopril therapy, the plasma renin  [9015-94-5] activity was increased and the plasma angiotensin II concn. was suppressed.  The mechanism responsible for the late rise of the plasma concn. of I during long-term angiotensin II suppression with captopril remains to be elucidated.  A sizeable and lasting hypotensive effect was obsd. in all patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdzoaBfSc9hrVg90H21EOLACvtfcHk0lh96WMc9uhN6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XhtFGlurw%253D&md5=e4ca8eb95b55d6c4b6cd6c4be8c8e108</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1677%2Fjoe.0.0910457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Fjoe.0.0910457%26sid%3Dliteratum%253Aachs%26aulast%3DStaessen%26aufirst%3DJ.%26aulast%3DLijnen%26aufirst%3DP.%26aulast%3DFagard%26aufirst%3DR.%26aulast%3DVerschueren%26aufirst%3DL.%2BJ.%26aulast%3DAmery%26aufirst%3DA.%26atitle%3DRise%2520in%2520plasma%2520concentration%2520of%2520aldosterone%2520during%2520long-term%2520angiotensin%2520II%2520suppression%26jtitle%3DJ.%2520Endocrinol.%26date%3D1981%26volume%3D91%26spage%3D457%26epage%3D465%26doi%3D10.1677%2Fjoe.0.0910457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Struthers, A. D.</span><span> </span><span class="NLM_article-title">Aldosterone escape during ACE inhibitor therapy in chronic heart failure</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.1093/eurheartj/16.suppl_N.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1093%2Feurheartj%2F16.suppl_N.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=8682054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADyaK28XitlGlsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1995&pages=103-106&author=A.+D.+Struthers&title=Aldosterone+escape+during+ACE+inhibitor+therapy+in+chronic+heart+failure&doi=10.1093%2Feurheartj%2F16.suppl_N.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone escape during ACE inhibitor therapy in chronic heart failure</span></div><div class="casAuthors">Struthers, A. D.</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">Suppl. N, Heart Failure 95</span>),
    <span class="NLM_cas:pages">103-6</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">A review with 26 refs.  In the setting of chronic heart failure (CHF), therapy with angiotensin converting enzyme (ACE) inhibitors generally reduces serum aldosterone levels acutely.  However, long-term ACE inhibition is assocd. with aldosterone suppression that is weak, variable, and unsustained, i.e. aldosterone escape.  The adverse effects of such aldosterone escape are discussed.  In addn., the beneficial effects of spironolactone therapy added to the regimen of an ACE inhibitor and diuretic are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj_wPo6Vf28bVg90H21EOLACvtfcHk0lh96WMc9uhN6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitlGlsrY%253D&md5=7c42fbe1abf3668a5516c2ba01755203</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2F16.suppl_N.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252F16.suppl_N.103%26sid%3Dliteratum%253Aachs%26aulast%3DStruthers%26aufirst%3DA.%2BD.%26atitle%3DAldosterone%2520escape%2520during%2520ACE%2520inhibitor%2520therapy%2520in%2520chronic%2520heart%2520failure%26jtitle%3DEur.%2520Heart%2520J.%26date%3D1995%26volume%3D16%26spage%3D103%26epage%3D106%26doi%3D10.1093%2Feurheartj%2F16.suppl_N.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pitt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zannad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remme, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cody, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaigne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palensky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittes, J.</span><span> </span><span class="NLM_article-title">Randomized Aldactone Evaluation Study Investigators.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">717</span><span class="refDoi"> DOI: 10.1056/NEJM199909023411001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1056%2FNEJM199909023411001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10471456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVyrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1999&pages=709-717&author=B.+Pittauthor=F.+Zannadauthor=W.+J.+Remmeauthor=R.+Codyauthor=A.+Castaigneauthor=A.+Perezauthor=J.+Palenskyauthor=J.+Wittes&title=Randomized+Aldactone+Evaluation+Study+Investigators..+The+effect+of+spironolactone+on+morbidity+and+mortality+in+patients+with+severe+heart+failure&doi=10.1056%2FNEJM199909023411001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of spironolactone on morbidity and mortality in patients with severe heart failure</span></div><div class="casAuthors">Pitt, Bertram; Zannad, Faiez; Remme, Willem J.; Cody, Robert; Castaigne, Alain; Perez, Alfonso; Palensky, Jolie; Wittes, Janet</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">709-717</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Aldosterone is important in the pathophysiol. of heart failure.  In a double-blind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an angiotensin-converting-enzyme inhibitor, a loop diuretic, and in most cases digoxin.  A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo.  The primary end point was death from all causes.  The trial was discontinued early, after a mean follow-up period of 24 mo, because an interim anal. detd. that spironolactone was efficacious.  There were 386 deaths in the placebo group (46 percent) and 284 in the spironolactone group (35 percent; relative risk of death, 0.70; 95 percent confidence interval, 0.60 to 0.82; P<0.001).  This 30 percent redn. in the risk of death among patients in the spironolactone group was attributed to a lower risk of both death from progressive heart failure and sudden death from cardiac causes.  The frequency of hospitalization for worsening heart failure was 35 percent lower in the spironolactone group than in the placebo group (relative risk of hospitalization, 0.65; 95 percent confidence interval, 0.54 to 0.77; P<0.001).  In addn., patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Assocn. functional class (P<0.001).  Gynecomastia or breast pain was reported in 10 percent of men who were treated with spironolactone, as compared with 1 percent of men in the placebo group (P<0.001).  The incidence of serious hyperkalemia was minimal in both groups of patients.  Blockade of aldosterone receptors by spironolactone, in addn. to std. therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwOy-U1QzrSbVg90H21EOLACvtfcHk0lh96WMc9uhN6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVyrurk%253D&md5=3e34cf3cd2ac38b96cefdfda593a02f5</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1056%2FNEJM199909023411001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199909023411001%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DB.%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DRemme%26aufirst%3DW.%2BJ.%26aulast%3DCody%26aufirst%3DR.%26aulast%3DCastaigne%26aufirst%3DA.%26aulast%3DPerez%26aufirst%3DA.%26aulast%3DPalensky%26aufirst%3DJ.%26aulast%3DWittes%26aufirst%3DJ.%26atitle%3DRandomized%2520Aldactone%2520Evaluation%2520Study%2520Investigators..%2520The%2520effect%2520of%2520spironolactone%2520on%2520morbidity%2520and%2520mortality%2520in%2520patients%2520with%2520severe%2520heart%2520failure%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1999%26volume%3D341%26spage%3D709%26epage%3D717%26doi%3D10.1056%2FNEJM199909023411001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zannad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krum, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Veldhuisen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swedberg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pocock, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, B.</span><span> </span><span class="NLM_article-title">Eplerenone in patients with systolic heart failure and mild symptoms</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1056/NEJMoa1009492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1056%2FNEJMoa1009492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=21073363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisValuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=11-21&author=F.+Zannadauthor=J.+J.+McMurrayauthor=H.+Krumauthor=D.+J.+van+Veldhuisenauthor=K.+Swedbergauthor=H.+Shiauthor=J.+Vincentauthor=S.+J.+Pocockauthor=B.+Pitt&title=Eplerenone+in+patients+with+systolic+heart+failure+and+mild+symptoms&doi=10.1056%2FNEJMoa1009492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Eplerenone in patients with systolic heart failure and mild symptoms</span></div><div class="casAuthors">Zannad, Faiez; McMurray, John J. V.; Krum, Henry; van Veldhuisen, Dirk J.; Swedberg, Karl; Shi, Harry; Vincent, John; Pocock, Stuart J.; Pitt, Bertram</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-21</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction.  We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms.  In this randomized, double-blind trial, we randomly assigned 2737 patients with New York Heart Assocn. class II heart failure and an ejection fraction of no more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addn. to recommended therapy.  The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure.  The trial was stopped prematurely, according to prespecified rules, after a median follow-up period of 21 mo.  The primary outcome occurred in 18.3% of patients in the eplerenone group as compared with 25.9% in the placebo group (hazard ratio, 0.63; 95% confidence interval [CI], 0.54 to 0.74; P < 0.001).  A total of 12.5% of patients receiving eplerenone and 15.5% of those receiving placebo died (hazard ratio, 0.76; 95% CI, 0.62 to 0.93; P = 0.008); 10.8% and 13.5%, resp., died of cardiovascular causes (hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P = 0.01).  Hospitalizations for heart failure and for any cause were also reduced with eplerenone.  A serum potassium level exceeding 5.5 mmol per L occurred in 11.8% of patients in the eplerenone group and 7.2% of those in the placebo group (P < 0.001).  Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRI60N9G6VWrVg90H21EOLACvtfcHk0lh96WMc9uhN6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisValuw%253D%253D&md5=70f8085ca6ac39316015b1c349312771</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1009492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1009492%26sid%3Dliteratum%253Aachs%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26aulast%3DKrum%26aufirst%3DH.%26aulast%3Dvan%2BVeldhuisen%26aufirst%3DD.%2BJ.%26aulast%3DSwedberg%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DJ.%26aulast%3DPocock%26aufirst%3DS.%2BJ.%26aulast%3DPitt%26aufirst%3DB.%26atitle%3DEplerenone%2520in%2520patients%2520with%2520systolic%2520heart%2520failure%2520and%2520mild%2520symptoms%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D11%26epage%3D21%26doi%3D10.1056%2FNEJMoa1009492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Pitt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remme, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zannad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neaton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roniker, B.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">1309</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span><span class="refDoi"> DOI: 10.1056/NEJMoa030207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1056%2FNEJMoa030207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=12668699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1ehurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=1309-1321&author=B.+Pittauthor=W.+Remmeauthor=F.+Zannadauthor=J.+Neatonauthor=F.+Martinezauthor=B.+Roniker&title=Eplerenone%2C+a+selective+aldosterone+blocker%2C+in+patients+with+left+ventricular+dysfunction+after+myocardial+infarction&doi=10.1056%2FNEJMoa030207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction</span></div><div class="casAuthors">Pitt, Bertram; Remme, Willem; Zannad, Faiez; Neaton, James; Martinez, Felipe; Roniker, Barbara; Bittman, Richard; Hurley, Steve; Kleiman, Jay; Gatlin, Marjorie; Ambrosioni, E.; Anderson, J. L.; Apetrei, E.; Aschermann, M.; Banas, J.; Cardoso, S.; Caspi, A.; Chung, N.; Corbalan, R.; Dargie, H. J.; Bietz, R.; Erhardt, L.; Garcia-Castillo, A.; Gheorghiade, M.; Hernandez, E.; Hess, O.; Jamerson, K.; Kjekshus, J.; Klug, E.; Krum, H.; Lee, Y.-T.; Lopez, N.; Lopez-Sendon, J.-L.; Martinez, F.; Murin, J.; Neaton, J.; Nicolau, J.-C.; Ostor, E.; Parkhomenko, A.; Pitt, B.; Ross, H.; Stepinska, J.; Torp-Pedersen, C.; Van Mieghem, W.; van Veldhuisen, D.-J.; White, H.; Wilvox, R. G.; Willenbrock, R.; Yotov, Y.-T.; Zannad, F.; Boissel, J.-P.; Furberg, C.; Julian, D.; Kulbertus, H.; Pocock, S.; Wittes, J.; Battler, A.; Blumenfeld, J.; Brilla, C.; Duprez, D.; Fowler, M.; Gavazzi, A.; Hildebrandt, P.; Komajda, M.; Korewicki, J.; Kosturakis, D.; Marin-Neto, J. A.; Miller, A.; Munoz Aguilera, R.; Oliveri, R.; Remme, W.; White, M.; Widimsky, P.; Bakris, G.; Castaigne, A.; Deedwania, P.; Duprez, D.; Ketelslegers, J. M.; Liu, P.; Mancia, G.; Nicklas, J.; Rouleau, J.-L.; Ruilope, L.; Sasayama, S.; Schiffrin, E.; Spertus, J.; Struthers, A.; Vaughan, D.; Weber, M.; Williams, G.; Abinader, E.; Adams, J.; Adams, P. C.; Adamus, J.; Ahlstrom, P.; Akesson, H. S.; Akhmedzhanov, N.; Alcasena Juango, S.; Ali Khan, S.; Alonso Garcia, A.; Amat, G.; Amerena, J.; Arnosova, K. M.; Andreoli, L.; Angelo-Nielsen, K.; Antonio de Velasco, J.; Apetrei, E.; Aroutiounov, G.; Aschermann, M.; Asklund, M.; Assmann, I.; Aumont, M.-C.; Avtandilov, A.; Azarin, O.; Bada, V.; Bakoumov, P.; Balazovjech, L.; Baldjiev, E.; Baluda, M.; Barrazueta, R.; Barsi, B.; Bashir, Y.; Batin, P. D.; Belenky, D.; Belyi, Y.; Bendermacher, P. E. F.; Berget, K.; Bergmeier, C.; Berning, J.; Berrazueta-Fernandez, J. R.; Block, P.; Boberg, G.; Bocek, P.; Bohlscheid, V.; Bokarev, I.; Bolinska, H.; Boman, K.; Bondarev, S.; Bonzel, T.; Boreux, J.-L.; Borggrefe, M.; Borisov, M.; Boxho, G.; Boyarkin, M.; Brachmann, J.; Brack, M.; Branea, I.; Breivik, K.; Brigden, G. S.; Bronzwaer, P. N. A.; Bruce, D.; Bruckner, I.; Brunvand, H.; Bryukhovetski, A.; Buser, P.; Campbell, T.; Campeanu, A.; Capucci, A.; Carasca, E.; Cardoso, J.; Carrageta, M.; Caspi, A.; Cassim, S.; Caturla, J.; Ceia, F.; Cernosek, B.; Channer, K.; Chati, Z.; Christensen, P. D.; Chung, N. S.; Cinteza, M.; Cleland, J. G. F.; Cocchieri, M.; Commerford, P.; Conti, U.; Corsini, G.; Cortina Liosa, A.; Coupez, J.-M.; Cribier, A.; Csillag, J.; Cyran, J.; Dahlstrom, U.; Dalby, A.; Dalin, L. J.; Dalkowski, M.; Dargie, H. J.; Darius, H.; Datcu, D. M.; David, D.; De Myttenaere, M.; De Teresa, E.; De Velasco, J.; de Vries, A. G.; den Hartog, F. R.; Desjoyaux, E.; Dezerbi, A.; Dhawan, J.; Biaz Molina, B.; Dickstein, K.; Dorobantu, M.; Doschitsin, V.; Doubell, A.; Dovgalevsky, P.; Dragulescu, S. I.; Drapkina, O.; Dubourg, O.; Dunselman, P. H. J. M.; Dyadyk, O. I.; Dykun, Y. V.; Dzyak, G. V.; Egorova, L. P.; Egstrup, K.; Eha, J.; Ehrenbergerova, M.; El Allaf, D.; Elenkova, A.; Ellis, C. J.; Engbers, J. G.; Fainyk, A. F.; Falck, G.; Fanelli, R.; Farre-Mun, J.; Favier, J.; Ferrari, G.; Ferreira, I.; Rischer, H.; Fotyanov, S.; Freericks, M. P.; Froeland, G.; Galve, E.; Garcia, M. M.; Garcia, A. A.; Garnier, L. F.; Gazaryan, G.; Georgescu, C.; Geraedts, J.; Glezer, M. G.; Goloborodko, B. I.; Goloshchekin, B.; Gonsorcik, J.; Gotchev, D.; Gotcheva, N.; Gottwik, M. G.; Grande, P.; Gratsiansky, N.; Grishina, E. I.; Groch, L.; Gruzdev, A.; Guenova, D.; Gundersen, T.; Hagerman, I.; Hambrecht, R.; Hammermann, H.; Hansen, O.; Hansteen, V.; Hart, H.; Hauf, G. F.; Hecker, U.; Hegyi, I.; Herlitz, J.; Hertzberger, D. P.; Herweijer, A. H.; Heyndrickx, G. R.; Hittinger, L.; Hoang, V.; Hobbach, H.-P.; Hofman-Bang, C.; Holwerda, N. J.; Hong, K. P.; Horacek, T.; Hormann, J.; Horowitz, J. D.; Hradec, J.; Hurtig, U.; Ikram, H.; Ioan, A.; Jaarsma, W.; Jadraque, L. M.; Jakobsen, T. J.; Janicki, K. J.; Jankelow, D.; Janosi, A.; Jansky, P.; Janssens, L.; Janzen, I.; Jensen, P.; Jirmar, R.; Jobic, Y.; Jones, A.; Jonsson, J.; Kahles, H.; Kaliska, G.; Kamensky, G.; Kappenberger, L.; Karlsson, J. E.; Karpati, P.; Karpenko, O. I.; Karpov, Y.; Kawecka-Jaszcz, J.; Keeling, P. J.; Keren, G.; Khalife, K.; Khrakovskaya, M.; Khrustalev, O. A.; Klarlund, K. K.; Kleber, E.-X.; Klug, E.; Koenig, W.; Komarek, J.; Kononenko, L. G.; Konz, K.; Komacewicz-Jach, Z.; Kostenko, V.; Kotous, J.; Kovalsky, I.; Kozak, P.; Kreider-Stempfle, H. U.; Kromer, E. P.; Krum, H.; Krzeminska-Pakula, M.; Kuc, K.; Kucera, P.; Kurowski, M.; Lach, L.; Lai, C.; Lane, G.; Lang, E.; Lankes, W.; Lankisch, P.-G.; Laraudogoitia, E.; Larsen, J.; Larsson, L.-E.; Laruelle, C.; Lazar, A.; Lee, Y.-T.; Legkonogov, A. V.; Leitch, J.; Lengfelder, W.; Lescot, C. D.; Lewis, B. S.; Lewis, P.; Libov, I. A.; Liel-Cohen, N.; Lim, H. K.; Lin, C.-S.; Linssen, G. C. M.; Liu, C.-P.; Lok, D. J. A.; Lopatin, Y. M.; Lopez De Sa, E.; Lotan, C.; Lousada, N.; Lucas, C.; Lucatti, A.; Lusov, V.; Mabin, T. A.; Macleod, D. C.; Maeurer, W.; Magnusson, J.-O.; Maisch, B.; Malinski, A.; Maltchougine, M.; Manga, P.; Mantov, S.; Marchi, S.; Marcinowska-Suchowierska, E.; Marenne, F.; Maresca, F. S.; Markov, V.; Marmor, A. T.; Martines, C.; Martinez, A.; Martin-Jadraque, L.; Martins, L. F. R.; Martos Ferres, R.; Mary, D. A. S. G.; Masini, F.; Matta, F.; Maurer, W.; Mazzini, A. C.; McDonald, K. M. A.; Meeder, J. G.; Melandri, F.; Melin, J.; Menezes, C.; Michels, H. R.; Missault, L.; Mitrovic, V.; Mntla, P.; Mobilij, A.; Mogilevsky, A.; Moiseev, V.; Mokan, M.; Moeller, B.; Moreira, I.; Mouhoub, D.; Moura, B.; Muders, E.; Mudra, H.; Munz, J.; Murin, J.; Musial, W. J.; Myburgh, D. P.; Naqvi, N.; Naumann, G.; Nazimov, S. V.; Nadelec, G.; Nedogoda, S. V.; Nielsen, I.; Nielsen, T.; Nierop, P. R.; Nilsson, G.; Notaristefano, A.; Novitsky, I. N.; Nykl, L.; Ofner, P.; Olariu, C.; Olbrich, H. G.; Oldroyd, K. G.; Olinic, N.; Oliveira, J.; Omland, T.; Orus, J.; Owensby, D.; Page, A.; Park, K. S.; Parkhomenko, O. M.; Pasotti, C.; Pasowicz, M.; Pecce, P.; Pell, A. C. H.; Penkov, N. I.; Perez de Juan, M.; Perez, H.; Petersen, M.; Petrov, A. A.; Peuhkurinen, K.; Philonenko, X.; Pieper, M.; Pieske, B.; Pluta, W.; Podzemska, B.; Popeye, R.; Prost, C.; Purcaro, A.; Put, P.; Radchenko, V.; Radoi, M.; Rae, A. P.; Raev, D.; Ramik, C.; Rasmussen, S. L.; Reisin, L.; Renker, B.; Ribeiro, V. G.; Richardt, G.; Rjecansky, I.; Risenfors, M.; Rivis, I. A.; Robson, R. H.; Rocher, R.; Rodriquez Padial, L.; Rose, E. L.; Rosen, S. D.; Rosenfeld, T.; Rowlands, D. B.; Rozkovec, A.; Rudas, L.; Rudenko, L. V.; Ruiz-Rejon, F.; Rutsch, W.; Rybar, R.; Rybka, J.; Saetre, H. A.; Sarosi, I.; Savalle, L. H.; Schmidt, A.; Schuren, K. P.; Schwartz, Y.; Schwinger, R.; Schwob, J. P.; Scott, D.; Sechtem, U.; Sela, O.; Semrad, B.; Senni, M.; Shilkina, N. P.; Shpektor, A.; Silas, J.; Sindone, A.; Sinescu, C. J.; Sipila, R.; Sirek, J.; Skagen, K.; Shura, M.; Slanina, M.; Slowinski, S.; Smid, J.; Smielak-Korombel, W.; Solodky, A.; Spacek, R.; Squire, I.; Steingo, L.; Stepinska, J.; Stogowski, A.; Storzhakov, G.; Striouk, R.; Strunge, P.; Suter, T.; Svitil, P.; Swedberg, K.; Swidzinski, M.; Syvolap, V. D.; Sztajzel, J.; Tahk, S. J.; Tans, A. C.; Tans, J. G. M.; Targonski, R.; Tarjan, J.; Tartagni, F.; Tchartchoglian, R.; Tebloev, K.; Teesalu, R.; Ten Kate, J. B. L.; Terrosu, P.; Thompson, P. L.; Thybo, N. K.; Thygesen, K.; Tilon, P. A.; Timar, S.; Titkov, Y.; Titlbach, O. J.; Torp-Pedersen, C.; Torvik, D. T.; Touboul, P.; Trelawny, J. M.; Trillo Nouche, R.; Trochina, E.; Trojnar, R.; Tzekova, M. L.; Tzivoni, D.; Vahula, V.; Valagussa, F.; Valdes, M.; Van Der Heijden, R.; Van Der Sloot, J. A. P.; Van Hal, J. M. C.; Van Kempen, L. H. J.; Van Mieghem, W.; Van Rugge, F. P.; Van Veldhuisen, D. J.; Van Vlies, B.; Van Wijk, L. M.; Vasyuk, Y.; Vatutin, M.; Vered, Z.; Vergoni, W.; Vertkine, A.; Vigholt, E.; Vishnevskiy, A.; Voegelin, H.-P.; Voipio-Pulkki, L. M.; Von Mengden, H.-J.; Waites, J.; Watson, R. D. S.; Weiss, A. T.; Werner, H. A.; Wesdorp, J. C. L.; White, H.; Wiggers, P.; Wilcox, R. G.; Wilkinson, P.; Willems, A. R.; Willenbrock, R.; Wirth, M.; Wojciechowski, D.; Worth, H.; Wray, R.; Wu, C.-J.; Yakusevich, V. V.; Yang, S.-P.; Yarohno, N.; Zadionchenko, V. S.; Zaleska, T.; Zalewski, M.; Zannad, F.; Zateyshchikov, D.; Zeltin-Abramov, E.; Zeymer, U.; Zimmermann, R.; Albuquerque, D. C.; Alcaino, M.; Allall, O. A.; Beer, N.; Bortman, G.; Botero, R.; Cardoso, J. S.; Carrageta, M.; Carrillo, E.; Carvalho, A. C.; Castano, R.; Ceia, F.; Cesar, L. A. M.; Chevez, E.; Coelho, O. R.; Colombo, H. R.; Corbalan, R.; Doval, H.; Dutra, O.; Franken, R. A.; Gallardo, L.; Garcia, A.; Garcia, J.; Gomez, E. A.; Gomez, E.; Gonzalez, J.; Gonzalez, R. A.; Greque, G. V.; Guzman, L.; Haiek, J. C.; Hernandez, E.; Hominal, M. A.; Isea, J.; Lanas, F.; Leiva, J. L.; Lemus, J.; Llancaqueo, A.; Lopez, N.; Lousada, N.; Maia, L. N.; Maranhao, M. F.; Martinez, J. A.; Martinez, F. A.; Martins, F. A.; Martins, L.; Matadamas, N.; Matiz, H.; Mendoza, I.; Menezes, C.; Moises, O.; Moreira, J. I.; Moura, J. C.; Nicolau, J. C.; Nobrega, J.; Null, D.; Oliveira, M. S.; Palacios, A. O.; Pazin Filho, A.; Perrone, S. V.; Peigas, L. S.; Prieto, J. C.; Junior, A. R.; Rassi, S.; Ribeiro, V. G.; Rico, J. N.; Rivera, J. M.; Robledo, G.; Rodriguez, H.; Rosenthal, J.; Rossi, P. R. F.; Saraiva, J. F.; Soifer, S.; Sosa Liprandi, A.; Torres, H. G.; Uruchurtu, E.; Velasco, R. G.; Velasquez, J. G.; Vita, N.; Waich, S.; Zelaya, F. R.; Abariotis, N.; Abdollah, H.; Abraham, W.; Alaie, D.; Allison, W.; Ameen, A.; Amidi, M.; Anand, I.; Anderson, J. L.; Andreae, G. E.; Aquino, V.; Ballard, W.; Banas, J. S.; Baron, S. B.; Bata, I.; Berk, M. R.; Bhesania, T.; Binkley, P.; Booth, D. C.; Borts, D.; Brookfield, L. A.; Brown, C. S.; Browne, K. F.; Butman, S. M.; Capodilupo, R. C.; Caralis, D. G.; Carr, K. W.; Castan, R.; Chadow, H.; Chalavarya, G. K.; Chua, G. L.; Cinderella, J. A.; Clavette, P.; Clemson, B. S.; Cohen, T. J.; Colfer, H. T.; Corder, C. N.; Courtade, D. J.; Courtney, D. L.; Coutu, B.; Cucher, F. H.; Czarnecki, W.; Danisa, K.; D'Astous, M.; Dauber, I.; Davies, R.; Deedwania, P. C.; Delehanty, J. M.; Denny, D. M.; Denys, B. G.; DeYoung, P. J. P.; Dion, D.; Donohue, T. J.; El Shahawy, M.; Elkayam, U.; Escabi, J.; Essandoh, L. K.; Felicetta, J. V.; Fintel, D.; Fontaine, J. M.; Foster, R. E.; Frank, T. A.; Gin, K.; Goldberg, M. C.; Goldman, S.; Gossard, D.; Gosselin, G.; Gradman, A. H.; Grandmont, D.; Hack, T.; Hagar, J.; Haikal, M.; Hall, S. A.; Halpern, S.; Hanley, H. G.; Hanovich, G. D.; Hargrove, J. L.; Harlamert, E. A.; Hastings, T. E.; Hathaway, W. R.; Haught, W. H.; Hilliard, G. K.; Hodsden, J.; Hui, W.; Hurley, W.; Ibrahim, H. M.; Jafri, S.; Jain, A.; Jennison, S.; Jesse, R. L.; Joseph, J.; Kalman, J.; Karisberg, R. P.; Khant, R.; Koren, M.; Kosinski, E. J.; Kosolcharoen, P.; Kostuk, W. J.; Kouz, S. M.; Lai, C.; Langholz, D. E.; LeJemtel, T. H.; Leader, R.; Leblanc, M.-H.; Lee, H.; Lepage, S.; Lopez, M.; Lu, D. Y.; Lubelsky, B. J.; Luckasen, G. J.; Ma, P.-T.-S.; MacCallum, C. G.; Madu, E. C.; Maisel, A. S.; Mallis, G. I.; Mann, J. T.; Marr, D. R.; McGrew, F. A., III; McKay, R. J.; Mclellan, B.; Meisner, J.; Meyer, T.; Mikati, I.; Miller, L. A.; Miller, L. W.; Moe, G. W.; Mohiuddin, S. M.; Moir, G. D.; Morgan, A. W.; Morris, A.; Murphy, B. J.; Nallasivan, M.; Narula, J.; Nicklas, J. M.; Niederman, A. L.; Nitkin, R.; O'Keefe, J. H.; Oken, K. R.; O'Neill, P. G.; Orchard, R. C.; O'Riordan, W. D.; Paraboschi, C. F.; Patel, R. I.; Pennock, G.; Pesant, Y.; Phaneuf, D.; Phillips, D. F.; Plehn, J.; Promisloff, S.; Rajakumar, A. J.; Ramadurai, R.; Rashkow, A.; Rauh, R. A.; Rebane, T. M.; Riba, A. L.; Richard, C.; Riddle, J. C.; Ringuette, G.; Rivera, E.; Rockson, S.; Rogers, E.; Ross, H.; Roux, R.; Rupka, D.; Saenz, A.; Sampson, J.; Schulman, S. P.; Schuyler, G.; Sequeira, R. F.; Shah, A. R.; Shah, P. K.; Shakar, S. F.; Shalev, Y.; Sheikh, K. H.; Shettigar, U. R.; Siegel, R. M.; Sigal, S. L.; Singh, V. N.; Sotolongo, C. M.; Soucier, R. J.; Stagaman, D. J.; Stephan, W. J.; Stine, M.; Stoever, W. W.; Talano, J. V.; Tan, J. L.; Tanser, P. H.; Taussig, A. S.; Thadani, U.; Timmis, S. B. H.; Timothee, J. R.; Tragoon, S.; Tremblay, B.; Upadhya, K. J.; Vijay, N. K.; Wagoner, L. E.; Walker, J. L.; Wickemeyer, W. J.; Williams, G. A.; Williams, M. B.; Williams, R. E.; Wiseman, A. H.; Wool, K. J.; Yasin, M.; Zabalgoitia, M.; Zarich, S.; Zimmermann, R.; Zucker, R. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1309-1321</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure.  We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.  Methods: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a max. of 50 mg per day; 3313 patients) or placebo (3319 patients) in addn. to optimal medical therapy.  The study continued until 1012 deaths occurred.  The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia.  Results: During a mean follow-up of 16 mo, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008).  Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P= 0.005).  The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02).  There was also a redn. in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03).  The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001).  Conclusions: The addn. of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTXvg9fCdjlrVg90H21EOLACvtfcHk0lgVItf1lVJFww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1ehurY%253D&md5=cee432bc75bcca5f33098fe3bc8575df</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa030207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa030207%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DB.%26aulast%3DRemme%26aufirst%3DW.%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DNeaton%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DF.%26aulast%3DRoniker%26aufirst%3DB.%26atitle%3DEplerenone%252C%2520a%2520selective%2520aldosterone%2520blocker%252C%2520in%2520patients%2520with%2520left%2520ventricular%2520dysfunction%2520after%2520myocardial%2520infarction%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D1309%26epage%3D1321%26doi%3D10.1056%2FNEJMoa030207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Pitt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeffer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assmann, S. F.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Spironolactone for heart failure with preserved ejection fraction</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1383</span><span class="NLM_x">–</span> <span class="NLM_lpage">1392</span><span class="refDoi"> DOI: 10.1056/NEJMoa1313731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1056%2FNEJMoa1313731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=24716680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVWruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1383-1392&author=B.+Pittauthor=M.+A.+Pfefferauthor=S.+F.+Assmann&title=Spironolactone+for+heart+failure+with+preserved+ejection+fraction&doi=10.1056%2FNEJMoa1313731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Spironolactone for heart failure with preserved ejection fraction</span></div><div class="casAuthors">Pitt, Bertram; Pfeffer, Marc A.; Assmann, Susan F.; Boineau, Robin; Anand, Inder S.; Claggett, Brian; Clausell, Nadine; Desai, Akshay S.; Diaz, Rafael; Fleg, Jerome L.; Gordeev, Ivan; Harty, Brian; Heitner, John F.; Kenwood, Christopher T.; Lewis, Eldrin F.; O'Meara, Eileen; Probstfield, Jeffrey L.; Shaburishvili, Tamaz; Shah, Sanjiv J.; Solomon, Scott D.; Sweitzer, Nancy K.; Yang, Song; McKinlay, Sonja M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1383-1392</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction.  We evaluated the effects of spironolactone in patients with heart failure and a preserved left ventricular ejection fraction.  Methods: In this randomized, double-blind trial, we assigned 3445 patients with symptomatic heart failure and a left ventricular ejection fraction of 45% or more to receive either spironolactone (15 to 45 mg daily) or placebo.  The primary outcome was a composite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure.  Results: With a mean follow-up of 3.3 years, the primary outcome occurred in 320 of 1722 patients in the spironolactone group (18.6%) and 351 of 1723 patients in the placebo group (20.4%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.77 to 1.04; P = 0.14).  Of the components of the primary outcome, only hospitalization for heart failure had a significantly lower incidence in the spironolactone group than in the placebo group (206 patients [12.0%] vs. 245 patients [14.2%]; hazard ratio, 0.83; 95% CI, 0.69 to 0.99, P = 0.04).  Neither total deaths nor hospitalizations for any reason were significantly reduced by spironolactone.  Treatment with spironolactone was assocd. with increased serum creatinine levels and a doubling of the rate of hyperkalemia (18.7%, vs. 9.1% in the placebo group) but reduced hypokalemia.  With frequent monitoring, there were no significant differences in the incidence of serious adverse events, a serum creatinine level of 3.0 mg per dL (265 μmol per L) or higher, or dialysis.  Conclusions: In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquf161Fxn0rbVg90H21EOLACvtfcHk0lgVItf1lVJFww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVWruro%253D&md5=10f6b7c33366f3aea226f3e1210c25bc</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1313731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1313731%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DB.%26aulast%3DPfeffer%26aufirst%3DM.%2BA.%26aulast%3DAssmann%26aufirst%3DS.%2BF.%26atitle%3DSpironolactone%2520for%2520heart%2520failure%2520with%2520preserved%2520ejection%2520fraction%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1383%26epage%3D1392%26doi%3D10.1056%2FNEJMoa1313731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, S.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Sanchez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, R. B.</span><span> </span><span class="NLM_article-title">Does aldosterone upregulate the brain renin- angiotensin system in rats with heart failure?</span> <span class="citation_source-journal">Hypertension</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">733</span><span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.107.099796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1161%2FHYPERTENSIONAHA.107.099796" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=727-733&author=Y.+Yuauthor=S.-G.+Weiauthor=Z.-H.+Zhangauthor=E.+Gomez-Sanchezauthor=R.+M.+Weissauthor=R.+B.+Felder&title=Does+aldosterone+upregulate+the+brain+renin-+angiotensin+system+in+rats+with+heart+failure%3F&doi=10.1161%2FHYPERTENSIONAHA.107.099796"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.107.099796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.107.099796%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DS.-G.%26aulast%3DZhang%26aufirst%3DZ.-H.%26aulast%3DGomez-Sanchez%26aufirst%3DE.%26aulast%3DWeiss%26aufirst%3DR.%2BM.%26aulast%3DFelder%26aufirst%3DR.%2BB.%26atitle%3DDoes%2520aldosterone%2520upregulate%2520the%2520brain%2520renin-%2520angiotensin%2520system%2520in%2520rats%2520with%2520heart%2520failure%253F%26jtitle%3DHypertension%26date%3D2008%26volume%3D51%26spage%3D727%26epage%3D733%26doi%3D10.1161%2FHYPERTENSIONAHA.107.099796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Williams, J. S.</span><span> </span><span class="NLM_article-title">Evolving research in nongenomic actions of aldosterone</span> <span class="citation_source-journal">Curr. Opin. Endocrinol., Diabetes Obes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1097/MED.0b013e328360c200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1097%2FMED.0b013e328360c200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=23519092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1ens7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=198-203&author=J.+S.+Williams&title=Evolving+research+in+nongenomic+actions+of+aldosterone&doi=10.1097%2FMED.0b013e328360c200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Evolving research in nongenomic actions of aldosterone</span></div><div class="casAuthors">Williams, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Endocrinology, Diabetes and Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">COEDFK</span>;
        ISSN:<span class="NLM_cas:issn">1752-296X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Aldosterone is now recognized as an increasingly important contributor to cardiometabolic pathol. via inflammatory and fibrosis-related pathways in addn. to its classically described role in sodium and vol. regulation.  Consequently, much effort has been directed towards characterizing the mol. pathways involved in aldosterone-mediated fibrosis and inflammation.  What was once viewed as straightforward steroid hormone biol. is now appreciated as a highly complex and tightly regulated series of pathways and interactions.  These recognitions have fuelled a multidisciplinary effort to identify precisely how aldosterone mediates intracellular activation of both genomic (latent) and nongenomic (rapid) mechanisms of influence.  This review will explore recent novel pathways regulating aldosterone action, focusing on the nongenomic pathways.  Recent findings: Several recent discoveries have redefined our understanding of aldosterone interactions at the cellular level.  This includes activation of the mineralocorticoid receptor at the plasma membrane instead of via classical nuclear hormone receptor interaction, and identification of novel cofactor scaffolding proteins that modify aldosterone influence at the cellular level.  In addn., aldosterone activation of secondary messenger system cascades can occur directly and independent of mineralocorticoid receptor interaction.  Summary: Substantial progress in detailing the mol. biol. of aldosterone regulation and action should facilitate study of how it exerts detrimental effects in cardiometabolic diseases.  However, to date, the clin. impact of these discoveries has not been validated.  Translational efforts are now required to det. if novel therapeutic targets can be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAysZZicBVGbVg90H21EOLACvtfcHk0lgVItf1lVJFww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1ens7w%253D&md5=a81a4387404a0cca288612daf8473973</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2FMED.0b013e328360c200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMED.0b013e328360c200%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DJ.%2BS.%26atitle%3DEvolving%2520research%2520in%2520nongenomic%2520actions%2520of%2520aldosterone%26jtitle%3DCurr.%2520Opin.%2520Endocrinol.%252C%2520Diabetes%2520Obes.%26date%3D2013%26volume%3D20%26spage%3D198%26epage%3D203%26doi%3D10.1097%2FMED.0b013e328360c200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mellin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMeglio, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuillez, C.</span><span> </span><span class="NLM_article-title">Long-term aldosterone synthase inhibition improves cardiac function and myocardial structure in chronic heart failure</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x"> (</span><span class="NLM_issue">17, Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">III-102</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2004&pages=III-102&issue=17%2C+Suppl.+3&author=V.+Mellinauthor=P.+Mulderauthor=B.+DiMeglioauthor=J.+P.+Henryauthor=A.+Y.+Jengauthor=R.+L.+Webbauthor=C.+Thuillez&title=Long-term+aldosterone+synthase+inhibition+improves+cardiac+function+and+myocardial+structure+in+chronic+heart+failure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMellin%26aufirst%3DV.%26aulast%3DMulder%26aufirst%3DP.%26aulast%3DDiMeglio%26aufirst%3DB.%26aulast%3DHenry%26aufirst%3DJ.%2BP.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DWebb%26aufirst%3DR.%2BL.%26aulast%3DThuillez%26aufirst%3DC.%26atitle%3DLong-term%2520aldosterone%2520synthase%2520inhibition%2520improves%2520cardiac%2520function%2520and%2520myocardial%2520structure%2520in%2520chronic%2520heart%2520failure%26jtitle%3DCirculation%26date%3D2004%26volume%3D110%26issue%3D17%252C%2520Suppl.%25203%26spage%3DIII-102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fiebeler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussberger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shagdarsuren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilfenhaus, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Saadi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dechend, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meiners, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maser-Gluth, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luft, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, D. N.</span><span> </span><span class="NLM_article-title">Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">3087</span><span class="NLM_x">–</span> <span class="NLM_lpage">3094</span><span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.104.521625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1161%2FCIRCULATIONAHA.104.521625" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2005&pages=3087-3094&author=A.+Fiebelerauthor=J.+Nussbergerauthor=E.+Shagdarsurenauthor=S.+Rongauthor=G.+Hilfenhausauthor=N.+Al-Saadiauthor=R.+Dechendauthor=M.+Wellnerauthor=S.+Meinersauthor=C.+Maser-Gluthauthor=A.+Y.+Jengauthor=R.+L.+Webbauthor=F.+C.+Luftauthor=D.+N.+Muller&title=Aldosterone+synthase+inhibitor+ameliorates+angiotensin+II-induced+organ+damage&doi=10.1161%2FCIRCULATIONAHA.104.521625"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.104.521625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.104.521625%26sid%3Dliteratum%253Aachs%26aulast%3DFiebeler%26aufirst%3DA.%26aulast%3DNussberger%26aufirst%3DJ.%26aulast%3DShagdarsuren%26aufirst%3DE.%26aulast%3DRong%26aufirst%3DS.%26aulast%3DHilfenhaus%26aufirst%3DG.%26aulast%3DAl-Saadi%26aufirst%3DN.%26aulast%3DDechend%26aufirst%3DR.%26aulast%3DWellner%26aufirst%3DM.%26aulast%3DMeiners%26aufirst%3DS.%26aulast%3DMaser-Gluth%26aufirst%3DC.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DWebb%26aufirst%3DR.%2BL.%26aulast%3DLuft%26aufirst%3DF.%2BC.%26aulast%3DMuller%26aufirst%3DD.%2BN.%26atitle%3DAldosterone%2520synthase%2520inhibitor%2520ameliorates%2520angiotensin%2520II-induced%2520organ%2520damage%26jtitle%3DCirculation%26date%3D2005%26volume%3D111%26spage%3D3087%26epage%3D3094%26doi%3D10.1161%2FCIRCULATIONAHA.104.521625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rigel, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span> </span><span class="NLM_article-title">Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: Comparison with the 11β-hydroxylase inhibitor metyrapone</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">334</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span><span class="refDoi"> DOI: 10.1124/jpet.110.167148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1124%2Fjpet.110.167148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=20354176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Kltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2010&pages=232-243&author=D.+F.+Rigelauthor=F.+Fuauthor=M.+Beilauthor=C.-W.+Huauthor=G.+Liangauthor=A.+Y.+Jeng&title=Pharmacodynamic+and+pharmacokinetic+characterization+of+the+aldosterone+synthase+inhibitor+FAD286+in+two+rodent+models+of+hyperaldosteronism%3A+Comparison+with+the+11%CE%B2-hydroxylase+inhibitor+metyrapone&doi=10.1124%2Fjpet.110.167148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: Comparison with the 11β-hydroxylase inhibitor metyrapone</span></div><div class="casAuthors">Rigel, Dean F.; Fu, Fumin; Beil, Michael; Hu, Chii-Whei; Liang, Guiqing; Jeng, Arco Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">232-243</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Aldosterone synthase (CYP11B2) inhibitors (ASIs) represent an attractive therapeutic approach for mitigating the untoward effects of aldosterone.  We characterized the pharmacokinetic/pharmacodynamic relationships of a prototypical ASI, (+)-(5R)-4-(5,6,7,8)-tetrahydroimidazo[1,5-a]pyridin[-5-yl]benzonitrile hydrochloride (CGS020286A, FAD286, FAD) and compared these profiles to those of the 11β-hydroxylase inhibitor metyrapone (MET) in two rodent models of secondary hyperaldosteronism and corticosteronism.  In chronically cannulated Sprague-Dawley rats, angiotensin II (ANG II) (300 ng/kg bolus + 100 ng/kg/min infusion) or ACTH (100 ng/kg + 30 ng/kg/min) acutely elevated plasma aldosterone concn. (PAC) from ∼0.26 nM to a sustained level of ∼2.5 nM for 9 h.  ACTH but not ANG II elicited a sustained increase in plasma corticosterone concn. (PCC) from ∼300 to ∼1340 nM.  After 1 h of Ang II or ACTH infusion, FAD (0.01-100 mg/kg p.o.) or MET (0.1-300 mg/kg p.o.) dose- and drug plasma concn.-dependently reduced the elevated PACs over the ensuing 8 h.  FAD was ∼12 times more dose-potent than MET in reducing PAC but of similar or slightly greater potency on a plasma drug concn. basis.  Both agents also decreased PCC in the ACTH model at relatively higher doses and with similar dose potencies, whereas FAD was 6-fold weaker based on drug exposures.  FAD was ∼50-fold selective for reducing PAC vs. PCC, whereas MET was only ∼3-fold selective.  We conclude that FAD is a potent, orally active, and relatively selective ASI in two rat models of hyperaldosteronism.  MET is an order of magnitude less selective than FAD but is, nevertheless, more potent as an ASI than as an 11β-hydroxylase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrWGil-eW3uLVg90H21EOLACvtfcHk0ljObm0Cvc2rzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Kltbw%253D&md5=0b3cfae4e1717c658e944a9bab8bd11b</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.167148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.167148%26sid%3Dliteratum%253Aachs%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DFu%26aufirst%3DF.%26aulast%3DBeil%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DC.-W.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26atitle%3DPharmacodynamic%2520and%2520pharmacokinetic%2520characterization%2520of%2520the%2520aldosterone%2520synthase%2520inhibitor%2520FAD286%2520in%2520two%2520rodent%2520models%2520of%2520hyperaldosteronism%253A%2520Comparison%2520with%2520the%252011%25CE%25B2-hydroxylase%2520inhibitor%2520metyrapone%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D334%26spage%3D232%26epage%3D243%26doi%3D10.1124%2Fjpet.110.167148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Lea, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fowler, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogo, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N. J.</span><span> </span><span class="NLM_article-title">Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt</span> <span class="citation_source-journal">Kidney Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">936</span><span class="NLM_x">–</span> <span class="NLM_lpage">944</span><span class="refDoi"> DOI: 10.1038/ki.2009.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1038%2Fki.2009.9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=19225557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1Sjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2009&pages=936-944&author=W.+B.+Leaauthor=E.+S.+Kwakauthor=J.+M.+Lutherauthor=S.+M.+Fowlerauthor=Z.+Wangauthor=J.+Maauthor=A.+B.+Fogoauthor=N.+J.+Brown&title=Aldosterone+antagonism+or+synthase+inhibition+reduces+end-organ+damage+induced+by+treatment+with+angiotensin+and+high+salt&doi=10.1038%2Fki.2009.9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10d</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt</span></div><div class="casAuthors">Lea, William B.; Kwak, Eun Soo; Luther, James M.; Fowler, Susan M.; Wang, Zuofei; Ma, Ji; Fogo, Agnes B.; Brown, Nancy J.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">936-944</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the setting of high salt intake, aldosterone stimulates fibrosis in the heart, great vessels, and kidney of rats.  We used uninephrectomized rats treated with angiotensin II and placed on a high salt diet to exaggerate renal fibrosis.  We then tested whether mineralocorticoid receptor blockade by spironolactone or aldosterone synthase inhibition by FAD286 have similar effects on end-organ damage and gene expression.  Individually, both drugs prevented the hypertensive response to uninephrectomy and high salt intake but not when angiotensin II was administered.  Following 4 wk of treatment with FAD286, plasma aldosterone was reduced, whereas spironolactone increased aldosterone at 8 wk of treatment.  Angiotensin II and high salt treatment caused albuminuria, azotemia, renovascular hypertrophy, glomerular injury, increased plasminogen activator inhibitor-1 (PAI-1), and osteopontin mRNA expression, as well as tubulointerstitial fibrosis in the kidney.  Both drugs prevented these renal effects and attenuated cardiac and aortic medial hypertrophy while reducing osteopontin and transforming growth factor-β mRNA expression in the aorta.  The two drugs also reduced cardiac interstitial fibrosis but had no effect on that of the perivascular region.  Although spironolactone enhanced angiotensin II and salt-stimulated PAI-1 mRNA expression in aorta and heart, spironolactone and FAD286 prevented renal PAI-1 mRNA protein expression.  Our study shows that mineralocorticoid receptor antagonism and aldosterone synthase inhibition similarly decrease hypertrophy and interstitial fibrosis of the kidney and heart caused by angiotensin II and high salt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGtACkjwhczrVg90H21EOLACvtfcHk0ljObm0Cvc2rzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1Sjs7o%253D&md5=1f691ea9e6284a314792e478e8162566</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1038%2Fki.2009.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2009.9%26sid%3Dliteratum%253Aachs%26aulast%3DLea%26aufirst%3DW.%2BB.%26aulast%3DKwak%26aufirst%3DE.%2BS.%26aulast%3DLuther%26aufirst%3DJ.%2BM.%26aulast%3DFowler%26aufirst%3DS.%2BM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DFogo%26aufirst%3DA.%2BB.%26aulast%3DBrown%26aufirst%3DN.%2BJ.%26atitle%3DAldosterone%2520antagonism%2520or%2520synthase%2520inhibition%2520reduces%2520end-organ%2520damage%2520induced%2520by%2520treatment%2520with%2520angiotensin%2520and%2520high%2520salt%26jtitle%3DKidney%2520Int.%26date%3D2009%26volume%3D75%26spage%3D936%26epage%3D944%26doi%3D10.1038%2Fki.2009.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Mulder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vercauteren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remy-Jouet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteil, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuillez, C.</span><span> </span><span class="NLM_article-title">Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2171</span><span class="NLM_x">–</span> <span class="NLM_lpage">2179</span><span class="refDoi"> DOI: 10.1093/eurheartj/ehn277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1093%2Feurheartj%2Fehn277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=18586661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFOmsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=2171-2179&author=P.+Mulderauthor=V.+Mellinauthor=J.+Favreauthor=M.+Vercauterenauthor=I.+Remy-Jouetauthor=C.+Monteilauthor=V.+Richardauthor=S.+Renetauthor=J.+P.+Henryauthor=A.+Y.+Jengauthor=R.+L.+Webbauthor=C.+Thuillez&title=Aldosterone+synthase+inhibition+improves+cardiovascular+function+and+structure+in+rats+with+heart+failure%3A+a+comparison+with+spironolactone&doi=10.1093%2Feurheartj%2Fehn277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10eR"><div class="casContent"><span class="casTitleNuber">10e</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone</span></div><div class="casAuthors">Mulder, Paul; Mellin, Virginie; Favre, Julie; Vercauteren, Magali; Remy-Jouet, Isabelle; Monteil, Christelle; Richard, Vincent; Renet, Sylvanie; Henry, Jean Paul; Jeng, Arco Y.; Webb, Randy L.; Thuillez, Christian</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2171-2179</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims: Inhibition of aldosterone synthase, the key enzyme in aldosterone formation, could be an alternative strategy for mineralocorticoid-receptor antagonists in congestive heart failure (CHF), but its effect in CHF is unknown.  Methods and results: We compared, in rats with CHF, the effects of a 7 day and a 12 wk treatment with the aldosterone synthase inhibitor FAD286 (4 mg kg-1 day-1) with those induced by spironolactone (80 mg kg-1 day-1).  FAD286/spironolactone increased cardiac output without modifying arterial pressure.  Long-term FAD286 and spironolactone reduced left ventricular (LV) end-diastolic pressure, LV relaxation const., and LV dilatation, and these effects were more marked with FAD286, whereas both drugs reduced LV hypertrophy and collagen accumulation to the same extent.  Long-term FAD286/spironolactone prevented CHF-related enhancement in LV ACE and redn. in LV ACE-2, but only FAD286 prevented the redn. in LV AT2 receptors.  FAD286, but not long-term spironolactone, reduced the CHF-related enhancements in LV reactive oxygen species, reduced-oxidized glutathione ratio, and aortic NADP oxidase activity.  FAD286 normalized the CHF-induced impairment of endothelium-dependent vasodilatation.  Conclusion: In exptl. CHF, FAD286 and spironolactone improve LV hemodynamics, remodelling, and function, but only FAD286 persistently normalizes LV 'redox status'.  These results suggest that aldosterone synthase inhibition is a potential therapeutic strategy for the treatment of CHF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0uwXfSDx1HbVg90H21EOLACvtfcHk0liT1oAza4hXdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFOmsrjE&md5=5791341d03c3c8e58bbe3a6e134c3db8</span></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehn277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehn277%26sid%3Dliteratum%253Aachs%26aulast%3DMulder%26aufirst%3DP.%26aulast%3DMellin%26aufirst%3DV.%26aulast%3DFavre%26aufirst%3DJ.%26aulast%3DVercauteren%26aufirst%3DM.%26aulast%3DRemy-Jouet%26aufirst%3DI.%26aulast%3DMonteil%26aufirst%3DC.%26aulast%3DRichard%26aufirst%3DV.%26aulast%3DRenet%26aufirst%3DS.%26aulast%3DHenry%26aufirst%3DJ.%2BP.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DWebb%26aufirst%3DR.%2BL.%26aulast%3DThuillez%26aufirst%3DC.%26atitle%3DAldosterone%2520synthase%2520inhibition%2520improves%2520cardiovascular%2520function%2520and%2520structure%2520in%2520rats%2520with%2520heart%2520failure%253A%2520a%2520comparison%2520with%2520spironolactone%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2008%26volume%3D29%26spage%3D2171%26epage%3D2179%26doi%3D10.1093%2Feurheartj%2Fehn277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Huang, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leenen, F. H. H.</span><span> </span><span class="NLM_article-title">Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in Wistar rats</span> <span class="citation_source-journal">Am. J. Phys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">R166</span><span class="NLM_x">–</span> <span class="NLM_lpage">R172</span><span class="refDoi"> DOI: 10.1152/ajpregu.90352.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1152%2Fajpregu.90352.2008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2008&pages=R166-R172&author=B.+S.+Huangauthor=R.+A.+Whiteauthor=M.+Ahmadauthor=A.+Y.+Jengauthor=F.+H.+H.+Leenen&title=Central+infusion+of+aldosterone+synthase+inhibitor+prevents+sympathetic+hyperactivity+and+hypertension+by+central+Na%2B+in+Wistar+rats&doi=10.1152%2Fajpregu.90352.2008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10f&amp;dbid=16384&amp;doi=10.1152%2Fajpregu.90352.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpregu.90352.2008%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DB.%2BS.%26aulast%3DWhite%26aufirst%3DR.%2BA.%26aulast%3DAhmad%26aufirst%3DM.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DLeenen%26aufirst%3DF.%2BH.%2BH.%26atitle%3DCentral%2520infusion%2520of%2520aldosterone%2520synthase%2520inhibitor%2520prevents%2520sympathetic%2520hyperactivity%2520and%2520hypertension%2520by%2520central%2520Na%252B%2520in%2520Wistar%2520rats%26jtitle%3DAm.%2520J.%2520Phys.%26date%3D2008%26volume%3D295%26spage%3DR166%26epage%3DR172%26doi%3D10.1152%2Fajpregu.90352.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Minnaard-Huiban, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmen, J. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roumen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beugels, I. P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohuet, G. M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Essen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruijters, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieterse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilbers, P. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottenheijm, H. C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plate, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Gooyer, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, J. F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermans, J. J. R.</span><span> </span><span class="NLM_article-title">Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1210/en.2007-0584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1210%2Fen.2007-0584" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2008&pages=28-31&author=M.+Minnaard-Huibanauthor=J.+M.+A.+Emmenauthor=L.+Roumenauthor=I.+P.+E.+Beugelsauthor=G.+M.+S.+Cohuetauthor=H.+van+Essenauthor=E.+Ruijtersauthor=K.+Pieterseauthor=P.+A.+J.+Hilbersauthor=H.+C.+J.+Ottenheijmauthor=R.+Plateauthor=M.+E.+de+Gooyerauthor=J.+F.+M.+Smitsauthor=J.+J.+R.+Hermans&title=Fadrozole+reverses+cardiac+fibrosis+in+spontaneously+hypertensive+heart+failure+rats%3A+discordant+enantioselectivity+versus+reduction+of+plasma+aldosterone&doi=10.1210%2Fen.2007-0584"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10g&amp;dbid=16384&amp;doi=10.1210%2Fen.2007-0584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2007-0584%26sid%3Dliteratum%253Aachs%26aulast%3DMinnaard-Huiban%26aufirst%3DM.%26aulast%3DEmmen%26aufirst%3DJ.%2BM.%2BA.%26aulast%3DRoumen%26aufirst%3DL.%26aulast%3DBeugels%26aufirst%3DI.%2BP.%2BE.%26aulast%3DCohuet%26aufirst%3DG.%2BM.%2BS.%26aulast%3Dvan%2BEssen%26aufirst%3DH.%26aulast%3DRuijters%26aufirst%3DE.%26aulast%3DPieterse%26aufirst%3DK.%26aulast%3DHilbers%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DOttenheijm%26aufirst%3DH.%2BC.%2BJ.%26aulast%3DPlate%26aufirst%3DR.%26aulast%3Dde%2BGooyer%26aufirst%3DM.%2BE.%26aulast%3DSmits%26aufirst%3DJ.%2BF.%2BM.%26aulast%3DHermans%26aufirst%3DJ.%2BJ.%2BR.%26atitle%3DFadrozole%2520reverses%2520cardiac%2520fibrosis%2520in%2520spontaneously%2520hypertensive%2520heart%2520failure%2520rats%253A%2520discordant%2520enantioselectivity%2520versus%2520reduction%2520of%2520plasma%2520aldosterone%26jtitle%3DEndocrinology%26date%3D2008%26volume%3D149%26spage%3D28%26epage%3D31%26doi%3D10.1210%2Fen.2007-0584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Ménard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascoe, L.</span><span> </span><span class="NLM_article-title">Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?</span> <span class="citation_source-journal">J. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">997</span><span class="refDoi"> DOI: 10.1097/01.hjh.0000226183.98439.b3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1097%2F01.hjh.0000226183.98439.b3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=16685193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD28Xktlartrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=993-997&author=J.+M%C3%A9nardauthor=L.+Pascoe&title=Can+the+dextroenantiomer+of+the+aromatase+inhibitor+fadrozole+be+useful+for+clinical+investigation+of+aldosterone-synthase+inhibition%3F&doi=10.1097%2F01.hjh.0000226183.98439.b3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10hR"><div class="casContent"><span class="casTitleNuber">10h</span><div class="casTitle"><span class="NLM_cas:atitle">Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?</span></div><div class="casAuthors">Menard, Joel; Pascoe, Leigh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">993-997</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The beneficial effects of spironolactone, eplerenone, amiloride, and potassium in preventing cardiovascular damage in various exptl. models of salt-induced hypertension can be dissocd. from blood pressure effects, and have drawn attention to the direct genomic and non-genomic actions of aldosterone at the level of the vessels, the heart, and the kidneys.  Exposure to endogenous aldosterone could be decreased by direct and specific aldosterone-synthase inhibition.  FAD 286A, the dextroenantiomer of the aromatase inhibitor fadrozole, might be a 1st candidate to investigate in humans, the physiol. impact and therapeutic properties of aldosterone-synthase inhibition, esp. in various forms of primary aldosteronism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-EGh20MtIxLVg90H21EOLACvtfcHk0ljxeKJvUSptMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xktlartrk%253D&md5=e56a1f5ec586a4dfa515f6f995f731c9</span></div><a href="/servlet/linkout?suffix=cit10h&amp;dbid=16384&amp;doi=10.1097%2F01.hjh.0000226183.98439.b3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.hjh.0000226183.98439.b3%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9nard%26aufirst%3DJ.%26aulast%3DPascoe%26aufirst%3DL.%26atitle%3DCan%2520the%2520dextroenantiomer%2520of%2520the%2520aromatase%2520inhibitor%2520fadrozole%2520be%2520useful%2520for%2520clinical%2520investigation%2520of%2520aldosterone-synthase%2520inhibition%253F%26jtitle%3DJ.%2520Hypertens.%26date%3D2006%26volume%3D24%26spage%3D993%26epage%3D997%26doi%3D10.1097%2F01.hjh.0000226183.98439.b3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Meredith, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ksander, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monovich, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papillon, J. P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capparelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigel, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaSala, D.</span><span> </span><span class="NLM_article-title">Discovery and in vivo evaluation of potent dual CYP11B2 (aldosterone synthase) and CYP11B1 inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1203</span><span class="NLM_x">–</span> <span class="NLM_lpage">1207</span><span class="refDoi"> DOI: 10.1021/ml400324c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400324c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Ckt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1203-1207&author=E.+L.+Meredithauthor=G.+Ksanderauthor=L.+G.+Monovichauthor=J.+P.+N.+Papillonauthor=Q.+Liuauthor=K.+Mirandaauthor=P.+Morrisauthor=C.+Raoauthor=R.+Burgisauthor=M.+Capparelliauthor=Q.-Y.+Huauthor=A.+Singhauthor=D.+F.+Rigelauthor=A.+Y.+Jengauthor=M.+Beilauthor=F.+Fuauthor=C.-W.+Huauthor=D.+LaSala&title=Discovery+and+in+vivo+evaluation+of+potent+dual+CYP11B2+%28aldosterone+synthase%29+and+CYP11B1+inhibitors&doi=10.1021%2Fml400324c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors</span></div><div class="casAuthors">Meredith, Erik L.; Ksander, Gary; Monovich, Lauren G.; Papillon, Julien P. N.; Liu, Qian; Miranda, Karl; Morris, Patrick; Rao, Chang; Burgis, Robin; Capparelli, Michael; Hu, Qi-Ying; Singh, Alok; Rigel, Dean F.; Jeng, Arco Y.; Beil, Michael; Fu, Fumin; Hu, Chii-Whei; LaSala, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1203-1207</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aldosterone is a key signaling component of the renin-angiotensin-aldosterone system and as such has been shown to contribute to cardiovascular pathol. such as hypertension and heart failure.  Aldosterone synthase (CYP11B2) is responsible for the final three steps of aldosterone synthesis and thus is a viable therapeutic target.  A series of imidazole derived inhibitors, including clin. candidate I, have been identified through design and structure-activity relationship studies both in vitro and in vivo.  Compd. I was also found to be a potent inhibitor of 11β-hydroxylase (CYP11B1), which is responsible for cortisol prodn.  Inhibition of CYP11B1 is being evaluated in the clinic for potential treatment of hypercortisol diseases such as Cushing's syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZqZXmMc5qE7Vg90H21EOLACvtfcHk0ljxeKJvUSptMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Ckt7vP&md5=3f2301a71dfd1bf91a99ac68f5ca91ff</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fml400324c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400324c%26sid%3Dliteratum%253Aachs%26aulast%3DMeredith%26aufirst%3DE.%2BL.%26aulast%3DKsander%26aufirst%3DG.%26aulast%3DMonovich%26aufirst%3DL.%2BG.%26aulast%3DPapillon%26aufirst%3DJ.%2BP.%2BN.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMiranda%26aufirst%3DK.%26aulast%3DMorris%26aufirst%3DP.%26aulast%3DRao%26aufirst%3DC.%26aulast%3DBurgis%26aufirst%3DR.%26aulast%3DCapparelli%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DQ.-Y.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DBeil%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DC.-W.%26aulast%3DLaSala%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520in%2520vivo%2520evaluation%2520of%2520potent%2520dual%2520CYP11B2%2520%2528aldosterone%2520synthase%2529%2520and%2520CYP11B1%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D1203%26epage%3D1207%26doi%3D10.1021%2Fml400324c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Ménard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigel, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung-Chu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaSala, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dole, W. P.</span><span> </span><span class="NLM_article-title">Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects</span> <span class="citation_source-journal">J. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span><span class="refDoi"> DOI: 10.1186/s12967-014-0340-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1186%2Fs12967-014-0340-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=25491597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVWqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=340-361&author=J.+M%C3%A9nardauthor=D.+F.+Rigelauthor=C.+Watsonauthor=A.+Y.+Jengauthor=F.+Fuauthor=M.+Beilauthor=J.+Liuauthor=W.+Chenauthor=C.-W.+Huauthor=J.+Leung-Chuauthor=D.+LaSalaauthor=G.+Liangauthor=S.+Rebelloauthor=Y.+Zhangauthor=W.+P.+Dole&title=Aldosterone+synthase+inhibition%3A+cardiorenal+protection+in+animal+disease+models+and+translation+of+hormonal+effects+to+human+subjects&doi=10.1186%2Fs12967-014-0340-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects</span></div><div class="casAuthors">Menard, Joel; Rigel, Dean F.; Watson, Catherine; Jeng, Arco Y.; Fu, Fumin; Beil, Michael; Liu, Jing; Chen, Wei; Hu, Chii-Whei; Chu, Jennifer Leung; LaSala, Daniel; Liang, Guiqing; Rebello, Sam; Zhang, Yiming; Dole, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">340/1-340/43</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Aldosterone synthase inhibition provides the potential to attenuate both the mineralocorticoid receptor-dependent and independent actions of aldosterone.  In vitro studies with recombinant human enzymes showed LCI699 to be a potent, reversible, competitive inhibitor of aldosterone synthase (Ki ≃ 1.4 ± 0.2 nmol/L in humans) with relative selectivity over 11β-hydroxylase.  Methods: Hormonal effects of orally administered LCI699 were examd. in rat and monkey in vivo models of adrenocorticotropic hormone (ACTH) and angiotensin-II-stimulated aldosterone release, and were compared with the mineralocorticoid receptor antagonist eplerenone in a randomized, placebo-controlled study conducted in 99 healthy human subjects.  The effects of LCI699 and eplerenone on cardiac and renal sequelae of aldosterone excess were investigated in a double-transgenic rat (dTGR) model overexpressing human renin and angiotensinogen.  Results: Rat and monkey in vivo models of stimulated aldosterone release predicted human dose- and exposure-response relationships, but overestimated the selectivity of LCI699 in humans.  In the dTGR model, LCI699 dose-dependently blocked increases in aldosterone, prevented development of cardiac and renal functional abnormalities independent of blood pressure changes, and prolonged survival.  Eplerenone prolonged survival to a similar extent, but was less effective in preventing cardiac and renal damage.  In healthy human subjects, LCI699 0.5 mg selectively reduced plasma and 24 h urinary aldosterone by 49 ± 3% and 39 ± 6% resp. (Day 1, mean ± SEM; P < 0.001 vs placebo), which was assocd. with natriuresis and an increase in plasma renin activity.  Doses of LCI699 greater than 1 mg inhibited basal and ACTH-stimulated cortisol.  Eplerenone 100 mg increased plasma and 24 h urinary aldosterone while stimulating natriuresis and increasing renin activity.  In contrast to eplerenone, LCI699 increased the aldosterone precursor 11-deoxycorticosterone and urinary potassium excretion.  Conclusions: These results provide new insights into the cardiac and renal effects of inhibiting aldosterone synthase in exptl. models and translation of the hormonal effects to humans.  Selective inhibition of aldosterone synthase appears to be a promising approach to treat diseases assocd. with aldosterone excess.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbaUntldMlobVg90H21EOLACvtfcHk0ljxeKJvUSptMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVWqs7c%253D&md5=c538103c9462fd0a16111a7a7be27bfb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1186%2Fs12967-014-0340-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-014-0340-9%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9nard%26aufirst%3DJ.%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DFu%26aufirst%3DF.%26aulast%3DBeil%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.-W.%26aulast%3DLeung-Chu%26aufirst%3DJ.%26aulast%3DLaSala%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DRebello%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDole%26aufirst%3DW.%2BP.%26atitle%3DAldosterone%2520synthase%2520inhibition%253A%2520cardiorenal%2520protection%2520in%2520animal%2520disease%2520models%2520and%2520translation%2520of%2520hormonal%2520effects%2520to%2520human%2520subjects%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2014%26volume%3D12%26spage%3D340%26epage%3D361%26doi%3D10.1186%2Fs12967-014-0340-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Amar, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azizi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ménard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyrard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plouin, P. F.</span><span> </span><span class="NLM_article-title">Aldosterone synthase inhibition with LCI699: a proof-ofconcept study in patients with primary aldosteronism</span> <span class="citation_source-journal">Hypertension</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">831</span><span class="NLM_x">–</span> <span class="NLM_lpage">838</span><span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.110.157271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1161%2FHYPERTENSIONAHA.110.157271" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2010&pages=831-838&author=L.+Amarauthor=M.+Aziziauthor=J.+M%C3%A9nardauthor=S.+Peyrardauthor=C.+Watsonauthor=P.+F.+Plouin&title=Aldosterone+synthase+inhibition+with+LCI699%3A+a+proof-ofconcept+study+in+patients+with+primary+aldosteronism&doi=10.1161%2FHYPERTENSIONAHA.110.157271"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.110.157271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.110.157271%26sid%3Dliteratum%253Aachs%26aulast%3DAmar%26aufirst%3DL.%26aulast%3DAzizi%26aufirst%3DM.%26aulast%3DM%25C3%25A9nard%26aufirst%3DJ.%26aulast%3DPeyrard%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DPlouin%26aufirst%3DP.%2BF.%26atitle%3DAldosterone%2520synthase%2520inhibition%2520with%2520LCI699%253A%2520a%2520proof-ofconcept%2520study%2520in%2520patients%2520with%2520primary%2520aldosteronism%26jtitle%3DHypertension%26date%3D2010%26volume%3D56%26spage%3D831%26epage%3D838%26doi%3D10.1161%2FHYPERTENSIONAHA.110.157271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Amar, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azizi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ménard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyrard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plouin, P.-F.</span><span> </span><span class="NLM_article-title">Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism</span> <span class="citation_source-journal">J. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">624</span><span class="NLM_x">–</span> <span class="NLM_lpage">629</span><span class="refDoi"> DOI: 10.1097/HJH.0b013e32835d6d49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1097%2FHJH.0b013e32835d6d49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=23314743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslWlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=624-629&author=L.+Amarauthor=M.+Aziziauthor=J.+M%C3%A9nardauthor=S.+Peyrardauthor=P.-F.+Plouin&title=Sequential+comparison+of+aldosterone+synthase+inhibition+and+mineralocorticoid+blockade+in+patients+with+primary+aldosteronism&doi=10.1097%2FHJH.0b013e32835d6d49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism</span></div><div class="casAuthors">Amar, Laurence; Azizi, Michel; Menard, Joel; Peyrard, Severine; Plouin, Pierre-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">624-629</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We compared the effects of aldosterone synthase inhibition with LCI699 with those of mineralocorticoid receptor blockade in patients with primary aldosteronism.  After a 2-wk placebo run-in, 14 patients with primary aldosteronism received oral LCI699 (0.5 mg b.i.d.) from day 1 to 14, LCI699 (1 mg b.i.d.) from day 15 to 29, and placebo from day 29 to 36.  From day 36 to day 66, patients were treated with eplerenone (50 mg b.i.d., up-titrated to 100 mg b.i.d. in 12/14 patients), in addn. to their previous antihypertensive treatment, which was maintained unchanged.  Eplerenone significantly decreased more 24-h ambulatory SBP on day 66 than LCI699 on day 29 and the difference between the two treatment was -5.34 [95% confidence interval (CI) -10.30; -0.38] mmHg (P = 0.027).  Plasma potassium concn. achieved on eplerenone (4.30 ± 0.45 mmol/l) was significantly greater than on LCI699 (3.89 ± 0.35 mmol/l; P = 0.009).  The increase in plasma renin concn. was significantly greater after eplerenone [+131% (range 61; 231)] than on LCI699 on day 29 [+39% (range 5; 86); P = 0.023].  LCI699 markedly decreased plasma aldosterone concn. by 75% (range -84;-63), whereas eplerenone markedly increased this concn., from day 36, by 89% (range 40;154; P < 0.0001 vs. day 29).  In patients with primary aldosteronism, the effects on blood pressure and plasma potassium and renin concns. of 4 wk of eplerenone treatment (50-100 mg b.i.d.) were more marked than those of 4 wk of LCI699 treatment (0.5-1 mg b.i.d.).  These two drugs had opposite effects on plasma aldosterone concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4xKF2Xmcp2LVg90H21EOLACvtfcHk0lhq7x6Yrzq_uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslWlu7g%253D&md5=603bce57deb8f50e576790a8948fad1b</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1097%2FHJH.0b013e32835d6d49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FHJH.0b013e32835d6d49%26sid%3Dliteratum%253Aachs%26aulast%3DAmar%26aufirst%3DL.%26aulast%3DAzizi%26aufirst%3DM.%26aulast%3DM%25C3%25A9nard%26aufirst%3DJ.%26aulast%3DPeyrard%26aufirst%3DS.%26aulast%3DPlouin%26aufirst%3DP.-F.%26atitle%3DSequential%2520comparison%2520of%2520aldosterone%2520synthase%2520inhibition%2520and%2520mineralocorticoid%2520blockade%2520in%2520patients%2520with%2520primary%2520aldosteronism%26jtitle%3DJ.%2520Hypertens.%26date%3D2013%26volume%3D31%26spage%3D624%26epage%3D629%26doi%3D10.1097%2FHJH.0b013e32835d6d49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Calhoun, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krum, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bermann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trapani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftkoowitz, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ménard, J.</span><span> </span><span class="NLM_article-title">Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: Results of a randomized, double-blind, placebo</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">1945</span><span class="NLM_x">–</span> <span class="NLM_lpage">1955</span><span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.111.029892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1161%2FCIRCULATIONAHA.111.029892" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2011&pages=1945-1955&author=D.+B.+Calhounauthor=W.+B.+Whiteauthor=H.+Krumauthor=G.+Guoauthor=G.+Bermannauthor=A.+Trapaniauthor=M.+P.+Leftkoowitzauthor=J.+M%C3%A9nard&title=Effects+of+a+novel+aldosterone+synthase+inhibitor+for+treatment+of+primary+hypertension%3A+Results+of+a+randomized%2C+double-blind%2C+placebo&doi=10.1161%2FCIRCULATIONAHA.111.029892"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.029892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.029892%26sid%3Dliteratum%253Aachs%26aulast%3DCalhoun%26aufirst%3DD.%2BB.%26aulast%3DWhite%26aufirst%3DW.%2BB.%26aulast%3DKrum%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DG.%26aulast%3DBermann%26aufirst%3DG.%26aulast%3DTrapani%26aufirst%3DA.%26aulast%3DLeftkoowitz%26aufirst%3DM.%2BP.%26aulast%3DM%25C3%25A9nard%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520a%2520novel%2520aldosterone%2520synthase%2520inhibitor%2520for%2520treatment%2520of%2520primary%2520hypertension%253A%2520Results%2520of%2520a%2520randomized%252C%2520double-blind%252C%2520placebo%26jtitle%3DCirculation%26date%3D2011%26volume%3D124%26spage%3D1945%26epage%3D1955%26doi%3D10.1161%2FCIRCULATIONAHA.111.029892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Andersen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peppard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Ess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trapani, A.</span><span> </span><span class="NLM_article-title">The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study</span> <span class="citation_source-journal">J. Clin. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">580</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span><span class="refDoi"> DOI: 10.1111/j.1751-7176.2012.00667.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1111%2Fj.1751-7176.2012.00667.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1emsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=580-587&author=K.+Andersenauthor=D.+Hartmanauthor=T.+Peppardauthor=D.+Hermannauthor=P.+Van+Essauthor=M.+Lefkowitzauthor=A.+Trapani&title=The+effects+of+aldosterone+synthase+inhibition+on+aldosterone+and+cortisol+in+patients+with+hypertension%3A+a+phase+II%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+multicenter+study&doi=10.1111%2Fj.1751-7176.2012.00667.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study</span></div><div class="casAuthors">Andersen, Karl; Hartman, Daniel; Peppard, Thomas; Hermann, David; Van Ess, Peter; Lefkowitz, Martin; Trapani, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Hypertension (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">580-587</span>CODEN:
                <span class="NLM_cas:coden">JCHYFN</span>;
        ISSN:<span class="NLM_cas:issn">1524-6175</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Blockade of the renin-angiotensin-aldosterone system (RAAS) is an established method to lower blood pressure in patients with hypertension.  Aldosterone, the end product of the RAAS cascade, acts by increasing salt reabsorption in the kidney and catecholamine release from the adrenal medulla.  Currently available aldosterone inhibitors have the disadvantage of increasing circulating aldosterone and thus may lead to aldosterone breakthrough.  Aldosterone synthase inhibition (ASI) is a novel approach to suppressing the RAAS.  Due to homol. between the enzymes responsible for aldosterone synthesis (CYP11B2) and cortisol synthesis (CYP11B1), the blockade of aldosterone synthesis may also suppress cortisol release.  The authors evaluated the effect of the novel ASI LCI699 on the cortisol response to adrenocorticotropic hormone (ACTH) stimulation in patients with hypertension in order to find the maximally tolerated dose (MTD) in this patient population.  Among the 63 patients evaluated, there was a dose- and time-dependent effect of LCI699 on both aldosterone and ACTH-stimulated cortisol.  Based on exposure-response anal., the MTD was estd. to be 1.30 mg once daily with a 90% prediction interval of 0.88 mg once daily to 1.81 mg once daily.  No patients required intervention for adrenal insufficiency.  LCI699 was well tolerated with no serious adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpukpr21vCoqLVg90H21EOLACvtfcHk0lhq7x6Yrzq_uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1emsbbP&md5=04285bca878ef4e6ffdeb60c7207b5ab</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1111%2Fj.1751-7176.2012.00667.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1751-7176.2012.00667.x%26sid%3Dliteratum%253Aachs%26aulast%3DAndersen%26aufirst%3DK.%26aulast%3DHartman%26aufirst%3DD.%26aulast%3DPeppard%26aufirst%3DT.%26aulast%3DHermann%26aufirst%3DD.%26aulast%3DVan%2BEss%26aufirst%3DP.%26aulast%3DLefkowitz%26aufirst%3DM.%26aulast%3DTrapani%26aufirst%3DA.%26atitle%3DThe%2520effects%2520of%2520aldosterone%2520synthase%2520inhibition%2520on%2520aldosterone%2520and%2520cortisol%2520in%2520patients%2520with%2520hypertension%253A%2520a%2520phase%2520II%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520multicenter%2520study%26jtitle%3DJ.%2520Clin.%2520Hypertens.%26date%3D2012%26volume%3D14%26spage%3D580%26epage%3D587%26doi%3D10.1111%2Fj.1751-7176.2012.00667.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Karns, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bral, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peppard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumacher, C.</span><span> </span><span class="NLM_article-title">Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension</span> <span class="citation_source-journal">J. Clin. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.1111/jch.12051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1111%2Fjch.12051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslSmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=186-192&author=A.+D.+Karnsauthor=J.+M.+Bralauthor=D.+Hartmanauthor=T.+Peppardauthor=C.+Schumacher&title=Study+of+aldosterone+synthase+inhibition+as+an+add-on+therapy+in+resistant+hypertension&doi=10.1111%2Fjch.12051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension</span></div><div class="casAuthors">Karns, Adam D.; Bral, Jacqueline M.; Hartman, Daniel; Peppard, Thomas; Schumacher, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Hypertension (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">186-192</span>CODEN:
                <span class="NLM_cas:coden">JCHYFN</span>;
        ISSN:<span class="NLM_cas:issn">1524-6175</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aldosterone inhibition with mineralcorticoid receptor antagonists (MRAs) is an effective treatment for resistant hypertension.  Aldosterone synthase inhibitors (ASIs) are currently being investigated as a new therapeutic strategy to reduce aldosterone secretion from the adrenal gland.  In this study, the efficacy and safety of the first-generation ASI LCI699 (0.25 mg twice daily, 1 mg 4 once daily, and 0.5 mg/1 mg twice daily) was compared with placebo and eplerenone (50 mg twice daily), in patients with resistant hypertension.  Placebo-adjusted decreases in systolic blood pressure (BP) with LCI699 ranged from 2.6 mm Hg to 4.3 mm Hg at week 8; changes in diastolic BP ranged from +0.3 mm Hg to -1.2 mm Hg.  However, redns. were smaller than obsd. with eplerenone 50 mg twice daily (9.9 mm Hg and 2.9 mm Hg for systolic and diastolic BP, resp.) and not statistically significant vs placebo.  LCI699 suppressed plasma aldosterone levels in a dose-related manner with corresponding dose-dependent increases in plasma renin activity and plasma 11-deoxycorticosterone.  LCI699 and eplerenone were well tolerated.  These data demonstrate that aldosterone synthesis inhibition with LCI699 lowers BP modestly in patients with resistant hypertension.  Aldosterone synthesis inhibition might offer an attractive adjunct to aldosterone receptor blockade, although the potential of a combination MRA/ASI has not yet been tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSJxQuOsY8XrVg90H21EOLACvtfcHk0ljd35Wmeopb8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslSmt7c%253D&md5=e6147f9496d529818be6bdc0137bf72b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fjch.12051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjch.12051%26sid%3Dliteratum%253Aachs%26aulast%3DKarns%26aufirst%3DA.%2BD.%26aulast%3DBral%26aufirst%3DJ.%2BM.%26aulast%3DHartman%26aufirst%3DD.%26aulast%3DPeppard%26aufirst%3DT.%26aulast%3DSchumacher%26aufirst%3DC.%26atitle%3DStudy%2520of%2520aldosterone%2520synthase%2520inhibition%2520as%2520an%2520add-on%2520therapy%2520in%2520resistant%2520hypertension%26jtitle%3DJ.%2520Clin.%2520Hypertens.%26date%3D2013%26volume%3D15%26spage%3D186%26epage%3D192%26doi%3D10.1111%2Fjch.12051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Bertagna, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pivonello, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleseriu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maldonado, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamrahian, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boscaro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biller, B. M. K.</span><span> </span><span class="NLM_article-title">LCI699, a potent 11-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1375</span><span class="NLM_x">–</span> <span class="NLM_lpage">1383</span><span class="refDoi"> DOI: 10.1210/jc.2013-2117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1210%2Fjc.2013-2117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=24423285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtlekt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2014&pages=1375-1383&author=X.+Bertagnaauthor=R.+Pivonelloauthor=M.+Fleseriuauthor=Y.+Zhangauthor=P.+Robinsonauthor=A.+Taylorauthor=C.+E.+Watsonauthor=M.+Maldonadoauthor=A.+H.+Hamrahianauthor=M.+Boscaroauthor=B.+M.+K.+Biller&title=LCI699%2C+a+potent+11-hydroxylase+inhibitor%2C+normalizes+urinary+cortisol+in+patients+with+Cushing%E2%80%99s+disease%3A+results+from+a+multicenter%2C+proof-of-concept+study&doi=10.1210%2Fjc.2013-2117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study</span></div><div class="casAuthors">Bertagna, Xavier; Pivonello, Rosario; Fleseriu, Maria; Zhang, Yiming; Robinson, Paul; Taylor, Ann; Watson, Catherine E.; Maldonado, Mario; Hamrahian, Amir H.; Boscaro, Marco; Biller, Beverly M. K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1375-1383</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Introduction: The clin. features and increased mortality assocd. with Cushing's syndrome result from a chronic excess of circulating cortisol.  As LCI699 potently inhibits 11β-hydroxylase, which catalyzes the final step of cortisol synthesis, it is a potential new treatment for Cushing's disease, the most common cause of endogenous Cushing's syndrome.  Methods: Adult patients with moderate-to-severe Cushing's disease (urinary free cortisol [UFC] levels >1.5 × ULN [upper limit of normal]) received oral LCI699 for 10 wk in this proof-of-concept study.  LCI699 was initiated at 4 mg/d in two equal doses; the dose was escalated every 14 days to 10, 20, 40, and 100 mg/d until UFC normalized, whereupon the dose was maintained until treatment ended (day 70).  The primary endpoint was UFC ≤ ULN or a ≥50% decrease from baseline at day 70.  Results: Twelve patients were enrolled and completed the study.  Baseline UFC ranged over 1.6-17.0 × ULN.  All 12 patients achieved UFC ≤ ULN or a ≥50% decrease from baseline at day 70; 11 (92%) had normal UFC levels at that time.  After treatment discontinuation (day 84), UFC was >ULN in 10 patients with available measurements.  Mean 11-deoxycortisol, 11-deoxycorticosterone, and adrenocorticotropic hormone levels increased during treatment and declined after discontinuation.  Mean systolic and diastolic blood pressure decreased from baseline by 10.0 and 6.0 mmHg, resp.  LCI699 was generally well tolerated; most adverse events (AEs) were mild or moderate.  The most common AEs included fatigue (7/12), nausea (5/12), and headache (3/12).  No serious drug-related AEs were reported.  Conclusions: LCI699 was efficacious and well tolerated in patients with Cushing's disease enrolled in this proof-of-concept study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEiDQVlHlvpbVg90H21EOLACvtfcHk0ljd35Wmeopb8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtlekt7c%253D&md5=fefaaf5d26879f79a9b45707c5a6d3ba</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1210%2Fjc.2013-2117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2013-2117%26sid%3Dliteratum%253Aachs%26aulast%3DBertagna%26aufirst%3DX.%26aulast%3DPivonello%26aufirst%3DR.%26aulast%3DFleseriu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DRobinson%26aufirst%3DP.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DWatson%26aufirst%3DC.%2BE.%26aulast%3DMaldonado%26aufirst%3DM.%26aulast%3DHamrahian%26aufirst%3DA.%2BH.%26aulast%3DBoscaro%26aufirst%3DM.%26aulast%3DBiller%26aufirst%3DB.%2BM.%2BK.%26atitle%3DLCI699%252C%2520a%2520potent%252011-hydroxylase%2520inhibitor%252C%2520normalizes%2520urinary%2520cortisol%2520in%2520patients%2520with%2520Cushing%25E2%2580%2599s%2520disease%253A%2520results%2520from%2520a%2520multicenter%252C%2520proof-of-concept%2520study%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2014%26volume%3D99%26spage%3D1375%26epage%3D1383%26doi%3D10.1210%2Fjc.2013-2117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Papillon, J. P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carvalho, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amaral, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beil, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangl, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaSala, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniara, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigel, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ksander, G. M.</span><span> </span><span class="NLM_article-title">Structure–Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4749</span><span class="NLM_x">–</span> <span class="NLM_lpage">4770</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00407</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00407" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4749-4770&author=J.+P.+N.+Papillonauthor=C.+M.+Adamsauthor=Q.-Y.+Huauthor=C.+Louauthor=A.+K.+Singhauthor=C.+Zhangauthor=J.+Carvalhoauthor=S.+Rajanauthor=A.+Amaralauthor=M.+E.+Beilauthor=F.+Fuauthor=E.+Ganglauthor=C.-W.+Huauthor=A.+Y.+Jengauthor=D.+LaSalaauthor=G.+Liangauthor=M.+Logmanauthor=W.+M.+Maniaraauthor=D.+F.+Rigelauthor=S.+A.+Smithauthor=G.+M.+Ksander&title=Structure%E2%80%93Activity+Relationships%2C+Pharmacokinetics%2C+and+in+Vivo+Activity+of+CYP11B2+and+CYP11B1+Inhibitors&doi=10.1021%2Facs.jmedchem.5b00407"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00407%26sid%3Dliteratum%253Aachs%26aulast%3DPapillon%26aufirst%3DJ.%2BP.%2BN.%26aulast%3DAdams%26aufirst%3DC.%2BM.%26aulast%3DHu%26aufirst%3DQ.-Y.%26aulast%3DLou%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DCarvalho%26aufirst%3DJ.%26aulast%3DRajan%26aufirst%3DS.%26aulast%3DAmaral%26aufirst%3DA.%26aulast%3DBeil%26aufirst%3DM.%2BE.%26aulast%3DFu%26aufirst%3DF.%26aulast%3DGangl%26aufirst%3DE.%26aulast%3DHu%26aufirst%3DC.-W.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DLaSala%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DLogman%26aufirst%3DM.%26aulast%3DManiara%26aufirst%3DW.%2BM.%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DSmith%26aufirst%3DS.%2BA.%26aulast%3DKsander%26aufirst%3DG.%2BM.%26atitle%3DStructure%25E2%2580%2593Activity%2520Relationships%252C%2520Pharmacokinetics%252C%2520and%2520in%2520Vivo%2520Activity%2520of%2520CYP11B2%2520and%2520CYP11B1%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4749%26epage%3D4770%26doi%3D10.1021%2Facs.jmedchem.5b00407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Emmerich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Cushing’s syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6022</span><span class="NLM_x">–</span> <span class="NLM_lpage">6032</span><span class="refDoi"> DOI: 10.1021/jm400240r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400240r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeqsrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6022-6032&author=J.+Emmerichauthor=Q.+Huauthor=N.+Hankeauthor=R.+W.+Hartmann&title=Cushing%E2%80%99s+syndrome%3A+development+of+highly+potent+and+selective+CYP11B1+inhibitors+of+the+%28pyridylmethyl%29pyridine+type&doi=10.1021%2Fjm400240r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Cushing's Syndrome: Development of Highly Potent and Selective CYP11B1 Inhibitors of the (Pyridylmethyl)pyridine Type</span></div><div class="casAuthors">Emmerich, Juliette; Hu, Qingzhong; Hanke, Nina; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6022-6032</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Potent and selective CYP11B1 inhibitors could be promising therapeutics for the treatment of Cushing's syndrome.  Optimization of 5-((1H-imidazol-1-yl)methyl)-2-phenylpyridine(I) led to 5-((5-methylpyridin-3-yl)methyl)-2-phenylpyridine(II) with a 50-fold improved IC50 value of 2 nM toward human CYP11B1 and an enhanced inhibition of the rat enzyme (IC50 = 2440 nM) compared to I (IC50 > 10000 nM).  Furthermore, selectivities over CYP11B2, CYP17, and CYP19 were obsd., as well as satisfying metabolic stability not only in human and rat plasma but also in liver S9 fraction.  Investigation of cytotoxicity and inhibition of hepatic CYP2A6 and CYP3A4 showed that II fulfills first safety criteria and can be considered for further in vivo evaluation in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovo4jVVP4sVLVg90H21EOLACvtfcHk0lgDHFtet6N-5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeqsrfI&md5=7f62b0c451e5e3647e5f10dfd612b23f</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1021%2Fjm400240r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400240r%26sid%3Dliteratum%253Aachs%26aulast%3DEmmerich%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DHanke%26aufirst%3DN.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DCushing%25E2%2580%2599s%2520syndrome%253A%2520development%2520of%2520highly%2520potent%2520and%2520selective%2520CYP11B1%2520inhibitors%2520of%2520the%2520%2528pyridylmethyl%2529pyridine%2520type%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6022%26epage%3D6032%26doi%3D10.1021%2Fjm400240r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hille, U. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haupenthal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Optimization of the first selective steroid-11β-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">564</span><span class="refDoi"> DOI: 10.1021/ml100283h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100283h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=559-564&author=U.+E.+Hilleauthor=C.+Zimmerauthor=J.+Haupenthalauthor=R.+W.+Hartmann&title=Optimization+of+the+first+selective+steroid-11%CE%B2-hydroxylase+%28CYP11B1%29+inhibitors+for+the+treatment+of+cortisol+dependent+diseases&doi=10.1021%2Fml100283h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1021%2Fml100283h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100283h%26sid%3Dliteratum%253Aachs%26aulast%3DHille%26aufirst%3DU.%2BE.%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DHaupenthal%26aufirst%3DJ.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DOptimization%2520of%2520the%2520first%2520selective%2520steroid-11%25CE%25B2-hydroxylase%2520%2528CYP11B1%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cortisol%2520dependent%2520diseases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D559%26epage%3D564%26doi%3D10.1021%2Fml100283h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmaier, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydro-pyrrolo-[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing’s syndrome</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6629</span><span class="NLM_x">–</span> <span class="NLM_lpage">6633</span><span class="refDoi"> DOI: 10.1021/jm3003872</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003872" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6629-6633&author=L.+Yinauthor=S.+Lucasauthor=F.+Maurerauthor=U.+Kazmaierauthor=Q.+Huauthor=R.+W.+Hartmann&title=Novel+imidazol-1-ylmethyl+substituted+1%2C2%2C5%2C6-tetrahydro-pyrrolo-%5B3%2C2%2C1-ij%5Dquinolin-4-ones+as+potent+and+selective+CYP11B1+inhibitors+for+the+treatment+of+Cushing%E2%80%99s+syndrome&doi=10.1021%2Fjm3003872"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17d&amp;dbid=16384&amp;doi=10.1021%2Fjm3003872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003872%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DF.%26aulast%3DKazmaier%26aufirst%3DU.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DNovel%2520imidazol-1-ylmethyl%2520substituted%25201%252C2%252C5%252C6-tetrahydro-pyrrolo-%255B3%252C2%252C1-ij%255Dquinolin-4-ones%2520as%2520potent%2520and%2520selective%2520CYP11B1%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Cushing%25E2%2580%2599s%2520syndrome%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6629%26epage%3D6633%26doi%3D10.1021%2Fjm3003872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Azizi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menard, J.</span><span> </span><span class="NLM_article-title">Aldosterone synthase inhibition in humans</span> <span class="citation_source-journal">Nephrol., Dial., Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1093/ndt/gfs388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1093%2Fndt%2Fgfs388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=23045428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Cnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2013&pages=36-43&author=M.+Aziziauthor=L.+Amarauthor=J.+Menard&title=Aldosterone+synthase+inhibition+in+humans&doi=10.1093%2Fndt%2Fgfs388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone synthase inhibition in humans</span></div><div class="casAuthors">Azizi, Michel; Amar, Laurence; Menard, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology, Dialysis, Transplantation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-43</span>CODEN:
                <span class="NLM_cas:coden">NDTREA</span>;
        ISSN:<span class="NLM_cas:issn">0931-0509</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Aldosterone synthase (CYP11B2) inhibition has emerged as a new option for the treatment of hypertension, heart failure and renal disorders, in addn. to mineralocorticoid receptor (MR) blockade.  The aim is to decrease aldosterone concns. in both plasma and tissues, thereby decreasing MR-dependent and MR-independent effects in the cardiac, vascular and renal target organs.  LCI699 was the first orally active aldosterone-synthase inhibitor to be developed for human use.  Its structure is similar to that of FAD286, the dextroenantiomer of the aromatase inhibitor, fadrozole.  It dose-dependently decreases plasma and urine aldosterone concns. by up to 70 or 80% and increases plasma renin activity in healthy male subjects on a low-sodium diet.  LCI699 does not decrease basal plasma cortisol concns. at doses of 0.5-3 mg q.d., but it blocks the cortisol response to adrenocorticotropic hormone (ACTH) at doses ≥3 mg q.d.  In a proof-of-concept study in patients with primary aldosteronism (PA), LCI699 (0.5-1 mg b.i.d.) induced a dose-dependent and reversible 70-80% decrease in plasma and urinary aldosterone concn. accompanied by a massive dose-dependent accumulation of deoxycorticosterone (>+700%), the aldosterone precursor, in the plasma, thereby confirming the inhibition of the CYP11B2 gene product.  This effect was assocd. with a rapid correction of hypokalemia, a modest decrease in blood pressure (BP) and a mild increase in plasma renin concn. in patients with PA.  LCI699 administration induced biol. signs of partial inhibition of the glucocorticoid axis, such as dose-dependent increases in both plasma ACTH and 11-deoxycortisol (the precursor of cortisol) concns., consistent with the inhibition of the CYP11B1 gene product.  An 8-wk placebo-controlled dose-response study on patients with Stage 1 and 2 essential hypertension reported an optimal decrease in BP with a dose of 1 mg LCI699 q.d., which had an antihypertensive effect similar to that of 50 mg b.i.d. eplerenone.  A blunted cortisol response to ACTH was obsd. in 20% of patients, but the clin. and biol. safety and tolerability of LCI699 were similar to those of placebo and eplerenone.  The discovery of this first orally active aldosterone synthase inhibitor, LCI699, has provided new opportunities to assess the feasibility and the haemodynamic, biol. and safety consequences as well as the limitations of this new approach to block the aldosterone pathway in hypertensive patients.  However, as the effects of LCI699 on the glucocorticoid axis limit the use of higher doses range because of the loss of selectivity for CYP11B2, this aldosterone synthase inhibitor cannot replace the MR blockade in patients with hypertension, other cardiovascular or renal disorders.  The development of second-generation aldosterone synthase inhibitors with a higher selectivity index for CYP11B2 than LCI699 should make it possible to test this approach at much higher doses in these patients, after the necessary toxicol. and Phase I studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpry7oeFoXKGbVg90H21EOLACvtfcHk0lgDHFtet6N-5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Cnur4%253D&md5=0674cf3cafdb5809dc4db29f1b840320</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgfs388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgfs388%26sid%3Dliteratum%253Aachs%26aulast%3DAzizi%26aufirst%3DM.%26aulast%3DAmar%26aufirst%3DL.%26aulast%3DMenard%26aufirst%3DJ.%26atitle%3DAldosterone%2520synthase%2520inhibition%2520in%2520humans%26jtitle%3DNephrol.%252C%2520Dial.%252C%2520Transplant.%26date%3D2013%26volume%3D28%26spage%3D36%26epage%3D43%26doi%3D10.1093%2Fndt%2Fgfs388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5011</span><span class="NLM_x">–</span> <span class="NLM_lpage">5022</span><span class="refDoi"> DOI: 10.1021/jm401430e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401430e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVelsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5011-5022&author=Q.+Huauthor=L.+Yinauthor=R.+W.+Hartmann&title=Aldosterone+synthase+inhibitors+as+promising+treatments+for+mineralocorticoid+dependent+cardiovascular+and+renal+diseases&doi=10.1021%2Fjm401430e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone Synthase Inhibitors as Promising Treatments for Mineralocorticoid Dependent Cardiovascular and Renal Diseases</span></div><div class="casAuthors">Hu, Qingzhong; Yin, Lina; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5011-5022</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Besides the well-known roles of aldosterone as a mineralocorticoid in regulating homeostasis of electrolytes and vol., recent studies revealed that it is also a potent proinflammation factor inducing reactive oxygen species and up-regulating a panel of fibrosis related genes.  Under pathol. circumstances, excessive aldosterone is involved in a lot of chronic diseases, including hypertension, cardiac fibrosis, congestive heart failure, ventricular remodeling, and diabetic nephropathy.  Therefore, the inhibition of aldosterone synthase (CYP11B2), which is the pivotal enzyme in aldosterone biosynthesis, was proposed as a superior approach.  Expected pharmacodynamic effects have been demonstrated in both animal models and clin. trials after the application of CYP11B2 inhibitors.  The importance of selectivity over other steroidogenic CYP enzymes, in particular 11β-hydroxylase (CYP11B1), was also revealed.  Recently, much more selective CYP11B2 inhibitors have been reported, which could be promising drug candidates for the treatment of aldosterone related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp22wShTUgyNrVg90H21EOLACvtfcHk0liT8YqLI36V9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVelsQ%253D%253D&md5=585f8d88a1df8d22382e6a58ab0283b0</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Fjm401430e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401430e%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DAldosterone%2520synthase%2520inhibitors%2520as%2520promising%2520treatments%2520for%2520mineralocorticoid%2520dependent%2520cardiovascular%2520and%2520renal%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5011%26epage%3D5022%26doi%3D10.1021%2Fjm401430e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cerny, M. A.</span><span> </span><span class="NLM_article-title">Progress towards clinically useful aldosterone synthase inhibitors</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1385</span><span class="NLM_x">–</span> <span class="NLM_lpage">1401</span><span class="refDoi"> DOI: 10.2174/1568026611313120003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.2174%2F1568026611313120003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=23688131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wgu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1385-1401&author=M.+A.+Cerny&title=Progress+towards+clinically+useful+aldosterone+synthase+inhibitors&doi=10.2174%2F1568026611313120003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18c</span><div class="casTitle"><span class="NLM_cas:atitle">Progress Towards Clinically Useful Aldosterone Synthase Inhibitors</span></div><div class="casAuthors">Cerny, Matthew A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1385-1401</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Owing to the high degree of similarity between aldosterone synthase (CYP11B2) and cortisol synthase (CYP11B1), the design of selective inhibitors of one or the other of these two enzymes was, at one time, thought to be impossible.  Through development of novel enzyme screening assays and significant medicinal chem. efforts, highly potent inhibitors of CYP11B2 have been identified with selectivities approaching 1000-fold between the two enzymes.  Many of these mols. also possess selectivity against other steroidogenic cytochromes P 450 (e.g. CYP17A1 and CYP19A1) as well as hepatic drug metabolizing P450s.  Though not as well developed or explored, inhibitors of CYP11B1, with selectivities approaching 50-fold, have also been identified.  The therapeutic benefits of affecting the renin-angiotensin-aldosterone system have been well established with the therapeutically useful angiotensin-converting enzymes inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists.  Data regarding the addnl. benefits of an aldosterone synthase inhibitor (ASi) are beginning to emerge from animal models and human clin. trials.  Despite great promise and much progress, addnl. challenges still exist in the path towards development of a therapeutically useful ASi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNrk4wlx7NurVg90H21EOLACvtfcHk0liT8YqLI36V9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wgu77O&md5=bce9e566a086d1c2c58df2811ced6230</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.2174%2F1568026611313120003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611313120003%26sid%3Dliteratum%253Aachs%26aulast%3DCerny%26aufirst%3DM.%2BA.%26atitle%3DProgress%2520towards%2520clinically%2520useful%2520aldosterone%2520synthase%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D1385%26epage%3D1401%26doi%3D10.2174%2F1568026611313120003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hoyt, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carswell, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLean, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belshaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cully, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bopp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sok, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, T.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stribling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pai, L.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metzger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verras, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMasters, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buist, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuethe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxwell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catro-Perez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szeto, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span> </span><span class="NLM_article-title">Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVWku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=573-578&author=S.+B.+Hoytauthor=M.+K.+Parkauthor=C.+Londonauthor=Y.+Xiongauthor=J.+Tataauthor=D.+J.+Bennettauthor=A.+Cookeauthor=J.+Caiauthor=E.+Carswellauthor=J.+Robinsonauthor=J.+MacLeanauthor=L.+Brownauthor=S.+Belshawauthor=T.+R.+Clarksonauthor=K.+Liuauthor=G.-B.+Liangauthor=M.+Struthersauthor=D.+Cullyauthor=T.+Wisniewskiauthor=N.+Renauthor=C.+Boppauthor=A.+Sokauthor=T.-Q.+Caiauthor=S.+Striblingauthor=L.-Y.+Paiauthor=X.+Maauthor=J.+Metzgerauthor=A.+Verrasauthor=D.+McMastersauthor=Q.+Chenauthor=E.+Tungauthor=W.+Tangauthor=G.+Salituroauthor=N.+Buistauthor=J.+Kuetheauthor=N.+Riveraauthor=J.+Clemasauthor=G.+Zhouauthor=J.+Gibsonauthor=C.+A.+Maxwellauthor=M.+Lassmanauthor=T.+McLaughlinauthor=J.+Catro-Perezauthor=D.+Szetoauthor=G.+Forrestauthor=R.+Hajduauthor=M.+Rosenbachauthor=A.+Ali&title=Discovery+of+Benzimidazole+CYP11B2+Inhibitors+with+in+Vivo+Activity+in+Rhesus+Monkeys&doi=10.1021%2Facsmedchemlett.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys</span></div><div class="casAuthors">Hoyt, Scott B.; Park, Min K.; London, Clare; Xiong, Yusheng; Tata, Jim; Bennett, D. Jonathan; Cooke, Andrew; Cai, Jiaqiang; Carswell, Emma; Robinson, John; MacLean, John; Brown, Lindsay; Belshaw, Simone; Clarkson, Thomas R.; Liu, Kun; Liang, Gui-Bai; Struthers, Mary; Cully, Doris; Wisniewski, Tom; Ren, Ning; Bopp, Charlene; Sok, Andrea; Cai, Tian-Quan; Stribling, Sloan; Pai, Lee-Yuh; Ma, Xiuying; Metzger, Joe; Verras, Andreas; McMasters, Daniel; Chen, Qing; Tung, Elaine; Tang, Wei; Salituro, Gino; Buist, Nicole; Kuethe, Jeff; Rivera, Nelo; Clemas, Joe; Zhou, Gaochao; Gibson, Jack; Maxwell, Carrie Ann; Lassman, Mike; McLaughlin, Theresa; Castro-Perez, Jose; Szeto, Daphne; Forrest, Gail; Hajdu, Richard; Rosenbach, Mark; Ali, Amjad</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">573-578</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report the discovery of a benzimidazole series of CYP11B2 inhibitors.  Hit-to-lead and lead optimization studies identified compds. such as I, which displays potent CYP11B2 inhibition, high selectivity vs. related CYP targets, and good pharmacokinetic properties in rat and rhesus.  In a rhesus pharmacodynamic model, I produces dose-dependent aldosterone lowering efficacy, with no apparent effect on cortisol levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLik9a_Au3C7Vg90H21EOLACvtfcHk0liT8YqLI36V9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVWku7k%253D&md5=aa1785399c4b3387b1d3f169efa1dc6f</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DHoyt%26aufirst%3DS.%2BB.%26aulast%3DPark%26aufirst%3DM.%2BK.%26aulast%3DLondon%26aufirst%3DC.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DTata%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DCarswell%26aufirst%3DE.%26aulast%3DRobinson%26aufirst%3DJ.%26aulast%3DMacLean%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DL.%26aulast%3DBelshaw%26aufirst%3DS.%26aulast%3DClarkson%26aufirst%3DT.%2BR.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DG.-B.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DCully%26aufirst%3DD.%26aulast%3DWisniewski%26aufirst%3DT.%26aulast%3DRen%26aufirst%3DN.%26aulast%3DBopp%26aufirst%3DC.%26aulast%3DSok%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DT.-Q.%26aulast%3DStribling%26aufirst%3DS.%26aulast%3DPai%26aufirst%3DL.-Y.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DMetzger%26aufirst%3DJ.%26aulast%3DVerras%26aufirst%3DA.%26aulast%3DMcMasters%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DTung%26aufirst%3DE.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DSalituro%26aufirst%3DG.%26aulast%3DBuist%26aufirst%3DN.%26aulast%3DKuethe%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DN.%26aulast%3DClemas%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DGibson%26aufirst%3DJ.%26aulast%3DMaxwell%26aufirst%3DC.%2BA.%26aulast%3DLassman%26aufirst%3DM.%26aulast%3DMcLaughlin%26aufirst%3DT.%26aulast%3DCatro-Perez%26aufirst%3DJ.%26aulast%3DSzeto%26aufirst%3DD.%26aulast%3DForrest%26aufirst%3DG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DAli%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520Benzimidazole%2520CYP11B2%2520Inhibitors%2520with%2520in%2520Vivo%2520Activity%2520in%2520Rhesus%2520Monkeys%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D573%26epage%3D578%26doi%3D10.1021%2Facsmedchemlett.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratcliffe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metzger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Novel Pyridyl Substituted 4,5-Dihydro-[1,2,4]triazolo[4,3-a]quinolines as Potent and Selective Aldosterone Synthase Inhibitors with Improved in Vitro Metabolic Stability</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2530</span><span class="NLM_x">–</span> <span class="NLM_lpage">2537</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00079</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2530-2537&author=Q.+Huauthor=L.+Yinauthor=A.+Aliauthor=A.+J.+Cookeauthor=J.+Bennettauthor=P.+Ratcliffeauthor=M.+M.+Loauthor=E.+Metzgerauthor=S.+Hoytauthor=R.+W.+Hartmann&title=Novel+Pyridyl+Substituted+4%2C5-Dihydro-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dquinolines+as+Potent+and+Selective+Aldosterone+Synthase+Inhibitors+with+Improved+in+Vitro+Metabolic+Stability&doi=10.1021%2Facs.jmedchem.5b00079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00079%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DCooke%26aufirst%3DA.%2BJ.%26aulast%3DBennett%26aufirst%3DJ.%26aulast%3DRatcliffe%26aufirst%3DP.%26aulast%3DLo%26aufirst%3DM.%2BM.%26aulast%3DMetzger%26aufirst%3DE.%26aulast%3DHoyt%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DNovel%2520Pyridyl%2520Substituted%25204%252C5-Dihydro-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dquinolines%2520as%2520Potent%2520and%2520Selective%2520Aldosterone%2520Synthase%2520Inhibitors%2520with%2520Improved%2520in%2520Vitro%2520Metabolic%2520Stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2530%26epage%3D2537%26doi%3D10.1021%2Facs.jmedchem.5b00079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Grombein, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: a new class of potent and selective aldosterone synthase inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">605</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.10.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.ejmech.2014.10.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=25462268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGjtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=597-605&author=C.+M.+Grombeinauthor=Q.+Huauthor=R.+Heimauthor=S.+Rauauthor=C.+Zimmerauthor=R.+W.+Hartmann&title=1-Phenylsulfinyl-3-%28pyridin-3-yl%29naphthalen-2-ols%3A+a+new+class+of+potent+and+selective+aldosterone+synthase+inhibitors&doi=10.1016%2Fj.ejmech.2014.10.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: A new class of potent and selective aldosterone synthase inhibitors</span></div><div class="casAuthors">Grombein, Cornelia M.; Hu, Qingzhong; Heim, Ralf; Rau, Sabrina; Zimmer, Christina; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">597-605</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols and related compds. were synthesized and evaluated for inhibition of aldosterone synthase (CYP11B2), a potential target for cardiovascular diseases assocd. with elevated plasma aldosterone levels like congestive heart failure and myocardial fibrosis.  Introduction of substituents at the phenylsulfinyl moiety and changes of the substitution pattern at the naphthalene core were examd.  Potent compds. were further examd. for selectivity vs. other important steroidogenic CYP enzymes, i.e. the highly homologous 11β-hydroxylase (CYP11B1), CYP17 and CYP19.  The most potent compd. (IC50 = 14 nM) discovered was the meta-trifluoromethoxy deriv. I, which also exhibited excellent selectivity toward CYP11B1 (SF = 415), and showed no inhibition of CYP17 and CYP19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptMcfkz8HvtrVg90H21EOLACvtfcHk0lixKnmSlAgfxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGjtrnL&md5=abf32be6d9cf844b50257b46f46c4f2c</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.027%26sid%3Dliteratum%253Aachs%26aulast%3DGrombein%26aufirst%3DC.%2BM.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DHeim%26aufirst%3DR.%26aulast%3DRau%26aufirst%3DS.%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3D1-Phenylsulfinyl-3-%2528pyridin-3-yl%2529naphthalen-2-ols%253A%2520a%2520new%2520class%2520of%2520potent%2520and%2520selective%2520aldosterone%2520synthase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D89%26spage%3D597%26epage%3D605%26doi%3D10.1016%2Fj.ejmech.2014.10.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Grombein, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.ejmech.2014.12.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2015&pages=788-796&author=C.+M.+Grombeinauthor=Q.+Huauthor=S.+Rauauthor=C.+Zimmerauthor=R.+W.+Hartmann&title=Heteroatom+insertion+into+3%2C4-dihydro-1H-quinolin-2-ones+leads+to+potent+and+selective+inhibitors+of+human+and+rat+aldosterone+synthase&doi=10.1016%2Fj.ejmech.2014.12.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19d&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DGrombein%26aufirst%3DC.%2BM.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DRau%26aufirst%3DS.%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DHeteroatom%2520insertion%2520into%25203%252C4-dihydro-1H-quinolin-2-ones%2520leads%2520to%2520potent%2520and%2520selective%2520inhibitors%2520of%2520human%2520and%2520rat%2520aldosterone%2520synthase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D90%26spage%3D788%26epage%3D796%26doi%3D10.1016%2Fj.ejmech.2014.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmerich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metzger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5179</span><span class="NLM_x">–</span> <span class="NLM_lpage">5189</span><span class="refDoi"> DOI: 10.1021/jm500140c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500140c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5179-5189&author=L.+Yinauthor=Q.+Huauthor=J.+Emmerichauthor=M.+M.+Loauthor=E.+Metzgerauthor=A.+Aliauthor=R.+W.+Hartmann&title=Novel+pyridyl-+or+isoquinolinyl-substituted+indolines+and+indoles+as+potent+and+selective+aldosterone+synthase+inhibitors&doi=10.1021%2Fjm500140c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19e&amp;dbid=16384&amp;doi=10.1021%2Fjm500140c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500140c%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DEmmerich%26aufirst%3DJ.%26aulast%3DLo%26aufirst%3DM.%2BM.%26aulast%3DMetzger%26aufirst%3DE.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DNovel%2520pyridyl-%2520or%2520isoquinolinyl-substituted%2520indolines%2520and%2520indoles%2520as%2520potent%2520and%2520selective%2520aldosterone%2520synthase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5179%26epage%3D5189%26doi%3D10.1021%2Fjm500140c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Lucas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Fine-tuning the selectivity of aldosterone synthase inhibitors: insights from studies from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinoline-4-one derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2307</span><span class="NLM_x">–</span> <span class="NLM_lpage">2319</span><span class="refDoi"> DOI: 10.1021/jm101470k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101470k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2307-2319&author=S.+Lucasauthor=M.+Negriauthor=R.+Heimauthor=C.+Zimmerauthor=R.+W.+Hartmann&title=Fine-tuning+the+selectivity+of+aldosterone+synthase+inhibitors%3A+insights+from+studies+from+studies+of+heteroaryl+substituted+1%2C2%2C5%2C6-tetrahydropyrrolo%5B3%2C2%2C1-ij%5Dquinoline-4-one+derivatives&doi=10.1021%2Fjm101470k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19f&amp;dbid=16384&amp;doi=10.1021%2Fjm101470k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101470k%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DHeim%26aufirst%3DR.%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DFine-tuning%2520the%2520selectivity%2520of%2520aldosterone%2520synthase%2520inhibitors%253A%2520insights%2520from%2520studies%2520from%2520studies%2520of%2520heteroaryl%2520substituted%25201%252C2%252C5%252C6-tetrahydropyrrolo%255B3%252C2%252C1-ij%255Dquinoline-4-one%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2307%26epage%3D2319%26doi%3D10.1021%2Fjm101470k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Roumen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmen, J. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beugels, I. P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Custers, E. M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Gooyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plate, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieterse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilbers, P. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, J. F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vekemans, J. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leysen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottenheijm, H. C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermans, J. J. R.</span><span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1712</span><span class="NLM_x">–</span> <span class="NLM_lpage">1725</span><span class="refDoi"> DOI: 10.1021/jm901356d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901356d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCgtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1712-1725&author=L.+Roumenauthor=J.+W.+Peetersauthor=J.+M.+A.+Emmenauthor=I.+P.+E.+Beugelsauthor=E.+M.+G.+Custersauthor=M.+de+Gooyerauthor=R.+Plateauthor=K.+Pieterseauthor=P.+A.+J.+Hilbersauthor=J.+F.+M.+Smitsauthor=J.+A.+J.+Vekemansauthor=D.+Leysenauthor=H.+C.+J.+Ottenheijmauthor=H.+M.+Janssenauthor=J.+J.+R.+Hermans&title=Synthesis%2C+biological+evaluation%2C+and+molecular+modeling+of+1-benzyl-1H-imidazoles+as+selective+inhibitors+of+aldosterone+synthase+%28CYP11B2%29&doi=10.1021%2Fjm901356d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19gR"><div class="casContent"><span class="casTitleNuber">19g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Biological Evaluation, and Molecular Modeling of 1-Benzyl-1H-imidazoles as Selective Inhibitors of Aldosterone Synthase (CYP11B2)</span></div><div class="casAuthors">Roumen, Luc; Peeters, Joris W.; Emmen, Judith M. A.; Beugels, Ilona P. E.; Custers, Erica M. G.; de Gooyer, Marcel; Plate, Ralf; Pieterse, Koen; Hilbers, Peter A. J.; Smits, Jos F. M.; Vekemans, Jef A. J.; Leysen, Dirk; Ottenheijm, Harry C. J.; Janssen, Henk M.; Hermans, J. J. Rob</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1712-1725</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reducing aldosterone action is beneficial in various major diseases such as heart failure.  Currently, this is achieved with mineralocorticoid receptor antagonists, however, aldosterone synthase (CYP11B2) inhibitors may offer a promising alternative.  In this study, three-dimensional modeling of CYP11B2 was used to model the binding modes of the natural substrate 18-hydroxycorticosterone and the recently published CYP11B2 inhibitor R-fadrozole (I) as a rational guide to design 44 structurally simple and achiral 1-benzyl-1H-imidazoles.  Their syntheses, in vitro inhibitor potencies, and in silico docking are described.  Some promising CYP11B2 inhibitors were identified, with the novel lead MOERAS115 (II) displaying an IC50 for CYP11B2 of 1.7 nM, and a CYP11B2 (vs. CYP11B1) selectivity of 16.5, comparable to R-fadrozole (IC50 for CYP11B2 6.0 nM, selectivity 19.8).  Mol. docking of the inhibitors in the models enabled the generation of posthoc hypotheses on their binding modes, providing a valuable basis for future studies and further design of CYP11B2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz3kri2YpzBLVg90H21EOLACvtfcHk0ljcaFFqZyYv0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCgtrY%253D&md5=95b05f5ad57464a12715c4cf15502b83</span></div><a href="/servlet/linkout?suffix=cit19g&amp;dbid=16384&amp;doi=10.1021%2Fjm901356d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901356d%26sid%3Dliteratum%253Aachs%26aulast%3DRoumen%26aufirst%3DL.%26aulast%3DPeeters%26aufirst%3DJ.%2BW.%26aulast%3DEmmen%26aufirst%3DJ.%2BM.%2BA.%26aulast%3DBeugels%26aufirst%3DI.%2BP.%2BE.%26aulast%3DCusters%26aufirst%3DE.%2BM.%2BG.%26aulast%3Dde%2BGooyer%26aufirst%3DM.%26aulast%3DPlate%26aufirst%3DR.%26aulast%3DPieterse%26aufirst%3DK.%26aulast%3DHilbers%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DSmits%26aufirst%3DJ.%2BF.%2BM.%26aulast%3DVekemans%26aufirst%3DJ.%2BA.%2BJ.%26aulast%3DLeysen%26aufirst%3DD.%26aulast%3DOttenheijm%26aufirst%3DH.%2BC.%2BJ.%26aulast%3DJanssen%26aufirst%3DH.%2BM.%26aulast%3DHermans%26aufirst%3DJ.%2BJ.%2BR.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520modeling%2520of%25201-benzyl-1H-imidazoles%2520as%2520selective%2520inhibitors%2520of%2520aldosterone%2520synthase%2520%2528CYP11B2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1712%26epage%3D1725%26doi%3D10.1021%2Fjm901356d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Adams, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.-W</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ksander, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaSala, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung-Chu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meredith, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigel, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span> </span><span class="NLM_article-title">The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-β-hydroxylase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4324</span><span class="NLM_x">–</span> <span class="NLM_lpage">4327</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.bmcl.2010.06.086" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4324-4327&author=C.+M.+Adamsauthor=C.-W+Huauthor=A.+Y.+Jengauthor=R.+Karkiauthor=G.+M.+Ksanderauthor=D.+LaSalaauthor=J.+Leung-Chuauthor=G.+Liangauthor=Q.+Liuauthor=E.+L.+Meredithauthor=C.+Raoauthor=D.+F.+Rigelauthor=J.+Shiauthor=S.+Smithauthor=C.+Springerauthor=C.+Zhang&title=The+discovery+of+potent+inhibitors+of+aldosterone+synthase+that+exhibit+selectivity+over+11-%CE%B2-hydroxylase&doi=10.1016%2Fj.bmcl.2010.06.086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19h&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.086%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DC.%2BM.%26aulast%3DHu%26aufirst%3DC.-W%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKsander%26aufirst%3DG.%2BM.%26aulast%3DLaSala%26aufirst%3DD.%26aulast%3DLeung-Chu%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMeredith%26aufirst%3DE.%2BL.%26aulast%3DRao%26aufirst%3DC.%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%26atitle%3DThe%2520discovery%2520of%2520potent%2520inhibitors%2520of%2520aldosterone%2520synthase%2520that%2520exhibit%2520selectivity%2520over%252011-%25CE%25B2-hydroxylase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4324%26epage%3D4327%26doi%3D10.1016%2Fj.bmcl.2010.06.086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Lucas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ries, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schewe, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">8077</span><span class="NLM_x">–</span> <span class="NLM_lpage">8087</span><span class="refDoi"> DOI: 10.1021/jm800888q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800888q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVOjs7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=8077-8087&author=S.+Lucasauthor=R.+Heimauthor=C.+Riesauthor=K.+E.+Scheweauthor=B.+Birkauthor=R.+W.+Hartmann&title=In+vivo+active+aldosterone+synthase+inhibitors+with+improved+selectivity%3A+lead+optimization+providing+a+series+of+pyridine+substituted+3%2C4-dihydro-1H-quinolin-2-one+derivatives&doi=10.1021%2Fjm800888q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19iR"><div class="casContent"><span class="casTitleNuber">19i</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Active Aldosterone Synthase Inhibitors with Improved Selectivity: Lead Optimization Providing a Series of Pyridine Substituted 3,4-Dihydro-1H-quinolin-2-one Derivatives</span></div><div class="casAuthors">Lucas, Simon; Heim, Ralf; Ries, Christina; Schewe, Katarzyna E.; Birk, Barbara; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8077-8087</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyridine substituted naphthalenes (e.g., I-III) constitute a class of potent inhibitors of aldosterone synthase (CYP11B2).  To overcome the unwanted inhibition of the hepatic enzyme CYP1A2, we aimed at reducing the no. of arom. carbons of these mols. because aromaticity has previously been identified to correlate pos. with CYP1A2 inhibition.  As hypothesized, inhibitors with a tetrahydronaphthalene type mol. scaffold (1-11) exhibit a decreased CYP1A2 inhibition.  However, tetralone 9 turned out to be cytotoxic to the human cell line U-937 at higher concns.  Consequent structural optimization culminated in the discovery of heteroaryl substituted 3,4-dihydro-1H-quinolin-2-ones (12-26), with 12, a bioisostere of 9, being nontoxic up to 200 μM.  The investigated mols. are highly selective toward both CYP1A2 and a wide range of other cytochrome P 450 enzymes and show a good pharmacokinetic profile in vivo (e.g., 12 with a peroral bioavailability of 71%).  Furthermore, isoquinoline deriv. 21 proved to significantly reduce plasma aldosterone levels of ACTH stimulated rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq85RK4G2Dhm7Vg90H21EOLACvtfcHk0ljcaFFqZyYv0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVOjs7nK&md5=fbf108702b03dc714fbd27619119ead9</span></div><a href="/servlet/linkout?suffix=cit19i&amp;dbid=16384&amp;doi=10.1021%2Fjm800888q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800888q%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DHeim%26aufirst%3DR.%26aulast%3DRies%26aufirst%3DC.%26aulast%3DSchewe%26aufirst%3DK.%2BE.%26aulast%3DBirk%26aufirst%3DB.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DIn%2520vivo%2520active%2520aldosterone%2520synthase%2520inhibitors%2520with%2520improved%2520selectivity%253A%2520lead%2520optimization%2520providing%2520a%2520series%2520of%2520pyridine%2520substituted%25203%252C4-dihydro-1H-quinolin-2-one%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D8077%26epage%3D8087%26doi%3D10.1021%2Fjm800888q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Voets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antes, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller-Vieira, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biemel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barassin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchais-Oberwinkler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Heteroaryl-Substituted Naphthalenes and Structurally Modified Derivatives: Selective Inhibitors of CYP11B2 for the Treatment of Congestive Heart Failure and Myocardial Fibrosis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6632</span><span class="NLM_x">–</span> <span class="NLM_lpage">6642</span><span class="refDoi"> DOI: 10.1021/jm0503704</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0503704" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6632-6642&author=M.+Voetsauthor=I.+Antesauthor=C.+Schererauthor=U.+M%C3%BCller-Vieiraauthor=K.+Biemelauthor=C.+Barassinauthor=S.+Marchais-Oberwinklerauthor=R.+W.+Hartmann&title=Heteroaryl-Substituted+Naphthalenes+and+Structurally+Modified+Derivatives%3A+Selective+Inhibitors+of+CYP11B2+for+the+Treatment+of+Congestive+Heart+Failure+and+Myocardial+Fibrosis&doi=10.1021%2Fjm0503704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19j&amp;dbid=16384&amp;doi=10.1021%2Fjm0503704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0503704%26sid%3Dliteratum%253Aachs%26aulast%3DVoets%26aufirst%3DM.%26aulast%3DAntes%26aufirst%3DI.%26aulast%3DScherer%26aufirst%3DC.%26aulast%3DM%25C3%25BCller-Vieira%26aufirst%3DU.%26aulast%3DBiemel%26aufirst%3DK.%26aulast%3DBarassin%26aufirst%3DC.%26aulast%3DMarchais-Oberwinkler%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DHeteroaryl-Substituted%2520Naphthalenes%2520and%2520Structurally%2520Modified%2520Derivatives%253A%2520Selective%2520Inhibitors%2520of%2520CYP11B2%2520for%2520the%2520Treatment%2520of%2520Congestive%2520Heart%2520Failure%2520and%2520Myocardial%2520Fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6632%26epage%3D6642%26doi%3D10.1021%2Fjm0503704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Pfenninger, H. A.</span><span> </span><span class="NLM_article-title">Certain 2-pyridyl-substituted indole derivatives</span>. US 3468894, September 23,<span class="NLM_x"> </span><span class="NLM_year">1969</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1969&author=H.+A.+Pfenninger&title=Certain+2-pyridyl-substituted+indole+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPfenninger%26aufirst%3DH.%2BA.%26atitle%3DCertain%25202-pyridyl-substituted%2520indole%2520derivatives%26date%3D1969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Bird, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanley, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Word, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainey, W.</span><span> </span><span class="NLM_article-title">Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II responsive aldosterone secretion</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">1555</span><span class="NLM_x">–</span> <span class="NLM_lpage">1561</span><span class="refDoi"> DOI: 10.1210/endo.133.4.8404594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1210%2Fendo.133.4.8404594" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=1993&pages=1555-1561&author=L.+Birdauthor=N.+Hanleyauthor=R.+Wordauthor=J.+Mathisauthor=J.+Masonauthor=W.+Rainey&title=Human+NCI-H295+adrenocortical+carcinoma+cells%3A+a+model+for+angiotensin-II+responsive+aldosterone+secretion&doi=10.1210%2Fendo.133.4.8404594"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1210%2Fendo.133.4.8404594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo.133.4.8404594%26sid%3Dliteratum%253Aachs%26aulast%3DBird%26aufirst%3DL.%26aulast%3DHanley%26aufirst%3DN.%26aulast%3DWord%26aufirst%3DR.%26aulast%3DMathis%26aufirst%3DJ.%26aulast%3DMason%26aufirst%3DJ.%26aulast%3DRainey%26aufirst%3DW.%26atitle%3DHuman%2520NCI-H295%2520adrenocortical%2520carcinoma%2520cells%253A%2520a%2520model%2520for%2520angiotensin-II%2520responsive%2520aldosterone%2520secretion%26jtitle%3DEndocrinology%26date%3D1993%26volume%3D133%26spage%3D1555%26epage%3D1561%26doi%3D10.1210%2Fendo.133.4.8404594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">LaSala, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span> </span><span class="NLM_article-title">Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">394</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1016/j.ab.2009.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.ab.2009.07.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=19622340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A280%3ADC%252BD1MrovVSktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2009&pages=56-61&author=D.+LaSalaauthor=Y.+Shibanakaauthor=A.+Y.+Jeng&title=Coexpression+of+CYP11B2+or+CYP11B1+with+adrenodoxin+and+adrenodoxin+reductase+for+assessing+the+potency+and+selectivity+of+aldosterone+synthase+inhibitors&doi=10.1016%2Fj.ab.2009.07.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors</span></div><div class="casAuthors">LaSala Daniel; Shibanaka Yasuhiko; Jeng Arco Y</div><div class="citationInfo"><span class="NLM_cas:title">Analytical biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Excessive production of aldosterone has been implicated in the pathogenesis of hypertension and heart failure.  One approach to ameliorate the deleterious effects of aldosterone is to suppress its biosynthesis.  The enzyme aldosterone synthase (CYP11B2) is responsible for the final step of aldosterone synthesis.  It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone.  A stable cell line simultaneously overexpressing recombinant human CYP11B2 as well as human adrenodoxin and adrenodoxin reductase was established to help maximize the enzyme activity.  The homogenate of these cells was used to develop an in vitro CYP11B2 assay using 11-deoxycorticosterone as a substrate.  By the same strategy, another stable cell line simultaneously overexpressing human 11beta-hydroxylase (CYP11B1), an enzyme responsible for the final step of cortisol biosynthesis, and the two electron transfer proteins was also established, and an in vitro CYP11B1 assay using 11-deoxycortisol as a substrate was likewise developed to assess the selectivity of CYP11B2 inhibitors.  FAD286, a reference CYP11B2 inhibitor, inhibited CYP11B2 and CYP11B1 activities with IC(50) values of 1.6+/-0.1 and 9.9+/-0.9 nM (mean+/-SEM, n=3-6), respectively.  Kinetics studies revealed that the compound inhibited the activity of both enzymes competitively with respective K(i) values of 0.8+/-0.04 and 2.2+/-0.2 nM (n=3-4).  These assays can be used for assessing the potency and selectivity of CYP11B2 inhibitors for the treatment of hypertension and heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKI6OChpO8UCsZ1x6zOs0vfW6udTcc2ebNaUsNeDEaPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrovVSktQ%253D%253D&md5=38f4fae017fa10e538270366bdc5b568</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2009.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2009.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DLaSala%26aufirst%3DD.%26aulast%3DShibanaka%26aufirst%3DY.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26atitle%3DCoexpression%2520of%2520CYP11B2%2520or%2520CYP11B1%2520with%2520adrenodoxin%2520and%2520adrenodoxin%2520reductase%2520for%2520assessing%2520the%2520potency%2520and%2520selectivity%2520of%2520aldosterone%2520synthase%2520inhibitors%26jtitle%3DAnal.%2520Biochem.%26date%3D2009%26volume%3D394%26spage%3D56%26epage%3D61%26doi%3D10.1016%2Fj.ab.2009.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Anderson, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCrodden, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tipton, K. F.</span><span> </span><span class="NLM_article-title">Monoamine oxidase inhibitors and the cheese effect</span> <span class="citation_source-journal">Neurochem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1145</span><span class="NLM_x">–</span> <span class="NLM_lpage">1149</span><span class="refDoi"> DOI: 10.1007/BF00978365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1007%2FBF00978365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=8255365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADyaK2cXitlWjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1993&pages=1145-1149&author=M.+C.+Andersonauthor=F.+Hasanauthor=J.+M.+McCroddenauthor=K.+F.+Tipton&title=Monoamine+oxidase+inhibitors+and+the+cheese+effect&doi=10.1007%2FBF00978365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase inhibitors and the cheese effect</span></div><div class="casAuthors">Anderson, Mary C.; Hasan, Farris; McCrodden, John M.; Tipton, Keith F.</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemical Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1145-9</span>CODEN:
                <span class="NLM_cas:coden">NEREDZ</span>;
        ISSN:<span class="NLM_cas:issn">0364-3190</span>.
    </div><div class="casAbstract">The behavior of inhibitors of monoamine oxidase-A (MAO-A) is considered in terms of the possibility of having an effective antidepressant that does not give rise to hypertensive interactions with dietary tyramine.  Studies with punch-biopsy samples of human intestine and rat intestinal samples show MAO-A to be the predominant form of the enzyme in both species.  Transport studies with everted rat intestinal prepns. indicate that tyramine is extensively metabolized during transport through the intestine.  Selective inhibition of MAO-A by clorgyline results in a large increase in the amt. of unchanged tyramine transported, whereas selective inhibition of MAO-B with L-deprenyl (selegiline) has no significant effect.  The behavior of reversible MAO-A inhibitors can significantly reduce, but not entirely eliminate, these effects on the intestinal metab. of tyramine, but only if the inhibition is competitive in nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDISgk8VH-8LVg90H21EOLACvtfcHk0liDzhzXWhrlIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlWjsQ%253D%253D&md5=e9d85b743f7fdde68276428940940cac</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2FBF00978365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00978365%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DM.%2BC.%26aulast%3DHasan%26aufirst%3DF.%26aulast%3DMcCrodden%26aufirst%3DJ.%2BM.%26aulast%3DTipton%26aufirst%3DK.%2BF.%26atitle%3DMonoamine%2520oxidase%2520inhibitors%2520and%2520the%2520cheese%2520effect%26jtitle%3DNeurochem.%2520Res.%26date%3D1993%26volume%3D18%26spage%3D1145%26epage%3D1149%26doi%3D10.1007%2FBF00978365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Sun-Edelstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tepper, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, R. E.</span><span> </span><span class="NLM_article-title">Drug-induced serotonin syndrome: a review</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">596</span><span class="refDoi"> DOI: 10.1517/14740338.7.5.587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1517%2F14740338.7.5.587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=18759711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGktrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=587-596&author=C.+Sun-Edelsteinauthor=S.+J.+Tepperauthor=R.+E.+Shapiro&title=Drug-induced+serotonin+syndrome%3A+a+review&doi=10.1517%2F14740338.7.5.587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced serotonin syndrome: a review</span></div><div class="casAuthors">Sun-Edelstein, Christina; Tepper, Stewart J.; Shapiro, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">587-596</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Serotonin syndrome, or serotonin toxicity (ST), is a clin. condition that occurs as a result of an iatrogenic drug-induced increase in intrasynaptic serotonin levels primarily resulting in activation of serotonin2A receptors in the central nervous system.  The severity of symptoms spans a spectrum of toxicity that correlates with the intrasynaptic serotonin concn.  Although numerous drugs have been implicated in ST, life-threatening cases generally occur only when monoamine oxidase inhibitors are combined with either selective or nonselective serotonin re-uptake inhibitors.  The triad of clin. features consists of neuromuscular hyperactivity, autonomic hyperactivity and altered mental status, which may present abruptly and progress rapidly.  The awareness of ST is crucial not only in avoiding the unintentional lethal combination of therapeutic drugs but also in recognizing the clin. picture when it occurs so that treatment can be promptly initiated.  In this review, the pathophysiol., clin. features, implicated drugs, diagnosis and treatment of ST are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvkxGg7l0hqrVg90H21EOLACvtfcHk0liDzhzXWhrlIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGktrnF&md5=610a9ca388256dd29ffe95aea3fdd82f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1517%2F14740338.7.5.587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.7.5.587%26sid%3Dliteratum%253Aachs%26aulast%3DSun-Edelstein%26aufirst%3DC.%26aulast%3DTepper%26aufirst%3DS.%2BJ.%26aulast%3DShapiro%26aufirst%3DR.%2BE.%26atitle%3DDrug-induced%2520serotonin%2520syndrome%253A%2520a%2520review%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2008%26volume%3D7%26spage%3D587%26epage%3D596%26doi%3D10.1517%2F14740338.7.5.587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="note"><p class="first last">Greater than 1000-fold selectivities over CYP3A4/5, CYP2D6, CYP2C9, and CYP1A2 enzymes were also observed.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last"><b>8</b> is a reversible inhibitor of CYP11B2 with a <i>k</i><sub>off</sub> = 0.013 ± 0.003 min<sup>–1</sup> (<i>n</i> = 4) and residence half-life <i>t</i><sub>1/2</sub> = 52 ± 9 min (<i>n</i> = 4); <b>8</b> is a substrate-competitive inhibitor, as determined from IC<sub>50</sub> shifts experiments with increasing 11-deoxycorticosterone concentrations.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit28"><span><div class="note"><p class="first last">After these studies were completed, a similar model was published:</p></div><span class="NLM_contrib-group">Cai, T.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stribling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontenot, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinsanya, K. O.</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span><span class="refDoi"> DOI: 10.1016/j.vascn.2014.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.vascn.2014.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=25304940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGns73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=After+these+studies+were+completed%2C+a+similar+model+was+published%3ACai%2C+T.-Q.%3B+Stribling%2C+S.%3B+Tong%2C+X.%3B+Xu%2C+L.%3B+Wisniewski%2C+T.%3B+Fontenot%2C+J.+A.%3B+Struthers%2C+M.%3B+Akinsanya%2C+K.+O.J.+Pharmacol.+Toxicol.+Methods+2015%2C+71%2C+137%E2%80%93146+10.1016%2Fj.vascn.2014.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors</span></div><div class="casAuthors">Cai, Tian-Quan; Stribling, Sloan; Tong, Xinchun; Xu, Ling; Wisniewski, Thomas; Fontenot, Jane A.; Struthers, Mary; Akinsanya, Karen O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">137-146</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In vivo profiles of aldosterone synthase inhibitors (ASIs) have been investigated utilizing various rodent models.  Due to lack of CYP17 activity, rodents produce corticosterone rather than cortisol as that of humans, which raised concern to their effectiveness in translational pharmacol. characterization of ASI.  A rhesus monkey model that combines a low sodium diet with ACTH (ACTH) treatment was developed.  Plasma concns. of steroid metabolites assocd. with reactions catalyzed by CYP11B2 and CYP11B1 were measured concurrently by a UPLC/MS method.  Plasma concn. of aldosterone in regular diet fed rhesus monkeys was low at 109 pg/mL.  Aldosterone concns. were increased to 252 pg/mL when animals were maintained on a low sodium diet for 3 wk, and to 300 pg/mL with ACTH treatment at 0.3 mg/kg.  The combination of low sodium diet with ACTH treatment further increased plasma concn. of aldosterone to 730 pg/mL and other steroid metabolites at various levels.  I.v. administration of ASI, fadrozole (0.001-1 mg/kg) or LCI699 (0.003-3 mg/kg), led to dose-dependent redns. in aldosterone and 18-hydroxycorticosterone, increases in 11-deoxycorticosterone and 11-deoxycortisol, and bell-shaped changes in cortisol and corticosterone.  In vivo selectivity of CYP11B2/CYP11B1 for fadrazole was 26-fold and LCI-699 was 27-fold, which was consistent with relative selectivity using in vitro values from recombinant cells transfected with rhesus monkey CYP11B2 and CYP11B1.  This model enables concurrent characterization of pharmacokinetics, pharmacodynamics and selectivity of CYP11B2 over CYP11B1 inhibition in the same animal.  It may be used as a translational model for pharmacol. characterization of ASI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgHmCwgc290bVg90H21EOLACvtfcHk0lj3mZISp5DzXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGns73K&md5=912a384735308d52a410cc2397ff9e83</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2014.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2014.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DT.-Q.%26aulast%3DStribling%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DWisniewski%26aufirst%3DT.%26aulast%3DFontenot%26aufirst%3DJ.%2BA.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DAkinsanya%26aufirst%3DK.%2BO.%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2015%26volume%3D71%26spage%3D137%26epage%3D146%26doi%3D10.1016%2Fj.vascn.2014.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Wacker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasireddy, P.</span><span> </span><span class="NLM_article-title">Efficient solid-phase synthesis of 2,3-substituted indoles</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">5189</span><span class="NLM_x">–</span> <span class="NLM_lpage">5191</span><span class="refDoi"> DOI: 10.1016/S0040-4039(02)01025-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2FS0040-4039%2802%2901025-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVenu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=5189-5191&author=D.+A.+Wackerauthor=P.+Kasireddy&title=Efficient+solid-phase+synthesis+of+2%2C3-substituted+indoles&doi=10.1016%2FS0040-4039%2802%2901025-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient solid-phase synthesis of 2,3-substituted indoles</span></div><div class="casAuthors">Wacker, Dean A.; Kasireddy, Padmaja</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">5189-5191</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The development of the solid-phase version of the modified Madelung indole synthesis is reported.  The chem. was initiated with the reductive amination of Bal resin using an ortho substituted aniline.  The resin bound aniline was acylated with a variety of acid chlorides followed by cyclization with base to provide the desired indole after TFA-promoted cleavage from the resin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovpxngdleI2LVg90H21EOLACvtfcHk0lj3mZISp5DzXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVenu70%253D&md5=b1025fc6ecbd86601ec45233775c59a9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2802%2901025-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252802%252901025-0%26sid%3Dliteratum%253Aachs%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DKasireddy%26aufirst%3DP.%26atitle%3DEfficient%2520solid-phase%2520synthesis%2520of%25202%252C3-substituted%2520indoles%26jtitle%3DTetrahedron%2520Lett.%26date%3D2002%26volume%3D43%26spage%3D5189%26epage%3D5191%26doi%3D10.1016%2FS0040-4039%2802%2901025-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Mehta, G.</span><span> </span><span class="NLM_article-title">Reaction of indoles with chlorosulphonyl isocyanate; a versatile route to 3-substituted indoles</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">1978</span><span class="NLM_x">, </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">376</span><span class="refDoi"> DOI: 10.1055/s-1978-24751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1055%2Fs-1978-24751" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1978&publication_year=1978&pages=374-376&author=G.+Mehta&title=Reaction+of+indoles+with+chlorosulphonyl+isocyanate%3B+a+versatile+route+to+3-substituted+indoles&doi=10.1055%2Fs-1978-24751"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1055%2Fs-1978-24751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1978-24751%26sid%3Dliteratum%253Aachs%26aulast%3DMehta%26aufirst%3DG.%26atitle%3DReaction%2520of%2520indoles%2520with%2520chlorosulphonyl%2520isocyanate%253B%2520a%2520versatile%2520route%2520to%25203-substituted%2520indoles%26jtitle%3DSynthesis%26date%3D1978%26volume%3D1978%26spage%3D374%26epage%3D376%26doi%3D10.1055%2Fs-1978-24751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c','cit1d'],'ref2':['cit2'],'ref3':['cit3a','cit3b','cit3c','cit3d','cit3e','cit3f'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10a','cit10b','cit10c','cit10d','cit10e','cit10f','cit10g','cit10h'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b','cit17c','cit17d'],'ref18':['cit18a','cit18b','cit18c'],'ref19':['cit19a','cit19b','cit19c','cit19d','cit19e','cit19f','cit19g','cit19h','cit19i','cit19j'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':[],'ref26':[],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 18 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Kerstin Sander, Thibault Gendron, Klaudia A. Cybulska, Fatih Sirindil, Junhua Zhou, Tammy L. Kalber, Mark F. Lythgoe, Tom R. Kurzawinski, Morris J. Brown, Bryan Williams, <span class="NLM_string-name hlFld-ContribAuthor">Erik Årstad</span>. </span><span class="cited-content_cbyCitation_article-title">Development of [18F]AldoView as the First Highly Selective Aldosterone Synthase PET Tracer for Imaging of Primary Hyperaldosteronism. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 9321-9329. <a href="https://doi.org/10.1021/acs.jmedchem.1c00539" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00539</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00539%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252B%25255B18F%25255DAldoView%252Bas%252Bthe%252BFirst%252BHighly%252BSelective%252BAldosterone%252BSynthase%252BPET%252BTracer%252Bfor%252BImaging%252Bof%252BPrimary%252BHyperaldosteronism%26aulast%3DSander%26aufirst%3DKerstin%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D24032021%26date%3D17062021%26volume%3D64%26issue%3D13%26spage%3D9321%26epage%3D9329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yongfu Liu, Jun Wu, Mingwei Zhou, Wenming Chen, Dongbo Li, Zhanguo Wang, Benoit Hornsperger, Johannes D. Aebi, Hans-Peter Märki, Bernd Kuhn, Lisha Wang, Andreas Kuglstatter, Jörg Benz, Stephan Müller, Remo Hochstrasser, Giorgio Ottaviani, Jian Xin, Stephan Kirchner, Susanne Mohr, Philippe Verry, William Riboulet, Hong C. Shen, Alexander V. Mayweg, Kurt Amrein, <span class="NLM_string-name hlFld-ContribAuthor">Xuefei Tan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 6876-6897. <a href="https://doi.org/10.1021/acs.jmedchem.0c00233" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00233%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B3-Pyridyl%252BIsoindolin-1-one%252BDerivatives%252Bas%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BActive%252BAldosterone%252BSynthase%252B%252528CYP11B2%252529%252BInhibitors%26aulast%3DLiu%26aufirst%3DYongfu%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D14022020%26date%3D25062020%26date%3D12062020%26volume%3D63%26issue%3D13%26spage%3D6876%26epage%3D6897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Steven M. Sparks, Dana P. Danger, William J. Hoekstra, Tony Leesnitzer, Robert J. Schotzinger, Christopher M. Yates, <span class="NLM_string-name hlFld-ContribAuthor">J. David Becherer</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Highly Selective Pyrimidine-Based Aldosterone Synthase (CYP11B2) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (7)
                                     , 1056-1060. <a href="https://doi.org/10.1021/acsmedchemlett.9b00152" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00152%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDevelopment%252Bof%252BHighly%252BSelective%252BPyrimidine-Based%252BAldosterone%252BSynthase%252B%252528CYP11B2%252529%252BInhibitors%26aulast%3DSparks%26aufirst%3DSteven%2BM.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03042019%26date%3D06062019%26date%3D10062019%26date%3D07062019%26volume%3D10%26issue%3D7%26spage%3D1056%26epage%3D1060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ryo Sakakibara, Wataru Sasaki, Yuichi Onda, Minami Yamaguchi, Hideki Ushirogochi, Yuki Hiraga, Kanako Sato, Masashi Nishio, Yasuhiro Egi, Kei Takedomi, Hidetoshi Shimizu, Tomoko Ohbora, <span class="NLM_string-name hlFld-ContribAuthor">Fumihiko Akahoshi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pyrazole-Based Selective Aldosterone Synthase (CYP11B2) Inhibitors: A New Template to Coordinate the Heme-Iron Motif of CYP11B2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (13)
                                     , 5594-5608. <a href="https://doi.org/10.1021/acs.jmedchem.8b00328" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00328%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPyrazole-Based%252BSelective%252BAldosterone%252BSynthase%252B%252528CYP11B2%252529%252BInhibitors%25253A%252BA%252BNew%252BTemplate%252Bto%252BCoordinate%252Bthe%252BHeme-Iron%252BMotif%252Bof%252BCYP11B2%26aulast%3DSakakibara%26aufirst%3DRyo%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27022018%26date%3D22062018%26date%3D07062018%26volume%3D61%26issue%3D13%26spage%3D5594%26epage%3D5608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Whitney L.  Petrilli</span>, <span class="hlFld-ContribAuthor ">Scott B.  Hoyt</span>, <span class="hlFld-ContribAuthor ">Clare  London</span>, <span class="hlFld-ContribAuthor ">Daniel  McMasters</span>, <span class="hlFld-ContribAuthor ">Andreas  Verras</span>, <span class="hlFld-ContribAuthor ">Mary  Struthers</span>, <span class="hlFld-ContribAuthor ">Doris  Cully</span>, <span class="hlFld-ContribAuthor ">Thomas  Wisniewski</span>, <span class="hlFld-ContribAuthor ">Ning  Ren</span>, <span class="hlFld-ContribAuthor ">Charlene  Bopp</span>, <span class="hlFld-ContribAuthor ">Andrea  Sok</span>, <span class="hlFld-ContribAuthor ">Qing  Chen</span>, <span class="hlFld-ContribAuthor ">Ying  Li</span>, <span class="hlFld-ContribAuthor ">Elaine  Tung</span>, <span class="hlFld-ContribAuthor ">Wei  Tang</span>, <span class="hlFld-ContribAuthor ">Gino  Salituro</span>, <span class="hlFld-ContribAuthor ">Ian  Knemeyer</span>, <span class="hlFld-ContribAuthor ">Bindhu  Karanam</span>, <span class="hlFld-ContribAuthor ">Joseph  Clemas</span>, <span class="hlFld-ContribAuthor ">Gaochao  Zhou</span>, <span class="hlFld-ContribAuthor ">Jack  Gibson</span>, <span class="hlFld-ContribAuthor ">Carrie Ann  Shipley</span>, <span class="hlFld-ContribAuthor ">Douglas J.  MacNeil</span>, <span class="hlFld-ContribAuthor ">Ruth  Duffy</span>, <span class="hlFld-ContribAuthor ">James R.  Tata</span>, <span class="hlFld-ContribAuthor ">Feroze  Ujjainwalla</span>, <span class="hlFld-ContribAuthor ">Amjad  Ali</span>, and <span class="hlFld-ContribAuthor ">Yusheng  Xiong</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant Hypertension. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (1)
                                     , 128-132. <a href="https://doi.org/10.1021/acsmedchemlett.6b00455" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00455</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00455%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BSpirocyclic%252BAldosterone%252BSynthase%252BInhibitors%252Bas%252BPotential%252BTreatments%252Bfor%252BResistant%252BHypertension%26aulast%3DPetrilli%26aufirst%3DWhitney%2BL.%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D11112016%26date%3D22112016%26date%3D06122016%26date%3D12012017%26date%3D22112016%26volume%3D8%26issue%3D1%26spage%3D128%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Livia  Lenzini</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Zanotti</span>, <span class="hlFld-ContribAuthor ">Marcella  Bonchio</span>, <span class="hlFld-ContribAuthor ">Gian Paolo  Rossi</span>. </span><span class="cited-content_cbyCitation_article-title">Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2021,</strong> <em>163 </em>, 105332. <a href="https://doi.org/10.1016/j.phrs.2020.105332" title="DOI URL">https://doi.org/10.1016/j.phrs.2020.105332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2020.105332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2020.105332%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DAldosterone%252Bsynthase%252Binhibitors%252Bfor%252Bcardiovascular%252Bdiseases%25253A%252BA%252Bcomprehensive%252Breview%252Bof%252Bpreclinical%25252C%252Bclinical%252Band%252Bin%252Bsilico%252Bdata%26aulast%3DLenzini%26aufirst%3DLivia%26date%3D2021%26volume%3D163%26spage%3D105332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Gobbi</span>, <span class="hlFld-ContribAuthor ">Qingzhong  Hu</span>, <span class="hlFld-ContribAuthor ">Giacomo  Foschi</span>, <span class="hlFld-ContribAuthor ">Elena  Catanzaro</span>, <span class="hlFld-ContribAuthor ">Federica  Belluti</span>, <span class="hlFld-ContribAuthor ">Angela  Rampa</span>, <span class="hlFld-ContribAuthor ">Carmela  Fimognari</span>, <span class="hlFld-ContribAuthor ">Rolf W.  Hartmann</span>, <span class="hlFld-ContribAuthor ">Alessandra  Bisi</span>. </span><span class="cited-content_cbyCitation_article-title">Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>86 </em>, 401-409. <a href="https://doi.org/10.1016/j.bioorg.2019.01.066" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.01.066</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.01.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.01.066%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DBenzophenones%252Bas%252Bxanthone-open%252Bmodel%252BCYP11B1%252Binhibitors%252Bpotentially%252Buseful%252Bfor%252Bpromoting%252Bwound%252Bhealing%26aulast%3DGobbi%26aufirst%3DSilvia%26date%3D2019%26volume%3D86%26spage%3D401%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard A  Feelders</span>, <span class="hlFld-ContribAuthor ">John  Newell-Price</span>, <span class="hlFld-ContribAuthor ">Rosario  Pivonello</span>, <span class="hlFld-ContribAuthor ">Lynnette K  Nieman</span>, <span class="hlFld-ContribAuthor ">Leo J  Hofland</span>, <span class="hlFld-ContribAuthor ">Andre  Lacroix</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in the medical treatment of Cushing's syndrome. </span><span class="cited-content_cbyCitation_journal-name">The Lancet Diabetes & Endocrinology</span><span> <strong>2019,</strong> <em>7 </em>
                                    (4)
                                     , 300-312. <a href="https://doi.org/10.1016/S2213-8587(18)30155-4" title="DOI URL">https://doi.org/10.1016/S2213-8587(18)30155-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S2213-8587(18)30155-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS2213-8587%2818%2930155-4%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Lancet%2520Diabetes%2520%2526%2520Endocrinology%26atitle%3DAdvances%252Bin%252Bthe%252Bmedical%252Btreatment%252Bof%252BCushing%252527s%252Bsyndrome%26aulast%3DFeelders%26aufirst%3DRichard%2BA%26date%3D2019%26volume%3D7%26issue%3D4%26spage%3D300%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven M.  Weldon</span>, <span class="hlFld-ContribAuthor ">Nicholas F.  Brown</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of Aldosterone Synthase. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 211-239. <a href="https://doi.org/10.1016/bs.vh.2018.10.002" title="DOI URL">https://doi.org/10.1016/bs.vh.2018.10.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.vh.2018.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.vh.2018.10.002%26sid%3Dliteratum%253Aachs%26atitle%3DInhibitors%252Bof%252BAldosterone%252BSynthase%26aulast%3DWeldon%26aufirst%3DSteven%2BM.%26date%3D2019%26spage%3D211%26epage%3D239%26pub%3DElsevier%26atitle%3DAldosterone%26date%3D2019%26volume%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rene  Baudrand</span>, <span class="hlFld-ContribAuthor ">Luminita  Pojoga</span>, <span class="hlFld-ContribAuthor ">Jose R.  Romero</span>. </span><span class="cited-content_cbyCitation_article-title">Aldosterone’s Mechanism of Action. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 173-188. <a href="https://doi.org/10.1016/B978-0-12-803247-3.00010-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-803247-3.00010-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-803247-3.00010-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-803247-3.00010-6%26sid%3Dliteratum%253Aachs%26atitle%3DAldosterone%2525E2%252580%252599s%252BMechanism%252Bof%252BAction%26aulast%3DBaudrand%26aufirst%3DRene%26date%3D2018%26spage%3D173%26epage%3D188%26pub%3DElsevier%26atitle%3DTextbook%252Bof%252BNephro-Endocrinology%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Gobbi</span>, <span class="hlFld-ContribAuthor ">Qingzhong  Hu</span>, <span class="hlFld-ContribAuthor ">Christina  Zimmer</span>, <span class="hlFld-ContribAuthor ">Federica  Belluti</span>, <span class="hlFld-ContribAuthor ">Angela  Rampa</span>, <span class="hlFld-ContribAuthor ">Rolf W.  Hartmann</span>, <span class="hlFld-ContribAuthor ">Alessandra  Bisi</span>. </span><span class="cited-content_cbyCitation_article-title">Drifting of heme-coordinating group in imidazolylmethylxanthones leading to improved selective inhibition of CYP11B1. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>139 </em>, 60-67. <a href="https://doi.org/10.1016/j.ejmech.2017.07.078" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.07.078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.07.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.07.078%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrifting%252Bof%252Bheme-coordinating%252Bgroup%252Bin%252Bimidazolylmethylxanthones%252Bleading%252Bto%252Bimproved%252Bselective%252Binhibition%252Bof%252BCYP11B1%26aulast%3DGobbi%26aufirst%3DSilvia%26date%3D2017%26volume%3D139%26spage%3D60%26epage%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter J.  Lindsay-Scott</span>, <span class="hlFld-ContribAuthor ">Peter T.  Gallagher</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of heterocycles from arylacetonitriles: Powerful tools for medicinal chemists. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2017,</strong> <em>58 </em>
                                    (27)
                                     , 2629-2635. <a href="https://doi.org/10.1016/j.tetlet.2017.05.089" title="DOI URL">https://doi.org/10.1016/j.tetlet.2017.05.089</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2017.05.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2017.05.089%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DSynthesis%252Bof%252Bheterocycles%252Bfrom%252Barylacetonitriles%25253A%252BPowerful%252Btools%252Bfor%252Bmedicinal%252Bchemists%26aulast%3DLindsay-Scott%26aufirst%3DPeter%2BJ.%26date%3D2017%26volume%3D58%26issue%3D27%26spage%3D2629%26epage%3D2635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott B.  Hoyt</span>, <span class="hlFld-ContribAuthor ">Jerry  Taylor</span>, <span class="hlFld-ContribAuthor ">Clare  London</span>, <span class="hlFld-ContribAuthor ">Amjad  Ali</span>, <span class="hlFld-ContribAuthor ">Feroze  Ujjainwalla</span>, <span class="hlFld-ContribAuthor ">Jim  Tata</span>, <span class="hlFld-ContribAuthor ">Mary  Struthers</span>, <span class="hlFld-ContribAuthor ">Doris  Cully</span>, <span class="hlFld-ContribAuthor ">Tom  Wisniewski</span>, <span class="hlFld-ContribAuthor ">Ning  Ren</span>, <span class="hlFld-ContribAuthor ">Charlene  Bopp</span>, <span class="hlFld-ContribAuthor ">Andrea  Sok</span>, <span class="hlFld-ContribAuthor ">Andreas  Verras</span>, <span class="hlFld-ContribAuthor ">Daniel  McMasters</span>, <span class="hlFld-ContribAuthor ">Qing  Chen</span>, <span class="hlFld-ContribAuthor ">Elaine  Tung</span>, <span class="hlFld-ContribAuthor ">Wei  Tang</span>, <span class="hlFld-ContribAuthor ">Gino  Salituro</span>, <span class="hlFld-ContribAuthor ">Joe  Clemas</span>, <span class="hlFld-ContribAuthor ">Gaochao  Zhou</span>, <span class="hlFld-ContribAuthor ">Douglas  MacNeil</span>, <span class="hlFld-ContribAuthor ">Ruth  Duffy</span>, <span class="hlFld-ContribAuthor ">Yusheng  Xiong</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (11)
                                     , 2384-2388. <a href="https://doi.org/10.1016/j.bmcl.2017.04.021" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.04.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.04.021%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bindazole%252Baldosterone%252Bsynthase%252B%252528CYP11B2%252529%252Binhibitors%252Bas%252Bpotential%252Btreatments%252Bfor%252Bhypertension%26aulast%3DHoyt%26aufirst%3DScott%2BB.%26date%3D2017%26volume%3D27%26issue%3D11%26spage%3D2384%26epage%3D2388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masaki  Meguro</span>, <span class="hlFld-ContribAuthor ">Satoru  Miyauchi</span>, <span class="hlFld-ContribAuthor ">Yukiko  Kanao</span>, <span class="hlFld-ContribAuthor ">Satoru  Naito</span>, <span class="hlFld-ContribAuthor ">Kanae  Suzuki</span>, <span class="hlFld-ContribAuthor ">Shinichi  Inoue</span>, <span class="hlFld-ContribAuthor ">Keisuke  Yamada</span>, <span class="hlFld-ContribAuthor ">Tsuyoshi  Homma</span>, <span class="hlFld-ContribAuthor ">Kiyoshi  Chiba</span>, <span class="hlFld-ContribAuthor ">Futoshi  Nara</span>, <span class="hlFld-ContribAuthor ">Shinji  Furuzono</span>. </span><span class="cited-content_cbyCitation_article-title">4-Anilino-pyrimidine, novel aldosterone synthase (CYP11B2) inhibitors bearing pyrimidine structures. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (9)
                                     , 1902-1906. <a href="https://doi.org/10.1016/j.bmcl.2017.03.034" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.03.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.03.034%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3D4-Anilino-pyrimidine%25252C%252Bnovel%252Baldosterone%252Bsynthase%252B%252528CYP11B2%252529%252Binhibitors%252Bbearing%252Bpyrimidine%252Bstructures%26aulast%3DMeguro%26aufirst%3DMasaki%26date%3D2017%26volume%3D27%26issue%3D9%26spage%3D1902%26epage%3D1906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brent R.  Whitehead</span>, <span class="hlFld-ContribAuthor ">Michael M.-C.  Lo</span>, <span class="hlFld-ContribAuthor ">Amjad  Ali</span>, <span class="hlFld-ContribAuthor ">Min K.  Park</span>, <span class="hlFld-ContribAuthor ">Scott B.  Hoyt</span>, <span class="hlFld-ContribAuthor ">Yusheng  Xiong</span>, <span class="hlFld-ContribAuthor ">Jiaqiang  Cai</span>, <span class="hlFld-ContribAuthor ">Emma  Carswell</span>, <span class="hlFld-ContribAuthor ">Andrew  Cooke</span>, <span class="hlFld-ContribAuthor ">John  MacLean</span>, <span class="hlFld-ContribAuthor ">Paul  Ratcliffe</span>, <span class="hlFld-ContribAuthor ">John  Robinson</span>, <span class="hlFld-ContribAuthor ">D. Jonathan  Bennett</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Clemas</span>, <span class="hlFld-ContribAuthor ">Tom  Wisniewski</span>, <span class="hlFld-ContribAuthor ">Mary  Struthers</span>, <span class="hlFld-ContribAuthor ">Doris  Cully</span>, <span class="hlFld-ContribAuthor ">Douglas J.  MacNeil</span>. </span><span class="cited-content_cbyCitation_article-title">Imidazopyridyl compounds as aldosterone synthase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (2)
                                     , 143-146. <a href="https://doi.org/10.1016/j.bmcl.2016.12.003" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.12.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.12.003%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DImidazopyridyl%252Bcompounds%252Bas%252Baldosterone%252Bsynthase%252Binhibitors%26aulast%3DWhitehead%26aufirst%3DBrent%2BR.%26date%3D2017%26volume%3D27%26issue%3D2%26spage%3D143%26epage%3D146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katrijn  Bogman</span>, <span class="hlFld-ContribAuthor ">Dietmar  Schwab</span>, <span class="hlFld-ContribAuthor ">Marie-Laure  Delporte</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Palermo</span>, <span class="hlFld-ContribAuthor ">Kurt  Amrein</span>, <span class="hlFld-ContribAuthor ">Susanne  Mohr</span>, <span class="hlFld-ContribAuthor ">Maria Cristina  De Vera Mudry</span>, <span class="hlFld-ContribAuthor ">Morris J.  Brown</span>, <span class="hlFld-ContribAuthor ">Philippe  Ferber</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2). </span><span class="cited-content_cbyCitation_journal-name">Hypertension</span><span> <strong>2017,</strong> <em>69 </em>
                                    (1)
                                     , 189-196. <a href="https://doi.org/10.1161/HYPERTENSIONAHA.116.07716" title="DOI URL">https://doi.org/10.1161/HYPERTENSIONAHA.116.07716</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1161/HYPERTENSIONAHA.116.07716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1161%2FHYPERTENSIONAHA.116.07716%26sid%3Dliteratum%253Aachs%26jtitle%3DHypertension%26atitle%3DPreclinical%252Band%252BEarly%252BClinical%252BProfile%252Bof%252Ba%252BHighly%252BSelective%252Band%252BPotent%252BOral%252BInhibitor%252Bof%252BAldosterone%252BSynthase%252B%252528CYP11B2%252529%26aulast%3DBogman%26aufirst%3DKatrijn%26date%3D2017%26volume%3D69%26issue%3D1%26spage%3D189%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Gobbi</span>, <span class="hlFld-ContribAuthor ">Qingzhong  Hu</span>, <span class="hlFld-ContribAuthor ">Christina  Zimmer</span>, <span class="hlFld-ContribAuthor ">Federica  Belluti</span>, <span class="hlFld-ContribAuthor ">Angela  Rampa</span>, <span class="hlFld-ContribAuthor ">Rolf W.  Hartmann</span>, <span class="hlFld-ContribAuthor ">Alessandra  Bisi</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Steroidogenic Cytochromes P450 (CYPs) with 6-Substituted 1-Imidazolylmethylxanthones. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2016,</strong> <em>11 </em>
                                    (16)
                                     , 1770-1777. <a href="https://doi.org/10.1002/cmdc.201600078" title="DOI URL">https://doi.org/10.1002/cmdc.201600078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201600078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201600078%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DTargeting%252BSteroidogenic%252BCytochromes%252BP450%252B%252528CYPs%252529%252Bwith%252B6-Substituted%252B1-Imidazolylmethylxanthones%26aulast%3DGobbi%26aufirst%3DSilvia%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D16%26spage%3D1770%26epage%3D1777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rainer E.  Martin</span>, <span class="hlFld-ContribAuthor ">Johannes  Lehmann</span>, <span class="hlFld-ContribAuthor ">Thibaut  Alzieu</span>, <span class="hlFld-ContribAuthor ">Mario  Lenz</span>, <span class="hlFld-ContribAuthor ">Marjorie A.  Carnero Corrales</span>, <span class="hlFld-ContribAuthor ">Johannes D.  Aebi</span>, <span class="hlFld-ContribAuthor ">Hans Peter  Märki</span>, <span class="hlFld-ContribAuthor ">Bernd  Kuhn</span>, <span class="hlFld-ContribAuthor ">Kurt  Amrein</span>, <span class="hlFld-ContribAuthor ">Alexander V.  Mayweg</span>, <span class="hlFld-ContribAuthor ">Robert  Britton</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2). </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2016,</strong> <em>14 </em>
                                    (25)
                                     , 5922-5927. <a href="https://doi.org/10.1039/C6OB00848H" title="DOI URL">https://doi.org/10.1039/C6OB00848H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6OB00848H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6OB00848H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bannulated%252Bpyridines%252Bas%252Binhibitors%252Bof%252Baldosterone%252Bsynthase%252B%252528CYP11B2%252529%26aulast%3DMartin%26aufirst%3DRainer%2BE.%26date%3D2016%26date%3D2016%26volume%3D14%26issue%3D25%26spage%3D5922%26epage%3D5927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Rat CYP11B2 IC<sub>50</sub> plotted against human CYP11B1/CYP11B2 IC<sub>50</sub> ratio for 786 compounds with human CYP11B2 IC<sub>50</sub> < 20 nM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0012.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Time courses of total compound plasma concentration, PAC and PCC following administration of methylcellulose vehicle (<i>n</i> = 6) and <b>8</b> at 0.03, 0.1, 0.3, and 3 mg/kg (<i>n</i> = 3/dose), and an ACTH challenge 3 h postdosing (error bars excluded for clarity).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0001.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Plasma aldosterone AUC(0–24 h) (left panel) and amount of aldosterone excreted in urine over 24 h (right panel), expressed as mean placebo-adjusted percent of baseline, following 30, 60, 100, and 200 mg bid dosing of <b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0002.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Amount of cortisol (left panel) and 11-deoxycortisol (right panel) excreted in urine over 24 h, expressed as mean placebo-adjusted percent of baseline, following 30, 60, 100, and 200 mg bid dosing of <b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of ASIs <b>1</b> and <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Phenylhydrazine hydrochloride (0.95 equiv), ethanol, reflux, 1 h, then catalytic HCl, reflux, 3 h, 63%; (b) NaH (60%, 2.2 equiv), DMF, 0 °C, 30 min, then MeI (1.1 equiv), 1.5 h, then NaH (60%, 1.4 equiv), 16 h, 16%.</p></p></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of ASIs <b>3</b> and <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Nicotinoyl chloride (1.1 equiv), diisopropylethylamine (2.5 equiv), DCM, rt, 16 h, 31%; (b) NaH (60%, 1.0 equiv), DMF, 130 °C, 18 h, 45%; (c) NaH (60%, 3.0 equiv), DMF, 30 min, then MeI (1.5 equiv), rt, 1 h, 65%. (d) <i>N</i>-chlorosuccinimide (2.5 equiv), dichloroethane, reflux, 2 days, 10%.</p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of ASIs <b>5</b>–<b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) K<sub>3</sub>PO<sub>4</sub> (2.0 equiv), s-Phos (0.05 equiv), Pd<sub>2</sub>dba<sub>3</sub> (0.02 equiv), toluene, 85 °C, 45–90 min, 87% (<b>19</b>), 72% (<b>20</b>) [Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05 equiv) in DMF was used for <b>22</b>, 89%]; (b) ethanesulfonyl chloride (3–5 equiv), di-isopropylethylamine (3–4 equiv), DCM, rt, 1–16 h, 98% (<b>21</b>); (c) silica gel, 60–65 °C under high vacuum, 2–48 h, 73% (2 steps, <b>24</b>); (d) MeI (1.4 equiv), NaH (60%, 1.6 equiv), DMF, 0 °C to rt, 1 h, quant. (<b>25</b>); (e) chlorosulfonyl isocyanate (3–5 equiv), DCM, or acetonitrile, rt, 10–45 min, then DMF, 10–120 min, 19% (<b>5</b>); (f) aqueous NaOH, methanol, rt, 1 h, 51% (2 steps, <b>6</b>), 53% (4 steps, <b>7</b>); (g) ethanesulfonamide (2 equiv), Ti(O<i>i</i>Pr)<sub>4</sub> (1.5 equiv), toluene, reflux, 16 h then NaBH<sub>4</sub> (2 equiv), DCM, MeOH, 0 °C, 30 min, 37% (2 steps, <b>8</b>).</p></p></figure><figure data-id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of ASI <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Trimethylsilylacetylene (3.0 equiv), CuI (0.05 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (0.05 equiv), TEA, 50 °C, 1 h; (b) K<sub>2</sub>CO<sub>3</sub> (0.25 equiv), MeOH, rt, 30 min, 67% (2 steps); (c) ICl (1.05 equiv), NaOAc (6 equiv), acetic acid, 60 °C, 2 h, 45%; (d) <b>30</b> (1.0 equiv), CuI (0.05 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (0.05 equiv), TEA, 100 °C, 3 h; (e) KO<i>t</i>Bu (3.0 equiv), NMP, rt, 16 h, then MeI (3.0 equiv), 0 °C, 30 min; (f) LAH (2.0 equiv), THF, 0 °C to rt, 45 min, 11% (3 steps); (g) MnO<sub>2</sub> (10 equiv), dioxane, reflux, 16 h; (h) ethanesulfonamide (2 equiv), Ti(O<i>i</i>Pr)<sub>4</sub>, (1.5 equiv), toluene, reflux, 16 h then NaBH<sub>4</sub> (4 equiv), DCM, MeOH, 0 °C, 30 min, 17% (2 steps).</p></p></figure><figure data-id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/medium/jm-2015-015452_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of ASI <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01545/20151204/images/large/jm-2015-015452_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01545&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) NaH (2.0 equiv), DMF, 0 °C, 20 min then MeI (1.2 equiv), 0 °C to rt, 2 h; (b) <i>t</i>BuLi (2.5 equiv), THF, – 78 °C, 2 h, then B(OMe)<sub>3</sub> (1.5 equiv), – 78 °C to rt, 16 h; (c) 5-bromo-3-pyridine carboxaldehyde (0.66 equiv), 2 M aqueous K<sub>2</sub>CO<sub>3</sub> (2 equiv), PS-Pd(PPh<sub>3</sub>)<sub>4</sub> (0.03 equiv), dioxane, 85 °C, 2 h, 31% (3 steps); (d) ethanesulfonamide (2 equiv), Ti(O<i>i</i>Pr)<sub>4</sub>, (1.5 equiv), toluene, reflux, 16 h then NaBH<sub>4</sub> (4 equiv), DCM, MeOH, 0 °C, 30 min, 20%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i52">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76004" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76004" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Vasan, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meigs, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, D.</span><span> </span><span class="NLM_article-title">Serum aldosterone and the incidence of hypertension in non-hypertensive persons</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span><span class="refDoi"> DOI: 10.1056/NEJMoa033263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1056%2FNEJMoa033263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=15229305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltlOjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2004&pages=33-41&author=R.+S.+Vasanauthor=J.+C.+Evansauthor=M.+G.+Larsonauthor=P.+W.+Wilsonauthor=J.+B.+Meigsauthor=N.+Rifaiauthor=E.+J.+Benjaminauthor=D.+Levy&title=Serum+aldosterone+and+the+incidence+of+hypertension+in+non-hypertensive+persons&doi=10.1056%2FNEJMoa033263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Serum aldosterone and the incidence of hypertension in non-hypertensive persons</span></div><div class="casAuthors">Vasan, Ramachandran S.; Evans, Jane C.; Larson, Martin G.; Wilson, Peter W. F.; Meigs, James B.; Rifai, Nader; Benjamin, Emelia J.; Levy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-41</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Primary hyperaldosteronism is a well-recognized cause of secondary hypertension.  It is unknown whether serum aldosterone levels within the physiol. range influence the risk of hypertension.  METHODS: We investigated the relation of baseline serum aldosterone levels to increases in blood pressure and the incidence of hypertension after four years in 1688 non-hypertensive participants in the Framingham Offspring Study (mean age, 55 yr), 58 % of whom were women.  We defined an increase in blood pressure as an increment of at least one blood-pressure category (as defined by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) and defined hypertension as a systolic blood pressure of 140 mm Hg or higher, a diastolic blood pressure of 90 mm Hg or higher, or the use of antihypertensive medications.  RESULTS: At follow-up, the blood-pressure category had increased in 33.6 % of the participants, and hypertension had developed in 14.8 %.  In multivariable models, a 16 % increase in the risk of an elevation in blood pressure (P=0.002) and a 17 % increase in the risk of hypertension (P=0.03) were obsd. per quartile increment in the serum aldosterone level.  The highest serum aldosterone quartile, relative to the lowest, was assocd. with a 1.60-fold risk of an elevation in blood pressure (95 % confidence interval, 1.19 to 2.14) and a 1.61-fold risk of hypertension (95 % confidence interval, 1.05 to 2.46). The assocns. between the serum aldosterone level and blood-pressure outcomes were not significantly affected by adjustment for urinary sodium excretion or left ventricular thickness or internal dimensions.  CONCLUSIONS: In our community-based sample, increased aldosterone levels within the physiol. range predisposed persons to the development of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM3YrkjLmb_7Vg90H21EOLACvtfcHk0ljK-CLwE6yHRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltlOjsLY%253D&md5=f1f72f54aac5a12fc11795492949a8be</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa033263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa033263%26sid%3Dliteratum%253Aachs%26aulast%3DVasan%26aufirst%3DR.%2BS.%26aulast%3DEvans%26aufirst%3DJ.%2BC.%26aulast%3DLarson%26aufirst%3DM.%2BG.%26aulast%3DWilson%26aufirst%3DP.%2BW.%26aulast%3DMeigs%26aufirst%3DJ.%2BB.%26aulast%3DRifai%26aufirst%3DN.%26aulast%3DBenjamin%26aufirst%3DE.%2BJ.%26aulast%3DLevy%26aufirst%3DD.%26atitle%3DSerum%2520aldosterone%2520and%2520the%2520incidence%2520of%2520hypertension%2520in%2520non-hypertensive%2520persons%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D351%26spage%3D33%26epage%3D41%26doi%3D10.1056%2FNEJMoa033263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Xanthakis, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasan, R. S.</span><span> </span><span class="NLM_article-title">Aldosterone and the risk of hypertension</span> <span class="citation_source-journal">Curr. Hypertens. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1007/s11906-013-0330-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1007%2Fs11906-013-0330-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=23378101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslSnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=102-107&author=V.+Xanthakisauthor=R.+S.+Vasan&title=Aldosterone+and+the+risk+of+hypertension&doi=10.1007%2Fs11906-013-0330-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone and the Risk of Hypertension</span></div><div class="casAuthors">Xanthakis, Vanessa; Vasan, Ramachandran S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Hypertension Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">102-107</span>CODEN:
                <span class="NLM_cas:coden">CHRUCG</span>;
        ISSN:<span class="NLM_cas:issn">1522-6417</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Aldosterone, the key hormone in the mineralocorticoid pathway, plays a fundamental role in salt and water homeostasis, blood pressure regulation, and cardiovascular remodeling.  Both genomic and nongenomic mechanisms influence aldosterone-induced renal sodium reabsorption.  Furthermore, the mineralocorticoid receptors in nonepithelial tissues, including the heart and vascular smooth muscle cells, have recently been discovered.  Thus, aldosterone likely has pleiotropic effects that contribute to the modulation of blood pressure.  Among patients with hypertension in general, and among those with more severe or resistant hypertension in particular, a higher-than-expected prevalence of primary hyperaldosteronism is noted.  Among individuals with resistant hypertension, aldosterone antagonists have also been shown to be effective in lowering blood pressure.  Most significantly, recent community-based studies among non-hypertensive individuals in the general population have demonstrated that both higher serum aldosterone concns. and a higher aldosterone to renin ratio portend a greater risk of developing hypertension.  The combination of the aforementioned observations underscores the importance of the mineralocorticoid pathway in the pathogenesis of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj7vTvphddlrVg90H21EOLACvtfcHk0liT4bXcj6-kZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslSnu70%253D&md5=ee82a738d920d666ae9465eee5dd9b38</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1007%2Fs11906-013-0330-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11906-013-0330-y%26sid%3Dliteratum%253Aachs%26aulast%3DXanthakis%26aufirst%3DV.%26aulast%3DVasan%26aufirst%3DR.%2BS.%26atitle%3DAldosterone%2520and%2520the%2520risk%2520of%2520hypertension%26jtitle%3DCurr.%2520Hypertens.%2520Rep.%26date%3D2013%26volume%3D15%26spage%3D102%26epage%3D107%26doi%3D10.1007%2Fs11906-013-0330-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Clark, D.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calhoun, D. A.</span><span> </span><span class="NLM_article-title">Resistant hypertension and aldosterone: an update</span> <span class="citation_source-journal">Can. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span><span class="refDoi"> DOI: 10.1016/j.cjca.2012.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.cjca.2012.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=22521297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCmu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2012&pages=318-325&author=D.+Clarkauthor=M.+I.+Ahmedauthor=D.+A.+Calhoun&title=Resistant+hypertension+and+aldosterone%3A+an+update&doi=10.1016%2Fj.cjca.2012.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Resistant Hypertension and Aldosterone: An Update</span></div><div class="casAuthors">Clark, Donald, III; Ahmed, Mustafa I.; Calhoun, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Cardiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-325</span>CODEN:
                <span class="NLM_cas:coden">CJCAEX</span>;
        ISSN:<span class="NLM_cas:issn">0828-282X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Resistant hypertension (RHTN) is defined as a blood pressure remaining above goal despite the concurrent use of 3 antihypertensive medications of different classes, including, ideally a diuretic.  RHTN is an important health problem with a prevalence rate expected to increase as populations become older, more obese, and at higher risk of having diabetes and chronic kidney disease, all of which are important risk factors for development of RHTN.  The role of aldosterone has gained increasing recognition as a significant contributor to antihypertensive treatment resistance.  In prospective studies, the prevalence of primary aldosteronism (PA) has ranged from 14%-21% in patients with RHTN, which is considerably higher than in the general hypertensive population.  Furthermore, marked antihypertensive effects are seen when mineralocorticoid antagonists are added to the treatment regimen of patients with RHTN, further supporting aldosterone excess as an important cause of RHTN.  A close assocn. exists between hyperaldosteronism, RHTN, and obstructive sleep apnea (OSA) based upon recent studies which indicate that OSA is worsened by aldosterone-mediated fluid retention.  This interaction is supported by preliminary data which demonstrates improvement in OSA severity after treatment with spironolactone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOYBTBPO5DibVg90H21EOLACvtfcHk0liT4bXcj6-kZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCmu7%252FM&md5=1851d4f473b75f7ac84395fa1351fe73</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1016%2Fj.cjca.2012.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cjca.2012.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DD.%26aulast%3DAhmed%26aufirst%3DM.%2BI.%26aulast%3DCalhoun%26aufirst%3DD.%2BA.%26atitle%3DResistant%2520hypertension%2520and%2520aldosterone%253A%2520an%2520update%26jtitle%3DCan.%2520J.%2520Cardiol.%26date%3D2012%26volume%3D28%26spage%3D318%26epage%3D325%26doi%3D10.1016%2Fj.cjca.2012.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Calhoun, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Textor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goff, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toto, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cushman, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sica, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferdinand, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falkner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carey, R. M.</span><span> </span><span class="NLM_article-title">Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research</span> <span class="citation_source-journal">Hypertension</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1403</span><span class="NLM_x">–</span> <span class="NLM_lpage">1419</span><span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.108.189141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1161%2FHYPERTENSIONAHA.108.189141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=18391085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvFaitLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1403-1419&author=D.+A.+Calhounauthor=D.+Jonesauthor=S.+Textorauthor=D.+C.+Goffauthor=T.+P.+Murphyauthor=R.+D.+Totoauthor=A.+Whiteauthor=W.+C.+Cushmanauthor=W.+Whiteauthor=D.+Sicaauthor=K.+Ferdinandauthor=T.+D.+Gilesauthor=B.+Falknerauthor=R.+M.+Carey&title=Resistant+hypertension%3A+Diagnosis%2C+evaluation%2C+and+treatment.+A+scientific+statement+from+the+American+Heart+Association+Professional+Education+Committee+of+the+Council+for+High+Blood+Pressure+Research&doi=10.1161%2FHYPERTENSIONAHA.108.189141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Resistant Hypertension: Diagnosis, Evaluation, and Treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research</span></div><div class="casAuthors">Calhoun, David A.; Jones, Daniel; Textor, Stephen; Goff, David C.; Murphy, Timothy P.; Toto, Robert D.; White, Anthony; Cushman, William C.; White, William; Sica, Domenic; Ferdinand, Keith; Giles, Thomas D.; Falkner, Bonita; Carey, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1403-1419</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Resistant hypertension is a common clin. problem faced by both primary care clinicians and specialists.  While the exact prevalence of resistant hypertension is unknown, clin. trials suggest that it is not rare, involving perhaps 20% to 30% of study participants.  As older age and obesity are 2 of the strongest risk factors for uncontrolled hypertension, the incidence of resistant hypertension will likely increase as the population becomes more elderly and heavier.  The prognosis of resistant hypertension is unknown, but cardiovascular risk is undoubtedly increased as patients often have a history of long-standing, severe hypertension complicated by multiple other cardiovascular risk factors such as obesity, sleep apnea, diabetes, and chronic kidney disease.  The diagnosis of resistant hypertension requires use of good blood pressure technique to confirm persistently elevated blood pressure levels.  Pseudoresistance, including lack of blood pressure control secondary to poor medication adherence or white coat hypertension, must be excluded.  Resistant hypertension is almost always multifactorial in etiol.  Successful treatment requires identification and reversal of lifestyle factors contributing to treatment resistance; diagnosis and appropriate treatment of secondary causes of hypertension; and use of effective multidrug regimens.  As a subgroup, patients with resistant hypertension have not been widely studied.  Observational assessments have allowed for identification of demog. and lifestyle characteristics assocd. with resistant hypertension, and the role of secondary causes of hypertension in promoting treatment resistance is well documented; however, identification of broader mechanisms of treatment resistance is lacking.  In particular, attempts to elucidate potential genetic causes of resistant hypertension have been limited.  Recommendations for the pharmacol. treatment of resistant hypertension remain largely empiric due to the lack of systematic assessments of 3 or 4 drug combinations.  Studies of resistant hypertension are limited by the high cardiovascular risk of patients within this subgroup, which generally precludes safe withdrawal of medications; the presence of multiple disease processes (eg, sleep apnea, diabetes, chronic kidney disease, atherosclerotic disease) and their assocd. medical therapies, which confound interpretation of study results; and the difficulty in enrolling large nos. of study participants.  Expanding our understanding of the causes of resistant hypertension and thereby potentially allowing for more effective prevention and/or treatment will be essential to improve the long-term clin. management of this disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1K_lQcMkaSLVg90H21EOLACvtfcHk0liT4bXcj6-kZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvFaitLw%253D&md5=f03659a23f19e2f89439672dfdb416e6</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.108.189141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.108.189141%26sid%3Dliteratum%253Aachs%26aulast%3DCalhoun%26aufirst%3DD.%2BA.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DTextor%26aufirst%3DS.%26aulast%3DGoff%26aufirst%3DD.%2BC.%26aulast%3DMurphy%26aufirst%3DT.%2BP.%26aulast%3DToto%26aufirst%3DR.%2BD.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DCushman%26aufirst%3DW.%2BC.%26aulast%3DWhite%26aufirst%3DW.%26aulast%3DSica%26aufirst%3DD.%26aulast%3DFerdinand%26aufirst%3DK.%26aulast%3DGiles%26aufirst%3DT.%2BD.%26aulast%3DFalkner%26aufirst%3DB.%26aulast%3DCarey%26aufirst%3DR.%2BM.%26atitle%3DResistant%2520hypertension%253A%2520Diagnosis%252C%2520evaluation%252C%2520and%2520treatment.%2520A%2520scientific%2520statement%2520from%2520the%2520American%2520Heart%2520Association%2520Professional%2520Education%2520Committee%2520of%2520the%2520Council%2520for%2520High%2520Blood%2520Pressure%2520Research%26jtitle%3DHypertension%26date%3D2008%26volume%3D51%26spage%3D1403%26epage%3D1419%26doi%3D10.1161%2FHYPERTENSIONAHA.108.189141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Daugherty, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magid, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masoudi, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolis, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P. M.</span><span> </span><span class="NLM_article-title">Incidence and prognosis of resistant hypertension in hypertensive patients</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">1635</span><span class="NLM_x">–</span> <span class="NLM_lpage">1642</span><span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.111.068064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1161%2FCIRCULATIONAHA.111.068064" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=1635-1642&author=S.+L.+Daughertyauthor=J.+D.+Powersauthor=D.+J.+Magidauthor=H.+M.+Tavelauthor=F.+A.+Masoudiauthor=K.+L.+Margolisauthor=P.+J.+O%E2%80%99Connorauthor=J.+V.+Selbyauthor=P.+M.+Ho&title=Incidence+and+prognosis+of+resistant+hypertension+in+hypertensive+patients&doi=10.1161%2FCIRCULATIONAHA.111.068064"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.068064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.068064%26sid%3Dliteratum%253Aachs%26aulast%3DDaugherty%26aufirst%3DS.%2BL.%26aulast%3DPowers%26aufirst%3DJ.%2BD.%26aulast%3DMagid%26aufirst%3DD.%2BJ.%26aulast%3DTavel%26aufirst%3DH.%2BM.%26aulast%3DMasoudi%26aufirst%3DF.%2BA.%26aulast%3DMargolis%26aufirst%3DK.%2BL.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%2BJ.%26aulast%3DSelby%26aufirst%3DJ.%2BV.%26aulast%3DHo%26aufirst%3DP.%2BM.%26atitle%3DIncidence%2520and%2520prognosis%2520of%2520resistant%2520hypertension%2520in%2520hypertensive%2520patients%26jtitle%3DCirculation%26date%3D2012%26volume%3D125%26spage%3D1635%26epage%3D1642%26doi%3D10.1161%2FCIRCULATIONAHA.111.068064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">He, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M. E.</span><span> </span><span class="NLM_article-title">Aldosterone and cardiovascular disease: the heart of the matter</span> <span class="citation_source-journal">Trends Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1016/j.tem.2012.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.tem.2012.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=23040074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKgsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=21-30&author=B.+J.+Heauthor=M.+E.+Anderson&title=Aldosterone+and+cardiovascular+disease%3A+the+heart+of+the+matter&doi=10.1016%2Fj.tem.2012.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone and cardiovascular disease: the heart of the matter</span></div><div class="casAuthors">He, B. Julie; Anderson, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Aldosterone contributes to the endocrine basis of heart failure, and studies on cardiac aldosterone signaling have reinforced its value as a therapeutic target.  Recent focus has shifted to new roles of aldosterone that appear to depend on coexisting pathol. stimuli, cell type, and disease etiol.  This review evaluates recent advances in mechanisms underlying aldosterone-induced cardiac disease and highlights the interplay between aldosterone and Ca2+/calmodulin dependent protein kinase II, whose hyperactivity during heart failure contributes to disease progression.  Increasing evidence implicates aldosterone in diastolic dysfunction, and there is a need to develop more targeted therapeutics such as aldosterone synthase inhibitors and molecularly specific antioxidants.  Despite accumulating knowledge, many questions still persist and will likely dictate areas of future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT-5BWMzRWh7Vg90H21EOLACvtfcHk0ligik6OTXMzSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKgsLzE&md5=8d77025ca07baf45d782d00baab87355</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2012.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2012.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DM.%2BE.%26atitle%3DAldosterone%2520and%2520cardiovascular%2520disease%253A%2520the%2520heart%2520of%2520the%2520matter%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D24%26spage%3D21%26epage%3D30%26doi%3D10.1016%2Fj.tem.2012.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Briet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffrin, E. L.</span><span> </span><span class="NLM_article-title">Vascular actions of aldosterone</span> <span class="citation_source-journal">J. Vasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span><span class="refDoi"> DOI: 10.1159/000345243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1159%2F000345243" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2013&pages=88-99&author=M.+Brietauthor=E.+L.+Schiffrin&title=Vascular+actions+of+aldosterone&doi=10.1159%2F000345243"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1159%2F000345243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000345243%26sid%3Dliteratum%253Aachs%26aulast%3DBriet%26aufirst%3DM.%26aulast%3DSchiffrin%26aufirst%3DE.%2BL.%26atitle%3DVascular%2520actions%2520of%2520aldosterone%26jtitle%3DJ.%2520Vasc.%2520Res.%26date%3D2013%26volume%3D50%26spage%3D88%26epage%3D99%26doi%3D10.1159%2F000345243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Young, M. J.</span><span> </span><span class="NLM_article-title">Mechanisms of mineralocorticoid receptor mediated cardiac fibrosis and vascular inflammation</span> <span class="citation_source-journal">Curr. Opin. Nephrol. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">174</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1097/MNH.0b013e3282f56854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1097%2FMNH.0b013e3282f56854" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=174-180&author=M.+J.+Young&title=Mechanisms+of+mineralocorticoid+receptor+mediated+cardiac+fibrosis+and+vascular+inflammation&doi=10.1097%2FMNH.0b013e3282f56854"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.1097%2FMNH.0b013e3282f56854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMNH.0b013e3282f56854%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DM.%2BJ.%26atitle%3DMechanisms%2520of%2520mineralocorticoid%2520receptor%2520mediated%2520cardiac%2520fibrosis%2520and%2520vascular%2520inflammation%26jtitle%3DCurr.%2520Opin.%2520Nephrol.%2520Hypertens.%26date%3D2008%26volume%3D17%26spage%3D174%26epage%3D180%26doi%3D10.1097%2FMNH.0b013e3282f56854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Brown, N. J.</span><span> </span><span class="NLM_article-title">Aldosterone and end-organ damage</span> <span class="citation_source-journal">Curr. Opin. Nephrol. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">241</span><span class="refDoi"> DOI: 10.1097/01.mnh.0000165889.60254.98</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1097%2F01.mnh.0000165889.60254.98" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2005&pages=235-241&author=N.+J.+Brown&title=Aldosterone+and+end-organ+damage&doi=10.1097%2F01.mnh.0000165889.60254.98"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3d&amp;dbid=16384&amp;doi=10.1097%2F01.mnh.0000165889.60254.98&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.mnh.0000165889.60254.98%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%2BJ.%26atitle%3DAldosterone%2520and%2520end-organ%2520damage%26jtitle%3DCurr.%2520Opin.%2520Nephrol.%2520Hypertens.%26date%3D2005%26volume%3D14%26spage%3D235%26epage%3D241%26doi%3D10.1097%2F01.mnh.0000165889.60254.98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Stowasser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marwick, T. H.</span><span> </span><span class="NLM_article-title">Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type 1</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">5070</span><span class="NLM_x">–</span> <span class="NLM_lpage">5076</span><span class="refDoi"> DOI: 10.1210/jc.2005-0681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1210%2Fjc.2005-0681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=15941863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWkur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2005&pages=5070-5076&author=M.+Stowasserauthor=J.+Sharmanauthor=R.+Leanoauthor=R.+D.+Gordonauthor=G.+Wardauthor=D.+Cowleyauthor=T.+H.+Marwick&title=Evidence+for+abnormal+left+ventricular+structure+and+function+in+normotensive+individuals+with+familial+hyperaldosteronism+type+1&doi=10.1210%2Fjc.2005-0681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3eR"><div class="casContent"><span class="casTitleNuber">3e</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I</span></div><div class="casAuthors">Stowasser, Michael; Sharman, James; Leano, Rodel; Gordon, Richard D.; Ward, Gregory; Cowley, Diane; Marwick, Thomas H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5070-5076</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">To explore whether aldosterone excess can induce adverse cardiovascular effects independently of effects on blood pressure (BP), we sought evidence of disturbed cardiovascular structure or function in normotensive individuals with primary aldosteronism.  Eight normotensive subjects with genetically proven familial hyperaldosteronism type I (FH-I) were compared with 24 age- and sex-matched normotensive controls in terms of BP, biochem. parameters, pulse wave velocity, and echocardiog. characteristics.  Subjects with FH-I demonstrated higher serum aldosterone levels and aldosterone/renin ratios than controls, as expected.  Despite having similar 24-h ambulatory BPs, subjects with FH-I demonstrated evidence of concentric remodeling with greater septal (mean ± SD, 9.4±1.1 vs. 7.9±0.9 mm; P < 0.001), posterior wall (9.2±1.7 vs. 7.7±1.0 mm; P < 0.01), and relative wall (0.29±0.03 vs. 0.24±0.02; P < 0.001) thicknesses, and lower mitral early peak velocities (0.74±0.10 vs. 0.90±0.16 m/s; P < 0.05), ratios of early to late peak diastolic transmitral flow velocity (1.56±0.24 vs. 2.06±0.41; P < 0.01), and myocardial early peak velocities (8.3±1.8 vs. 10.3±2.6 cm/s; P < 0.05).  There were no significant differences in pulse wave velocity or left ventricular ejection fraction, long axis strain rate, peak systolic strain, cyclic variation of integrated backscatter, or posterior wall calibrated integrated backscatter.  Aldosterone excess is assocd. with increased left ventricular wall thicknesses and reduced diastolic function, even in the absence of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppRlwdEw69ULVg90H21EOLACvtfcHk0ligik6OTXMzSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWkur%252FN&md5=9b40580fbaa4779e62ced778554fcf43</span></div><a href="/servlet/linkout?suffix=cit3e&amp;dbid=16384&amp;doi=10.1210%2Fjc.2005-0681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2005-0681%26sid%3Dliteratum%253Aachs%26aulast%3DStowasser%26aufirst%3DM.%26aulast%3DSharman%26aufirst%3DJ.%26aulast%3DLeano%26aufirst%3DR.%26aulast%3DGordon%26aufirst%3DR.%2BD.%26aulast%3DWard%26aufirst%3DG.%26aulast%3DCowley%26aufirst%3DD.%26aulast%3DMarwick%26aufirst%3DT.%2BH.%26atitle%3DEvidence%2520for%2520abnormal%2520left%2520ventricular%2520structure%2520and%2520function%2520in%2520normotensive%2520individuals%2520with%2520familial%2520hyperaldosteronism%2520type%25201%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2005%26volume%3D90%26spage%3D5070%26epage%3D5076%26doi%3D10.1210%2Fjc.2005-0681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Milliez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girerd, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plouin, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blacher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safar, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mourad, J. J.</span><span> </span><span class="NLM_article-title">Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1243</span><span class="NLM_x">–</span> <span class="NLM_lpage">1248</span><span class="refDoi"> DOI: 10.1016/j.jacc.2005.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.jacc.2005.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=15837256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlagt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=1243-1248&author=P.+Milliezauthor=X.+Girerdauthor=P.+F.+Plouinauthor=J.+Blacherauthor=M.+E.+Safarauthor=J.+J.+Mourad&title=Evidence+for+an+increased+rate+of+cardiovascular+events+in+patients+with+primary+aldosteronism&doi=10.1016%2Fj.jacc.2005.01.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3fR"><div class="casContent"><span class="casTitleNuber">3f</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism</span></div><div class="casAuthors">Milliez, Paul; Girerd, Xavier; Plouin, Pierre-Francois; Blacher, Jacques; Safar, Michel E.; Mourad, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1243-1248</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The aim of this report was to show that the rate of cardiovascular events is increased in patients with either subtype of primary aldosteronism (PA).  Primary aldosteronism involves hypertension (HTN), hypokalemia, and low plasma renin.  The two major PA subtypes are unilateral aldosterone-producing adenoma (APA) and bilateral adrenal hyperplasia.  During a three-year period, the diagnosis of PA was made in 124 of 5,500 patients referred for comprehensive evaluation and management.  Adenomas were diagnosed in 65 patients and idiopathic hyperaldosteronism in 59 patients.  During the same period, clin. characteristics and cardiovascular events of this group were compared with those of 465 patients with essential hypertension (EHT) randomly matched for age, gender, and systolic and diastolic blood pressure.  A history of stroke was found in 12.9% of patients with PA and 3.4% of patients with EHT (odds ratio [OR] = 4.2;95% confidence interval [CI]2.0 to 8.6).  Non-fatal myocardial infarction was diagnosed in 4.0% of patients with PA and in 0.6% of patients with EHT (OR = 6.5;95% CI 1.5 to 27.4).  A history of atrial fibrillation was diagnosed in 7.3% of patients with PA and 0.6% of patients with EHT (OR = 12.1; 95% CI 3.2 to 45.2).  The occurrence of cardiovascular complications was comparable in both subtypes of PA.  Patients presenting with PA experienced more cardiovascular events than did EHT patients independent of blood pressure.  The presence of PA should be detected, not only to det. the cause of HTN, but also to prevent such complications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9B0Dj7HXiQbVg90H21EOLACvtfcHk0lhJqZqC_HUdbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlagt70%253D&md5=17c6f546d21e178ea28008ed26521185</span></div><a href="/servlet/linkout?suffix=cit3f&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2005.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2005.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DMilliez%26aufirst%3DP.%26aulast%3DGirerd%26aufirst%3DX.%26aulast%3DPlouin%26aufirst%3DP.%2BF.%26aulast%3DBlacher%26aufirst%3DJ.%26aulast%3DSafar%26aufirst%3DM.%2BE.%26aulast%3DMourad%26aufirst%3DJ.%2BJ.%26atitle%3DEvidence%2520for%2520an%2520increased%2520rate%2520of%2520cardiovascular%2520events%2520in%2520patients%2520with%2520primary%2520aldosteronism%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2005%26volume%3D45%26spage%3D1243%26epage%3D1248%26doi%3D10.1016%2Fj.jacc.2005.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Staessen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lijnen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verschueren, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amery, A.</span><span> </span><span class="NLM_article-title">Rise in plasma concentration of aldosterone during long-term angiotensin II suppression</span> <span class="citation_source-journal">J. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">457</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span><span class="refDoi"> DOI: 10.1677/joe.0.0910457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1677%2Fjoe.0.0910457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=7035596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADyaL38XhtFGlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1981&pages=457-465&author=J.+Staessenauthor=P.+Lijnenauthor=R.+Fagardauthor=L.+J.+Verschuerenauthor=A.+Amery&title=Rise+in+plasma+concentration+of+aldosterone+during+long-term+angiotensin+II+suppression&doi=10.1677%2Fjoe.0.0910457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Rise in plasma concentration of aldosterone during long-term angiotensin II suppression</span></div><div class="casAuthors">Staessen, J.; Lijnen, P.; Fagard, R.; Verschueren, L. J.; Amery, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endocrinology</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">457-65</span>CODEN:
                <span class="NLM_cas:coden">JOENAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-0795</span>.
    </div><div class="casAbstract">The plasma concn. of aldosterone (I)  [52-39-1] was followed in 7 hypertensive patients before and during long-term angiotensin II  [11128-99-7] suppression with the orally active angiotensin I converting enzyme inhibitor captopril  [62571-86-2].  The plasma concn. of I decreased initially from 74 to 21 pg/mL after 1 mo of administration of captopril (≤600 mg/day).  Thereafter, the plasma concn. of I began to rise and after 1 yr reached a level of 165 pg/mL.  During long-term captopril therapy, the plasma renin  [9015-94-5] activity was increased and the plasma angiotensin II concn. was suppressed.  The mechanism responsible for the late rise of the plasma concn. of I during long-term angiotensin II suppression with captopril remains to be elucidated.  A sizeable and lasting hypotensive effect was obsd. in all patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdzoaBfSc9hrVg90H21EOLACvtfcHk0lhJqZqC_HUdbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XhtFGlurw%253D&md5=e4ca8eb95b55d6c4b6cd6c4be8c8e108</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1677%2Fjoe.0.0910457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Fjoe.0.0910457%26sid%3Dliteratum%253Aachs%26aulast%3DStaessen%26aufirst%3DJ.%26aulast%3DLijnen%26aufirst%3DP.%26aulast%3DFagard%26aufirst%3DR.%26aulast%3DVerschueren%26aufirst%3DL.%2BJ.%26aulast%3DAmery%26aufirst%3DA.%26atitle%3DRise%2520in%2520plasma%2520concentration%2520of%2520aldosterone%2520during%2520long-term%2520angiotensin%2520II%2520suppression%26jtitle%3DJ.%2520Endocrinol.%26date%3D1981%26volume%3D91%26spage%3D457%26epage%3D465%26doi%3D10.1677%2Fjoe.0.0910457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Struthers, A. D.</span><span> </span><span class="NLM_article-title">Aldosterone escape during ACE inhibitor therapy in chronic heart failure</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.1093/eurheartj/16.suppl_N.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1093%2Feurheartj%2F16.suppl_N.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=8682054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADyaK28XitlGlsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1995&pages=103-106&author=A.+D.+Struthers&title=Aldosterone+escape+during+ACE+inhibitor+therapy+in+chronic+heart+failure&doi=10.1093%2Feurheartj%2F16.suppl_N.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone escape during ACE inhibitor therapy in chronic heart failure</span></div><div class="casAuthors">Struthers, A. D.</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">Suppl. N, Heart Failure 95</span>),
    <span class="NLM_cas:pages">103-6</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">A review with 26 refs.  In the setting of chronic heart failure (CHF), therapy with angiotensin converting enzyme (ACE) inhibitors generally reduces serum aldosterone levels acutely.  However, long-term ACE inhibition is assocd. with aldosterone suppression that is weak, variable, and unsustained, i.e. aldosterone escape.  The adverse effects of such aldosterone escape are discussed.  In addn., the beneficial effects of spironolactone therapy added to the regimen of an ACE inhibitor and diuretic are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj_wPo6Vf28bVg90H21EOLACvtfcHk0lgUddQWiQOvgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitlGlsrY%253D&md5=7c42fbe1abf3668a5516c2ba01755203</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2F16.suppl_N.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252F16.suppl_N.103%26sid%3Dliteratum%253Aachs%26aulast%3DStruthers%26aufirst%3DA.%2BD.%26atitle%3DAldosterone%2520escape%2520during%2520ACE%2520inhibitor%2520therapy%2520in%2520chronic%2520heart%2520failure%26jtitle%3DEur.%2520Heart%2520J.%26date%3D1995%26volume%3D16%26spage%3D103%26epage%3D106%26doi%3D10.1093%2Feurheartj%2F16.suppl_N.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pitt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zannad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remme, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cody, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaigne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palensky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittes, J.</span><span> </span><span class="NLM_article-title">Randomized Aldactone Evaluation Study Investigators.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">717</span><span class="refDoi"> DOI: 10.1056/NEJM199909023411001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1056%2FNEJM199909023411001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10471456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVyrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1999&pages=709-717&author=B.+Pittauthor=F.+Zannadauthor=W.+J.+Remmeauthor=R.+Codyauthor=A.+Castaigneauthor=A.+Perezauthor=J.+Palenskyauthor=J.+Wittes&title=Randomized+Aldactone+Evaluation+Study+Investigators..+The+effect+of+spironolactone+on+morbidity+and+mortality+in+patients+with+severe+heart+failure&doi=10.1056%2FNEJM199909023411001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of spironolactone on morbidity and mortality in patients with severe heart failure</span></div><div class="casAuthors">Pitt, Bertram; Zannad, Faiez; Remme, Willem J.; Cody, Robert; Castaigne, Alain; Perez, Alfonso; Palensky, Jolie; Wittes, Janet</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">709-717</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Aldosterone is important in the pathophysiol. of heart failure.  In a double-blind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an angiotensin-converting-enzyme inhibitor, a loop diuretic, and in most cases digoxin.  A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo.  The primary end point was death from all causes.  The trial was discontinued early, after a mean follow-up period of 24 mo, because an interim anal. detd. that spironolactone was efficacious.  There were 386 deaths in the placebo group (46 percent) and 284 in the spironolactone group (35 percent; relative risk of death, 0.70; 95 percent confidence interval, 0.60 to 0.82; P<0.001).  This 30 percent redn. in the risk of death among patients in the spironolactone group was attributed to a lower risk of both death from progressive heart failure and sudden death from cardiac causes.  The frequency of hospitalization for worsening heart failure was 35 percent lower in the spironolactone group than in the placebo group (relative risk of hospitalization, 0.65; 95 percent confidence interval, 0.54 to 0.77; P<0.001).  In addn., patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Assocn. functional class (P<0.001).  Gynecomastia or breast pain was reported in 10 percent of men who were treated with spironolactone, as compared with 1 percent of men in the placebo group (P<0.001).  The incidence of serious hyperkalemia was minimal in both groups of patients.  Blockade of aldosterone receptors by spironolactone, in addn. to std. therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwOy-U1QzrSbVg90H21EOLACvtfcHk0lgUddQWiQOvgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVyrurk%253D&md5=3e34cf3cd2ac38b96cefdfda593a02f5</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1056%2FNEJM199909023411001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199909023411001%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DB.%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DRemme%26aufirst%3DW.%2BJ.%26aulast%3DCody%26aufirst%3DR.%26aulast%3DCastaigne%26aufirst%3DA.%26aulast%3DPerez%26aufirst%3DA.%26aulast%3DPalensky%26aufirst%3DJ.%26aulast%3DWittes%26aufirst%3DJ.%26atitle%3DRandomized%2520Aldactone%2520Evaluation%2520Study%2520Investigators..%2520The%2520effect%2520of%2520spironolactone%2520on%2520morbidity%2520and%2520mortality%2520in%2520patients%2520with%2520severe%2520heart%2520failure%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1999%26volume%3D341%26spage%3D709%26epage%3D717%26doi%3D10.1056%2FNEJM199909023411001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zannad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krum, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Veldhuisen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swedberg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pocock, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, B.</span><span> </span><span class="NLM_article-title">Eplerenone in patients with systolic heart failure and mild symptoms</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1056/NEJMoa1009492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1056%2FNEJMoa1009492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=21073363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisValuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=11-21&author=F.+Zannadauthor=J.+J.+McMurrayauthor=H.+Krumauthor=D.+J.+van+Veldhuisenauthor=K.+Swedbergauthor=H.+Shiauthor=J.+Vincentauthor=S.+J.+Pocockauthor=B.+Pitt&title=Eplerenone+in+patients+with+systolic+heart+failure+and+mild+symptoms&doi=10.1056%2FNEJMoa1009492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Eplerenone in patients with systolic heart failure and mild symptoms</span></div><div class="casAuthors">Zannad, Faiez; McMurray, John J. V.; Krum, Henry; van Veldhuisen, Dirk J.; Swedberg, Karl; Shi, Harry; Vincent, John; Pocock, Stuart J.; Pitt, Bertram</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-21</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction.  We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms.  In this randomized, double-blind trial, we randomly assigned 2737 patients with New York Heart Assocn. class II heart failure and an ejection fraction of no more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addn. to recommended therapy.  The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure.  The trial was stopped prematurely, according to prespecified rules, after a median follow-up period of 21 mo.  The primary outcome occurred in 18.3% of patients in the eplerenone group as compared with 25.9% in the placebo group (hazard ratio, 0.63; 95% confidence interval [CI], 0.54 to 0.74; P < 0.001).  A total of 12.5% of patients receiving eplerenone and 15.5% of those receiving placebo died (hazard ratio, 0.76; 95% CI, 0.62 to 0.93; P = 0.008); 10.8% and 13.5%, resp., died of cardiovascular causes (hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P = 0.01).  Hospitalizations for heart failure and for any cause were also reduced with eplerenone.  A serum potassium level exceeding 5.5 mmol per L occurred in 11.8% of patients in the eplerenone group and 7.2% of those in the placebo group (P < 0.001).  Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRI60N9G6VWrVg90H21EOLACvtfcHk0liLV3KWfiH0ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisValuw%253D%253D&md5=70f8085ca6ac39316015b1c349312771</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1009492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1009492%26sid%3Dliteratum%253Aachs%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26aulast%3DKrum%26aufirst%3DH.%26aulast%3Dvan%2BVeldhuisen%26aufirst%3DD.%2BJ.%26aulast%3DSwedberg%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DJ.%26aulast%3DPocock%26aufirst%3DS.%2BJ.%26aulast%3DPitt%26aufirst%3DB.%26atitle%3DEplerenone%2520in%2520patients%2520with%2520systolic%2520heart%2520failure%2520and%2520mild%2520symptoms%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D11%26epage%3D21%26doi%3D10.1056%2FNEJMoa1009492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Pitt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remme, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zannad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neaton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roniker, B.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">1309</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span><span class="refDoi"> DOI: 10.1056/NEJMoa030207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1056%2FNEJMoa030207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=12668699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1ehurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=1309-1321&author=B.+Pittauthor=W.+Remmeauthor=F.+Zannadauthor=J.+Neatonauthor=F.+Martinezauthor=B.+Roniker&title=Eplerenone%2C+a+selective+aldosterone+blocker%2C+in+patients+with+left+ventricular+dysfunction+after+myocardial+infarction&doi=10.1056%2FNEJMoa030207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction</span></div><div class="casAuthors">Pitt, Bertram; Remme, Willem; Zannad, Faiez; Neaton, James; Martinez, Felipe; Roniker, Barbara; Bittman, Richard; Hurley, Steve; Kleiman, Jay; Gatlin, Marjorie; Ambrosioni, E.; Anderson, J. L.; Apetrei, E.; Aschermann, M.; Banas, J.; Cardoso, S.; Caspi, A.; Chung, N.; Corbalan, R.; Dargie, H. J.; Bietz, R.; Erhardt, L.; Garcia-Castillo, A.; Gheorghiade, M.; Hernandez, E.; Hess, O.; Jamerson, K.; Kjekshus, J.; Klug, E.; Krum, H.; Lee, Y.-T.; Lopez, N.; Lopez-Sendon, J.-L.; Martinez, F.; Murin, J.; Neaton, J.; Nicolau, J.-C.; Ostor, E.; Parkhomenko, A.; Pitt, B.; Ross, H.; Stepinska, J.; Torp-Pedersen, C.; Van Mieghem, W.; van Veldhuisen, D.-J.; White, H.; Wilvox, R. G.; Willenbrock, R.; Yotov, Y.-T.; Zannad, F.; Boissel, J.-P.; Furberg, C.; Julian, D.; Kulbertus, H.; Pocock, S.; Wittes, J.; Battler, A.; Blumenfeld, J.; Brilla, C.; Duprez, D.; Fowler, M.; Gavazzi, A.; Hildebrandt, P.; Komajda, M.; Korewicki, J.; Kosturakis, D.; Marin-Neto, J. A.; Miller, A.; Munoz Aguilera, R.; Oliveri, R.; Remme, W.; White, M.; Widimsky, P.; Bakris, G.; Castaigne, A.; Deedwania, P.; Duprez, D.; Ketelslegers, J. M.; Liu, P.; Mancia, G.; Nicklas, J.; Rouleau, J.-L.; Ruilope, L.; Sasayama, S.; Schiffrin, E.; Spertus, J.; Struthers, A.; Vaughan, D.; Weber, M.; Williams, G.; Abinader, E.; Adams, J.; Adams, P. C.; Adamus, J.; Ahlstrom, P.; Akesson, H. S.; Akhmedzhanov, N.; Alcasena Juango, S.; Ali Khan, S.; Alonso Garcia, A.; Amat, G.; Amerena, J.; Arnosova, K. M.; Andreoli, L.; Angelo-Nielsen, K.; Antonio de Velasco, J.; Apetrei, E.; Aroutiounov, G.; Aschermann, M.; Asklund, M.; Assmann, I.; Aumont, M.-C.; Avtandilov, A.; Azarin, O.; Bada, V.; Bakoumov, P.; Balazovjech, L.; Baldjiev, E.; Baluda, M.; Barrazueta, R.; Barsi, B.; Bashir, Y.; Batin, P. D.; Belenky, D.; Belyi, Y.; Bendermacher, P. E. F.; Berget, K.; Bergmeier, C.; Berning, J.; Berrazueta-Fernandez, J. R.; Block, P.; Boberg, G.; Bocek, P.; Bohlscheid, V.; Bokarev, I.; Bolinska, H.; Boman, K.; Bondarev, S.; Bonzel, T.; Boreux, J.-L.; Borggrefe, M.; Borisov, M.; Boxho, G.; Boyarkin, M.; Brachmann, J.; Brack, M.; Branea, I.; Breivik, K.; Brigden, G. S.; Bronzwaer, P. N. A.; Bruce, D.; Bruckner, I.; Brunvand, H.; Bryukhovetski, A.; Buser, P.; Campbell, T.; Campeanu, A.; Capucci, A.; Carasca, E.; Cardoso, J.; Carrageta, M.; Caspi, A.; Cassim, S.; Caturla, J.; Ceia, F.; Cernosek, B.; Channer, K.; Chati, Z.; Christensen, P. D.; Chung, N. S.; Cinteza, M.; Cleland, J. G. F.; Cocchieri, M.; Commerford, P.; Conti, U.; Corsini, G.; Cortina Liosa, A.; Coupez, J.-M.; Cribier, A.; Csillag, J.; Cyran, J.; Dahlstrom, U.; Dalby, A.; Dalin, L. J.; Dalkowski, M.; Dargie, H. J.; Darius, H.; Datcu, D. M.; David, D.; De Myttenaere, M.; De Teresa, E.; De Velasco, J.; de Vries, A. G.; den Hartog, F. R.; Desjoyaux, E.; Dezerbi, A.; Dhawan, J.; Biaz Molina, B.; Dickstein, K.; Dorobantu, M.; Doschitsin, V.; Doubell, A.; Dovgalevsky, P.; Dragulescu, S. I.; Drapkina, O.; Dubourg, O.; Dunselman, P. H. J. M.; Dyadyk, O. I.; Dykun, Y. V.; Dzyak, G. V.; Egorova, L. P.; Egstrup, K.; Eha, J.; Ehrenbergerova, M.; El Allaf, D.; Elenkova, A.; Ellis, C. J.; Engbers, J. G.; Fainyk, A. F.; Falck, G.; Fanelli, R.; Farre-Mun, J.; Favier, J.; Ferrari, G.; Ferreira, I.; Rischer, H.; Fotyanov, S.; Freericks, M. P.; Froeland, G.; Galve, E.; Garcia, M. M.; Garcia, A. A.; Garnier, L. F.; Gazaryan, G.; Georgescu, C.; Geraedts, J.; Glezer, M. G.; Goloborodko, B. I.; Goloshchekin, B.; Gonsorcik, J.; Gotchev, D.; Gotcheva, N.; Gottwik, M. G.; Grande, P.; Gratsiansky, N.; Grishina, E. I.; Groch, L.; Gruzdev, A.; Guenova, D.; Gundersen, T.; Hagerman, I.; Hambrecht, R.; Hammermann, H.; Hansen, O.; Hansteen, V.; Hart, H.; Hauf, G. F.; Hecker, U.; Hegyi, I.; Herlitz, J.; Hertzberger, D. P.; Herweijer, A. H.; Heyndrickx, G. R.; Hittinger, L.; Hoang, V.; Hobbach, H.-P.; Hofman-Bang, C.; Holwerda, N. J.; Hong, K. P.; Horacek, T.; Hormann, J.; Horowitz, J. D.; Hradec, J.; Hurtig, U.; Ikram, H.; Ioan, A.; Jaarsma, W.; Jadraque, L. M.; Jakobsen, T. J.; Janicki, K. J.; Jankelow, D.; Janosi, A.; Jansky, P.; Janssens, L.; Janzen, I.; Jensen, P.; Jirmar, R.; Jobic, Y.; Jones, A.; Jonsson, J.; Kahles, H.; Kaliska, G.; Kamensky, G.; Kappenberger, L.; Karlsson, J. E.; Karpati, P.; Karpenko, O. I.; Karpov, Y.; Kawecka-Jaszcz, J.; Keeling, P. J.; Keren, G.; Khalife, K.; Khrakovskaya, M.; Khrustalev, O. A.; Klarlund, K. K.; Kleber, E.-X.; Klug, E.; Koenig, W.; Komarek, J.; Kononenko, L. G.; Konz, K.; Komacewicz-Jach, Z.; Kostenko, V.; Kotous, J.; Kovalsky, I.; Kozak, P.; Kreider-Stempfle, H. U.; Kromer, E. P.; Krum, H.; Krzeminska-Pakula, M.; Kuc, K.; Kucera, P.; Kurowski, M.; Lach, L.; Lai, C.; Lane, G.; Lang, E.; Lankes, W.; Lankisch, P.-G.; Laraudogoitia, E.; Larsen, J.; Larsson, L.-E.; Laruelle, C.; Lazar, A.; Lee, Y.-T.; Legkonogov, A. V.; Leitch, J.; Lengfelder, W.; Lescot, C. D.; Lewis, B. S.; Lewis, P.; Libov, I. A.; Liel-Cohen, N.; Lim, H. K.; Lin, C.-S.; Linssen, G. C. M.; Liu, C.-P.; Lok, D. J. A.; Lopatin, Y. M.; Lopez De Sa, E.; Lotan, C.; Lousada, N.; Lucas, C.; Lucatti, A.; Lusov, V.; Mabin, T. A.; Macleod, D. C.; Maeurer, W.; Magnusson, J.-O.; Maisch, B.; Malinski, A.; Maltchougine, M.; Manga, P.; Mantov, S.; Marchi, S.; Marcinowska-Suchowierska, E.; Marenne, F.; Maresca, F. S.; Markov, V.; Marmor, A. T.; Martines, C.; Martinez, A.; Martin-Jadraque, L.; Martins, L. F. R.; Martos Ferres, R.; Mary, D. A. S. G.; Masini, F.; Matta, F.; Maurer, W.; Mazzini, A. C.; McDonald, K. M. A.; Meeder, J. G.; Melandri, F.; Melin, J.; Menezes, C.; Michels, H. R.; Missault, L.; Mitrovic, V.; Mntla, P.; Mobilij, A.; Mogilevsky, A.; Moiseev, V.; Mokan, M.; Moeller, B.; Moreira, I.; Mouhoub, D.; Moura, B.; Muders, E.; Mudra, H.; Munz, J.; Murin, J.; Musial, W. J.; Myburgh, D. P.; Naqvi, N.; Naumann, G.; Nazimov, S. V.; Nadelec, G.; Nedogoda, S. V.; Nielsen, I.; Nielsen, T.; Nierop, P. R.; Nilsson, G.; Notaristefano, A.; Novitsky, I. N.; Nykl, L.; Ofner, P.; Olariu, C.; Olbrich, H. G.; Oldroyd, K. G.; Olinic, N.; Oliveira, J.; Omland, T.; Orus, J.; Owensby, D.; Page, A.; Park, K. S.; Parkhomenko, O. M.; Pasotti, C.; Pasowicz, M.; Pecce, P.; Pell, A. C. H.; Penkov, N. I.; Perez de Juan, M.; Perez, H.; Petersen, M.; Petrov, A. A.; Peuhkurinen, K.; Philonenko, X.; Pieper, M.; Pieske, B.; Pluta, W.; Podzemska, B.; Popeye, R.; Prost, C.; Purcaro, A.; Put, P.; Radchenko, V.; Radoi, M.; Rae, A. P.; Raev, D.; Ramik, C.; Rasmussen, S. L.; Reisin, L.; Renker, B.; Ribeiro, V. G.; Richardt, G.; Rjecansky, I.; Risenfors, M.; Rivis, I. A.; Robson, R. H.; Rocher, R.; Rodriquez Padial, L.; Rose, E. L.; Rosen, S. D.; Rosenfeld, T.; Rowlands, D. B.; Rozkovec, A.; Rudas, L.; Rudenko, L. V.; Ruiz-Rejon, F.; Rutsch, W.; Rybar, R.; Rybka, J.; Saetre, H. A.; Sarosi, I.; Savalle, L. H.; Schmidt, A.; Schuren, K. P.; Schwartz, Y.; Schwinger, R.; Schwob, J. P.; Scott, D.; Sechtem, U.; Sela, O.; Semrad, B.; Senni, M.; Shilkina, N. P.; Shpektor, A.; Silas, J.; Sindone, A.; Sinescu, C. J.; Sipila, R.; Sirek, J.; Skagen, K.; Shura, M.; Slanina, M.; Slowinski, S.; Smid, J.; Smielak-Korombel, W.; Solodky, A.; Spacek, R.; Squire, I.; Steingo, L.; Stepinska, J.; Stogowski, A.; Storzhakov, G.; Striouk, R.; Strunge, P.; Suter, T.; Svitil, P.; Swedberg, K.; Swidzinski, M.; Syvolap, V. D.; Sztajzel, J.; Tahk, S. J.; Tans, A. C.; Tans, J. G. M.; Targonski, R.; Tarjan, J.; Tartagni, F.; Tchartchoglian, R.; Tebloev, K.; Teesalu, R.; Ten Kate, J. B. L.; Terrosu, P.; Thompson, P. L.; Thybo, N. K.; Thygesen, K.; Tilon, P. A.; Timar, S.; Titkov, Y.; Titlbach, O. J.; Torp-Pedersen, C.; Torvik, D. T.; Touboul, P.; Trelawny, J. M.; Trillo Nouche, R.; Trochina, E.; Trojnar, R.; Tzekova, M. L.; Tzivoni, D.; Vahula, V.; Valagussa, F.; Valdes, M.; Van Der Heijden, R.; Van Der Sloot, J. A. P.; Van Hal, J. M. C.; Van Kempen, L. H. J.; Van Mieghem, W.; Van Rugge, F. P.; Van Veldhuisen, D. J.; Van Vlies, B.; Van Wijk, L. M.; Vasyuk, Y.; Vatutin, M.; Vered, Z.; Vergoni, W.; Vertkine, A.; Vigholt, E.; Vishnevskiy, A.; Voegelin, H.-P.; Voipio-Pulkki, L. M.; Von Mengden, H.-J.; Waites, J.; Watson, R. D. S.; Weiss, A. T.; Werner, H. A.; Wesdorp, J. C. L.; White, H.; Wiggers, P.; Wilcox, R. G.; Wilkinson, P.; Willems, A. R.; Willenbrock, R.; Wirth, M.; Wojciechowski, D.; Worth, H.; Wray, R.; Wu, C.-J.; Yakusevich, V. V.; Yang, S.-P.; Yarohno, N.; Zadionchenko, V. S.; Zaleska, T.; Zalewski, M.; Zannad, F.; Zateyshchikov, D.; Zeltin-Abramov, E.; Zeymer, U.; Zimmermann, R.; Albuquerque, D. C.; Alcaino, M.; Allall, O. A.; Beer, N.; Bortman, G.; Botero, R.; Cardoso, J. S.; Carrageta, M.; Carrillo, E.; Carvalho, A. C.; Castano, R.; Ceia, F.; Cesar, L. A. M.; Chevez, E.; Coelho, O. R.; Colombo, H. R.; Corbalan, R.; Doval, H.; Dutra, O.; Franken, R. A.; Gallardo, L.; Garcia, A.; Garcia, J.; Gomez, E. A.; Gomez, E.; Gonzalez, J.; Gonzalez, R. A.; Greque, G. V.; Guzman, L.; Haiek, J. C.; Hernandez, E.; Hominal, M. A.; Isea, J.; Lanas, F.; Leiva, J. L.; Lemus, J.; Llancaqueo, A.; Lopez, N.; Lousada, N.; Maia, L. N.; Maranhao, M. F.; Martinez, J. A.; Martinez, F. A.; Martins, F. A.; Martins, L.; Matadamas, N.; Matiz, H.; Mendoza, I.; Menezes, C.; Moises, O.; Moreira, J. I.; Moura, J. C.; Nicolau, J. C.; Nobrega, J.; Null, D.; Oliveira, M. S.; Palacios, A. O.; Pazin Filho, A.; Perrone, S. V.; Peigas, L. S.; Prieto, J. C.; Junior, A. R.; Rassi, S.; Ribeiro, V. G.; Rico, J. N.; Rivera, J. M.; Robledo, G.; Rodriguez, H.; Rosenthal, J.; Rossi, P. R. F.; Saraiva, J. F.; Soifer, S.; Sosa Liprandi, A.; Torres, H. G.; Uruchurtu, E.; Velasco, R. G.; Velasquez, J. G.; Vita, N.; Waich, S.; Zelaya, F. R.; Abariotis, N.; Abdollah, H.; Abraham, W.; Alaie, D.; Allison, W.; Ameen, A.; Amidi, M.; Anand, I.; Anderson, J. L.; Andreae, G. E.; Aquino, V.; Ballard, W.; Banas, J. S.; Baron, S. B.; Bata, I.; Berk, M. R.; Bhesania, T.; Binkley, P.; Booth, D. C.; Borts, D.; Brookfield, L. A.; Brown, C. S.; Browne, K. F.; Butman, S. M.; Capodilupo, R. C.; Caralis, D. G.; Carr, K. W.; Castan, R.; Chadow, H.; Chalavarya, G. K.; Chua, G. L.; Cinderella, J. A.; Clavette, P.; Clemson, B. S.; Cohen, T. J.; Colfer, H. T.; Corder, C. N.; Courtade, D. J.; Courtney, D. L.; Coutu, B.; Cucher, F. H.; Czarnecki, W.; Danisa, K.; D'Astous, M.; Dauber, I.; Davies, R.; Deedwania, P. C.; Delehanty, J. M.; Denny, D. M.; Denys, B. G.; DeYoung, P. J. P.; Dion, D.; Donohue, T. J.; El Shahawy, M.; Elkayam, U.; Escabi, J.; Essandoh, L. K.; Felicetta, J. V.; Fintel, D.; Fontaine, J. M.; Foster, R. E.; Frank, T. A.; Gin, K.; Goldberg, M. C.; Goldman, S.; Gossard, D.; Gosselin, G.; Gradman, A. H.; Grandmont, D.; Hack, T.; Hagar, J.; Haikal, M.; Hall, S. A.; Halpern, S.; Hanley, H. G.; Hanovich, G. D.; Hargrove, J. L.; Harlamert, E. A.; Hastings, T. E.; Hathaway, W. R.; Haught, W. H.; Hilliard, G. K.; Hodsden, J.; Hui, W.; Hurley, W.; Ibrahim, H. M.; Jafri, S.; Jain, A.; Jennison, S.; Jesse, R. L.; Joseph, J.; Kalman, J.; Karisberg, R. P.; Khant, R.; Koren, M.; Kosinski, E. J.; Kosolcharoen, P.; Kostuk, W. J.; Kouz, S. M.; Lai, C.; Langholz, D. E.; LeJemtel, T. H.; Leader, R.; Leblanc, M.-H.; Lee, H.; Lepage, S.; Lopez, M.; Lu, D. Y.; Lubelsky, B. J.; Luckasen, G. J.; Ma, P.-T.-S.; MacCallum, C. G.; Madu, E. C.; Maisel, A. S.; Mallis, G. I.; Mann, J. T.; Marr, D. R.; McGrew, F. A., III; McKay, R. J.; Mclellan, B.; Meisner, J.; Meyer, T.; Mikati, I.; Miller, L. A.; Miller, L. W.; Moe, G. W.; Mohiuddin, S. M.; Moir, G. D.; Morgan, A. W.; Morris, A.; Murphy, B. J.; Nallasivan, M.; Narula, J.; Nicklas, J. M.; Niederman, A. L.; Nitkin, R.; O'Keefe, J. H.; Oken, K. R.; O'Neill, P. G.; Orchard, R. C.; O'Riordan, W. D.; Paraboschi, C. F.; Patel, R. I.; Pennock, G.; Pesant, Y.; Phaneuf, D.; Phillips, D. F.; Plehn, J.; Promisloff, S.; Rajakumar, A. J.; Ramadurai, R.; Rashkow, A.; Rauh, R. A.; Rebane, T. M.; Riba, A. L.; Richard, C.; Riddle, J. C.; Ringuette, G.; Rivera, E.; Rockson, S.; Rogers, E.; Ross, H.; Roux, R.; Rupka, D.; Saenz, A.; Sampson, J.; Schulman, S. P.; Schuyler, G.; Sequeira, R. F.; Shah, A. R.; Shah, P. K.; Shakar, S. F.; Shalev, Y.; Sheikh, K. H.; Shettigar, U. R.; Siegel, R. M.; Sigal, S. L.; Singh, V. N.; Sotolongo, C. M.; Soucier, R. J.; Stagaman, D. J.; Stephan, W. J.; Stine, M.; Stoever, W. W.; Talano, J. V.; Tan, J. L.; Tanser, P. H.; Taussig, A. S.; Thadani, U.; Timmis, S. B. H.; Timothee, J. R.; Tragoon, S.; Tremblay, B.; Upadhya, K. J.; Vijay, N. K.; Wagoner, L. E.; Walker, J. L.; Wickemeyer, W. J.; Williams, G. A.; Williams, M. B.; Williams, R. E.; Wiseman, A. H.; Wool, K. J.; Yasin, M.; Zabalgoitia, M.; Zarich, S.; Zimmermann, R.; Zucker, R. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1309-1321</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure.  We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.  Methods: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a max. of 50 mg per day; 3313 patients) or placebo (3319 patients) in addn. to optimal medical therapy.  The study continued until 1012 deaths occurred.  The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia.  Results: During a mean follow-up of 16 mo, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008).  Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P= 0.005).  The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02).  There was also a redn. in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03).  The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001).  Conclusions: The addn. of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTXvg9fCdjlrVg90H21EOLACvtfcHk0liLV3KWfiH0ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1ehurY%253D&md5=cee432bc75bcca5f33098fe3bc8575df</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa030207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa030207%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DB.%26aulast%3DRemme%26aufirst%3DW.%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DNeaton%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DF.%26aulast%3DRoniker%26aufirst%3DB.%26atitle%3DEplerenone%252C%2520a%2520selective%2520aldosterone%2520blocker%252C%2520in%2520patients%2520with%2520left%2520ventricular%2520dysfunction%2520after%2520myocardial%2520infarction%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D1309%26epage%3D1321%26doi%3D10.1056%2FNEJMoa030207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Pitt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeffer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assmann, S. F.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Spironolactone for heart failure with preserved ejection fraction</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1383</span><span class="NLM_x">–</span> <span class="NLM_lpage">1392</span><span class="refDoi"> DOI: 10.1056/NEJMoa1313731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1056%2FNEJMoa1313731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=24716680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVWruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1383-1392&author=B.+Pittauthor=M.+A.+Pfefferauthor=S.+F.+Assmann&title=Spironolactone+for+heart+failure+with+preserved+ejection+fraction&doi=10.1056%2FNEJMoa1313731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Spironolactone for heart failure with preserved ejection fraction</span></div><div class="casAuthors">Pitt, Bertram; Pfeffer, Marc A.; Assmann, Susan F.; Boineau, Robin; Anand, Inder S.; Claggett, Brian; Clausell, Nadine; Desai, Akshay S.; Diaz, Rafael; Fleg, Jerome L.; Gordeev, Ivan; Harty, Brian; Heitner, John F.; Kenwood, Christopher T.; Lewis, Eldrin F.; O'Meara, Eileen; Probstfield, Jeffrey L.; Shaburishvili, Tamaz; Shah, Sanjiv J.; Solomon, Scott D.; Sweitzer, Nancy K.; Yang, Song; McKinlay, Sonja M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1383-1392</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction.  We evaluated the effects of spironolactone in patients with heart failure and a preserved left ventricular ejection fraction.  Methods: In this randomized, double-blind trial, we assigned 3445 patients with symptomatic heart failure and a left ventricular ejection fraction of 45% or more to receive either spironolactone (15 to 45 mg daily) or placebo.  The primary outcome was a composite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure.  Results: With a mean follow-up of 3.3 years, the primary outcome occurred in 320 of 1722 patients in the spironolactone group (18.6%) and 351 of 1723 patients in the placebo group (20.4%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.77 to 1.04; P = 0.14).  Of the components of the primary outcome, only hospitalization for heart failure had a significantly lower incidence in the spironolactone group than in the placebo group (206 patients [12.0%] vs. 245 patients [14.2%]; hazard ratio, 0.83; 95% CI, 0.69 to 0.99, P = 0.04).  Neither total deaths nor hospitalizations for any reason were significantly reduced by spironolactone.  Treatment with spironolactone was assocd. with increased serum creatinine levels and a doubling of the rate of hyperkalemia (18.7%, vs. 9.1% in the placebo group) but reduced hypokalemia.  With frequent monitoring, there were no significant differences in the incidence of serious adverse events, a serum creatinine level of 3.0 mg per dL (265 μmol per L) or higher, or dialysis.  Conclusions: In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquf161Fxn0rbVg90H21EOLACvtfcHk0liLV3KWfiH0ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVWruro%253D&md5=10f6b7c33366f3aea226f3e1210c25bc</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1313731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1313731%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DB.%26aulast%3DPfeffer%26aufirst%3DM.%2BA.%26aulast%3DAssmann%26aufirst%3DS.%2BF.%26atitle%3DSpironolactone%2520for%2520heart%2520failure%2520with%2520preserved%2520ejection%2520fraction%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1383%26epage%3D1392%26doi%3D10.1056%2FNEJMoa1313731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, S.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Sanchez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, R. B.</span><span> </span><span class="NLM_article-title">Does aldosterone upregulate the brain renin- angiotensin system in rats with heart failure?</span> <span class="citation_source-journal">Hypertension</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">733</span><span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.107.099796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1161%2FHYPERTENSIONAHA.107.099796" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=727-733&author=Y.+Yuauthor=S.-G.+Weiauthor=Z.-H.+Zhangauthor=E.+Gomez-Sanchezauthor=R.+M.+Weissauthor=R.+B.+Felder&title=Does+aldosterone+upregulate+the+brain+renin-+angiotensin+system+in+rats+with+heart+failure%3F&doi=10.1161%2FHYPERTENSIONAHA.107.099796"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.107.099796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.107.099796%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DS.-G.%26aulast%3DZhang%26aufirst%3DZ.-H.%26aulast%3DGomez-Sanchez%26aufirst%3DE.%26aulast%3DWeiss%26aufirst%3DR.%2BM.%26aulast%3DFelder%26aufirst%3DR.%2BB.%26atitle%3DDoes%2520aldosterone%2520upregulate%2520the%2520brain%2520renin-%2520angiotensin%2520system%2520in%2520rats%2520with%2520heart%2520failure%253F%26jtitle%3DHypertension%26date%3D2008%26volume%3D51%26spage%3D727%26epage%3D733%26doi%3D10.1161%2FHYPERTENSIONAHA.107.099796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Williams, J. S.</span><span> </span><span class="NLM_article-title">Evolving research in nongenomic actions of aldosterone</span> <span class="citation_source-journal">Curr. Opin. Endocrinol., Diabetes Obes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1097/MED.0b013e328360c200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1097%2FMED.0b013e328360c200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=23519092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1ens7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=198-203&author=J.+S.+Williams&title=Evolving+research+in+nongenomic+actions+of+aldosterone&doi=10.1097%2FMED.0b013e328360c200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Evolving research in nongenomic actions of aldosterone</span></div><div class="casAuthors">Williams, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Endocrinology, Diabetes and Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">COEDFK</span>;
        ISSN:<span class="NLM_cas:issn">1752-296X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Aldosterone is now recognized as an increasingly important contributor to cardiometabolic pathol. via inflammatory and fibrosis-related pathways in addn. to its classically described role in sodium and vol. regulation.  Consequently, much effort has been directed towards characterizing the mol. pathways involved in aldosterone-mediated fibrosis and inflammation.  What was once viewed as straightforward steroid hormone biol. is now appreciated as a highly complex and tightly regulated series of pathways and interactions.  These recognitions have fuelled a multidisciplinary effort to identify precisely how aldosterone mediates intracellular activation of both genomic (latent) and nongenomic (rapid) mechanisms of influence.  This review will explore recent novel pathways regulating aldosterone action, focusing on the nongenomic pathways.  Recent findings: Several recent discoveries have redefined our understanding of aldosterone interactions at the cellular level.  This includes activation of the mineralocorticoid receptor at the plasma membrane instead of via classical nuclear hormone receptor interaction, and identification of novel cofactor scaffolding proteins that modify aldosterone influence at the cellular level.  In addn., aldosterone activation of secondary messenger system cascades can occur directly and independent of mineralocorticoid receptor interaction.  Summary: Substantial progress in detailing the mol. biol. of aldosterone regulation and action should facilitate study of how it exerts detrimental effects in cardiometabolic diseases.  However, to date, the clin. impact of these discoveries has not been validated.  Translational efforts are now required to det. if novel therapeutic targets can be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAysZZicBVGbVg90H21EOLACvtfcHk0ljzZoqkupLO5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1ens7w%253D&md5=a81a4387404a0cca288612daf8473973</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2FMED.0b013e328360c200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMED.0b013e328360c200%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DJ.%2BS.%26atitle%3DEvolving%2520research%2520in%2520nongenomic%2520actions%2520of%2520aldosterone%26jtitle%3DCurr.%2520Opin.%2520Endocrinol.%252C%2520Diabetes%2520Obes.%26date%3D2013%26volume%3D20%26spage%3D198%26epage%3D203%26doi%3D10.1097%2FMED.0b013e328360c200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mellin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMeglio, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuillez, C.</span><span> </span><span class="NLM_article-title">Long-term aldosterone synthase inhibition improves cardiac function and myocardial structure in chronic heart failure</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x"> (</span><span class="NLM_issue">17, Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">III-102</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2004&pages=III-102&issue=17%2C+Suppl.+3&author=V.+Mellinauthor=P.+Mulderauthor=B.+DiMeglioauthor=J.+P.+Henryauthor=A.+Y.+Jengauthor=R.+L.+Webbauthor=C.+Thuillez&title=Long-term+aldosterone+synthase+inhibition+improves+cardiac+function+and+myocardial+structure+in+chronic+heart+failure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMellin%26aufirst%3DV.%26aulast%3DMulder%26aufirst%3DP.%26aulast%3DDiMeglio%26aufirst%3DB.%26aulast%3DHenry%26aufirst%3DJ.%2BP.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DWebb%26aufirst%3DR.%2BL.%26aulast%3DThuillez%26aufirst%3DC.%26atitle%3DLong-term%2520aldosterone%2520synthase%2520inhibition%2520improves%2520cardiac%2520function%2520and%2520myocardial%2520structure%2520in%2520chronic%2520heart%2520failure%26jtitle%3DCirculation%26date%3D2004%26volume%3D110%26issue%3D17%252C%2520Suppl.%25203%26spage%3DIII-102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fiebeler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussberger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shagdarsuren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilfenhaus, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Saadi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dechend, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meiners, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maser-Gluth, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luft, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, D. N.</span><span> </span><span class="NLM_article-title">Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">3087</span><span class="NLM_x">–</span> <span class="NLM_lpage">3094</span><span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.104.521625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1161%2FCIRCULATIONAHA.104.521625" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2005&pages=3087-3094&author=A.+Fiebelerauthor=J.+Nussbergerauthor=E.+Shagdarsurenauthor=S.+Rongauthor=G.+Hilfenhausauthor=N.+Al-Saadiauthor=R.+Dechendauthor=M.+Wellnerauthor=S.+Meinersauthor=C.+Maser-Gluthauthor=A.+Y.+Jengauthor=R.+L.+Webbauthor=F.+C.+Luftauthor=D.+N.+Muller&title=Aldosterone+synthase+inhibitor+ameliorates+angiotensin+II-induced+organ+damage&doi=10.1161%2FCIRCULATIONAHA.104.521625"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.104.521625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.104.521625%26sid%3Dliteratum%253Aachs%26aulast%3DFiebeler%26aufirst%3DA.%26aulast%3DNussberger%26aufirst%3DJ.%26aulast%3DShagdarsuren%26aufirst%3DE.%26aulast%3DRong%26aufirst%3DS.%26aulast%3DHilfenhaus%26aufirst%3DG.%26aulast%3DAl-Saadi%26aufirst%3DN.%26aulast%3DDechend%26aufirst%3DR.%26aulast%3DWellner%26aufirst%3DM.%26aulast%3DMeiners%26aufirst%3DS.%26aulast%3DMaser-Gluth%26aufirst%3DC.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DWebb%26aufirst%3DR.%2BL.%26aulast%3DLuft%26aufirst%3DF.%2BC.%26aulast%3DMuller%26aufirst%3DD.%2BN.%26atitle%3DAldosterone%2520synthase%2520inhibitor%2520ameliorates%2520angiotensin%2520II-induced%2520organ%2520damage%26jtitle%3DCirculation%26date%3D2005%26volume%3D111%26spage%3D3087%26epage%3D3094%26doi%3D10.1161%2FCIRCULATIONAHA.104.521625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rigel, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span> </span><span class="NLM_article-title">Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: Comparison with the 11β-hydroxylase inhibitor metyrapone</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">334</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span><span class="refDoi"> DOI: 10.1124/jpet.110.167148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1124%2Fjpet.110.167148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=20354176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Kltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2010&pages=232-243&author=D.+F.+Rigelauthor=F.+Fuauthor=M.+Beilauthor=C.-W.+Huauthor=G.+Liangauthor=A.+Y.+Jeng&title=Pharmacodynamic+and+pharmacokinetic+characterization+of+the+aldosterone+synthase+inhibitor+FAD286+in+two+rodent+models+of+hyperaldosteronism%3A+Comparison+with+the+11%CE%B2-hydroxylase+inhibitor+metyrapone&doi=10.1124%2Fjpet.110.167148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: Comparison with the 11β-hydroxylase inhibitor metyrapone</span></div><div class="casAuthors">Rigel, Dean F.; Fu, Fumin; Beil, Michael; Hu, Chii-Whei; Liang, Guiqing; Jeng, Arco Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">232-243</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Aldosterone synthase (CYP11B2) inhibitors (ASIs) represent an attractive therapeutic approach for mitigating the untoward effects of aldosterone.  We characterized the pharmacokinetic/pharmacodynamic relationships of a prototypical ASI, (+)-(5R)-4-(5,6,7,8)-tetrahydroimidazo[1,5-a]pyridin[-5-yl]benzonitrile hydrochloride (CGS020286A, FAD286, FAD) and compared these profiles to those of the 11β-hydroxylase inhibitor metyrapone (MET) in two rodent models of secondary hyperaldosteronism and corticosteronism.  In chronically cannulated Sprague-Dawley rats, angiotensin II (ANG II) (300 ng/kg bolus + 100 ng/kg/min infusion) or ACTH (100 ng/kg + 30 ng/kg/min) acutely elevated plasma aldosterone concn. (PAC) from ∼0.26 nM to a sustained level of ∼2.5 nM for 9 h.  ACTH but not ANG II elicited a sustained increase in plasma corticosterone concn. (PCC) from ∼300 to ∼1340 nM.  After 1 h of Ang II or ACTH infusion, FAD (0.01-100 mg/kg p.o.) or MET (0.1-300 mg/kg p.o.) dose- and drug plasma concn.-dependently reduced the elevated PACs over the ensuing 8 h.  FAD was ∼12 times more dose-potent than MET in reducing PAC but of similar or slightly greater potency on a plasma drug concn. basis.  Both agents also decreased PCC in the ACTH model at relatively higher doses and with similar dose potencies, whereas FAD was 6-fold weaker based on drug exposures.  FAD was ∼50-fold selective for reducing PAC vs. PCC, whereas MET was only ∼3-fold selective.  We conclude that FAD is a potent, orally active, and relatively selective ASI in two rat models of hyperaldosteronism.  MET is an order of magnitude less selective than FAD but is, nevertheless, more potent as an ASI than as an 11β-hydroxylase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrWGil-eW3uLVg90H21EOLACvtfcHk0lgDv9MZaw2tnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Kltbw%253D&md5=0b3cfae4e1717c658e944a9bab8bd11b</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.167148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.167148%26sid%3Dliteratum%253Aachs%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DFu%26aufirst%3DF.%26aulast%3DBeil%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DC.-W.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26atitle%3DPharmacodynamic%2520and%2520pharmacokinetic%2520characterization%2520of%2520the%2520aldosterone%2520synthase%2520inhibitor%2520FAD286%2520in%2520two%2520rodent%2520models%2520of%2520hyperaldosteronism%253A%2520Comparison%2520with%2520the%252011%25CE%25B2-hydroxylase%2520inhibitor%2520metyrapone%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D334%26spage%3D232%26epage%3D243%26doi%3D10.1124%2Fjpet.110.167148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Lea, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fowler, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogo, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N. J.</span><span> </span><span class="NLM_article-title">Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt</span> <span class="citation_source-journal">Kidney Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">936</span><span class="NLM_x">–</span> <span class="NLM_lpage">944</span><span class="refDoi"> DOI: 10.1038/ki.2009.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1038%2Fki.2009.9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=19225557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1Sjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2009&pages=936-944&author=W.+B.+Leaauthor=E.+S.+Kwakauthor=J.+M.+Lutherauthor=S.+M.+Fowlerauthor=Z.+Wangauthor=J.+Maauthor=A.+B.+Fogoauthor=N.+J.+Brown&title=Aldosterone+antagonism+or+synthase+inhibition+reduces+end-organ+damage+induced+by+treatment+with+angiotensin+and+high+salt&doi=10.1038%2Fki.2009.9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10d</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt</span></div><div class="casAuthors">Lea, William B.; Kwak, Eun Soo; Luther, James M.; Fowler, Susan M.; Wang, Zuofei; Ma, Ji; Fogo, Agnes B.; Brown, Nancy J.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">936-944</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the setting of high salt intake, aldosterone stimulates fibrosis in the heart, great vessels, and kidney of rats.  We used uninephrectomized rats treated with angiotensin II and placed on a high salt diet to exaggerate renal fibrosis.  We then tested whether mineralocorticoid receptor blockade by spironolactone or aldosterone synthase inhibition by FAD286 have similar effects on end-organ damage and gene expression.  Individually, both drugs prevented the hypertensive response to uninephrectomy and high salt intake but not when angiotensin II was administered.  Following 4 wk of treatment with FAD286, plasma aldosterone was reduced, whereas spironolactone increased aldosterone at 8 wk of treatment.  Angiotensin II and high salt treatment caused albuminuria, azotemia, renovascular hypertrophy, glomerular injury, increased plasminogen activator inhibitor-1 (PAI-1), and osteopontin mRNA expression, as well as tubulointerstitial fibrosis in the kidney.  Both drugs prevented these renal effects and attenuated cardiac and aortic medial hypertrophy while reducing osteopontin and transforming growth factor-β mRNA expression in the aorta.  The two drugs also reduced cardiac interstitial fibrosis but had no effect on that of the perivascular region.  Although spironolactone enhanced angiotensin II and salt-stimulated PAI-1 mRNA expression in aorta and heart, spironolactone and FAD286 prevented renal PAI-1 mRNA protein expression.  Our study shows that mineralocorticoid receptor antagonism and aldosterone synthase inhibition similarly decrease hypertrophy and interstitial fibrosis of the kidney and heart caused by angiotensin II and high salt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGtACkjwhczrVg90H21EOLACvtfcHk0lgDv9MZaw2tnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1Sjs7o%253D&md5=1f691ea9e6284a314792e478e8162566</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1038%2Fki.2009.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2009.9%26sid%3Dliteratum%253Aachs%26aulast%3DLea%26aufirst%3DW.%2BB.%26aulast%3DKwak%26aufirst%3DE.%2BS.%26aulast%3DLuther%26aufirst%3DJ.%2BM.%26aulast%3DFowler%26aufirst%3DS.%2BM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DFogo%26aufirst%3DA.%2BB.%26aulast%3DBrown%26aufirst%3DN.%2BJ.%26atitle%3DAldosterone%2520antagonism%2520or%2520synthase%2520inhibition%2520reduces%2520end-organ%2520damage%2520induced%2520by%2520treatment%2520with%2520angiotensin%2520and%2520high%2520salt%26jtitle%3DKidney%2520Int.%26date%3D2009%26volume%3D75%26spage%3D936%26epage%3D944%26doi%3D10.1038%2Fki.2009.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Mulder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vercauteren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remy-Jouet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteil, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuillez, C.</span><span> </span><span class="NLM_article-title">Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2171</span><span class="NLM_x">–</span> <span class="NLM_lpage">2179</span><span class="refDoi"> DOI: 10.1093/eurheartj/ehn277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1093%2Feurheartj%2Fehn277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=18586661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFOmsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=2171-2179&author=P.+Mulderauthor=V.+Mellinauthor=J.+Favreauthor=M.+Vercauterenauthor=I.+Remy-Jouetauthor=C.+Monteilauthor=V.+Richardauthor=S.+Renetauthor=J.+P.+Henryauthor=A.+Y.+Jengauthor=R.+L.+Webbauthor=C.+Thuillez&title=Aldosterone+synthase+inhibition+improves+cardiovascular+function+and+structure+in+rats+with+heart+failure%3A+a+comparison+with+spironolactone&doi=10.1093%2Feurheartj%2Fehn277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10eR"><div class="casContent"><span class="casTitleNuber">10e</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone</span></div><div class="casAuthors">Mulder, Paul; Mellin, Virginie; Favre, Julie; Vercauteren, Magali; Remy-Jouet, Isabelle; Monteil, Christelle; Richard, Vincent; Renet, Sylvanie; Henry, Jean Paul; Jeng, Arco Y.; Webb, Randy L.; Thuillez, Christian</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2171-2179</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims: Inhibition of aldosterone synthase, the key enzyme in aldosterone formation, could be an alternative strategy for mineralocorticoid-receptor antagonists in congestive heart failure (CHF), but its effect in CHF is unknown.  Methods and results: We compared, in rats with CHF, the effects of a 7 day and a 12 wk treatment with the aldosterone synthase inhibitor FAD286 (4 mg kg-1 day-1) with those induced by spironolactone (80 mg kg-1 day-1).  FAD286/spironolactone increased cardiac output without modifying arterial pressure.  Long-term FAD286 and spironolactone reduced left ventricular (LV) end-diastolic pressure, LV relaxation const., and LV dilatation, and these effects were more marked with FAD286, whereas both drugs reduced LV hypertrophy and collagen accumulation to the same extent.  Long-term FAD286/spironolactone prevented CHF-related enhancement in LV ACE and redn. in LV ACE-2, but only FAD286 prevented the redn. in LV AT2 receptors.  FAD286, but not long-term spironolactone, reduced the CHF-related enhancements in LV reactive oxygen species, reduced-oxidized glutathione ratio, and aortic NADP oxidase activity.  FAD286 normalized the CHF-induced impairment of endothelium-dependent vasodilatation.  Conclusion: In exptl. CHF, FAD286 and spironolactone improve LV hemodynamics, remodelling, and function, but only FAD286 persistently normalizes LV 'redox status'.  These results suggest that aldosterone synthase inhibition is a potential therapeutic strategy for the treatment of CHF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0uwXfSDx1HbVg90H21EOLACvtfcHk0lgDv9MZaw2tnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFOmsrjE&md5=5791341d03c3c8e58bbe3a6e134c3db8</span></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehn277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehn277%26sid%3Dliteratum%253Aachs%26aulast%3DMulder%26aufirst%3DP.%26aulast%3DMellin%26aufirst%3DV.%26aulast%3DFavre%26aufirst%3DJ.%26aulast%3DVercauteren%26aufirst%3DM.%26aulast%3DRemy-Jouet%26aufirst%3DI.%26aulast%3DMonteil%26aufirst%3DC.%26aulast%3DRichard%26aufirst%3DV.%26aulast%3DRenet%26aufirst%3DS.%26aulast%3DHenry%26aufirst%3DJ.%2BP.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DWebb%26aufirst%3DR.%2BL.%26aulast%3DThuillez%26aufirst%3DC.%26atitle%3DAldosterone%2520synthase%2520inhibition%2520improves%2520cardiovascular%2520function%2520and%2520structure%2520in%2520rats%2520with%2520heart%2520failure%253A%2520a%2520comparison%2520with%2520spironolactone%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2008%26volume%3D29%26spage%3D2171%26epage%3D2179%26doi%3D10.1093%2Feurheartj%2Fehn277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Huang, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leenen, F. H. H.</span><span> </span><span class="NLM_article-title">Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in Wistar rats</span> <span class="citation_source-journal">Am. J. Phys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">R166</span><span class="NLM_x">–</span> <span class="NLM_lpage">R172</span><span class="refDoi"> DOI: 10.1152/ajpregu.90352.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1152%2Fajpregu.90352.2008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2008&pages=R166-R172&author=B.+S.+Huangauthor=R.+A.+Whiteauthor=M.+Ahmadauthor=A.+Y.+Jengauthor=F.+H.+H.+Leenen&title=Central+infusion+of+aldosterone+synthase+inhibitor+prevents+sympathetic+hyperactivity+and+hypertension+by+central+Na%2B+in+Wistar+rats&doi=10.1152%2Fajpregu.90352.2008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10f&amp;dbid=16384&amp;doi=10.1152%2Fajpregu.90352.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpregu.90352.2008%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DB.%2BS.%26aulast%3DWhite%26aufirst%3DR.%2BA.%26aulast%3DAhmad%26aufirst%3DM.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DLeenen%26aufirst%3DF.%2BH.%2BH.%26atitle%3DCentral%2520infusion%2520of%2520aldosterone%2520synthase%2520inhibitor%2520prevents%2520sympathetic%2520hyperactivity%2520and%2520hypertension%2520by%2520central%2520Na%252B%2520in%2520Wistar%2520rats%26jtitle%3DAm.%2520J.%2520Phys.%26date%3D2008%26volume%3D295%26spage%3DR166%26epage%3DR172%26doi%3D10.1152%2Fajpregu.90352.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Minnaard-Huiban, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmen, J. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roumen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beugels, I. P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohuet, G. M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Essen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruijters, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieterse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilbers, P. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottenheijm, H. C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plate, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Gooyer, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, J. F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermans, J. J. R.</span><span> </span><span class="NLM_article-title">Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1210/en.2007-0584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1210%2Fen.2007-0584" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2008&pages=28-31&author=M.+Minnaard-Huibanauthor=J.+M.+A.+Emmenauthor=L.+Roumenauthor=I.+P.+E.+Beugelsauthor=G.+M.+S.+Cohuetauthor=H.+van+Essenauthor=E.+Ruijtersauthor=K.+Pieterseauthor=P.+A.+J.+Hilbersauthor=H.+C.+J.+Ottenheijmauthor=R.+Plateauthor=M.+E.+de+Gooyerauthor=J.+F.+M.+Smitsauthor=J.+J.+R.+Hermans&title=Fadrozole+reverses+cardiac+fibrosis+in+spontaneously+hypertensive+heart+failure+rats%3A+discordant+enantioselectivity+versus+reduction+of+plasma+aldosterone&doi=10.1210%2Fen.2007-0584"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10g&amp;dbid=16384&amp;doi=10.1210%2Fen.2007-0584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2007-0584%26sid%3Dliteratum%253Aachs%26aulast%3DMinnaard-Huiban%26aufirst%3DM.%26aulast%3DEmmen%26aufirst%3DJ.%2BM.%2BA.%26aulast%3DRoumen%26aufirst%3DL.%26aulast%3DBeugels%26aufirst%3DI.%2BP.%2BE.%26aulast%3DCohuet%26aufirst%3DG.%2BM.%2BS.%26aulast%3Dvan%2BEssen%26aufirst%3DH.%26aulast%3DRuijters%26aufirst%3DE.%26aulast%3DPieterse%26aufirst%3DK.%26aulast%3DHilbers%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DOttenheijm%26aufirst%3DH.%2BC.%2BJ.%26aulast%3DPlate%26aufirst%3DR.%26aulast%3Dde%2BGooyer%26aufirst%3DM.%2BE.%26aulast%3DSmits%26aufirst%3DJ.%2BF.%2BM.%26aulast%3DHermans%26aufirst%3DJ.%2BJ.%2BR.%26atitle%3DFadrozole%2520reverses%2520cardiac%2520fibrosis%2520in%2520spontaneously%2520hypertensive%2520heart%2520failure%2520rats%253A%2520discordant%2520enantioselectivity%2520versus%2520reduction%2520of%2520plasma%2520aldosterone%26jtitle%3DEndocrinology%26date%3D2008%26volume%3D149%26spage%3D28%26epage%3D31%26doi%3D10.1210%2Fen.2007-0584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Ménard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascoe, L.</span><span> </span><span class="NLM_article-title">Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?</span> <span class="citation_source-journal">J. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">997</span><span class="refDoi"> DOI: 10.1097/01.hjh.0000226183.98439.b3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1097%2F01.hjh.0000226183.98439.b3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=16685193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD28Xktlartrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=993-997&author=J.+M%C3%A9nardauthor=L.+Pascoe&title=Can+the+dextroenantiomer+of+the+aromatase+inhibitor+fadrozole+be+useful+for+clinical+investigation+of+aldosterone-synthase+inhibition%3F&doi=10.1097%2F01.hjh.0000226183.98439.b3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10hR"><div class="casContent"><span class="casTitleNuber">10h</span><div class="casTitle"><span class="NLM_cas:atitle">Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?</span></div><div class="casAuthors">Menard, Joel; Pascoe, Leigh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">993-997</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The beneficial effects of spironolactone, eplerenone, amiloride, and potassium in preventing cardiovascular damage in various exptl. models of salt-induced hypertension can be dissocd. from blood pressure effects, and have drawn attention to the direct genomic and non-genomic actions of aldosterone at the level of the vessels, the heart, and the kidneys.  Exposure to endogenous aldosterone could be decreased by direct and specific aldosterone-synthase inhibition.  FAD 286A, the dextroenantiomer of the aromatase inhibitor fadrozole, might be a 1st candidate to investigate in humans, the physiol. impact and therapeutic properties of aldosterone-synthase inhibition, esp. in various forms of primary aldosteronism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-EGh20MtIxLVg90H21EOLACvtfcHk0lisSBrF9EFXxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xktlartrk%253D&md5=e56a1f5ec586a4dfa515f6f995f731c9</span></div><a href="/servlet/linkout?suffix=cit10h&amp;dbid=16384&amp;doi=10.1097%2F01.hjh.0000226183.98439.b3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.hjh.0000226183.98439.b3%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9nard%26aufirst%3DJ.%26aulast%3DPascoe%26aufirst%3DL.%26atitle%3DCan%2520the%2520dextroenantiomer%2520of%2520the%2520aromatase%2520inhibitor%2520fadrozole%2520be%2520useful%2520for%2520clinical%2520investigation%2520of%2520aldosterone-synthase%2520inhibition%253F%26jtitle%3DJ.%2520Hypertens.%26date%3D2006%26volume%3D24%26spage%3D993%26epage%3D997%26doi%3D10.1097%2F01.hjh.0000226183.98439.b3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Meredith, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ksander, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monovich, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papillon, J. P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capparelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigel, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaSala, D.</span><span> </span><span class="NLM_article-title">Discovery and in vivo evaluation of potent dual CYP11B2 (aldosterone synthase) and CYP11B1 inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1203</span><span class="NLM_x">–</span> <span class="NLM_lpage">1207</span><span class="refDoi"> DOI: 10.1021/ml400324c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400324c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Ckt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1203-1207&author=E.+L.+Meredithauthor=G.+Ksanderauthor=L.+G.+Monovichauthor=J.+P.+N.+Papillonauthor=Q.+Liuauthor=K.+Mirandaauthor=P.+Morrisauthor=C.+Raoauthor=R.+Burgisauthor=M.+Capparelliauthor=Q.-Y.+Huauthor=A.+Singhauthor=D.+F.+Rigelauthor=A.+Y.+Jengauthor=M.+Beilauthor=F.+Fuauthor=C.-W.+Huauthor=D.+LaSala&title=Discovery+and+in+vivo+evaluation+of+potent+dual+CYP11B2+%28aldosterone+synthase%29+and+CYP11B1+inhibitors&doi=10.1021%2Fml400324c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors</span></div><div class="casAuthors">Meredith, Erik L.; Ksander, Gary; Monovich, Lauren G.; Papillon, Julien P. N.; Liu, Qian; Miranda, Karl; Morris, Patrick; Rao, Chang; Burgis, Robin; Capparelli, Michael; Hu, Qi-Ying; Singh, Alok; Rigel, Dean F.; Jeng, Arco Y.; Beil, Michael; Fu, Fumin; Hu, Chii-Whei; LaSala, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1203-1207</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aldosterone is a key signaling component of the renin-angiotensin-aldosterone system and as such has been shown to contribute to cardiovascular pathol. such as hypertension and heart failure.  Aldosterone synthase (CYP11B2) is responsible for the final three steps of aldosterone synthesis and thus is a viable therapeutic target.  A series of imidazole derived inhibitors, including clin. candidate I, have been identified through design and structure-activity relationship studies both in vitro and in vivo.  Compd. I was also found to be a potent inhibitor of 11β-hydroxylase (CYP11B1), which is responsible for cortisol prodn.  Inhibition of CYP11B1 is being evaluated in the clinic for potential treatment of hypercortisol diseases such as Cushing's syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZqZXmMc5qE7Vg90H21EOLACvtfcHk0lisSBrF9EFXxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Ckt7vP&md5=3f2301a71dfd1bf91a99ac68f5ca91ff</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fml400324c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400324c%26sid%3Dliteratum%253Aachs%26aulast%3DMeredith%26aufirst%3DE.%2BL.%26aulast%3DKsander%26aufirst%3DG.%26aulast%3DMonovich%26aufirst%3DL.%2BG.%26aulast%3DPapillon%26aufirst%3DJ.%2BP.%2BN.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMiranda%26aufirst%3DK.%26aulast%3DMorris%26aufirst%3DP.%26aulast%3DRao%26aufirst%3DC.%26aulast%3DBurgis%26aufirst%3DR.%26aulast%3DCapparelli%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DQ.-Y.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DBeil%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DC.-W.%26aulast%3DLaSala%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520in%2520vivo%2520evaluation%2520of%2520potent%2520dual%2520CYP11B2%2520%2528aldosterone%2520synthase%2529%2520and%2520CYP11B1%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D1203%26epage%3D1207%26doi%3D10.1021%2Fml400324c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Ménard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigel, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung-Chu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaSala, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dole, W. P.</span><span> </span><span class="NLM_article-title">Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects</span> <span class="citation_source-journal">J. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span><span class="refDoi"> DOI: 10.1186/s12967-014-0340-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1186%2Fs12967-014-0340-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=25491597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVWqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=340-361&author=J.+M%C3%A9nardauthor=D.+F.+Rigelauthor=C.+Watsonauthor=A.+Y.+Jengauthor=F.+Fuauthor=M.+Beilauthor=J.+Liuauthor=W.+Chenauthor=C.-W.+Huauthor=J.+Leung-Chuauthor=D.+LaSalaauthor=G.+Liangauthor=S.+Rebelloauthor=Y.+Zhangauthor=W.+P.+Dole&title=Aldosterone+synthase+inhibition%3A+cardiorenal+protection+in+animal+disease+models+and+translation+of+hormonal+effects+to+human+subjects&doi=10.1186%2Fs12967-014-0340-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects</span></div><div class="casAuthors">Menard, Joel; Rigel, Dean F.; Watson, Catherine; Jeng, Arco Y.; Fu, Fumin; Beil, Michael; Liu, Jing; Chen, Wei; Hu, Chii-Whei; Chu, Jennifer Leung; LaSala, Daniel; Liang, Guiqing; Rebello, Sam; Zhang, Yiming; Dole, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">340/1-340/43</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Aldosterone synthase inhibition provides the potential to attenuate both the mineralocorticoid receptor-dependent and independent actions of aldosterone.  In vitro studies with recombinant human enzymes showed LCI699 to be a potent, reversible, competitive inhibitor of aldosterone synthase (Ki ≃ 1.4 ± 0.2 nmol/L in humans) with relative selectivity over 11β-hydroxylase.  Methods: Hormonal effects of orally administered LCI699 were examd. in rat and monkey in vivo models of adrenocorticotropic hormone (ACTH) and angiotensin-II-stimulated aldosterone release, and were compared with the mineralocorticoid receptor antagonist eplerenone in a randomized, placebo-controlled study conducted in 99 healthy human subjects.  The effects of LCI699 and eplerenone on cardiac and renal sequelae of aldosterone excess were investigated in a double-transgenic rat (dTGR) model overexpressing human renin and angiotensinogen.  Results: Rat and monkey in vivo models of stimulated aldosterone release predicted human dose- and exposure-response relationships, but overestimated the selectivity of LCI699 in humans.  In the dTGR model, LCI699 dose-dependently blocked increases in aldosterone, prevented development of cardiac and renal functional abnormalities independent of blood pressure changes, and prolonged survival.  Eplerenone prolonged survival to a similar extent, but was less effective in preventing cardiac and renal damage.  In healthy human subjects, LCI699 0.5 mg selectively reduced plasma and 24 h urinary aldosterone by 49 ± 3% and 39 ± 6% resp. (Day 1, mean ± SEM; P < 0.001 vs placebo), which was assocd. with natriuresis and an increase in plasma renin activity.  Doses of LCI699 greater than 1 mg inhibited basal and ACTH-stimulated cortisol.  Eplerenone 100 mg increased plasma and 24 h urinary aldosterone while stimulating natriuresis and increasing renin activity.  In contrast to eplerenone, LCI699 increased the aldosterone precursor 11-deoxycorticosterone and urinary potassium excretion.  Conclusions: These results provide new insights into the cardiac and renal effects of inhibiting aldosterone synthase in exptl. models and translation of the hormonal effects to humans.  Selective inhibition of aldosterone synthase appears to be a promising approach to treat diseases assocd. with aldosterone excess.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbaUntldMlobVg90H21EOLACvtfcHk0ljbJeWLs4gv7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVWqs7c%253D&md5=c538103c9462fd0a16111a7a7be27bfb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1186%2Fs12967-014-0340-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-014-0340-9%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9nard%26aufirst%3DJ.%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DFu%26aufirst%3DF.%26aulast%3DBeil%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.-W.%26aulast%3DLeung-Chu%26aufirst%3DJ.%26aulast%3DLaSala%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DRebello%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDole%26aufirst%3DW.%2BP.%26atitle%3DAldosterone%2520synthase%2520inhibition%253A%2520cardiorenal%2520protection%2520in%2520animal%2520disease%2520models%2520and%2520translation%2520of%2520hormonal%2520effects%2520to%2520human%2520subjects%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2014%26volume%3D12%26spage%3D340%26epage%3D361%26doi%3D10.1186%2Fs12967-014-0340-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Amar, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azizi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ménard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyrard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plouin, P. F.</span><span> </span><span class="NLM_article-title">Aldosterone synthase inhibition with LCI699: a proof-ofconcept study in patients with primary aldosteronism</span> <span class="citation_source-journal">Hypertension</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">831</span><span class="NLM_x">–</span> <span class="NLM_lpage">838</span><span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.110.157271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1161%2FHYPERTENSIONAHA.110.157271" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2010&pages=831-838&author=L.+Amarauthor=M.+Aziziauthor=J.+M%C3%A9nardauthor=S.+Peyrardauthor=C.+Watsonauthor=P.+F.+Plouin&title=Aldosterone+synthase+inhibition+with+LCI699%3A+a+proof-ofconcept+study+in+patients+with+primary+aldosteronism&doi=10.1161%2FHYPERTENSIONAHA.110.157271"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.110.157271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.110.157271%26sid%3Dliteratum%253Aachs%26aulast%3DAmar%26aufirst%3DL.%26aulast%3DAzizi%26aufirst%3DM.%26aulast%3DM%25C3%25A9nard%26aufirst%3DJ.%26aulast%3DPeyrard%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DPlouin%26aufirst%3DP.%2BF.%26atitle%3DAldosterone%2520synthase%2520inhibition%2520with%2520LCI699%253A%2520a%2520proof-ofconcept%2520study%2520in%2520patients%2520with%2520primary%2520aldosteronism%26jtitle%3DHypertension%26date%3D2010%26volume%3D56%26spage%3D831%26epage%3D838%26doi%3D10.1161%2FHYPERTENSIONAHA.110.157271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Amar, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azizi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ménard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyrard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plouin, P.-F.</span><span> </span><span class="NLM_article-title">Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism</span> <span class="citation_source-journal">J. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">624</span><span class="NLM_x">–</span> <span class="NLM_lpage">629</span><span class="refDoi"> DOI: 10.1097/HJH.0b013e32835d6d49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1097%2FHJH.0b013e32835d6d49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=23314743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslWlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=624-629&author=L.+Amarauthor=M.+Aziziauthor=J.+M%C3%A9nardauthor=S.+Peyrardauthor=P.-F.+Plouin&title=Sequential+comparison+of+aldosterone+synthase+inhibition+and+mineralocorticoid+blockade+in+patients+with+primary+aldosteronism&doi=10.1097%2FHJH.0b013e32835d6d49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism</span></div><div class="casAuthors">Amar, Laurence; Azizi, Michel; Menard, Joel; Peyrard, Severine; Plouin, Pierre-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">624-629</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We compared the effects of aldosterone synthase inhibition with LCI699 with those of mineralocorticoid receptor blockade in patients with primary aldosteronism.  After a 2-wk placebo run-in, 14 patients with primary aldosteronism received oral LCI699 (0.5 mg b.i.d.) from day 1 to 14, LCI699 (1 mg b.i.d.) from day 15 to 29, and placebo from day 29 to 36.  From day 36 to day 66, patients were treated with eplerenone (50 mg b.i.d., up-titrated to 100 mg b.i.d. in 12/14 patients), in addn. to their previous antihypertensive treatment, which was maintained unchanged.  Eplerenone significantly decreased more 24-h ambulatory SBP on day 66 than LCI699 on day 29 and the difference between the two treatment was -5.34 [95% confidence interval (CI) -10.30; -0.38] mmHg (P = 0.027).  Plasma potassium concn. achieved on eplerenone (4.30 ± 0.45 mmol/l) was significantly greater than on LCI699 (3.89 ± 0.35 mmol/l; P = 0.009).  The increase in plasma renin concn. was significantly greater after eplerenone [+131% (range 61; 231)] than on LCI699 on day 29 [+39% (range 5; 86); P = 0.023].  LCI699 markedly decreased plasma aldosterone concn. by 75% (range -84;-63), whereas eplerenone markedly increased this concn., from day 36, by 89% (range 40;154; P < 0.0001 vs. day 29).  In patients with primary aldosteronism, the effects on blood pressure and plasma potassium and renin concns. of 4 wk of eplerenone treatment (50-100 mg b.i.d.) were more marked than those of 4 wk of LCI699 treatment (0.5-1 mg b.i.d.).  These two drugs had opposite effects on plasma aldosterone concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4xKF2Xmcp2LVg90H21EOLACvtfcHk0ljbJeWLs4gv7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslWlu7g%253D&md5=603bce57deb8f50e576790a8948fad1b</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1097%2FHJH.0b013e32835d6d49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FHJH.0b013e32835d6d49%26sid%3Dliteratum%253Aachs%26aulast%3DAmar%26aufirst%3DL.%26aulast%3DAzizi%26aufirst%3DM.%26aulast%3DM%25C3%25A9nard%26aufirst%3DJ.%26aulast%3DPeyrard%26aufirst%3DS.%26aulast%3DPlouin%26aufirst%3DP.-F.%26atitle%3DSequential%2520comparison%2520of%2520aldosterone%2520synthase%2520inhibition%2520and%2520mineralocorticoid%2520blockade%2520in%2520patients%2520with%2520primary%2520aldosteronism%26jtitle%3DJ.%2520Hypertens.%26date%3D2013%26volume%3D31%26spage%3D624%26epage%3D629%26doi%3D10.1097%2FHJH.0b013e32835d6d49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Calhoun, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krum, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bermann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trapani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftkoowitz, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ménard, J.</span><span> </span><span class="NLM_article-title">Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: Results of a randomized, double-blind, placebo</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">1945</span><span class="NLM_x">–</span> <span class="NLM_lpage">1955</span><span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.111.029892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1161%2FCIRCULATIONAHA.111.029892" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2011&pages=1945-1955&author=D.+B.+Calhounauthor=W.+B.+Whiteauthor=H.+Krumauthor=G.+Guoauthor=G.+Bermannauthor=A.+Trapaniauthor=M.+P.+Leftkoowitzauthor=J.+M%C3%A9nard&title=Effects+of+a+novel+aldosterone+synthase+inhibitor+for+treatment+of+primary+hypertension%3A+Results+of+a+randomized%2C+double-blind%2C+placebo&doi=10.1161%2FCIRCULATIONAHA.111.029892"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.029892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.029892%26sid%3Dliteratum%253Aachs%26aulast%3DCalhoun%26aufirst%3DD.%2BB.%26aulast%3DWhite%26aufirst%3DW.%2BB.%26aulast%3DKrum%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DG.%26aulast%3DBermann%26aufirst%3DG.%26aulast%3DTrapani%26aufirst%3DA.%26aulast%3DLeftkoowitz%26aufirst%3DM.%2BP.%26aulast%3DM%25C3%25A9nard%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520a%2520novel%2520aldosterone%2520synthase%2520inhibitor%2520for%2520treatment%2520of%2520primary%2520hypertension%253A%2520Results%2520of%2520a%2520randomized%252C%2520double-blind%252C%2520placebo%26jtitle%3DCirculation%26date%3D2011%26volume%3D124%26spage%3D1945%26epage%3D1955%26doi%3D10.1161%2FCIRCULATIONAHA.111.029892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Andersen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peppard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Ess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trapani, A.</span><span> </span><span class="NLM_article-title">The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study</span> <span class="citation_source-journal">J. Clin. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">580</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span><span class="refDoi"> DOI: 10.1111/j.1751-7176.2012.00667.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1111%2Fj.1751-7176.2012.00667.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1emsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=580-587&author=K.+Andersenauthor=D.+Hartmanauthor=T.+Peppardauthor=D.+Hermannauthor=P.+Van+Essauthor=M.+Lefkowitzauthor=A.+Trapani&title=The+effects+of+aldosterone+synthase+inhibition+on+aldosterone+and+cortisol+in+patients+with+hypertension%3A+a+phase+II%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+multicenter+study&doi=10.1111%2Fj.1751-7176.2012.00667.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study</span></div><div class="casAuthors">Andersen, Karl; Hartman, Daniel; Peppard, Thomas; Hermann, David; Van Ess, Peter; Lefkowitz, Martin; Trapani, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Hypertension (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">580-587</span>CODEN:
                <span class="NLM_cas:coden">JCHYFN</span>;
        ISSN:<span class="NLM_cas:issn">1524-6175</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Blockade of the renin-angiotensin-aldosterone system (RAAS) is an established method to lower blood pressure in patients with hypertension.  Aldosterone, the end product of the RAAS cascade, acts by increasing salt reabsorption in the kidney and catecholamine release from the adrenal medulla.  Currently available aldosterone inhibitors have the disadvantage of increasing circulating aldosterone and thus may lead to aldosterone breakthrough.  Aldosterone synthase inhibition (ASI) is a novel approach to suppressing the RAAS.  Due to homol. between the enzymes responsible for aldosterone synthesis (CYP11B2) and cortisol synthesis (CYP11B1), the blockade of aldosterone synthesis may also suppress cortisol release.  The authors evaluated the effect of the novel ASI LCI699 on the cortisol response to adrenocorticotropic hormone (ACTH) stimulation in patients with hypertension in order to find the maximally tolerated dose (MTD) in this patient population.  Among the 63 patients evaluated, there was a dose- and time-dependent effect of LCI699 on both aldosterone and ACTH-stimulated cortisol.  Based on exposure-response anal., the MTD was estd. to be 1.30 mg once daily with a 90% prediction interval of 0.88 mg once daily to 1.81 mg once daily.  No patients required intervention for adrenal insufficiency.  LCI699 was well tolerated with no serious adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpukpr21vCoqLVg90H21EOLACvtfcHk0ljURxyVj4C8Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1emsbbP&md5=04285bca878ef4e6ffdeb60c7207b5ab</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1111%2Fj.1751-7176.2012.00667.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1751-7176.2012.00667.x%26sid%3Dliteratum%253Aachs%26aulast%3DAndersen%26aufirst%3DK.%26aulast%3DHartman%26aufirst%3DD.%26aulast%3DPeppard%26aufirst%3DT.%26aulast%3DHermann%26aufirst%3DD.%26aulast%3DVan%2BEss%26aufirst%3DP.%26aulast%3DLefkowitz%26aufirst%3DM.%26aulast%3DTrapani%26aufirst%3DA.%26atitle%3DThe%2520effects%2520of%2520aldosterone%2520synthase%2520inhibition%2520on%2520aldosterone%2520and%2520cortisol%2520in%2520patients%2520with%2520hypertension%253A%2520a%2520phase%2520II%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520multicenter%2520study%26jtitle%3DJ.%2520Clin.%2520Hypertens.%26date%3D2012%26volume%3D14%26spage%3D580%26epage%3D587%26doi%3D10.1111%2Fj.1751-7176.2012.00667.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Karns, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bral, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peppard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumacher, C.</span><span> </span><span class="NLM_article-title">Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension</span> <span class="citation_source-journal">J. Clin. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.1111/jch.12051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1111%2Fjch.12051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslSmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=186-192&author=A.+D.+Karnsauthor=J.+M.+Bralauthor=D.+Hartmanauthor=T.+Peppardauthor=C.+Schumacher&title=Study+of+aldosterone+synthase+inhibition+as+an+add-on+therapy+in+resistant+hypertension&doi=10.1111%2Fjch.12051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension</span></div><div class="casAuthors">Karns, Adam D.; Bral, Jacqueline M.; Hartman, Daniel; Peppard, Thomas; Schumacher, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Hypertension (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">186-192</span>CODEN:
                <span class="NLM_cas:coden">JCHYFN</span>;
        ISSN:<span class="NLM_cas:issn">1524-6175</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aldosterone inhibition with mineralcorticoid receptor antagonists (MRAs) is an effective treatment for resistant hypertension.  Aldosterone synthase inhibitors (ASIs) are currently being investigated as a new therapeutic strategy to reduce aldosterone secretion from the adrenal gland.  In this study, the efficacy and safety of the first-generation ASI LCI699 (0.25 mg twice daily, 1 mg 4 once daily, and 0.5 mg/1 mg twice daily) was compared with placebo and eplerenone (50 mg twice daily), in patients with resistant hypertension.  Placebo-adjusted decreases in systolic blood pressure (BP) with LCI699 ranged from 2.6 mm Hg to 4.3 mm Hg at week 8; changes in diastolic BP ranged from +0.3 mm Hg to -1.2 mm Hg.  However, redns. were smaller than obsd. with eplerenone 50 mg twice daily (9.9 mm Hg and 2.9 mm Hg for systolic and diastolic BP, resp.) and not statistically significant vs placebo.  LCI699 suppressed plasma aldosterone levels in a dose-related manner with corresponding dose-dependent increases in plasma renin activity and plasma 11-deoxycorticosterone.  LCI699 and eplerenone were well tolerated.  These data demonstrate that aldosterone synthesis inhibition with LCI699 lowers BP modestly in patients with resistant hypertension.  Aldosterone synthesis inhibition might offer an attractive adjunct to aldosterone receptor blockade, although the potential of a combination MRA/ASI has not yet been tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSJxQuOsY8XrVg90H21EOLACvtfcHk0ljURxyVj4C8Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslSmt7c%253D&md5=e6147f9496d529818be6bdc0137bf72b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fjch.12051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjch.12051%26sid%3Dliteratum%253Aachs%26aulast%3DKarns%26aufirst%3DA.%2BD.%26aulast%3DBral%26aufirst%3DJ.%2BM.%26aulast%3DHartman%26aufirst%3DD.%26aulast%3DPeppard%26aufirst%3DT.%26aulast%3DSchumacher%26aufirst%3DC.%26atitle%3DStudy%2520of%2520aldosterone%2520synthase%2520inhibition%2520as%2520an%2520add-on%2520therapy%2520in%2520resistant%2520hypertension%26jtitle%3DJ.%2520Clin.%2520Hypertens.%26date%3D2013%26volume%3D15%26spage%3D186%26epage%3D192%26doi%3D10.1111%2Fjch.12051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Bertagna, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pivonello, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleseriu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maldonado, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamrahian, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boscaro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biller, B. M. K.</span><span> </span><span class="NLM_article-title">LCI699, a potent 11-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1375</span><span class="NLM_x">–</span> <span class="NLM_lpage">1383</span><span class="refDoi"> DOI: 10.1210/jc.2013-2117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1210%2Fjc.2013-2117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=24423285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtlekt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2014&pages=1375-1383&author=X.+Bertagnaauthor=R.+Pivonelloauthor=M.+Fleseriuauthor=Y.+Zhangauthor=P.+Robinsonauthor=A.+Taylorauthor=C.+E.+Watsonauthor=M.+Maldonadoauthor=A.+H.+Hamrahianauthor=M.+Boscaroauthor=B.+M.+K.+Biller&title=LCI699%2C+a+potent+11-hydroxylase+inhibitor%2C+normalizes+urinary+cortisol+in+patients+with+Cushing%E2%80%99s+disease%3A+results+from+a+multicenter%2C+proof-of-concept+study&doi=10.1210%2Fjc.2013-2117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study</span></div><div class="casAuthors">Bertagna, Xavier; Pivonello, Rosario; Fleseriu, Maria; Zhang, Yiming; Robinson, Paul; Taylor, Ann; Watson, Catherine E.; Maldonado, Mario; Hamrahian, Amir H.; Boscaro, Marco; Biller, Beverly M. K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1375-1383</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Introduction: The clin. features and increased mortality assocd. with Cushing's syndrome result from a chronic excess of circulating cortisol.  As LCI699 potently inhibits 11β-hydroxylase, which catalyzes the final step of cortisol synthesis, it is a potential new treatment for Cushing's disease, the most common cause of endogenous Cushing's syndrome.  Methods: Adult patients with moderate-to-severe Cushing's disease (urinary free cortisol [UFC] levels >1.5 × ULN [upper limit of normal]) received oral LCI699 for 10 wk in this proof-of-concept study.  LCI699 was initiated at 4 mg/d in two equal doses; the dose was escalated every 14 days to 10, 20, 40, and 100 mg/d until UFC normalized, whereupon the dose was maintained until treatment ended (day 70).  The primary endpoint was UFC ≤ ULN or a ≥50% decrease from baseline at day 70.  Results: Twelve patients were enrolled and completed the study.  Baseline UFC ranged over 1.6-17.0 × ULN.  All 12 patients achieved UFC ≤ ULN or a ≥50% decrease from baseline at day 70; 11 (92%) had normal UFC levels at that time.  After treatment discontinuation (day 84), UFC was >ULN in 10 patients with available measurements.  Mean 11-deoxycortisol, 11-deoxycorticosterone, and adrenocorticotropic hormone levels increased during treatment and declined after discontinuation.  Mean systolic and diastolic blood pressure decreased from baseline by 10.0 and 6.0 mmHg, resp.  LCI699 was generally well tolerated; most adverse events (AEs) were mild or moderate.  The most common AEs included fatigue (7/12), nausea (5/12), and headache (3/12).  No serious drug-related AEs were reported.  Conclusions: LCI699 was efficacious and well tolerated in patients with Cushing's disease enrolled in this proof-of-concept study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEiDQVlHlvpbVg90H21EOLACvtfcHk0ljURxyVj4C8Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtlekt7c%253D&md5=fefaaf5d26879f79a9b45707c5a6d3ba</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1210%2Fjc.2013-2117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2013-2117%26sid%3Dliteratum%253Aachs%26aulast%3DBertagna%26aufirst%3DX.%26aulast%3DPivonello%26aufirst%3DR.%26aulast%3DFleseriu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DRobinson%26aufirst%3DP.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DWatson%26aufirst%3DC.%2BE.%26aulast%3DMaldonado%26aufirst%3DM.%26aulast%3DHamrahian%26aufirst%3DA.%2BH.%26aulast%3DBoscaro%26aufirst%3DM.%26aulast%3DBiller%26aufirst%3DB.%2BM.%2BK.%26atitle%3DLCI699%252C%2520a%2520potent%252011-hydroxylase%2520inhibitor%252C%2520normalizes%2520urinary%2520cortisol%2520in%2520patients%2520with%2520Cushing%25E2%2580%2599s%2520disease%253A%2520results%2520from%2520a%2520multicenter%252C%2520proof-of-concept%2520study%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2014%26volume%3D99%26spage%3D1375%26epage%3D1383%26doi%3D10.1210%2Fjc.2013-2117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Papillon, J. P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carvalho, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amaral, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beil, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangl, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaSala, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniara, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigel, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ksander, G. M.</span><span> </span><span class="NLM_article-title">Structure–Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4749</span><span class="NLM_x">–</span> <span class="NLM_lpage">4770</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00407</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00407" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4749-4770&author=J.+P.+N.+Papillonauthor=C.+M.+Adamsauthor=Q.-Y.+Huauthor=C.+Louauthor=A.+K.+Singhauthor=C.+Zhangauthor=J.+Carvalhoauthor=S.+Rajanauthor=A.+Amaralauthor=M.+E.+Beilauthor=F.+Fuauthor=E.+Ganglauthor=C.-W.+Huauthor=A.+Y.+Jengauthor=D.+LaSalaauthor=G.+Liangauthor=M.+Logmanauthor=W.+M.+Maniaraauthor=D.+F.+Rigelauthor=S.+A.+Smithauthor=G.+M.+Ksander&title=Structure%E2%80%93Activity+Relationships%2C+Pharmacokinetics%2C+and+in+Vivo+Activity+of+CYP11B2+and+CYP11B1+Inhibitors&doi=10.1021%2Facs.jmedchem.5b00407"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00407%26sid%3Dliteratum%253Aachs%26aulast%3DPapillon%26aufirst%3DJ.%2BP.%2BN.%26aulast%3DAdams%26aufirst%3DC.%2BM.%26aulast%3DHu%26aufirst%3DQ.-Y.%26aulast%3DLou%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DCarvalho%26aufirst%3DJ.%26aulast%3DRajan%26aufirst%3DS.%26aulast%3DAmaral%26aufirst%3DA.%26aulast%3DBeil%26aufirst%3DM.%2BE.%26aulast%3DFu%26aufirst%3DF.%26aulast%3DGangl%26aufirst%3DE.%26aulast%3DHu%26aufirst%3DC.-W.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DLaSala%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DLogman%26aufirst%3DM.%26aulast%3DManiara%26aufirst%3DW.%2BM.%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DSmith%26aufirst%3DS.%2BA.%26aulast%3DKsander%26aufirst%3DG.%2BM.%26atitle%3DStructure%25E2%2580%2593Activity%2520Relationships%252C%2520Pharmacokinetics%252C%2520and%2520in%2520Vivo%2520Activity%2520of%2520CYP11B2%2520and%2520CYP11B1%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4749%26epage%3D4770%26doi%3D10.1021%2Facs.jmedchem.5b00407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Emmerich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Cushing’s syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6022</span><span class="NLM_x">–</span> <span class="NLM_lpage">6032</span><span class="refDoi"> DOI: 10.1021/jm400240r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400240r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeqsrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6022-6032&author=J.+Emmerichauthor=Q.+Huauthor=N.+Hankeauthor=R.+W.+Hartmann&title=Cushing%E2%80%99s+syndrome%3A+development+of+highly+potent+and+selective+CYP11B1+inhibitors+of+the+%28pyridylmethyl%29pyridine+type&doi=10.1021%2Fjm400240r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Cushing's Syndrome: Development of Highly Potent and Selective CYP11B1 Inhibitors of the (Pyridylmethyl)pyridine Type</span></div><div class="casAuthors">Emmerich, Juliette; Hu, Qingzhong; Hanke, Nina; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6022-6032</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Potent and selective CYP11B1 inhibitors could be promising therapeutics for the treatment of Cushing's syndrome.  Optimization of 5-((1H-imidazol-1-yl)methyl)-2-phenylpyridine(I) led to 5-((5-methylpyridin-3-yl)methyl)-2-phenylpyridine(II) with a 50-fold improved IC50 value of 2 nM toward human CYP11B1 and an enhanced inhibition of the rat enzyme (IC50 = 2440 nM) compared to I (IC50 > 10000 nM).  Furthermore, selectivities over CYP11B2, CYP17, and CYP19 were obsd., as well as satisfying metabolic stability not only in human and rat plasma but also in liver S9 fraction.  Investigation of cytotoxicity and inhibition of hepatic CYP2A6 and CYP3A4 showed that II fulfills first safety criteria and can be considered for further in vivo evaluation in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovo4jVVP4sVLVg90H21EOLACvtfcHk0liF-44x2Zn2hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeqsrfI&md5=7f62b0c451e5e3647e5f10dfd612b23f</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1021%2Fjm400240r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400240r%26sid%3Dliteratum%253Aachs%26aulast%3DEmmerich%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DHanke%26aufirst%3DN.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DCushing%25E2%2580%2599s%2520syndrome%253A%2520development%2520of%2520highly%2520potent%2520and%2520selective%2520CYP11B1%2520inhibitors%2520of%2520the%2520%2528pyridylmethyl%2529pyridine%2520type%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6022%26epage%3D6032%26doi%3D10.1021%2Fjm400240r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hille, U. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haupenthal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Optimization of the first selective steroid-11β-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">564</span><span class="refDoi"> DOI: 10.1021/ml100283h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100283h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=559-564&author=U.+E.+Hilleauthor=C.+Zimmerauthor=J.+Haupenthalauthor=R.+W.+Hartmann&title=Optimization+of+the+first+selective+steroid-11%CE%B2-hydroxylase+%28CYP11B1%29+inhibitors+for+the+treatment+of+cortisol+dependent+diseases&doi=10.1021%2Fml100283h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1021%2Fml100283h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100283h%26sid%3Dliteratum%253Aachs%26aulast%3DHille%26aufirst%3DU.%2BE.%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DHaupenthal%26aufirst%3DJ.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DOptimization%2520of%2520the%2520first%2520selective%2520steroid-11%25CE%25B2-hydroxylase%2520%2528CYP11B1%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cortisol%2520dependent%2520diseases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D559%26epage%3D564%26doi%3D10.1021%2Fml100283h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmaier, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydro-pyrrolo-[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing’s syndrome</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6629</span><span class="NLM_x">–</span> <span class="NLM_lpage">6633</span><span class="refDoi"> DOI: 10.1021/jm3003872</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003872" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6629-6633&author=L.+Yinauthor=S.+Lucasauthor=F.+Maurerauthor=U.+Kazmaierauthor=Q.+Huauthor=R.+W.+Hartmann&title=Novel+imidazol-1-ylmethyl+substituted+1%2C2%2C5%2C6-tetrahydro-pyrrolo-%5B3%2C2%2C1-ij%5Dquinolin-4-ones+as+potent+and+selective+CYP11B1+inhibitors+for+the+treatment+of+Cushing%E2%80%99s+syndrome&doi=10.1021%2Fjm3003872"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17d&amp;dbid=16384&amp;doi=10.1021%2Fjm3003872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003872%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DF.%26aulast%3DKazmaier%26aufirst%3DU.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DNovel%2520imidazol-1-ylmethyl%2520substituted%25201%252C2%252C5%252C6-tetrahydro-pyrrolo-%255B3%252C2%252C1-ij%255Dquinolin-4-ones%2520as%2520potent%2520and%2520selective%2520CYP11B1%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Cushing%25E2%2580%2599s%2520syndrome%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6629%26epage%3D6633%26doi%3D10.1021%2Fjm3003872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Azizi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menard, J.</span><span> </span><span class="NLM_article-title">Aldosterone synthase inhibition in humans</span> <span class="citation_source-journal">Nephrol., Dial., Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1093/ndt/gfs388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1093%2Fndt%2Fgfs388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=23045428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Cnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2013&pages=36-43&author=M.+Aziziauthor=L.+Amarauthor=J.+Menard&title=Aldosterone+synthase+inhibition+in+humans&doi=10.1093%2Fndt%2Fgfs388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone synthase inhibition in humans</span></div><div class="casAuthors">Azizi, Michel; Amar, Laurence; Menard, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology, Dialysis, Transplantation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-43</span>CODEN:
                <span class="NLM_cas:coden">NDTREA</span>;
        ISSN:<span class="NLM_cas:issn">0931-0509</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Aldosterone synthase (CYP11B2) inhibition has emerged as a new option for the treatment of hypertension, heart failure and renal disorders, in addn. to mineralocorticoid receptor (MR) blockade.  The aim is to decrease aldosterone concns. in both plasma and tissues, thereby decreasing MR-dependent and MR-independent effects in the cardiac, vascular and renal target organs.  LCI699 was the first orally active aldosterone-synthase inhibitor to be developed for human use.  Its structure is similar to that of FAD286, the dextroenantiomer of the aromatase inhibitor, fadrozole.  It dose-dependently decreases plasma and urine aldosterone concns. by up to 70 or 80% and increases plasma renin activity in healthy male subjects on a low-sodium diet.  LCI699 does not decrease basal plasma cortisol concns. at doses of 0.5-3 mg q.d., but it blocks the cortisol response to adrenocorticotropic hormone (ACTH) at doses ≥3 mg q.d.  In a proof-of-concept study in patients with primary aldosteronism (PA), LCI699 (0.5-1 mg b.i.d.) induced a dose-dependent and reversible 70-80% decrease in plasma and urinary aldosterone concn. accompanied by a massive dose-dependent accumulation of deoxycorticosterone (>+700%), the aldosterone precursor, in the plasma, thereby confirming the inhibition of the CYP11B2 gene product.  This effect was assocd. with a rapid correction of hypokalemia, a modest decrease in blood pressure (BP) and a mild increase in plasma renin concn. in patients with PA.  LCI699 administration induced biol. signs of partial inhibition of the glucocorticoid axis, such as dose-dependent increases in both plasma ACTH and 11-deoxycortisol (the precursor of cortisol) concns., consistent with the inhibition of the CYP11B1 gene product.  An 8-wk placebo-controlled dose-response study on patients with Stage 1 and 2 essential hypertension reported an optimal decrease in BP with a dose of 1 mg LCI699 q.d., which had an antihypertensive effect similar to that of 50 mg b.i.d. eplerenone.  A blunted cortisol response to ACTH was obsd. in 20% of patients, but the clin. and biol. safety and tolerability of LCI699 were similar to those of placebo and eplerenone.  The discovery of this first orally active aldosterone synthase inhibitor, LCI699, has provided new opportunities to assess the feasibility and the haemodynamic, biol. and safety consequences as well as the limitations of this new approach to block the aldosterone pathway in hypertensive patients.  However, as the effects of LCI699 on the glucocorticoid axis limit the use of higher doses range because of the loss of selectivity for CYP11B2, this aldosterone synthase inhibitor cannot replace the MR blockade in patients with hypertension, other cardiovascular or renal disorders.  The development of second-generation aldosterone synthase inhibitors with a higher selectivity index for CYP11B2 than LCI699 should make it possible to test this approach at much higher doses in these patients, after the necessary toxicol. and Phase I studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpry7oeFoXKGbVg90H21EOLACvtfcHk0lg0P3RwAitlcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Cnur4%253D&md5=0674cf3cafdb5809dc4db29f1b840320</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgfs388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgfs388%26sid%3Dliteratum%253Aachs%26aulast%3DAzizi%26aufirst%3DM.%26aulast%3DAmar%26aufirst%3DL.%26aulast%3DMenard%26aufirst%3DJ.%26atitle%3DAldosterone%2520synthase%2520inhibition%2520in%2520humans%26jtitle%3DNephrol.%252C%2520Dial.%252C%2520Transplant.%26date%3D2013%26volume%3D28%26spage%3D36%26epage%3D43%26doi%3D10.1093%2Fndt%2Fgfs388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5011</span><span class="NLM_x">–</span> <span class="NLM_lpage">5022</span><span class="refDoi"> DOI: 10.1021/jm401430e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401430e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVelsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5011-5022&author=Q.+Huauthor=L.+Yinauthor=R.+W.+Hartmann&title=Aldosterone+synthase+inhibitors+as+promising+treatments+for+mineralocorticoid+dependent+cardiovascular+and+renal+diseases&doi=10.1021%2Fjm401430e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone Synthase Inhibitors as Promising Treatments for Mineralocorticoid Dependent Cardiovascular and Renal Diseases</span></div><div class="casAuthors">Hu, Qingzhong; Yin, Lina; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5011-5022</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Besides the well-known roles of aldosterone as a mineralocorticoid in regulating homeostasis of electrolytes and vol., recent studies revealed that it is also a potent proinflammation factor inducing reactive oxygen species and up-regulating a panel of fibrosis related genes.  Under pathol. circumstances, excessive aldosterone is involved in a lot of chronic diseases, including hypertension, cardiac fibrosis, congestive heart failure, ventricular remodeling, and diabetic nephropathy.  Therefore, the inhibition of aldosterone synthase (CYP11B2), which is the pivotal enzyme in aldosterone biosynthesis, was proposed as a superior approach.  Expected pharmacodynamic effects have been demonstrated in both animal models and clin. trials after the application of CYP11B2 inhibitors.  The importance of selectivity over other steroidogenic CYP enzymes, in particular 11β-hydroxylase (CYP11B1), was also revealed.  Recently, much more selective CYP11B2 inhibitors have been reported, which could be promising drug candidates for the treatment of aldosterone related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp22wShTUgyNrVg90H21EOLACvtfcHk0lg0P3RwAitlcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVelsQ%253D%253D&md5=585f8d88a1df8d22382e6a58ab0283b0</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Fjm401430e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401430e%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DAldosterone%2520synthase%2520inhibitors%2520as%2520promising%2520treatments%2520for%2520mineralocorticoid%2520dependent%2520cardiovascular%2520and%2520renal%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5011%26epage%3D5022%26doi%3D10.1021%2Fjm401430e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cerny, M. A.</span><span> </span><span class="NLM_article-title">Progress towards clinically useful aldosterone synthase inhibitors</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1385</span><span class="NLM_x">–</span> <span class="NLM_lpage">1401</span><span class="refDoi"> DOI: 10.2174/1568026611313120003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.2174%2F1568026611313120003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=23688131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wgu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1385-1401&author=M.+A.+Cerny&title=Progress+towards+clinically+useful+aldosterone+synthase+inhibitors&doi=10.2174%2F1568026611313120003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18c</span><div class="casTitle"><span class="NLM_cas:atitle">Progress Towards Clinically Useful Aldosterone Synthase Inhibitors</span></div><div class="casAuthors">Cerny, Matthew A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1385-1401</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Owing to the high degree of similarity between aldosterone synthase (CYP11B2) and cortisol synthase (CYP11B1), the design of selective inhibitors of one or the other of these two enzymes was, at one time, thought to be impossible.  Through development of novel enzyme screening assays and significant medicinal chem. efforts, highly potent inhibitors of CYP11B2 have been identified with selectivities approaching 1000-fold between the two enzymes.  Many of these mols. also possess selectivity against other steroidogenic cytochromes P 450 (e.g. CYP17A1 and CYP19A1) as well as hepatic drug metabolizing P450s.  Though not as well developed or explored, inhibitors of CYP11B1, with selectivities approaching 50-fold, have also been identified.  The therapeutic benefits of affecting the renin-angiotensin-aldosterone system have been well established with the therapeutically useful angiotensin-converting enzymes inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists.  Data regarding the addnl. benefits of an aldosterone synthase inhibitor (ASi) are beginning to emerge from animal models and human clin. trials.  Despite great promise and much progress, addnl. challenges still exist in the path towards development of a therapeutically useful ASi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNrk4wlx7NurVg90H21EOLACvtfcHk0lg0P3RwAitlcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wgu77O&md5=bce9e566a086d1c2c58df2811ced6230</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.2174%2F1568026611313120003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611313120003%26sid%3Dliteratum%253Aachs%26aulast%3DCerny%26aufirst%3DM.%2BA.%26atitle%3DProgress%2520towards%2520clinically%2520useful%2520aldosterone%2520synthase%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D1385%26epage%3D1401%26doi%3D10.2174%2F1568026611313120003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hoyt, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carswell, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLean, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belshaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cully, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bopp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sok, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, T.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stribling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pai, L.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metzger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verras, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMasters, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buist, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuethe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxwell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catro-Perez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szeto, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span> </span><span class="NLM_article-title">Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVWku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=573-578&author=S.+B.+Hoytauthor=M.+K.+Parkauthor=C.+Londonauthor=Y.+Xiongauthor=J.+Tataauthor=D.+J.+Bennettauthor=A.+Cookeauthor=J.+Caiauthor=E.+Carswellauthor=J.+Robinsonauthor=J.+MacLeanauthor=L.+Brownauthor=S.+Belshawauthor=T.+R.+Clarksonauthor=K.+Liuauthor=G.-B.+Liangauthor=M.+Struthersauthor=D.+Cullyauthor=T.+Wisniewskiauthor=N.+Renauthor=C.+Boppauthor=A.+Sokauthor=T.-Q.+Caiauthor=S.+Striblingauthor=L.-Y.+Paiauthor=X.+Maauthor=J.+Metzgerauthor=A.+Verrasauthor=D.+McMastersauthor=Q.+Chenauthor=E.+Tungauthor=W.+Tangauthor=G.+Salituroauthor=N.+Buistauthor=J.+Kuetheauthor=N.+Riveraauthor=J.+Clemasauthor=G.+Zhouauthor=J.+Gibsonauthor=C.+A.+Maxwellauthor=M.+Lassmanauthor=T.+McLaughlinauthor=J.+Catro-Perezauthor=D.+Szetoauthor=G.+Forrestauthor=R.+Hajduauthor=M.+Rosenbachauthor=A.+Ali&title=Discovery+of+Benzimidazole+CYP11B2+Inhibitors+with+in+Vivo+Activity+in+Rhesus+Monkeys&doi=10.1021%2Facsmedchemlett.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys</span></div><div class="casAuthors">Hoyt, Scott B.; Park, Min K.; London, Clare; Xiong, Yusheng; Tata, Jim; Bennett, D. Jonathan; Cooke, Andrew; Cai, Jiaqiang; Carswell, Emma; Robinson, John; MacLean, John; Brown, Lindsay; Belshaw, Simone; Clarkson, Thomas R.; Liu, Kun; Liang, Gui-Bai; Struthers, Mary; Cully, Doris; Wisniewski, Tom; Ren, Ning; Bopp, Charlene; Sok, Andrea; Cai, Tian-Quan; Stribling, Sloan; Pai, Lee-Yuh; Ma, Xiuying; Metzger, Joe; Verras, Andreas; McMasters, Daniel; Chen, Qing; Tung, Elaine; Tang, Wei; Salituro, Gino; Buist, Nicole; Kuethe, Jeff; Rivera, Nelo; Clemas, Joe; Zhou, Gaochao; Gibson, Jack; Maxwell, Carrie Ann; Lassman, Mike; McLaughlin, Theresa; Castro-Perez, Jose; Szeto, Daphne; Forrest, Gail; Hajdu, Richard; Rosenbach, Mark; Ali, Amjad</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">573-578</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report the discovery of a benzimidazole series of CYP11B2 inhibitors.  Hit-to-lead and lead optimization studies identified compds. such as I, which displays potent CYP11B2 inhibition, high selectivity vs. related CYP targets, and good pharmacokinetic properties in rat and rhesus.  In a rhesus pharmacodynamic model, I produces dose-dependent aldosterone lowering efficacy, with no apparent effect on cortisol levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLik9a_Au3C7Vg90H21EOLACvtfcHk0lgG0zvdPwPytw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVWku7k%253D&md5=aa1785399c4b3387b1d3f169efa1dc6f</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DHoyt%26aufirst%3DS.%2BB.%26aulast%3DPark%26aufirst%3DM.%2BK.%26aulast%3DLondon%26aufirst%3DC.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DTata%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DCarswell%26aufirst%3DE.%26aulast%3DRobinson%26aufirst%3DJ.%26aulast%3DMacLean%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DL.%26aulast%3DBelshaw%26aufirst%3DS.%26aulast%3DClarkson%26aufirst%3DT.%2BR.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DG.-B.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DCully%26aufirst%3DD.%26aulast%3DWisniewski%26aufirst%3DT.%26aulast%3DRen%26aufirst%3DN.%26aulast%3DBopp%26aufirst%3DC.%26aulast%3DSok%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DT.-Q.%26aulast%3DStribling%26aufirst%3DS.%26aulast%3DPai%26aufirst%3DL.-Y.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DMetzger%26aufirst%3DJ.%26aulast%3DVerras%26aufirst%3DA.%26aulast%3DMcMasters%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DTung%26aufirst%3DE.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DSalituro%26aufirst%3DG.%26aulast%3DBuist%26aufirst%3DN.%26aulast%3DKuethe%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DN.%26aulast%3DClemas%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DGibson%26aufirst%3DJ.%26aulast%3DMaxwell%26aufirst%3DC.%2BA.%26aulast%3DLassman%26aufirst%3DM.%26aulast%3DMcLaughlin%26aufirst%3DT.%26aulast%3DCatro-Perez%26aufirst%3DJ.%26aulast%3DSzeto%26aufirst%3DD.%26aulast%3DForrest%26aufirst%3DG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DAli%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520Benzimidazole%2520CYP11B2%2520Inhibitors%2520with%2520in%2520Vivo%2520Activity%2520in%2520Rhesus%2520Monkeys%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D573%26epage%3D578%26doi%3D10.1021%2Facsmedchemlett.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratcliffe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metzger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Novel Pyridyl Substituted 4,5-Dihydro-[1,2,4]triazolo[4,3-a]quinolines as Potent and Selective Aldosterone Synthase Inhibitors with Improved in Vitro Metabolic Stability</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2530</span><span class="NLM_x">–</span> <span class="NLM_lpage">2537</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00079</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2530-2537&author=Q.+Huauthor=L.+Yinauthor=A.+Aliauthor=A.+J.+Cookeauthor=J.+Bennettauthor=P.+Ratcliffeauthor=M.+M.+Loauthor=E.+Metzgerauthor=S.+Hoytauthor=R.+W.+Hartmann&title=Novel+Pyridyl+Substituted+4%2C5-Dihydro-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dquinolines+as+Potent+and+Selective+Aldosterone+Synthase+Inhibitors+with+Improved+in+Vitro+Metabolic+Stability&doi=10.1021%2Facs.jmedchem.5b00079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00079%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DCooke%26aufirst%3DA.%2BJ.%26aulast%3DBennett%26aufirst%3DJ.%26aulast%3DRatcliffe%26aufirst%3DP.%26aulast%3DLo%26aufirst%3DM.%2BM.%26aulast%3DMetzger%26aufirst%3DE.%26aulast%3DHoyt%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DNovel%2520Pyridyl%2520Substituted%25204%252C5-Dihydro-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dquinolines%2520as%2520Potent%2520and%2520Selective%2520Aldosterone%2520Synthase%2520Inhibitors%2520with%2520Improved%2520in%2520Vitro%2520Metabolic%2520Stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2530%26epage%3D2537%26doi%3D10.1021%2Facs.jmedchem.5b00079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Grombein, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: a new class of potent and selective aldosterone synthase inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">605</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.10.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.ejmech.2014.10.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=25462268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGjtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=597-605&author=C.+M.+Grombeinauthor=Q.+Huauthor=R.+Heimauthor=S.+Rauauthor=C.+Zimmerauthor=R.+W.+Hartmann&title=1-Phenylsulfinyl-3-%28pyridin-3-yl%29naphthalen-2-ols%3A+a+new+class+of+potent+and+selective+aldosterone+synthase+inhibitors&doi=10.1016%2Fj.ejmech.2014.10.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: A new class of potent and selective aldosterone synthase inhibitors</span></div><div class="casAuthors">Grombein, Cornelia M.; Hu, Qingzhong; Heim, Ralf; Rau, Sabrina; Zimmer, Christina; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">597-605</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols and related compds. were synthesized and evaluated for inhibition of aldosterone synthase (CYP11B2), a potential target for cardiovascular diseases assocd. with elevated plasma aldosterone levels like congestive heart failure and myocardial fibrosis.  Introduction of substituents at the phenylsulfinyl moiety and changes of the substitution pattern at the naphthalene core were examd.  Potent compds. were further examd. for selectivity vs. other important steroidogenic CYP enzymes, i.e. the highly homologous 11β-hydroxylase (CYP11B1), CYP17 and CYP19.  The most potent compd. (IC50 = 14 nM) discovered was the meta-trifluoromethoxy deriv. I, which also exhibited excellent selectivity toward CYP11B1 (SF = 415), and showed no inhibition of CYP17 and CYP19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptMcfkz8HvtrVg90H21EOLACvtfcHk0lgG0zvdPwPytw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGjtrnL&md5=abf32be6d9cf844b50257b46f46c4f2c</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.027%26sid%3Dliteratum%253Aachs%26aulast%3DGrombein%26aufirst%3DC.%2BM.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DHeim%26aufirst%3DR.%26aulast%3DRau%26aufirst%3DS.%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3D1-Phenylsulfinyl-3-%2528pyridin-3-yl%2529naphthalen-2-ols%253A%2520a%2520new%2520class%2520of%2520potent%2520and%2520selective%2520aldosterone%2520synthase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D89%26spage%3D597%26epage%3D605%26doi%3D10.1016%2Fj.ejmech.2014.10.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Grombein, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.ejmech.2014.12.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2015&pages=788-796&author=C.+M.+Grombeinauthor=Q.+Huauthor=S.+Rauauthor=C.+Zimmerauthor=R.+W.+Hartmann&title=Heteroatom+insertion+into+3%2C4-dihydro-1H-quinolin-2-ones+leads+to+potent+and+selective+inhibitors+of+human+and+rat+aldosterone+synthase&doi=10.1016%2Fj.ejmech.2014.12.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19d&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DGrombein%26aufirst%3DC.%2BM.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DRau%26aufirst%3DS.%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DHeteroatom%2520insertion%2520into%25203%252C4-dihydro-1H-quinolin-2-ones%2520leads%2520to%2520potent%2520and%2520selective%2520inhibitors%2520of%2520human%2520and%2520rat%2520aldosterone%2520synthase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D90%26spage%3D788%26epage%3D796%26doi%3D10.1016%2Fj.ejmech.2014.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmerich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metzger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5179</span><span class="NLM_x">–</span> <span class="NLM_lpage">5189</span><span class="refDoi"> DOI: 10.1021/jm500140c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500140c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5179-5189&author=L.+Yinauthor=Q.+Huauthor=J.+Emmerichauthor=M.+M.+Loauthor=E.+Metzgerauthor=A.+Aliauthor=R.+W.+Hartmann&title=Novel+pyridyl-+or+isoquinolinyl-substituted+indolines+and+indoles+as+potent+and+selective+aldosterone+synthase+inhibitors&doi=10.1021%2Fjm500140c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19e&amp;dbid=16384&amp;doi=10.1021%2Fjm500140c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500140c%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DEmmerich%26aufirst%3DJ.%26aulast%3DLo%26aufirst%3DM.%2BM.%26aulast%3DMetzger%26aufirst%3DE.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DNovel%2520pyridyl-%2520or%2520isoquinolinyl-substituted%2520indolines%2520and%2520indoles%2520as%2520potent%2520and%2520selective%2520aldosterone%2520synthase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5179%26epage%3D5189%26doi%3D10.1021%2Fjm500140c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Lucas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Fine-tuning the selectivity of aldosterone synthase inhibitors: insights from studies from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinoline-4-one derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2307</span><span class="NLM_x">–</span> <span class="NLM_lpage">2319</span><span class="refDoi"> DOI: 10.1021/jm101470k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101470k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2307-2319&author=S.+Lucasauthor=M.+Negriauthor=R.+Heimauthor=C.+Zimmerauthor=R.+W.+Hartmann&title=Fine-tuning+the+selectivity+of+aldosterone+synthase+inhibitors%3A+insights+from+studies+from+studies+of+heteroaryl+substituted+1%2C2%2C5%2C6-tetrahydropyrrolo%5B3%2C2%2C1-ij%5Dquinoline-4-one+derivatives&doi=10.1021%2Fjm101470k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19f&amp;dbid=16384&amp;doi=10.1021%2Fjm101470k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101470k%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DHeim%26aufirst%3DR.%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DFine-tuning%2520the%2520selectivity%2520of%2520aldosterone%2520synthase%2520inhibitors%253A%2520insights%2520from%2520studies%2520from%2520studies%2520of%2520heteroaryl%2520substituted%25201%252C2%252C5%252C6-tetrahydropyrrolo%255B3%252C2%252C1-ij%255Dquinoline-4-one%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2307%26epage%3D2319%26doi%3D10.1021%2Fjm101470k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Roumen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmen, J. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beugels, I. P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Custers, E. M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Gooyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plate, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieterse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilbers, P. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, J. F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vekemans, J. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leysen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottenheijm, H. C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermans, J. J. R.</span><span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1712</span><span class="NLM_x">–</span> <span class="NLM_lpage">1725</span><span class="refDoi"> DOI: 10.1021/jm901356d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901356d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCgtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1712-1725&author=L.+Roumenauthor=J.+W.+Peetersauthor=J.+M.+A.+Emmenauthor=I.+P.+E.+Beugelsauthor=E.+M.+G.+Custersauthor=M.+de+Gooyerauthor=R.+Plateauthor=K.+Pieterseauthor=P.+A.+J.+Hilbersauthor=J.+F.+M.+Smitsauthor=J.+A.+J.+Vekemansauthor=D.+Leysenauthor=H.+C.+J.+Ottenheijmauthor=H.+M.+Janssenauthor=J.+J.+R.+Hermans&title=Synthesis%2C+biological+evaluation%2C+and+molecular+modeling+of+1-benzyl-1H-imidazoles+as+selective+inhibitors+of+aldosterone+synthase+%28CYP11B2%29&doi=10.1021%2Fjm901356d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19gR"><div class="casContent"><span class="casTitleNuber">19g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Biological Evaluation, and Molecular Modeling of 1-Benzyl-1H-imidazoles as Selective Inhibitors of Aldosterone Synthase (CYP11B2)</span></div><div class="casAuthors">Roumen, Luc; Peeters, Joris W.; Emmen, Judith M. A.; Beugels, Ilona P. E.; Custers, Erica M. G.; de Gooyer, Marcel; Plate, Ralf; Pieterse, Koen; Hilbers, Peter A. J.; Smits, Jos F. M.; Vekemans, Jef A. J.; Leysen, Dirk; Ottenheijm, Harry C. J.; Janssen, Henk M.; Hermans, J. J. Rob</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1712-1725</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reducing aldosterone action is beneficial in various major diseases such as heart failure.  Currently, this is achieved with mineralocorticoid receptor antagonists, however, aldosterone synthase (CYP11B2) inhibitors may offer a promising alternative.  In this study, three-dimensional modeling of CYP11B2 was used to model the binding modes of the natural substrate 18-hydroxycorticosterone and the recently published CYP11B2 inhibitor R-fadrozole (I) as a rational guide to design 44 structurally simple and achiral 1-benzyl-1H-imidazoles.  Their syntheses, in vitro inhibitor potencies, and in silico docking are described.  Some promising CYP11B2 inhibitors were identified, with the novel lead MOERAS115 (II) displaying an IC50 for CYP11B2 of 1.7 nM, and a CYP11B2 (vs. CYP11B1) selectivity of 16.5, comparable to R-fadrozole (IC50 for CYP11B2 6.0 nM, selectivity 19.8).  Mol. docking of the inhibitors in the models enabled the generation of posthoc hypotheses on their binding modes, providing a valuable basis for future studies and further design of CYP11B2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz3kri2YpzBLVg90H21EOLACvtfcHk0lgltM8HUlG6kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCgtrY%253D&md5=95b05f5ad57464a12715c4cf15502b83</span></div><a href="/servlet/linkout?suffix=cit19g&amp;dbid=16384&amp;doi=10.1021%2Fjm901356d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901356d%26sid%3Dliteratum%253Aachs%26aulast%3DRoumen%26aufirst%3DL.%26aulast%3DPeeters%26aufirst%3DJ.%2BW.%26aulast%3DEmmen%26aufirst%3DJ.%2BM.%2BA.%26aulast%3DBeugels%26aufirst%3DI.%2BP.%2BE.%26aulast%3DCusters%26aufirst%3DE.%2BM.%2BG.%26aulast%3Dde%2BGooyer%26aufirst%3DM.%26aulast%3DPlate%26aufirst%3DR.%26aulast%3DPieterse%26aufirst%3DK.%26aulast%3DHilbers%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DSmits%26aufirst%3DJ.%2BF.%2BM.%26aulast%3DVekemans%26aufirst%3DJ.%2BA.%2BJ.%26aulast%3DLeysen%26aufirst%3DD.%26aulast%3DOttenheijm%26aufirst%3DH.%2BC.%2BJ.%26aulast%3DJanssen%26aufirst%3DH.%2BM.%26aulast%3DHermans%26aufirst%3DJ.%2BJ.%2BR.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520modeling%2520of%25201-benzyl-1H-imidazoles%2520as%2520selective%2520inhibitors%2520of%2520aldosterone%2520synthase%2520%2528CYP11B2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1712%26epage%3D1725%26doi%3D10.1021%2Fjm901356d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Adams, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.-W</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ksander, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaSala, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung-Chu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meredith, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigel, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span> </span><span class="NLM_article-title">The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-β-hydroxylase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4324</span><span class="NLM_x">–</span> <span class="NLM_lpage">4327</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.bmcl.2010.06.086" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4324-4327&author=C.+M.+Adamsauthor=C.-W+Huauthor=A.+Y.+Jengauthor=R.+Karkiauthor=G.+M.+Ksanderauthor=D.+LaSalaauthor=J.+Leung-Chuauthor=G.+Liangauthor=Q.+Liuauthor=E.+L.+Meredithauthor=C.+Raoauthor=D.+F.+Rigelauthor=J.+Shiauthor=S.+Smithauthor=C.+Springerauthor=C.+Zhang&title=The+discovery+of+potent+inhibitors+of+aldosterone+synthase+that+exhibit+selectivity+over+11-%CE%B2-hydroxylase&doi=10.1016%2Fj.bmcl.2010.06.086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19h&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.086%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DC.%2BM.%26aulast%3DHu%26aufirst%3DC.-W%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKsander%26aufirst%3DG.%2BM.%26aulast%3DLaSala%26aufirst%3DD.%26aulast%3DLeung-Chu%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMeredith%26aufirst%3DE.%2BL.%26aulast%3DRao%26aufirst%3DC.%26aulast%3DRigel%26aufirst%3DD.%2BF.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%26atitle%3DThe%2520discovery%2520of%2520potent%2520inhibitors%2520of%2520aldosterone%2520synthase%2520that%2520exhibit%2520selectivity%2520over%252011-%25CE%25B2-hydroxylase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4324%26epage%3D4327%26doi%3D10.1016%2Fj.bmcl.2010.06.086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Lucas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ries, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schewe, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">8077</span><span class="NLM_x">–</span> <span class="NLM_lpage">8087</span><span class="refDoi"> DOI: 10.1021/jm800888q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800888q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVOjs7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=8077-8087&author=S.+Lucasauthor=R.+Heimauthor=C.+Riesauthor=K.+E.+Scheweauthor=B.+Birkauthor=R.+W.+Hartmann&title=In+vivo+active+aldosterone+synthase+inhibitors+with+improved+selectivity%3A+lead+optimization+providing+a+series+of+pyridine+substituted+3%2C4-dihydro-1H-quinolin-2-one+derivatives&doi=10.1021%2Fjm800888q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19iR"><div class="casContent"><span class="casTitleNuber">19i</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Active Aldosterone Synthase Inhibitors with Improved Selectivity: Lead Optimization Providing a Series of Pyridine Substituted 3,4-Dihydro-1H-quinolin-2-one Derivatives</span></div><div class="casAuthors">Lucas, Simon; Heim, Ralf; Ries, Christina; Schewe, Katarzyna E.; Birk, Barbara; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8077-8087</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyridine substituted naphthalenes (e.g., I-III) constitute a class of potent inhibitors of aldosterone synthase (CYP11B2).  To overcome the unwanted inhibition of the hepatic enzyme CYP1A2, we aimed at reducing the no. of arom. carbons of these mols. because aromaticity has previously been identified to correlate pos. with CYP1A2 inhibition.  As hypothesized, inhibitors with a tetrahydronaphthalene type mol. scaffold (1-11) exhibit a decreased CYP1A2 inhibition.  However, tetralone 9 turned out to be cytotoxic to the human cell line U-937 at higher concns.  Consequent structural optimization culminated in the discovery of heteroaryl substituted 3,4-dihydro-1H-quinolin-2-ones (12-26), with 12, a bioisostere of 9, being nontoxic up to 200 μM.  The investigated mols. are highly selective toward both CYP1A2 and a wide range of other cytochrome P 450 enzymes and show a good pharmacokinetic profile in vivo (e.g., 12 with a peroral bioavailability of 71%).  Furthermore, isoquinoline deriv. 21 proved to significantly reduce plasma aldosterone levels of ACTH stimulated rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq85RK4G2Dhm7Vg90H21EOLACvtfcHk0ljP8BOALZfi9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVOjs7nK&md5=fbf108702b03dc714fbd27619119ead9</span></div><a href="/servlet/linkout?suffix=cit19i&amp;dbid=16384&amp;doi=10.1021%2Fjm800888q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800888q%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DHeim%26aufirst%3DR.%26aulast%3DRies%26aufirst%3DC.%26aulast%3DSchewe%26aufirst%3DK.%2BE.%26aulast%3DBirk%26aufirst%3DB.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DIn%2520vivo%2520active%2520aldosterone%2520synthase%2520inhibitors%2520with%2520improved%2520selectivity%253A%2520lead%2520optimization%2520providing%2520a%2520series%2520of%2520pyridine%2520substituted%25203%252C4-dihydro-1H-quinolin-2-one%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D8077%26epage%3D8087%26doi%3D10.1021%2Fjm800888q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Voets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antes, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller-Vieira, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biemel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barassin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchais-Oberwinkler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span> </span><span class="NLM_article-title">Heteroaryl-Substituted Naphthalenes and Structurally Modified Derivatives: Selective Inhibitors of CYP11B2 for the Treatment of Congestive Heart Failure and Myocardial Fibrosis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6632</span><span class="NLM_x">–</span> <span class="NLM_lpage">6642</span><span class="refDoi"> DOI: 10.1021/jm0503704</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0503704" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6632-6642&author=M.+Voetsauthor=I.+Antesauthor=C.+Schererauthor=U.+M%C3%BCller-Vieiraauthor=K.+Biemelauthor=C.+Barassinauthor=S.+Marchais-Oberwinklerauthor=R.+W.+Hartmann&title=Heteroaryl-Substituted+Naphthalenes+and+Structurally+Modified+Derivatives%3A+Selective+Inhibitors+of+CYP11B2+for+the+Treatment+of+Congestive+Heart+Failure+and+Myocardial+Fibrosis&doi=10.1021%2Fjm0503704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19j&amp;dbid=16384&amp;doi=10.1021%2Fjm0503704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0503704%26sid%3Dliteratum%253Aachs%26aulast%3DVoets%26aufirst%3DM.%26aulast%3DAntes%26aufirst%3DI.%26aulast%3DScherer%26aufirst%3DC.%26aulast%3DM%25C3%25BCller-Vieira%26aufirst%3DU.%26aulast%3DBiemel%26aufirst%3DK.%26aulast%3DBarassin%26aufirst%3DC.%26aulast%3DMarchais-Oberwinkler%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DHeteroaryl-Substituted%2520Naphthalenes%2520and%2520Structurally%2520Modified%2520Derivatives%253A%2520Selective%2520Inhibitors%2520of%2520CYP11B2%2520for%2520the%2520Treatment%2520of%2520Congestive%2520Heart%2520Failure%2520and%2520Myocardial%2520Fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6632%26epage%3D6642%26doi%3D10.1021%2Fjm0503704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Pfenninger, H. A.</span><span> </span><span class="NLM_article-title">Certain 2-pyridyl-substituted indole derivatives</span>. US 3468894, September 23,<span class="NLM_x"> </span><span class="NLM_year">1969</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1969&author=H.+A.+Pfenninger&title=Certain+2-pyridyl-substituted+indole+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPfenninger%26aufirst%3DH.%2BA.%26atitle%3DCertain%25202-pyridyl-substituted%2520indole%2520derivatives%26date%3D1969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Bird, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanley, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Word, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainey, W.</span><span> </span><span class="NLM_article-title">Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II responsive aldosterone secretion</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">1555</span><span class="NLM_x">–</span> <span class="NLM_lpage">1561</span><span class="refDoi"> DOI: 10.1210/endo.133.4.8404594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1210%2Fendo.133.4.8404594" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=1993&pages=1555-1561&author=L.+Birdauthor=N.+Hanleyauthor=R.+Wordauthor=J.+Mathisauthor=J.+Masonauthor=W.+Rainey&title=Human+NCI-H295+adrenocortical+carcinoma+cells%3A+a+model+for+angiotensin-II+responsive+aldosterone+secretion&doi=10.1210%2Fendo.133.4.8404594"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1210%2Fendo.133.4.8404594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo.133.4.8404594%26sid%3Dliteratum%253Aachs%26aulast%3DBird%26aufirst%3DL.%26aulast%3DHanley%26aufirst%3DN.%26aulast%3DWord%26aufirst%3DR.%26aulast%3DMathis%26aufirst%3DJ.%26aulast%3DMason%26aufirst%3DJ.%26aulast%3DRainey%26aufirst%3DW.%26atitle%3DHuman%2520NCI-H295%2520adrenocortical%2520carcinoma%2520cells%253A%2520a%2520model%2520for%2520angiotensin-II%2520responsive%2520aldosterone%2520secretion%26jtitle%3DEndocrinology%26date%3D1993%26volume%3D133%26spage%3D1555%26epage%3D1561%26doi%3D10.1210%2Fendo.133.4.8404594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">LaSala, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span> </span><span class="NLM_article-title">Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">394</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1016/j.ab.2009.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.ab.2009.07.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=19622340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A280%3ADC%252BD1MrovVSktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2009&pages=56-61&author=D.+LaSalaauthor=Y.+Shibanakaauthor=A.+Y.+Jeng&title=Coexpression+of+CYP11B2+or+CYP11B1+with+adrenodoxin+and+adrenodoxin+reductase+for+assessing+the+potency+and+selectivity+of+aldosterone+synthase+inhibitors&doi=10.1016%2Fj.ab.2009.07.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors</span></div><div class="casAuthors">LaSala Daniel; Shibanaka Yasuhiko; Jeng Arco Y</div><div class="citationInfo"><span class="NLM_cas:title">Analytical biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Excessive production of aldosterone has been implicated in the pathogenesis of hypertension and heart failure.  One approach to ameliorate the deleterious effects of aldosterone is to suppress its biosynthesis.  The enzyme aldosterone synthase (CYP11B2) is responsible for the final step of aldosterone synthesis.  It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone.  A stable cell line simultaneously overexpressing recombinant human CYP11B2 as well as human adrenodoxin and adrenodoxin reductase was established to help maximize the enzyme activity.  The homogenate of these cells was used to develop an in vitro CYP11B2 assay using 11-deoxycorticosterone as a substrate.  By the same strategy, another stable cell line simultaneously overexpressing human 11beta-hydroxylase (CYP11B1), an enzyme responsible for the final step of cortisol biosynthesis, and the two electron transfer proteins was also established, and an in vitro CYP11B1 assay using 11-deoxycortisol as a substrate was likewise developed to assess the selectivity of CYP11B2 inhibitors.  FAD286, a reference CYP11B2 inhibitor, inhibited CYP11B2 and CYP11B1 activities with IC(50) values of 1.6+/-0.1 and 9.9+/-0.9 nM (mean+/-SEM, n=3-6), respectively.  Kinetics studies revealed that the compound inhibited the activity of both enzymes competitively with respective K(i) values of 0.8+/-0.04 and 2.2+/-0.2 nM (n=3-4).  These assays can be used for assessing the potency and selectivity of CYP11B2 inhibitors for the treatment of hypertension and heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKI6OChpO8UCsZ1x6zOs0vfW6udTcc2eaJvaOLOGoaMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrovVSktQ%253D%253D&md5=38f4fae017fa10e538270366bdc5b568</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2009.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2009.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DLaSala%26aufirst%3DD.%26aulast%3DShibanaka%26aufirst%3DY.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26atitle%3DCoexpression%2520of%2520CYP11B2%2520or%2520CYP11B1%2520with%2520adrenodoxin%2520and%2520adrenodoxin%2520reductase%2520for%2520assessing%2520the%2520potency%2520and%2520selectivity%2520of%2520aldosterone%2520synthase%2520inhibitors%26jtitle%3DAnal.%2520Biochem.%26date%3D2009%26volume%3D394%26spage%3D56%26epage%3D61%26doi%3D10.1016%2Fj.ab.2009.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Anderson, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCrodden, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tipton, K. F.</span><span> </span><span class="NLM_article-title">Monoamine oxidase inhibitors and the cheese effect</span> <span class="citation_source-journal">Neurochem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1145</span><span class="NLM_x">–</span> <span class="NLM_lpage">1149</span><span class="refDoi"> DOI: 10.1007/BF00978365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1007%2FBF00978365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=8255365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADyaK2cXitlWjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1993&pages=1145-1149&author=M.+C.+Andersonauthor=F.+Hasanauthor=J.+M.+McCroddenauthor=K.+F.+Tipton&title=Monoamine+oxidase+inhibitors+and+the+cheese+effect&doi=10.1007%2FBF00978365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase inhibitors and the cheese effect</span></div><div class="casAuthors">Anderson, Mary C.; Hasan, Farris; McCrodden, John M.; Tipton, Keith F.</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemical Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1145-9</span>CODEN:
                <span class="NLM_cas:coden">NEREDZ</span>;
        ISSN:<span class="NLM_cas:issn">0364-3190</span>.
    </div><div class="casAbstract">The behavior of inhibitors of monoamine oxidase-A (MAO-A) is considered in terms of the possibility of having an effective antidepressant that does not give rise to hypertensive interactions with dietary tyramine.  Studies with punch-biopsy samples of human intestine and rat intestinal samples show MAO-A to be the predominant form of the enzyme in both species.  Transport studies with everted rat intestinal prepns. indicate that tyramine is extensively metabolized during transport through the intestine.  Selective inhibition of MAO-A by clorgyline results in a large increase in the amt. of unchanged tyramine transported, whereas selective inhibition of MAO-B with L-deprenyl (selegiline) has no significant effect.  The behavior of reversible MAO-A inhibitors can significantly reduce, but not entirely eliminate, these effects on the intestinal metab. of tyramine, but only if the inhibition is competitive in nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDISgk8VH-8LVg90H21EOLACvtfcHk0libpm1BDtKC8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlWjsQ%253D%253D&md5=e9d85b743f7fdde68276428940940cac</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2FBF00978365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00978365%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DM.%2BC.%26aulast%3DHasan%26aufirst%3DF.%26aulast%3DMcCrodden%26aufirst%3DJ.%2BM.%26aulast%3DTipton%26aufirst%3DK.%2BF.%26atitle%3DMonoamine%2520oxidase%2520inhibitors%2520and%2520the%2520cheese%2520effect%26jtitle%3DNeurochem.%2520Res.%26date%3D1993%26volume%3D18%26spage%3D1145%26epage%3D1149%26doi%3D10.1007%2FBF00978365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Sun-Edelstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tepper, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, R. E.</span><span> </span><span class="NLM_article-title">Drug-induced serotonin syndrome: a review</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">596</span><span class="refDoi"> DOI: 10.1517/14740338.7.5.587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1517%2F14740338.7.5.587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=18759711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGktrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=587-596&author=C.+Sun-Edelsteinauthor=S.+J.+Tepperauthor=R.+E.+Shapiro&title=Drug-induced+serotonin+syndrome%3A+a+review&doi=10.1517%2F14740338.7.5.587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced serotonin syndrome: a review</span></div><div class="casAuthors">Sun-Edelstein, Christina; Tepper, Stewart J.; Shapiro, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">587-596</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Serotonin syndrome, or serotonin toxicity (ST), is a clin. condition that occurs as a result of an iatrogenic drug-induced increase in intrasynaptic serotonin levels primarily resulting in activation of serotonin2A receptors in the central nervous system.  The severity of symptoms spans a spectrum of toxicity that correlates with the intrasynaptic serotonin concn.  Although numerous drugs have been implicated in ST, life-threatening cases generally occur only when monoamine oxidase inhibitors are combined with either selective or nonselective serotonin re-uptake inhibitors.  The triad of clin. features consists of neuromuscular hyperactivity, autonomic hyperactivity and altered mental status, which may present abruptly and progress rapidly.  The awareness of ST is crucial not only in avoiding the unintentional lethal combination of therapeutic drugs but also in recognizing the clin. picture when it occurs so that treatment can be promptly initiated.  In this review, the pathophysiol., clin. features, implicated drugs, diagnosis and treatment of ST are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvkxGg7l0hqrVg90H21EOLACvtfcHk0libpm1BDtKC8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGktrnF&md5=610a9ca388256dd29ffe95aea3fdd82f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1517%2F14740338.7.5.587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.7.5.587%26sid%3Dliteratum%253Aachs%26aulast%3DSun-Edelstein%26aufirst%3DC.%26aulast%3DTepper%26aufirst%3DS.%2BJ.%26aulast%3DShapiro%26aufirst%3DR.%2BE.%26atitle%3DDrug-induced%2520serotonin%2520syndrome%253A%2520a%2520review%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2008%26volume%3D7%26spage%3D587%26epage%3D596%26doi%3D10.1517%2F14740338.7.5.587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="note"><p class="first last">Greater than 1000-fold selectivities over CYP3A4/5, CYP2D6, CYP2C9, and CYP1A2 enzymes were also observed.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last"><b>8</b> is a reversible inhibitor of CYP11B2 with a <i>k</i><sub>off</sub> = 0.013 ± 0.003 min<sup>–1</sup> (<i>n</i> = 4) and residence half-life <i>t</i><sub>1/2</sub> = 52 ± 9 min (<i>n</i> = 4); <b>8</b> is a substrate-competitive inhibitor, as determined from IC<sub>50</sub> shifts experiments with increasing 11-deoxycorticosterone concentrations.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><div class="note"><p class="first last">After these studies were completed, a similar model was published:</p></div><span class="NLM_contrib-group">Cai, T.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stribling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontenot, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinsanya, K. O.</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span><span class="refDoi"> DOI: 10.1016/j.vascn.2014.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2Fj.vascn.2014.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=25304940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGns73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=After+these+studies+were+completed%2C+a+similar+model+was+published%3ACai%2C+T.-Q.%3B+Stribling%2C+S.%3B+Tong%2C+X.%3B+Xu%2C+L.%3B+Wisniewski%2C+T.%3B+Fontenot%2C+J.+A.%3B+Struthers%2C+M.%3B+Akinsanya%2C+K.+O.J.+Pharmacol.+Toxicol.+Methods+2015%2C+71%2C+137%E2%80%93146+10.1016%2Fj.vascn.2014.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors</span></div><div class="casAuthors">Cai, Tian-Quan; Stribling, Sloan; Tong, Xinchun; Xu, Ling; Wisniewski, Thomas; Fontenot, Jane A.; Struthers, Mary; Akinsanya, Karen O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">137-146</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In vivo profiles of aldosterone synthase inhibitors (ASIs) have been investigated utilizing various rodent models.  Due to lack of CYP17 activity, rodents produce corticosterone rather than cortisol as that of humans, which raised concern to their effectiveness in translational pharmacol. characterization of ASI.  A rhesus monkey model that combines a low sodium diet with ACTH (ACTH) treatment was developed.  Plasma concns. of steroid metabolites assocd. with reactions catalyzed by CYP11B2 and CYP11B1 were measured concurrently by a UPLC/MS method.  Plasma concn. of aldosterone in regular diet fed rhesus monkeys was low at 109 pg/mL.  Aldosterone concns. were increased to 252 pg/mL when animals were maintained on a low sodium diet for 3 wk, and to 300 pg/mL with ACTH treatment at 0.3 mg/kg.  The combination of low sodium diet with ACTH treatment further increased plasma concn. of aldosterone to 730 pg/mL and other steroid metabolites at various levels.  I.v. administration of ASI, fadrozole (0.001-1 mg/kg) or LCI699 (0.003-3 mg/kg), led to dose-dependent redns. in aldosterone and 18-hydroxycorticosterone, increases in 11-deoxycorticosterone and 11-deoxycortisol, and bell-shaped changes in cortisol and corticosterone.  In vivo selectivity of CYP11B2/CYP11B1 for fadrazole was 26-fold and LCI-699 was 27-fold, which was consistent with relative selectivity using in vitro values from recombinant cells transfected with rhesus monkey CYP11B2 and CYP11B1.  This model enables concurrent characterization of pharmacokinetics, pharmacodynamics and selectivity of CYP11B2 over CYP11B1 inhibition in the same animal.  It may be used as a translational model for pharmacol. characterization of ASI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgHmCwgc290bVg90H21EOLACvtfcHk0libpm1BDtKC8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGns73K&md5=912a384735308d52a410cc2397ff9e83</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2014.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2014.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DT.-Q.%26aulast%3DStribling%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DWisniewski%26aufirst%3DT.%26aulast%3DFontenot%26aufirst%3DJ.%2BA.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DAkinsanya%26aufirst%3DK.%2BO.%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2015%26volume%3D71%26spage%3D137%26epage%3D146%26doi%3D10.1016%2Fj.vascn.2014.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Wacker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasireddy, P.</span><span> </span><span class="NLM_article-title">Efficient solid-phase synthesis of 2,3-substituted indoles</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">5189</span><span class="NLM_x">–</span> <span class="NLM_lpage">5191</span><span class="refDoi"> DOI: 10.1016/S0040-4039(02)01025-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1016%2FS0040-4039%2802%2901025-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVenu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=5189-5191&author=D.+A.+Wackerauthor=P.+Kasireddy&title=Efficient+solid-phase+synthesis+of+2%2C3-substituted+indoles&doi=10.1016%2FS0040-4039%2802%2901025-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient solid-phase synthesis of 2,3-substituted indoles</span></div><div class="casAuthors">Wacker, Dean A.; Kasireddy, Padmaja</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">5189-5191</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The development of the solid-phase version of the modified Madelung indole synthesis is reported.  The chem. was initiated with the reductive amination of Bal resin using an ortho substituted aniline.  The resin bound aniline was acylated with a variety of acid chlorides followed by cyclization with base to provide the desired indole after TFA-promoted cleavage from the resin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovpxngdleI2LVg90H21EOLACvtfcHk0libpm1BDtKC8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVenu70%253D&md5=b1025fc6ecbd86601ec45233775c59a9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2802%2901025-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252802%252901025-0%26sid%3Dliteratum%253Aachs%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DKasireddy%26aufirst%3DP.%26atitle%3DEfficient%2520solid-phase%2520synthesis%2520of%25202%252C3-substituted%2520indoles%26jtitle%3DTetrahedron%2520Lett.%26date%3D2002%26volume%3D43%26spage%3D5189%26epage%3D5191%26doi%3D10.1016%2FS0040-4039%2802%2901025-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Mehta, G.</span><span> </span><span class="NLM_article-title">Reaction of indoles with chlorosulphonyl isocyanate; a versatile route to 3-substituted indoles</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">1978</span><span class="NLM_x">, </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">376</span><span class="refDoi"> DOI: 10.1055/s-1978-24751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;key=10.1055%2Fs-1978-24751" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1978&publication_year=1978&pages=374-376&author=G.+Mehta&title=Reaction+of+indoles+with+chlorosulphonyl+isocyanate%3B+a+versatile+route+to+3-substituted+indoles&doi=10.1055%2Fs-1978-24751"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1055%2Fs-1978-24751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1978-24751%26sid%3Dliteratum%253Aachs%26aulast%3DMehta%26aufirst%3DG.%26atitle%3DReaction%2520of%2520indoles%2520with%2520chlorosulphonyl%2520isocyanate%253B%2520a%2520versatile%2520route%2520to%25203-substituted%2520indoles%26jtitle%3DSynthesis%26date%3D1978%26volume%3D1978%26spage%3D374%26epage%3D376%26doi%3D10.1055%2Fs-1978-24751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-NOTES-d10718e3240-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i42"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01545">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_12738"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01545">10.1021/acs.jmedchem.5b01545</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Compound data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01545/suppl_file/jm5b01545_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01545/suppl_file/jm5b01545_si_001.csv">jm5b01545_si_001.csv (0.88 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01545&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-23%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01545" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01545" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799bc40cf943285","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
